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Abstract 
Author: David Mark Bunting 
Title:  The performance of circulating biomarkers in the prediction of response 
to   neoadjuvant therapy in patients with oesophago-gastric cancer 
Introduction 
The prognosis in oesophago-gastric cancer is poor with less than 15% patients surviving 
beyond 5 years after diagnosis. The addition of neoadjuvant therapy has been shown to 
increase survival in patients suitable for curative surgery. However, the additional gains 
are modest and the majority of patients do not respond sufficiently from therapy to gain 
any benefit. There is an urgent need to identify markers that can predict response to 
neoadjuvant therapy in order provide safer, more effective, individualised treatment 
regimes. 
Methods 
A prospective, multi-centre, collaborative study was undertaken in patients with 
oesophago-gastric cancer undergoing neoadjuvant therapy and potentially curative 
surgery. Levels of circulating biomarkers M2-Pyruvate kinase, alkaline phosphatase, 
CA19-9, CEA and CA 72-4 were measured in patients before and after administering the 
first cycle of chemotherapy. Binary logistic regression analysis was performed to assess 
the ability of biomarkers to predict histological response to therapy. 
Results 
165 patients were recruited to the main study. 105 patients had complete 
histopathological data for analysis. There were 27 responders and 78 non-responders to 
neoadjuvant therapy. There were no differences in pre-therapy demographic, 
pathological or treatment factors between the two groups. Responders had less post-
operative lymphovascular invasion (P= 0.004) and higher R0 resection rates (P=0.03). 
Pre-therapy M2-Pyruvate kinase levels were lower in responders compared to non-
responders (P=0.037) and levels were able to predict response with each unit increase 
in the biomarker level being associated with a 4.1% decrease in the likelihood of 
response (P=0.027). M2-PK levels were not associated with any pre-operative 
demographic, clinical or pathological factors. 
Conclusions 
Pre-therapy dimeric M2-PK levels can predict response to neoadjuvant therapy in 
patients with oesophago-gastric cancer. The test could be of clinical value for 1 in every 
8 patients undergoing the test. 
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CHAPTER 1 - INTRODUCTION 
Oesophageal and Gastric Cancer 
Background 
In the UK, oesophageal and gastric cancer together represent the 4th and 8th most 
common cancers in men and women respectively, see Figure 1 and Figure 21. Over the 
last decade, the incidence of oesophageal cancer has increased by 11% in males and 
decreased by 9% in females, Figure 32. The incidence of gastric cancer is on the decrease 
in Europe and the UK (Figure 4). Survival in oesophago-gastric cancer is poor.  The 5-year 
survival for oesophageal cancer in England is 13.1% in men and 14.4% in women, Figure 
53. The corresponding rates in gastric cancer are 17.8% and 19.9% in men and women 
respectively3. Disease-free survival rates are even lower.  As a result, oesophago-gastric 
cancers are the 4th and 5th leading UK cause of cancer deaths in men and women 
respectively4.
 
Figure 1 Male Cancer Incidence in the United Kingdom, 2008-10. Office for National Statistics 20121 
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Figure 2 Female Cancer Incidence and in the United Kingdom, 2008-10. Office for National Statistics 20121 
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Figure 3 European Age-Standardised incidence rates of oesophageal cancer by sex, Great Britain. Cancer Research 
UK, http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/oesophageal-cancer/incidence#heading-Two, Accessed October 2015.  
 
Figure 4 European Age-Standardised incidence rates of gastric cancer by sex, Great Britain. Cancer Research UK, 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/stomach-
cancer/incidence#heading-Two, Accessed October 2015. 
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Figure 5 Five-year age-standardised net survival for adults diagnosed during 2006–2010 and followed up to 2011: 
England, 10 common cancers, by sex. Office for National Statistics. Cancer Survival in England: Patients Diagnosed 
2006–2010 and Followed up to 2011, Summary 23-Oct-2012, accessed November 2012.)3 
Cancers of the oesophagus and stomach tend to present at a late stage5. Curative 
treatments, primarily surgery plus or minus neoadjuvant therapy are reserved for those 
with localised disease, representing only 20-25% of patients with oesophago-gastric 
cancer6. The incidence increases with age, most presenting after the age of 72 years7. In 
patients with advanced disease and those unfit for surgery due to age or comorbidity, 
palliation with chemotherapy/radiotherapy/stenting are often the only treatment 
options.  Between 20% and 42% of these patients receive chemotherapy (with or 
without endoscopic and radiological palliative therapy)5.  
Cancer sub-types 
Histological 
The great majority of oesophageal cancers fall into two main subtypes, adenocarcinoma 
and squamous cell carcinoma. The majority of malignant gastric cancers are 
adenocarcinomas. 
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Anatomical location 
Traditionally, upper gastrointestinal cancers have been divided into gastric and 
oesophageal according to their anatomical location. However, there are problems 
associated with this classification. The incidence of adenocarcinomas of the gastro-
oesophageal junction is increasing and it is becoming clear that they behave as a distinct 
subtype of their own.  This group have been classified separately as cancers of the 
gastro-oesophageal junction. These tumours can be divided into subtypes depending on 
the exact anatomical relationship to the cardia/gastro-oesophageal junction and were 
described by Siewert and Stein in 19988 (Figure 6).  
Type I Adenocarcinoma of the distal oesophagus that usually arises from an area 
of specialised intestinal metaplasia (Barrett’s oesophagus) and which may 
infiltrate the oesophago-gastric junction from above 
Type II True carcinoma of the cardia arising from the cardiac epithelium or short 
segments with intestinal metaplasia at the oesophago-gastric junction; this 
entity is also referred to as ‘junctional carcinoma’ 
Type III Subcardial gastric carcinoma, which infiltrates the oesophago-gastric 
junction and distal oesophagus from below 
Figure 6 Siewert Classification of gastro-oesophageal junction tumours8 
 
The following section describes how recent changes in the staging classification of 
oesophageal and gastric have taken account of these important anatomical 
considerations. 
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Staging in oesophago-gastric cancer 
Classification 
Since 1986, a single staging classification has been agreed by the American Joint 
Committee on Cancer (AJCC), the Japanese Joint Committee (JCC) and the International 
Union Against Cancer (UICC). It is an anatomical classification also referred to as the 
TNM classification where T represents the extent of the primary tumour, N nodal disease 
and M metastatic disease. There are specific classifications for each cancer subtype 
which are updated periodically as more accurate methods of staging cancers become 
available9. Figure 7 to Figure 12 show the up to date classifications (7th edition) for 
oesophageal/gastro-oesophageal junction and gastric cancer. 
One of the most important changes in this updated classification compared to the 6th 
edition reflects the anatomical considerations mentioned above. Tumours involving the 
oesophago-gastric junction but arising in the proximal 5cm of the stomach (Siewert Type 
III) are staged along with all other junctional cancers staged using the oesophageal 
cancer subtype classification. T categories in gastric cancer have also been harmonized 
with those of the oesophagus and small and large intestine10, 11. 
Accurate staging is critical in determining the optimal treatment for patients with 
oesophageal and gastric cancer. One of the most important aspects of treatment is 
avoiding unnecessary surgery which involves identifying those patients who will not 
benefit. The main goal of surgery in oesophageal and gastric cancer is improved survival. 
It is known that patients with metastatic disease at presentation and those with an 
unresectable tumour will not gain a survival benefit from resection of the primary 
tumour. The identification of unresectable nodal disease, resectability of the primary 
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tumour and identification of metastatic disease are therefore crucial requirements of 
the staging process. 
Stage Description 
TX Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
T1 Tumour invades lamina propria, muscularis mucosae, or 
submucosa. 
T1a Tumour invades lamina propria or muscularis mucosae. 
T1b Tumour invades submucosa. 
T2 Tumour invades muscularis propria. 
T3 Tumour invades adventitia. 
T4 Tumour invades adjacent structures. 
T4a Resectable tumour invading pleura, pericardium or 
diaphragm. 
T4b Unresectable tumour invading other adjacent structures, 
such as aorta, vertebral body, trachea etc. 
Figure 7 Local tumour staging for cancer of the oesophagus/oesophago-gastric junction, from AJCC: Esophageal 
and esophagogastric junction. In Edge SB, Byrd DR, Compton CC et al., eds.:AJCC Cancer Staging Manual. 7th ed 
New York, NY: Springer, 2010, pp103-15.9 
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Stage Description 
NX Regional lymph nodes cannot be assessed. 
N0 No regional lymph node metastasis. 
N1 Metastases in 1-2 regional lymph nodes. 
N2 Metastases in 3-6 regional lymph nodes. 
N3 Metastases in ≥7 regional lymph nodes. 
Figure 8 Nodal staging for cancer of the oesophagus/oesophago-gastric junction, from AJCC: Esophageal and 
esophagogastric junction. In Edge SB, Byrd DR, Compton CC et al., eds.:AJCC Cancer Staging Manual. 7th ed New 
York, NY: Springer, 2010, pp103-15.9 
 
Stage Description 
M0 No distant metastasis. 
M1 Distant metastasis. 
Figure 9 Metastasis staging for cancer of the oesophagus/oesophago-gastric junction, from AJCC: Esophageal and 
esophagogastric junction. In Edge SB, Byrd DR, Compton CC et al., eds.:AJCC Cancer Staging Manual. 7th ed New 
York, NY: Springer, 2010, pp103-15.9 
  
26 
 
Stage Description 
TX Primary tumour cannot be assessed. 
T0 No evidence of primary tumour. 
Tis Carcinoma in situ: intraepithelial tumor without invasion of 
the lamina propria. 
T1 Tumour invades lamina propria, muscularis mucosae, or 
submucosa. 
T1a Tumour invades lamina propria or muscularis mucosae. 
T1b Tumour invades submucosa. 
T2 Tumour invades muscularis propria. 
T3 Tumor penetrates subserosal connective tissue without 
invasion of visceral peritoneum or adjacent structures 
T4 Tumor invades serosa (visceral peritoneum) or adjacent 
structures. 
T4a Tumor invades serosa (visceral peritoneum). 
T4b Tumor invades adjacent structures. 
Figure 10 Local tumour staging for gastric cancer, from AJCC: Esophageal and esophagogastric junction. In Edge 
SB, Byrd DR, Compton CC et al., eds.:AJCC Cancer Staging Manual. 7th ed New York, NY: Springer, 2010, pp103-
15.8 
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Stage Description 
NX Regional lymph nodes cannot be assessed. 
N0 No regional lymph node metastasis. 
N1 Metastases in 1-2 regional lymph nodes. 
N2 Metastases in 3-6 regional lymph nodes. 
N3 Metastases in ≥7 regional lymph nodes. 
N3a Metastases in 7–15 regional lymph nodes. 
N3b Metastases in ≥16 regional lymph nodes. 
Figure 11 Nodal staging for gastric cancer, from AJCC: Esophageal and esophagogastric junction. In Edge SB, Byrd 
DR, Compton CC et al., eds.:AJCC Cancer Staging Manual. 7th ed New York, NY: Springer, 2010, pp103-15.8 
Stage Description 
M0 No distant metastasis. 
M1 Distant metastasis. 
Figure 12 Metastasis staging for gastric cancer, from AJCC: Esophageal and esophagogastric junction. In Edge SB, 
Byrd DR, Compton CC et al., eds.:AJCC Cancer Staging Manual. 7th ed New York, NY: Springer, 2010, pp103-15.8 
Staging Guidelines 
Guidelines for the management of oesophageal and gastric cancer were published in 
2011 by the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland 
(AUGIS), the British Society of Gastroenterology (BSG) and the British Association of 
Surgical Oncology (BASO)12. The recommendations on staging are summarised. Initial 
staging should be performed with a computed tomography (CT) scan including 
multiplanar reconstructions of the thorax, abdomen and pelvis. In T1 oesophageal 
tumours or nodularity in high grade dysplasia, staging by endoscopic resection (ER) 
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should be used to define depth of invasion. EUS should be used in oesophageal, 
oesophago-gastric junctional and selected gastric tumours. PET-CT scanning should be 
used in combination with EUS and CT for assessment of oesophageal and oesophago-
gastric junctional cancer. Staging laparoscopy should be undertaken in all gastric cancers 
and in selected patients with lower oesophageal and oesophago-gastric junctional 
tumours (whenever tumour extends below the diaphragm, according to the previous set 
of guidelines by the same group in 200213). 
Staging modalities 
In addition to those modalities mentioned above (endoscopy, endoscopic resection, CT, 
EUS, PET-CT and staging laparoscopy), additional techniques such as video-assisted 
thoracosopic surgery (VATS), endobronchial ultrasound (EBUS) and ultrasound guided 
biopsy of lymph nodes or suspicious peripheral lesions are sometimes employed by 
individual specialist centres on an individual patient basis. The typical staging pathway 
used in our specialist multidisciplinary team (MDT) is summarised in Figure 13. 
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Figure 13 Flow chart showing typical staging pathway. MDT, multidisciplinary team; EUS, endoscopic ultrasound; 
PET, positron emission tomography; CT, computed tomography.  
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Each modality can contribute in some way; however, none of the modalities are able to 
stage the disease with complete accuracy. Published guidelines reflect this and tend to 
lead to over-investigation which is costly, time-consuming and can delay definitive 
treatment. The result is that many patients undergoing a staging investigation will not 
have their management altered as a result of undergoing the test. 
In the same way that clinicians are trying to find ways of individualising treatment, it 
may be possible to tailor the staging investigations in each patient according to the 
results of initial tests rather than following a rigid protocol in all patients. 
One particular problem in assessing the accuracy of various staging modalities is the 
rapid pace of improvements in technology which means that even relatively recent 
reports may rely on imaging solutions that lag behind what is currently available. 
Modern multidetector CT (MDCT) scanners are able to produce images with better 
resolution allowing multiplanar 2D and 3D reconstructions, improving the accuracy of 
staging. Endoscopic equipment has also advanced significantly in recent years with high 
definition now being the standard in many units. 
This raises the question of whether there are features of endoscopy and CT 
examinations that are able to predict the tumour stage with sufficient accuracy that 
would obviate the need for further investigations such as PET scanning, endoscopic 
ultrasound, and staging laparoscopy in some patients. 
Clinical assessment 
Staging should always start with clinical assessment. This may direct investigations in 
order to identify metastatic disease at an early stage so that further unnecessary 
investigations can be avoided. 
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Endoscopy 
Endoscopy is the most important initial investigation in suspected oesophageal and 
gastric cancer since it is required to establish the histological diagnosis and can provide 
useful staging information. 
Endoscopic resection 
ER is very useful in the staging of early cancer. It is used in Barrett’s with dysplasia and 
nodularity where invasion is suspected. It has greater sensitivity than biopsy for 
detection of invasion and is superior to EUS in staging early T1 cancers14. 
CT scanning 
The main role of CT scanning is in the detection metastatic disease. Up to 50% patients 
present with metastatic disease, many of whom will be identified on CT and can be 
spared further staging investigations. For example, the accuracy in detecting liver 
metastases is between 86% and 98%15. CT is also important in determining resectability 
of the primary tumour. After endoscopy, it is usually the next staging investigation to be 
performed. The accuracy and role of CT in staging is explored further in Chapter 4 - 
Staging. 
Endoscopic ultrasound 
Since the outcome in units performing EUS is related to operator experience, it has been 
recommended that only experienced sonographers at centres performing at least 100 
examinations annually should be using this technique12. The main use of EUS is in 
assessment of T and N stage which it has been shown to do more accurately than CT. 
Accuracy is dependent on stage: for T-staging in gastric cancer, sensitivities ranges from 
82.3%-99.2% and specificity ranges from 94.7%-100%16. For N-staging in gastric cancer, 
sensitivity is around 58.2%-64.9% and specificity 87.2%-92.4%16. In oesophageal cancer, 
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the sensitivity for T stage ranges between 81.6% and 92.4%. The specificity ranges from 
97.4% to 99.4 %16. The main limitations of EUS are poor accuracy in staging early 
(intramucosal) neoplasia and in advanced (T3 and T4) lesions where the tumour cannot 
be traversed by the scope. Despite good overall accuracies, there has been limited 
evidence for improved outcomes associated with the additional information that EUS 
provides until results of the pragmatic randomised trial COGNATE (Cancer of 
Oesophagus or Gastricus - New Assessment of Technology of Endosonography) were 
published. These showed EUS improves survival and has the potential to reduce health-
care resources17. Perhaps the best use of EUS is in the assessment of mediastinal 
lymphadenopathy when a linear probe is used to facilitate guided fine needle aspiration 
(FNA). This improves sensitivity for nodal (N) staging from 84.7% to 96.7%18. 
PET-CT 
Metabolic imaging (PET) when combined with CT provides functional as well as 
anatomical information. Its main role is in the detection of distant nodal and metastatic 
disease. PET has demonstrated significantly better specificity than CT (even when 
combined with EUS) for the identification of both nodal and distant metastasis19, 
20Whilst some studies have shown that PET leads to a change in the staging in up to 20% 
patients compared to CT and EUS alone, a meta-analysis concluded that PET offered 
little improvement in the overall accuracy of staging in oesophageal cancer21. The role 
of PET-CT in staging of oesophageal cancer is explored further in CHAPTER 4 - 
INDIVIDUALISED STAGING INVESTIGATIONS. 
Staging laparoscopy 
CT, EUS and PET are poor at identifying low volume peritoneal/hepatic metastases and 
determining local resectability.  Laparoscopy (which is usually performed in conjunction 
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with a second endoscopy to aid tumour localisation) offers the ability to identify low 
volume metastases and can give useful information on resectability. Reports have 
shown that this provides additional treatment information in 17% patients with 
oesophageal/junctional tumours and 28% patients with gastric tumours22. The role of 
laparoscopy in the staging of gastric and gastro-oesophageal tumours is further explored 
in Chapter 4 - Staging. 
Video-assisted thoracoscopic surgery (VATS) 
VATS can be used to examine and take biopsies of thoracic lesions that may represent 
metastatic deposits outside the field of resection. The resectability of thoracic primary 
tumours can also be assessed. 
Endobronchial Ultrasound (EBUS) 
EBUS is used to examine possible direct tumour invasion into the respiratory tree and 
can be used to biopsy suspicious mediastinal nodes the lie outside the field of resection. 
Chemotherapy and Chemoradiotherapy 
Purpose of chemotherapy/chemoradiotherapy 
The aim of chemotherapy in the management of cancer is to improve overall quality of 
life and survival. Preoperative (neoadjuvant) chemotherapy is thought to improve 
operability and reduce local recurrence by primary tumour shrinkage. It is also thought 
to treat occult micro-metastases early, thereby reducing mortality from postoperative 
metastatic recurrence23. Survival benefits are achieved through cure in some and by 
prolonged survival in those that do recur. Neoadjuvant therapy is considered as 
preferable to adjuvant therapy in the treatment of oesophageal cancer not only due to 
the actions above but because it is associated with other factors such as improved 
tumour oxygenation at the time of therapy24; better tolerance of therapy before 
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surgery24, 25; improvements in swallowing allowing improved preoperative nutrition and 
it allows the sparing of surgery to those patients who progress early with metastatic 
disease24. Similarly, chemoradiotherapy is intended to down-stage disease in an effort 
to increase complete resection rates and reduce recurrence/survival24. 
Evidence - Oesophageal cancer 
Neoadjuvant chemotherapy 
The American Intergroup Trial (INT0113) randomised 440 patients to having 
neoadjuvant chemotherapy (3 cycles of cisplatin and fluorouracil) with or without 
postoperative chemotherapy or no chemotherapy at all26. They showed no difference in 
treatment related mortality, median survival or pattern of disease recurrence between 
the two groups although there was a higher R0 resection rate in those having 
chemotherapy. Criticisms of this study include a low (80%) operation rate in the 
chemotherapy arm put down to high levels of therapy-associated toxicity. 
The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial, 
which included 131 patients with oesophageal/junctional cancer, demonstrated that a 
combined strategy of three preoperative chemotherapy cycles (epirubicin, cisplatin & 
fluorouracil, ECF) and three postoperative chemotherapy cycles (ECF) decreased tumour 
size and significantly improved progression-free and overall survival25. 
The Medical Research Council (MRC) OE02 study is arguable the most influential study 
in the UK to date on this topic27. 802 patients were randomised to neoadjuvant 
chemotherapy with surgery (CS) or surgery alone (S) arms. Complete (R0) resection rate 
was somewhat higher in the chemotherapy group (60% vs. 53% P<0.0001) and the 
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overall survival was significantly better in the chemotherapy group with 5-year figures 
of 23% and 17% for CS and S groups respectively28. 
An updated Cochrane review of 11 randomised trials published in 2006 concluded that 
there was some evidence to suggest preoperative chemotherapy improves survival but 
that this was inconclusive (HR 0.88; 95% confidence interval (CI) 0.75-1.04)29. 
In an attempt to establish whether more chemotherapy (4 cycles epirubicin, cisplatin, 
capecitabine (ECX)) was more effective than ‘standard treatment’ given in the OE02 
study (2 cycles of Cisplatin, 5-FU), the OE05 study randomised 897 patients to either 
treatment30. Early results were presented at the 2015 American Society of Clinical 
Oncology (ASCO) meeting in June. There was no survival difference between the groups 
and chemotherapy-related toxicity was higher in the ECX group. It is not known whether 
a sub-group analysis according to observed therapy response would give different 
results, however, in any case these results suggest that overall, the therapeutic benefit 
of neoadjuvant therapy may have been reached with the standard regime and that 
potential benefits of more additional agents and cycles are negated by toxic effects. 
The ST03 trial set out to investigate whether the addition of the vascular endothelial 
growth factor monoclonal antibody, bevacizumab, to ECX neoadjuvant chemotherapy 
would improve overall survival. However, this part of the trial closed due to toxicity (high 
surgical complication rate) in the bevacizumab arm. This is further evidence supporting 
the notion that it is not possible to improve response rates and overall survival simply 
by adding more therapeutic agents. 
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Neoadjuvant chemoradiotherapy 
Walsh et al conducted a randomised trial comparing surgery alone with combined 
chemotherapy, radiotherapy and surgery31. 13 of 55 patients (25 per cent) treated with 
neoadjuvant therapy had complete pathological responses. Neoadjuvant 
chemoradiotherapy was associated with longer median survival, (16 months vs, 11 
months, P=0.01) and 3-year survival of 32% vs. 6%, P=0.01. This study has been criticised 
for the very poor survival in the surgery alone group of 6% at 3 years which is much 
lower than that expected even at the time the study was conducted. Staging during this 
time was less accurate than it is now and it could be that patients were under-staged in 
the control arm24. 
A meta-analysis of both chemotherapy (1724 patients) and chemoradiotherapy (1209 
patients) comparing each multimodality treatment with surgery alone demonstrated a 
significant survival benefit with the use of preoperative chemoradiotherapy compared 
to surgery alone amounting to an absolute benefit of difference in survival at 2 years of 
13% with similar findings in both adenocarcinoma and squamous cell carcinoma32. The 
survival benefit in patients undergoing chemotherapy compared to surgery alone was 
7% at 2 years. Outcomes in chemotherapy and chemoradiotherapy were not directly 
compared in this study. 
An updated meta-analysis published in 2011 comparing neoadjuvant chemotherapy 
with chemoradiotherapy reviewed 19 studies and showed strong evidence for a survival 
benefit of neoadjuvant chemotherapy or chemoradiotherapy over surgery alone 
however a clear advantage of chemoradiotherapy over chemotherapy was not 
demonstrated33. 
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In 2012, results from the Chemoradiotherapy for Oesophageal Cancer Followed by 
Surgery Study (CROSS) were published, demonstrating that chemoradiotherapy 
improved median survival (49.4 months vs. 24.0 months) among patients with 
potentially curable oesophageal or oesophago-gastric junctional cancer34. The regimes 
used in this study form the basis of current neoadjuvant chemoradiotherapy regimes in 
many specialist units in the UK. 
 
Stahl et al compared preoperative chemotherapy with preoperative chemoradiotherapy 
in 119 patients with adenocarcinoma of the oesophagus or gastric cardia35. The 3-year 
survival was 27.7% in the chemotherapy group compared to 47.4% in the 
chemoradiotherapy group, however, this difference was insignificant, possibly because 
the study closed early due to low accrual. 
Adjuvant therapy 
Most studies investigating the use of postoperative chemotherapy have used it together 
with pre-operative chemotherapy in a ‘peri-operative’ regime which makes it impossible 
to measure its individual impact25, 36. Only 32%-40% patients in these studies completed 
the postoperative phases, which highlights one of the main disadvantages of adjuvant 
therapy. 
Although there may be a role for postoperative radiotherapy in advanced squamous cell 
carcinoma, the evidence in support of its use in adenocarcinoma is not so clear. 
Evidence - Gastric cancer 
Chemotherapy 
Rather than downsizing primary tumours to facilitate greater R0 resection rates (as with 
oesophageal cancer) the goal of chemotherapy in gastric cancer has tended to focus on 
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reducing local/regional recurrence. Treatment has therefore concentrated on adjuvant 
and ‘peri-operative treatments’. The best evidence to date comes from the MAGIC trial 
mentioned in the oesophageal section above25. It included 372 patients randomised to 
have either peri-operative chemotherapy and surgery or surgery alone. The 
combination regime of epirubicin, cisplatin and fluorouracil (ECF) decreased tumour size 
and stage and significantly improved progression-free survival (hazard ratio for 
progression, 0.66; 95% confidence interval, 0.53-0.81; P<0.001) and overall survival 
(hazard ratio for death, 0.75; 05% confidence interval 0.60-0.93; P=0.009; five-year 
survival rate 36% vs 23%). This paper has radically changed the standard treatment of 
gastric cancer and pre-operative chemotherapy is now the standard of care for any 
tumours more advanced than T2N0 on initial staging. Post-operative chemotherapy 
tends to be considered after recovery from surgery depending on individual pathological 
and patient factors. 
Intraperitoneal chemotherapy has been used in an effort to reduce peritoneal and 
hepatic recurrence, particularly in Japan although there are concerns over toxicity and 
overall or recurrence-free survival have not been proven. 
Chemoradiotherapy 
In an effort to reduce local recurrence and improve survival, postoperative 
chemoradiotherapy has been used. The most significant trial in the area is the American 
Intergroup 0116 study37. It randomised patients to receiving adjuvant 
chemoradiotherapy or not and showed improvements in disease-free (49% vs 32%) and 
overall (52% vs 41%) survival, however, it has been criticised for poor radiotherapy 
technique, chemotherapy toxicity and less than adequate surgery with a D0 resection 
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rate as high as 54%. Survival in the surgery alone arm was surprisingly poor at 41%. As a 
result, postoperative radiotherapy has not been widely adopted. 
Guidelines for neoadjuvant chemotherapy/chemoradiotherapy 
When appraising the evidence for chemotherapy/chemoradiotherapy treatment, it 
must be remembered that patients with oesophago-gastric cancer are a heterogeneous 
group.  In particular the cancer subtypes (adenocarcinoma, squamous carcinoma etc.) 
behave differently in relation to chemotherapy. Likewise, the effectiveness of 
chemotherapy is dependent on anatomical tumour location38. Whilst most reports 
separate gastric and oesophageal cancer types, there is evidence to suggest that the 
three subtypes of gastro-oesophageal junction adenocarcinomas (types I, II and III) have 
different aetiologies, pathogeneses and natural histories and may therefore respond 
differently to chemotherapy38. Before the introduction of the latest version of the TNM 
staging system (7th edition in 2010) many junctional cancers now staged with the 
oesophageal classification would have been staged as gastric cancers. In studies using 
different staging systems it can be difficult to compare individual studies or combine 
results in a meta-analysis. 
There have been a number of important guidelines produced covering the management 
of oesophageal and gastric cancers in recent years.  The Scottish International Guidelines 
Network (SIGN) produced a national clinical guideline in 200639.  Following this, in 2011, 
guidelines produced on behalf of AUGIS, BSG and BASO were published in Gut12. 
Oesophageal cancer 
The 2006 SIGN guidelines suggest that patients with operable oesophageal cancer who 
are treated surgically should be considered for two cycles of preoperative chemotherapy 
with cisplatin and 5-flourouracil or offered entry into a clinical trial39. Preoperative 
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chemoradiotherapy was not recommended outside clinical trials and preoperative 
radiotherapy was not recommended. There is a role for chemoradiotherapy when 
surgery is not being considered. Postoperatively, neither chemotherapy nor 
chemoradiotherapy was recommended. Radiotherapy could be considered in those with 
a high risk of local recurrence but there was not sufficient evidence to for a 
recommendation. The guidelines were designed to be applicable to both squamous cell 
and adenocarcinoma subtypes. 
The AUGIS/BSG/BASO guidelines (2011) state that chemoradiation is the definitive 
treatment of choice in patients with localised squamous carcinomas of the proximal 
oesophagus12. Squamous tumours of the middle and lower oesophagus can be treated 
with chemoradiation alone or a combination of chemoradiation and surgery. In the 
treatment of adenocarcinoma, there is Grade IA evidence for preoperative 
chemoradiotherapy improving long-term survival over surgery alone. Similarly, 
chemotherapy using cisplatin and 5-flourouracil improves long-term survival over 
surgery alone12. Combined preoperative and postoperative (perioperative) 
chemotherapy is the preferred option for oesophago-gastric junctional types II and III 
adenocarcinoma12. 
Gastric cancer 
The 2006 guidelines suggested there is no evidence for the use of chemotherapy or 
radiotherapy preoperatively or postoperatively for patients with gastric cancer outside 
a clinical trial39. 
The 2011 guidelines differ from the above significantly; suggesting that perioperative 
chemotherapy should be the standard of care in patients with gastric adenocarcinoma12. 
Postoperative chemotherapy should be considered in patients at a high risk of 
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recurrence who have not received preoperative chemotherapy.  Chemoradiotherapy is 
an alternative in this group of patients. 
There are no guidelines supporting the use of intraperitoneal chemotherapy which 
remains experimental. 
Current chemotherapy practice 
In practice, most centres in the UK including ours adopt a policy based on individual 
patients’ comorbidity and disease staging. Patients with oesophageal cancer and disease 
equal to or more advanced than T2N0 are considered for neoadjuvant therapy. As a 
result, the majority of patients with oesophageal and gastric cancer are now being 
offered neoadjuvant therapy because the majority present with advanced disease. In 
the UK, neoadjuvant chemotherapy rather than chemoradiotherapy tends to be the 
standard of care. Chemoradiotherapy has been more popular in the United States but is 
being increasingly used in this country. Of those patients not undergoing neoadjuvant 
therapy, 7-9% patients receive chemotherapy/radiotherapy after surgery5. Moreover, 
the proportion of patients receiving chemotherapy is increasing both in those 
undergoing surgical resection and those not5. This trend is seen in oesophageal, gastric 
and junctional cancer types. 
Limitations of current chemotherapy regimes 
Resistance & Response rates 
Resistance to chemotherapy is a common problem. A complete histological response is 
achieved in only 0-12.5% (typically less than 6%) in patients receiving neoadjuvant 
chemotherapy40-43. Partial response rates are typically reported at 11-12%36, 40, 44. 
Complete response rates with chemoradiotherapy are somewhat higher, typically 
reported between 17 and 29%45-48. 
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Patients who do not respond to neoadjuvant therapy will have an unnecessary delay to 
surgery whist undergoing ineffective and potentially toxic chemotherapy which may be 
associated with poorer outcomes26, 36. In oesophageal squamous cell carcinoma for 
instance, it has been suggested that only complete pathological responders to 
neoadjuvant chemotherapy benefit from such additional treatment41. 
Current guidelines for multimodality therapy are based on studies reporting survival 
overall without considering whether outcomes differ according to how patients have 
responded to neoadjuvant therapy. 
If it can be demonstrated that outcome depends on the degree of response to 
neoadjuvant therapy, this raises the important question of whether we can predict 
which patients will benefit from neoadjuvant chemotherapy/chemoradiotherapy at any 
stage during the treatment process and a number of authors have recognised that this 
should be the focus of more research38, 44, 49-58 (see Figure 14). Recently this issue has 
received attention in the national press59. Predicting the response to therapy may 
enable clinicians to tailor treatment individually. This important issue is addressed in 
detail in the remainder of this thesis. 
There are numerous methods of measuring response to 
chemotherapy/chemoradiotherapy but no universally agreed definition. It is essential 
to understand what defines a response when analysing outcomes in this way or when 
investigating prediction of response. This merits further discussion and is detailed in 
Chapter 3. 
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Figure 14 Authors declaring a need for further research into finding a means of predicting the response to 
neoadjuvant therapy. 
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Toxicity 
The Cochrane review on preoperative chemotherapy for resectable thoracic 
oesophageal cancer reviewed the chemotherapy associated toxicity amongst the 12 
studies containing 2097 patients29. Not all studies reported the toxicity and those that 
did varied in the range of toxicities defined. However, overall toxicity was reported 
between 11% and 90%. Preoperative deaths in the chemotherapy arm ranged between 
0% and 9%. Preoperative deaths in the surgery only arm ranged from 0.5% to 2% (2 
studies), however this cannot be compared to the chemotherapy deaths since the 
timeframe to surgery is much longer in the chemotherapy group. A number of 
gastrointestinal complications were reported in the chemotherapy group including 
nausea and vomiting but comparison with the surgery-alone group was not possible due 
to heterogeneity. 
Therapeutic index 
In addition to the specific problem of resistance, any chemotherapy treatment is limited 
by its maximal clinical effectiveness and its adverse effects, together determining the 
therapeutic index. The investigation of novel chemotherapy targets for chemotherapy 
is an important area of on-going research with the intention of developing newer agents 
that may have a wider therapeutic index. The UK MRC ST03 trial will evaluate whether 
the addition of the bevacizumab to peri-operative ECX is associated with improved 
survival in oesophago-gastric adenocarcinoma. The REAL 3 trial looked to investigate the 
addition of the anti-EGFR monoclonal antibody, panitumumab to EOX treatment but 
was stopped early due to inferior outcomes in the experimental arm which highlights 
the difficulties encountered in the development of new therapeutic agents. 
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CHAPTER 2 – AIMS & OBJECTIVES 
The survival in oesophago-gastric cancer is poor but may be improved by the use of 
multimodality therapy. Neoadjuvant treatment agents are limited by a relatively narrow 
therapeutic index. The toxic effects of such treatment can be significant and are 
particularly important in patients who fail to respond to therapy. Reported rates of 
response to neoadjuvant therapy are poor and there is no agreed definition of response. 
Aim 1 
 To review the toxicity associated with neoadjuvant therapy in patients with 
potentially curable oesophago-gastric cancer treated with neoadjuvant therapy 
at the Peninsula Oesophago-gastric Surgery Unit. The efficacy of neoadjuvant 
therapy with respect to therapeutic response and disease stage will be analysed. 
Methods of measuring response to neoadjuvant therapy will be discussed and a 
revised definition of response will be defined from the regional population. 
Multi-modality treatments are thought to have a beneficial role in more advanced 
stages of disease. Pre-treatment clinical staging is used to determine the need for 
multimodality therapies; however, staging modalities have several limitations. The 
staging thresholds beyond which treatments become effective are not known.  Poor 
accuracy of radiological staging methods may mean that the wrong patients are being 
stratified for additional therapy. In the context of multiple imaging modalities, often 
individual investigations do not influence clinical management. Multiple staging 
investigations may introduce a delay in initiating potentially curative treatments. 
Aim 2 
 To investigate accuracy of imaging modalities used to determine pre-therapy 
disease stage and to seek whether the staging pathway could be streamlined by 
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limiting the use of certain modalities to those patients in whom management is 
likely to be altered. 
The problems of poor response rates to therapy can be tackled in a number of ways. 
Newer additional agents may offer a solution but recent evidence suggests that we may 
have reached a therapeutic plateau with the risks of additional treatment outweighing 
any potential benefit. 
Successful prediction of an individual patient’s response to therapy would enable 
personalised treatment. The relatively recent discovery of multiple genetic markers in 
oesophago-gastric cancers has helped us to appreciate the importance of individual 
tumour biology. This provides an explanation for the observation that individual 
tumours can behave differently and supports the development of personalised 
treatment strategies.  
Aim 3 
 To review the published literature on methods of predicting response to 
neoadjuvant therapy. 
Aim 4 
 To investigate the potential of a number of circulating biomarkers in predicting 
response to neoadjuvant therapy. 
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CHAPTER 3 – NEOADJUVANT THERAPY: EFFICACY, 
TOXICITY AND DEFINING RESPONSE 
Introduction 
Background 
Early studies investigating the potential benefits of neoadjuvant therapy showed 
conflicting results and it took many years before a survival advantage was demonstrated 
in randomised trials25, 27. This evidence is reflected in recent national guidelines 
supporting the use of neoadjuvant therapy (or perioperative therapy) in oesophago-
gastric cancer which has now been adopted into routine practice25, 28, 29, 32-34, 41. 
Not only has an overall benefit taken some time to establish but the gains associated 
with neoadjuvant therapy are modest with many patients developing progressive 
disease despite treatment. These factors may be explained by low response rates and 
therapy-associated toxicity. 
It can be difficult to know which of our patients are benefitting from this additional 
treatment. It has been suggested that only patients with a complete pathological 
response to therapy will benefit41. However, other factors such as tumour stage may 
also determine whether or not patients stand to gain any advantage. For instance, 
patients with early tumours without lymph node involvement are known to have good 
outcomes with surgery alone. Therefore, more advanced tumours may have more to 
gain from the addition of chemotherapy. Add to this the potential toxic effects of 
chemotherapy and it is easy to see why neoadjuvant therapy is often not given in early 
tumours. 
The MAGIC trial included patients with adenocarcinomas of the lower oesophagus, 
oesophago-gastric junction and stomach. It demonstrated 5-year-survival of 36% in 
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patients undergoing perioperative chemotherapy compared to 23% in those undergoing 
surgery only25. Patients with stage II disease or higher were included, which amounts to 
any tumours staged equal to or more advanced than T3 or N1, except that gastric T1N1 
cancer is considered stage I and oesophageal T2N0 tumours are considered stage II if 
poorly differentiated. In contrast, the Intergroup study did not show any survival 
advantage associated with preoperative chemotherapy and included some patients with 
stage I disease36. It may be that patients with more advanced disease gained some 
benefit but this was negated by a lack of benefit and/or toxic effects in patients with 
early stage disease. 
It is not known exactly what constitutes an early tumour and how this should be best 
determined. The latter is a matter of pre-operative staging which is subject to debate 
regarding accuracy and usefulness of different modalities. Chapter 4 further investigates 
which patients have the potential to benefit from the additional staging information 
provided by staging laparoscopy and PET-CT. CT is the only staging investigation whose 
benefit has not recently been questioned and is used routinely. Although other 
modalities may provide information that can modify preoperative staging to a degree, 
accuracy is critical when this information is used to make decisions on neoadjuvant 
therapy use. 
Questions raised 
The issues above have raised important questions that need addressing. Firstly, there 
are numerous ways of measuring response to neoadjuvant therapy but no established 
definition of what constitutes an adequate or beneficial response. 
Accurately defining response would give prognostic information, would inform decisions 
on adjuvant therapy, and if adopted widely, could help to standardise reporting in the 
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scientific literature. If a means to predict response is identified in order to provide 
personalised treatment then it will be essential to have a robust and standardised 
definition of response. 
Whichever methods are used to define response, they must be associated with 
improved survival in order to be clinically useful and these methods must reflect a true 
measure of neoadjuvant therapy response rather than simply acting as prognostic 
indicators or they will not influence neoadjuvant therapy decision making. 
The fate of patients who do not respond to neoadjuvant treatment is unknown although 
anecdotally, patients developing progressive disease on therapy seem to have poor 
outcomes. 
Clinical staging is an important aspect of neoadjuvant treatment for two reasons. Firstly, 
the decision whether or not to treat with neoadjuvant therapy is partly based on 
preoperative staging. Secondly, radiological staging is used as a means of measuring and 
defining response to neoadjuvant therapy. Therefore, clinical staging accuracy is of 
critical importance in multimodality therapy. 
Accuracy and usefulness of staging modalities aside, the relationship between stage of 
tumour and efficacy of neoadjuvant therapy is not known. Finally, any perceived benefit 
of therapy must be weighed against its toxic effects. Neoadjuvant therapy adverse 
events are therefore worthy of further discussion. 
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Chapter aims 
This chapter aims to redefine response to neoadjuvant therapy. It aims to describe the 
incidence and significance of neoadjuvant therapy-associated toxicity. It also aims to 
examine the efficacy of neoadjuvant therapy with respect to disease stage. 
Chapter overview 
A clinical review of the available methods used to define response to neoadjuvant 
therapy will be reported with particular attention paid to those methods that have been 
validated by association with survival outcomes. 
A hypothesis describing the most appropriate method for defining response to 
neoadjuvant therapy in patients with oesophago-gastric cancer will be proposed. 
The proposed definition of response will be applied in a survival analysis of a 
retrospective patient cohort. 
The accuracy of clinical staging will be investigated in a retrospective patient cohort to 
identify whether aspects of staging are valid for use in defining response. The hypothesis 
will be modified accordingly. 
The incidence and significance of neoadjuvant therapy-associated adverse events will 
be investigated in our patient cohort. 
The efficacy of neoadjuvant therapy with respect to disease stage and response to 
neoadjuvant therapy will be investigated using an analysis of survival.  
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Measuring response to neoadjuvant therapy: clinical review 
Why do we measure response to chemotherapy/radiotherapy? 
In the palliative setting, response to chemotherapy/radiotherapy is used to gauge 
efficacy of treatment and plan further treatment. Since there is usually no surgical 
resection, information on histopathological regression is lacking and response is 
therefore measured by clinical or radiological means. In the neoadjuvant setting, 
response after therapy is used to inform prognosis and is important in restaging, to rule 
out progressive disease that may deem a patient inoperable. It is also used after surgery 
with the benefit of histological measures of response when it can help in deciding 
whether or not to offer adjuvant chemotherapy and which agents to use. 
How is response to chemotherapy/chemoradiotherapy measured? 
In the clinical and radiological measures described here, accuracy in defining response 
to treatment is often compared to the postoperative histological response which 
although has its own limitations (discussed below), is considered the standard by which 
other tools should be compared. 
Clinical measures 
Forshaw et al investigated whether changes in dysphagia and weight correlated with 
radiological and pathological assessment of response and clinical decision making in 
patients with locally advanced oesophago-gastric cancer60. Although swallowing was 
improved in radiological responders, there was no association between pathological 
response and either swallowing or changes in body weight. A separate study showed 
that resolution of symptoms in patients undergoing neoadjuvant chemoradiotherapy 
for oesophageal cancer does not accurately correlate with pathologic response46. 
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Endoscopic measures 
Endoscopic assessment after neoadjuvant chemotherapy is not considered reliable for 
assessing the response largely because it cannot determine whether residual bulk is due 
to oedema, scarring or residual tumour51. Likewise, after chemoradiotherapy, 
endoscopic appearance was not able to accurately identify responders46. Biopsies can 
be taken but a negative result cannot be taken to indicate no residual tumour.  
Radiological measures 
Radiological measures are commonly used to assess the response to 
chemotherapy/chemoradiotherapy particularly in the palliative setting and after 
neoadjuvant therapy, prior to proceeding with resection. The classification proposed by 
the World Health Organisation (WHO) in 1981 for reporting results of cancer treatment 
is widely used to define clinical response61. A reduction in the tumour size of 50% when 
measured in two perpendicular diameters is considered a partial response. A working 
group set up by the National Cancer Institute of the United States, the National Cancer 
Institute of Canada and the European Organisation for Research and Treatment of 
Cancer revised this classification with a new system in 2000 known as the Response 
Evaluation Criteria in Solid Tumours (RECIST) guidelines. This proposed that a partial 
response should be defined by a decrease in the maximal tumour diameter of 30% 
rather than using bi-dimensional measurements62. Progressive disease is defined by a 
20% increase in maximal diameter and a complete response is marked by the 
disappearance of all target lesions. When using RECIST criteria, CT is the only valid 
assessment modality in oesophageal cancer (see below). 
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Barium oesophagram 
A barium oesophagram (barium swallow) can be performed before chemotherapy and 
after chemotherapy. Response can be measured according to set criteria for complete 
and partial radiographic response36. In the USA Intergroup 113 study 7% patients were 
considered as complete responders and 19% as partial responders. Survival was greater 
in responders with a hazard ratio of 2.83, 95% confidence interval 1.84-4.35, P0.000136. 
This result was seen as very significant because initial results of the trial had shown no 
overall survival benefit for patients undergoing neoadjuvant chemotherapy. However, 
this is not a widely used technique for measuring response and similar findings have not 
been demonstrated elsewhere. 
Endoscopic ultrasound (EUS) 
In a systematic review of CT, EUS and PET in the assessment of response to neoadjuvant 
therapy in oesophageal cancer, EUS was shown to have better accuracy than CT (85% vs 
54%)58. However, EUS was not feasible in 6% patients and in many centres it is only used 
selectively. As with endoscopy, EUS is unable to distinguish between oedema, fibrosis 
and residual tumour51. 
CT Scanning 
CT scanning has been used to assess response to therapy, usually alongside the WHO 
classification of clinical response and related updated guidelines (RECIST)61, 62 . However, 
the decrease in tumour size is a late event and fibrotic or necrotic tissue does not 
accurately reflect viable tumour tissue38, 58. In the systematic review by Westerterp, 
sensitivity of CT was between 33% and 55% and specificity was between 50% and 71%58. 
Accuracy of CT was significantly lower than that of EUS (P<0.003) or PET (P<0.006). 
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Griffith et al used CT to assess response to therapy in patients with squamous cell cancer 
of the oesophagus and found no correlation between tumour volume reduction at serial 
CT scan and pathological response or survival63. 
A recent study investigating the accuracy of 64-slice MDCT in restaging of oesophageal 
cancer after neoadjuvant chemotherapy demonstrated that prediction of complete 
histopathological response was poor with 80% patients over-staged64. They concluded 
that assessing response using CT has not improved with the use of MDCT compared to 
older generation CT. 
CT perfusion and the new area of radiomics may increase the potential for predictive 
information from CT, however, this is an area requiring further evaluation before any 
clinical utility can be established65-67. 
A combination of tumour size and density according to CT has been used to devise the 
Choi criteria described for use in gastrointestinal stromal tumours (GISTs)68. It can 
identify a subgroup of apparent non-responders according to the RECIST criteria that 
have decreased tumour density and improved survival. The system has not been 
validated in adenocarcinoma or squamous cell carcinoma. 
MRI 
Magnetic resonance imaging (MRI) is rarely used in the staging and assessment of 
oesophageal tumours although it is a modality of interest in current research. As yet 
there is no evidence available on its role in measuring response to therapy although as 
with CT, the new area of MRI radiomics is being investigated. 
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PET scanning 
PET scanning with fluorodeoxyglucose (FDG) gives a measure of the metabolic activity 
of tissues. Tumour tissues are more metabolically active than non-tumour tissues and 
take up more radio-labelled glucose therefore give a higher metabolic signal. A 
successful response to chemotherapy may be associated with a decrease in the 
standardised uptake value (SUV) of the tumour or involved lymph nodes even when 
there is no appreciable decrease in bulk on CT. For this reason, the use of PET assessing 
response has been extensively investigated. However, when compared to histological 
examination, PET has limitations. Complete metabolic response is not uniformly 
predictive of a pathologic response69. In one study, 59% patients with a complete 
metabolic response on PET, had residual disease on histopathological examination of 
the resected specimen69. A systematic review showed that PET was more accurate than 
CT in evaluating response when using pathological regression as the reference standard 
(P<0.006)58. Sensitivities ranged from 71% to 100% and specificities ranged from 55% to 
100%. 
Brucher et al reviewed 13 studies investigating the FDG–PET in assessment of response 
to neoadjuvant therapy in patients with oesophageal cancer51. Most studies 
demonstrated some association between PET-avidity and histological response. 10 
studies reported the relationship to survival and of these, 8 demonstrated a significant 
association. The authors of this review point out that studies differ with respect to the 
PET variables used to measure response (maximum SUV, change from baseline SUV, 
mean SUV) all of which can have different thresholds, which makes studies difficult to 
compare and consensus statements are difficult to generate. Whilst PET therefore 
demonstrates some association with histological response and survival, further studies 
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would benefit from standardisation of how accuracy is reported and which parameter is 
used to measure response. 
Updated RECIST guidelines published in 2009 acknowledge the potential of moving from 
the anatomic uni-dimensional assessment offered by CT to functional assessment using 
FDG-PET, however, in part due to the standardisation problems outlined above, they felt 
further clinical validation studies are required70. Likewise, new approach of volumetric 
assessment has been recognised but requires further validation70. 
Histopathological response 
Whilst clinical and radiological features have been used, the methods of measuring 
response to neoadjuvant therapy with the greatest prognostic value and most widely 
used are pathological38, 40, 51. There are a variety of histological measures used which 
involve examining the resected primary tumour or lymph nodes and measuring changes 
in size71, 72, residual tumour cells40, 73-75, fibrosis40, 73, 74, stage (e.g. T,N)44, 76-78, other 
morphological features79, 80 or a combination of the above. Of these, measurement of 
histological regression based on the degree of residual tumour cells and fibrosis have 
shown the most promise and there a number of systems described in the literature that 
use this approach. 
The Mandard scoring system was described in 1994 and was designed to classify the 
response to neoadjuvant chemoradiotherapy in patients with oesophageal cancer into 
one of five grades according to the relative proportions of residual tumour cells and 
fibrosis74 (see Figure 15). Tumour response grade (TRG) 1 is considered a complete 
response and TRG2 is considered a near-complete response40. It is standard practice in 
prognostic scoring to consider all patients with no or minimal residual tumour cells as 
responders (TRG 1 and TRG 2)40, 42, 44 . TRG 4-5 are considered as non-responders40. 
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There is some debate regarding the fate of TRG 3 patients, some authors classing them 
as responders76 and others as non-responders44. 
Grade Description 
TRG 1 Absence of residual cancer, fibrosis extending through different areas 
of oesophageal wall 
TRG 2 Rare residual cancer cells scattered through fibrosis 
TRG 3 Increase in number of residual cancer cells but fibrosis still 
predominant 
TRG 4 Residual cancer outgrowing fibrosis 
TRG 5 Absence of regressive changes 
Figure 15 Mandard scoring system for response to neoadjuvant chemoradiotherapy in oesophageal cancers. 
Tumour Regression Grade (TRG). 
In 1994, Ninomiya et al described a system for assessing response to chemotherapy in 
patients with gastric cancer based on the degree of tumour necrosis81 (Figure 16). 
Grade Description 
Grade 0 No change  neither necrosis nor cellular or structural change can be 
seen throughout the lesion 
Grade 1a Necrosis or disappearance of the tumour is present in less than 1/3 of 
the whole lesion 
Grade 1b Necrosis or disappearance of the tumour is present in no more than 
2/3 of the whole lesion 
Grade 2 Moderate change  necrosis or disappearance of the tumour is present 
in more than 2/3 of the whole lesion, but viable tumour cells remain 
Grade 3 Marked change  the whole lesion falls into necrosis and/or is replaced 
by fibrosis, with or without granulomatous changes. No viable tumour 
cells 
Figure 16 Ninomiya scoring system for histological response to neoadjuvant chemotherapy in gastric cancers 
In 2003, Becker et al described a system based on the proportion of viable tumour cells 
for assessing response in patients undergoing chemotherapy for gastric cancer (Figure 
17). It classifies patients into four grades that can be roughly matched to Mandard 
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grades: Grade 1A equating to TRG1 (complete response), Grade 1B roughly equivalent 
to TRG2 (near complete response), Grade 2 encompasses both TRG grades 3 and 4 
(partial/minimal response) and Grade 3 is equivalent to TRG5 (no response). 
Grade Description 
1A No residual tumour/tumour bed 
1B 10% tumour cells 
2 10-50% residual tumour/tumour bed 
3 50% no signs of neoplastic regression 
Figure 17 Becker scoring system for histological response to neoadjuvant chemotherapy in gastric cancers. 
The Japanese Society for Esophageal Diseases devised a set of response evaluation 
criteria on a scale of 0 to 3 indicating increasing effectiveness based on the proportion 
of viable cancer cells82. 
Grade Description 
0 no recognizable cytologic or histologic therapeutic effect 
1 slightly effective with apparently viable cancer cells accounting for 
one-third or more of the tumor tissue 
2 moderately effective with viable cancer cells accounting for less than 
one-third of the tumor tissue 
3 markedly effective, with no evident viable cancer cells 
(pathologic complete response, or pCR). 
Figure 18 Japan Esophageal Society scoring system for response to chemoradiotherapy in oesophageal cancer. 
When examining the literature on the relationship between histopathological response 
to neoadjuvant therapy and survival (below), for clarity, chemoradiotherapy and 
chemotherapy are considered separately as historically they have been used in different 
patient groups and have utilised different regression scoring systems. 
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Histopathological response to neoadjuvant chemoradiotherapy in oesophageal cancer 
In the case of chemoradiotherapy, the goal is usually considered to be complete 
pathological response and as such the particular type of regression/scoring system used 
is often of minimal consequence since a complete response is easily defined and 
comparable across scoring systems. Pathological complete response rates to 
neoadjuvant radiotherapy in oesophageal cancer are reported between 15% and 40%42, 
43, 45-48, 78. Rohatgi et al demonstrated that patients with a complete pathological 
response (29%) had longer median overall survival (133 months vs. 34 months, P=0.002) 
and disease-free survival (P=0.001) compared to those without a complete pathological 
response48. Hermann et al also showed that only patients with a complete pathological 
response defined as TRG 1 (17%) had longer overall survival (P=0.0008)43. A separate 
study investigating survival in 171 patients with oesophageal cancer demonstrated that 
complete response to preoperative chemoradiotherapy (35%) is associated with 
significantly improved survival42. Whether there is any benefit of neoadjuvant 
chemoradiotherapy to the majority of patients who do not achieve a complete response 
is not so clear. One study was able to demonstrate that a partial or complete response 
to chemoradiotherapy is associated with improved survival83. 
Histopathological response to neoadjuvant chemotherapy in oesophago-gastric 
cancer 
Compared to chemoradiotherapy, even fewer patients respond to neoadjuvant 
chemotherapy with rates of complete response reported at 0-13%40, 41, 44, 78 and rates of 
complete/near-complete response of 11-27%36, 40, 44. In the case of chemotherapy, lower 
rates of complete response mean that there is perhaps more attention paid to near-
complete/partial response and arguably, therefore, the choice of regression score used 
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becomes more important than after chemoradiotherapy where the focus is on complete 
response, which is simpler to define. 
In 2001, a randomised, controlled trial of preoperative chemotherapy (47 patients) 
versus surgery alone (47 patients) for resectable oesophageal squamous cell carcinoma 
showed that only pathological complete response to neoadjuvant chemotherapy 
improves significantly the long term survival41. 5-year survival was 60% in responders, 
which was significantly better than in non-responders (12%, P=0.0002) and in those 
undergoing surgery alone (26%, P=0.01). 
In a study of 66 patients with gastric/gastro-oesophageal junction adenocarcinoma 
undergoing neoadjuvant chemotherapy according to the MAGIC protocol, Mirza et al 
investigated the usefulness of the three main histopathological scoring systems 
described above40. Both the Mandard74 and Becker84 systems yielded prognostic 
information with acceptable inter-observer agreement whereas the Ninomiya81 system 
did not. In fact, although the Mandard system has 5 grades compared to the Becker 
system’s 4 grades, when patients were classified as either responders or non-
responders, outcomes were very similar. Of the 66 patients in total, The Mandard 
system identified 12 responders compared to the 11 using the Becker system. Using the 
Mandard system, 5-year overall survival was 100% for responders (TRG 1&2, 12% of 
total) and 35% for non-responders (TRG 3-5), P=0.035. There were similar findings using 
the Becker system with a 5-year survival of 100% for responders (Grades 1A and 1B, 11% 
of total) and 34% for non-responders. This study to some extent validates the Mandard 
score for measuring response to chemotherapy in gastric adenocarcinoma when 
considering the system was first described in relation to chemoradiotherapy for 
squamous cell carcinoma of the oesophagus74. 
61 
 
A recent study from Southampton in patients with oesophageal and gastro-oesophageal 
junction adenocarcinoma receiving neoadjuvant chemotherapy showed patients with a 
complete or near-complete response to chemotherapy (TRG 1&2) had a significant 
survival advantage compared to non-responders (TRG 3-5). Mean disease-free survival 
(DFS) in the TRG 1-2 group was 5.1 years and in the TRG 3-5 group was 2.8 years, P < 
0.000144. The effect of lymph node down-staging was also investigated in this study and 
is discussed below. 
The prognostic value and resulting widespread use of histological regression scoring 
systems mean that they are considered the gold standard, to which all other methods 
of measuring response are compared.  
Limitations of histopathological regression 
Unlike the radiological assessments above, histological regression depends on having a 
surgical resection for examination and can therefore only be used postoperatively. 
Whilst the relative proportions of viable tumour cells and areas of regression/fibrosis 
used in the systems above are valid means to assess response, these systems have 
limitations. Firstly, microscopic regression often displays heterogeneity within a tumour 
with some areas appearing as predominantly fibrosis with other areas of tumour not 
displaying any signs of regression. This system does not take into account any change in 
stage according to tumour depth which is frequently observed by histopathologists and 
is not necessarily matched by a proportional degree of regression. These systems also 
do not take account of any regression or down-staging in lymph nodes which is also 
frequently observed by histopathologists85. Lymph node stage is one of the most 
important prognostic indicators so down-staging as a result of neoadjuvant 
chemotherapy could reflect a clinically significant response. 
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The limitations above together with poor neoadjuvant therapy histological regression 
rates have led authors to seek other histological parameters which may identify a partial 
response and confer a survival advantage in patients otherwise considered non-
responders. 
Tumour (T) and Lymph node (N) stage response 
Staging according to tumour depth (T stage) is routinely recorded radiologically before 
starting anti-tumour therapy and after resection histologically. It is recognised that T 
stage can regress after neoadjuvant treatment, which together with the limitations of 
regression scoring above has prompted the suggestion that tumour (T) down-staging 
could be useful to define a response to therapy40, 84, 86.  
It has long been known that lymph node staging is an important and independent factor 
associated with poor prognosis. It has also been recognised that neoadjuvant therapy 
can downstage the nodal (N) status44, 85, 86. These observations have led to authors 
proposing that lymph node (N) down-staging may act as a measure of clinically 
significant response to chemotherapy44, 85. 
Korst et al evaluated the frequency of T and N down-staging after neoadjuvant 
chemotherapy in patients with oesophageal cancer and the relationship to survival78. 
Pre-treatment, clinical T and N stage were compared to post-resection, pathologic stage 
in the context of survival. Patients eliciting a down-staging of T or N (48%) had a 5-year 
survival of 63% compared with 23% for those who were not down-staged (p=0.002). 
In a retrospective non-randomised study comparing survival in patients receiving 
neoadjuvant therapy and surgery with that in patients having just surgery, only 
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responders had improved survival when defined by a down-staging of tumour or lymph 
node stage, or complete pathological response86. 
Noble et al assessed survival in 218 patients with adenocarcinoma of the oesophagus, 
136 of whom underwent neoadjuvant chemotherapy44. Histological non-responders 
(TRG3-5) were also subdivided according to whether they had evidence of lymph node 
down-staging (reduction in N stage between pre-chemotherapy radiological staging and 
postoperative N stage). Nodal down-staging was identified in 30% of non-responders 
and conferred a significant DFS advantage (mean DFS; TRG3-5 and nodal down-staging: 
5.5 years vs TRG3-5 and no nodal down-staging: 1.1 years, P < 0.0001). Therefore, a sub-
group of patients that would be classed as histological non-responders and therefore 
would be considered to have gained no benefit from chemotherapy demonstrate an 
improved prognosis if they have evidence of lymph node down-staging. 
Limitations of T and N down staging 
Both T and N down-staging rely on comparing pre-operative radiological staging with 
postoperative histological staging. A major criticism of this method is that apparent 
down-staging may simply reflect pre-operative over-staging. More specifically, there 
may be a tendency to over-stage earlier tumours. Over-staged tumours will appear to 
be down-staged and an observed survival benefit may be ascribed to the apparent 
down-staging when it is simply due to earlier disease stage. 
Noble et al have attempted to address this by comparing survival in patients with 
pathological N0 staging after chemotherapy with survival in patients undergoing surgery 
alone who had pathological N0 staging. Reduced disease free survival in the 
chemotherapy patients was found and used to indicate that pre-operative N stage must 
have been adequate. However, T-stage was also higher in the chemotherapy group 
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which would give rise to poorer survival. Furthermore 37.5% patients undergoing 
surgery alone had ‘nodal down-staging’ or rather must have been over-staged pre-
operatively. 
In the paper by Allan et al where T or N down-staging is shown to correlate with survival 
in patients undergoing neoadjuvant therapy, pre-operative T/N stage is not given in the 
results table and the ‘down-staging’ rate in the control group having surgery only is not 
reported which raises concern over the preoperative staging accuracy86. 
What is the outcome in non-responders compared to those undergoing surgery 
alone? 
The observation that non-responders have such a poor prognosis raises the question of 
whether there is any benefit at all in them receiving neoadjuvant therapy or even 
whether toxic effects and a delay to attempted resection outweigh any benefit and have 
an overall adverse effect on outcomes12, 28, 36, 41, 50, 56. 
The original results of the USA Intergroup 113 study failed to show any benefit from 
using neoadjuvant chemotherapy in patients with oesophageal cancer26. In the long-
term results the authors tried to identify a subset of patients that did benefit36. They 
classified patients according to chemotherapy response measured by barium swallow 
appearances and demonstrated improved overall survival in responders compared to 
non-responders and compared to those undergoing surgery alone. Therefore, it may be 
that overall the benefit in responders was negated by reduced survival in the non-
responders12. There was a trend towards poorer survival among non-responders 
compared to those randomised to surgery alone although this was not significant. 
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In a randomised controlled trial comparing surgery alone with preoperative 
chemotherapy, 5-year survival was 26% in those undergoing surgery alone, 60% in 
responders, and 12% in non-responders although there was no significant difference in 
the rates between the surgery only and non-responder groups41. 
A study in 84 patients undergoing neoadjuvant chemoradiotherapy for advanced 
oesophageal cancer demonstrated a trend towards poorer 2-year survival in non-
responders compared to those undergoing surgery alone (32% vs 54.3% P=0.06)87. 
Patients undergoing chemoradiotherapy were younger and had higher anatomically 
located tumours. Prognosis is known to be better in younger patients and those with 
upper oesophageal cancers which would have tended to increase the survival in the 
chemotherapy group although breakdown of demographics between responders and 
non-responders is not reported. 
In one study comparing survival in 63 neoadjuvant therapy non-responders with that in 
81 patients treated with primary oesophagectomy, overall survival and disease free 
survival were significantly poorer in the non-responders (P=0.024 and P<0.001 
respectively) within patients with stage 2 disease88. 
Summary of clinical review 
Whilst it is clear that patients responding to neoadjuvant 
chemotherapy/chemoradiotherapy gain a survival benefit from such therapy, it is also 
evident that those not responding, do not benefit from improved survival as a result of 
the additional treatment. 
Histopathological regression is still thought to be the most accurate method of assessing 
response to neoadjuvant therapy, it correlates well with survival and is likely to form the 
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basis of any method used to define response. The Mandard and Becker systems appear 
to be the most reliable. However, typical response rates are low and a proportion of 
non-responders defined by these methods may carry a survival benefit from therapy 
which could be considered a partial response. These patients may be identifiable from 
down-staging of the lymph node (N) or tumour (T) stage. If N of T down-staging is to be 
used in defining response, it is vital that we investigate pre-operative staging accuracy 
to ensure that there is no systematic over-staging which could lead to an apparent 
down-staging after therapy. In fact, the decision whether or not to offer neoadjuvant 
chemotherapy itself is determined largely by pre-operative staging, based on whichever 
staging modalities have been used and agreed by the MDT. Pre-operative staging 
accuracy is therefore fundamental to the rationale behind multimodality treatment. The 
next part of this chapter specifically addresses the accuracy of pre-operative staging by 
comparing pre-operative clinical/radiological staging with postoperative histological 
staging in a historic cohort of patients not undergoing neoadjuvant therapy. 
Hypothesis 
Based on the clinical review of methods used to measure and define response to 
neoadjuvant therapy, it can be hypothesised that responders could be defined as those 
with a histological regression according to either the Mandard or Becker systems. 
Tumour (T) and Lymph node (N) down-staging may also contribute to the definition if 
the pre-operative staging is reliable and they are associated with improved survival. 
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Cohort 
A historical cohort of patients was used for the following sections of this chapter: 
‘Clinical staging accuracy’, ‘Redefining response to neoadjuvant therapy’, ‘Neoadjuvant 
therapy toxicity’ and ‘Neoadjuvant therapy efficacy’. 
Patients 
Since January 2010, a database has been kept of all patients discussed in the MDT 
meetings at the Peninsula Oesophago-gastric Surgery Unit, Derriford Hospital, 
Plymouth. From this database, all patients planned to undergo surgical resection for 
malignant oesophago-gastric cancer and starting treatment between January 2010 and 
January 2015 were identified (i.e. patients undergoing radical chemoradiotherapy were 
not included). 
Data collection 
Data were collected on patients’ demographics, tumour characteristics, preoperative 
staging, neoadjuvant treatments, surgical treatment, adverse events, final outcomes 
and survival. Patients were divided according to prognostic stage groupings (e.g. 1, 2, 3, 
or 4) using the preoperative TNM staging data.  
Figure 19 shows the 587 patients identified from the database.  All patients were started 
on a curative treatment pathway for oesophago-gastric cancer that included intention 
for surgical resection. Mean age was 66.7 years and 73.9% were male. 64.1% underwent 
neoadjuvant therapy. Patient demographics, tumour characteristics, staging and 
neoadjuvant treatment details are shown in Table 1 below. 
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Figure 19 All patients identified from the database with broad treatment categories and outcomes shown. 
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Patient characteristics, n=587  
Demographics  
Age, in years; mean (range) 66.7 (25.4 to 87.9) 
Male; n (%)  434 (73.9) 
Tumour characteristics  
Histological type; n (%)  
Adenocarcinoma 518 (88.2) 
Squamous cell carcinoma 63 (10.7) 
Undifferentiated/other epithelial 6 (1.0) 
Anatomical tumour location; n (%)  
Upper third oesophagus 8 (1.4) 
Middle third oesophagus 21 (3.6) 
Lower third oesophagus 186 (31.7) 
Gastro-oesophageal junction 248 (42.2) 
Gastric 124 (21.1) 
Pre-operative staging  
Pre-operative T stage; n (%)  
≤T2 200 (34.1) 
T3 355 (60.5) 
T3/4 and T4 22 (3.7) 
Tx 10 (1.7) 
Pre-operative N stage; n (%)  
N0 316 (53.8) 
N1 216 (36.8) 
N2 54 (9.2) 
Nx 1 (0.2) 
Prognostic stage group (stage); n (%)  
0 15 (2.6) 
1 125 (21.3) 
2 230 (39.2) 
3 217 (37.0) 
Neoadjuvant therapy; n (%)  
Yes 376 (64.1) 
No 211 (35.9) 
Neoadjuvant regimen; n (%)  
CROSS 9 (2.4) 
CF/CX 57 (15.2) 
ECX/ECF/EOX/EOF 260 (69.1) 
ECarbo 1 (0.3) 
Carbo + paclitaxel/etoposide 3 (0.8) 
ECX+B 2 (0.5) 
OE05 3 (0.8) 
STO3 11 (2.9) 
missing 30 (8.0) 
Table 1 Patient cohort characteristics. 
Abbreviations: CROSS, as per the CROSS trial, carboplatin, paclitaxel and concurrent radiotherapy; CF, cisplatin and 
5-flourouracil; CX, Cisplatin and capecitabine, ECX, epirubicin, cisplatin, capecitabine; ECF, epirubicin, cisplatin, 
capecitabine; EOX, epirubicin, oxaliplatin, capecitabine; EOF, epirubicin, oxaliplatin, 5-flourouracil; ECarbo, 
epirubicin and carboplatin; ECX+B, ECX and bevacizumab; OEO5, as per the OEO5 study (ECX or CF); ST03, as per 
the ST03 study (ECX +/- bevacizumab). 
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Clinical staging accuracy 
Methods 
Patients 
To investigate staging accuracy, pre-operative staging according to CT, EUS, PET-CT and 
final pre-operative stage were compared to the postoperative histological staging in 
patients going straight to surgery (no neoadjuvant therapy). 
Staging protocol 
After histological confirmation of oesophago-gastric cancer via endoscopic biopsy, 
patients underwent staging with CT of thorax, abdomen and pelvis using 64-slice multi-
detector scanners using the same oesophago-gastric staging protocol (0.625-1.25mm 
slices, oral water as negative contrast and intravenous contrast with portal venous 
phase imaging). Staging was reported according to the AJCC 7th edition manuals for 
oesophageal and gastric cancer respectively (TNM staging). All CT scans were reviewed 
by at least one of three specialist upper gastrointestinal CT radiologists at a specialist 
MDT meeting. Oesophageal tumours were staged according to criteria similar to that 
described by Ba-Ssalamah et al89. Specifically, T2 tumours were characterised as having 
thickening of the oesophageal wall of less than 15mm with slight/mild stenosis and 
outer borders which are smooth or show stranding for less than one third of the tumour 
extension. T3 lesions were represented by thickening of greater than 15mm with mild 
to severe stenosis and marked stranding for over one third of the tumour extension or 
extensive blurring of the outer border. T4 lesions required invasion into adjacent 
structures such as pericardium, diaphragm, pleura, tracheobronchial tree or aorta. 
Gastric cancers were staged according to criteria similar to those described by Makino 
et al90. Tumours appearing as minimal thickening were staged as T2, those with more 
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demonstrable thickening of the stomach wall and a smooth outer layer with preserved 
perigastric fat plane were staged as T3 and those with a nodular/irregular outer border 
of the gastric wall or infiltration of the perigastric fat or adjacent structures were staged 
as T4. 
PET-CT was performed for N and M staging in oesophageal/gastro-oesophageal junction 
cancers with the potential for radical treatment and curative intent in accordance with 
current guidelines12. EUS was used in selected traversable oesophageal/gastro-
oesophageal junction tumours to further assess T and N stage which helped to 
determine resectability and the need for neoadjuvant therapy. 
Staging laparoscopy was performed in accordance with current guidelines to assess 
operability12. Specifically, laparoscopy was undertaken in all potentially resectable 
gastric cancers and lower oesophageal/gastro-oesophageal junction cancers with a 
component below the level of the diaphragm. 
US, EUS or Endobronchial ultrasound (EBUS) with Fine needle aspiration (FNA)/biopsy 
were used in selected cases where positive nodal involvement would change 
management. On the basis of all available staging modalities, the final pre-operative 
stage was then decided by the MDT and recorded on the database. 
Surgery 
Patients with resectable tumours who were still fit for operation underwent resection. 
Ivor-Lewis gastro-oesophagectomy was performed for lower oesophageal and gastro-
oesophageal junction tumours. Subtotal or total gastrectomy was performed for gastric 
tumours depending on site and extent of the tumour. Histopathological reporting 
followed the minimum dataset (minimum reporting detail) for oesophageal cancer in all 
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cases of oesophageal and gastro-oesophageal junction tumours and following the 
minimum dataset for gastric cancers in all gastric cancers. Routine histopathological 
reporting included recording the Mandard score (TRG) and pathological TNM staging 
according to the AJCC 6th or 7th Edition manual and was performed by a specialist 
gastrointestinal pathologist. 
Analysis 
Tables were used to present the data according to each staging modality. Over-staging 
was defined as recording a pre-operative stage (T or N) that was higher than the 
subsequent post-operative histological stage. Under-staging was defined similarly. For 
each staging modality, the percentage of patients over-staged or under-staged for each 
histopathological stage group was calculated. 
Patients were also divided into two groups depending on whether the post-operative 
histology was above the threshold for offering treating with neoadjuvant chemotherapy. 
All >T3 or >N0 tumours (locally advanced) were considered for such treatment whereas 
those with ≤T2, N0 tumours were generally not offered it. The accuracy of pre-operative 
staging was then analysed with respect to identification of patients with a stage above 
this threshold. 
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Results 
Patient characteristics 
Of the 587 patients who were identified from the database, 211 patients were planned 
to have surgical resection without neoadjuvant therapy. 7 patients were inoperable 
leaving 204 who were resected and are included in the analysis (Figure 19). Patient 
characteristics are shown in Table 2. Mean age was 69.9 years and 67.2% were male. 
The majority of patients were staged as T2 or less (64.7%) and the majority of patients 
were staged as N0 (82.8%). 
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Patient characteristics, n = 204  
Demographics  
Age, in years; mean (range) 69.9 (25.4 to 87.9) 
Male; n (%) 137 (67.2) 
Tumour characteristics  
Histological type; n (%)  
Adenocarcinoma 175 (85.8) 
Squamous cell carcinoma 25 (12.3) 
Other 4 (2.0) 
Anatomical tumour location; n (%)  
Upper third oesophagus 5 (2.5) 
Middle third oesophagus 6 (2.9) 
Lower third oesophagus 51 (25.0) 
Gastro-oesophageal junction 73 (35.8) 
Gastric 69 (33.8) 
Final (multimodality) pre-operative staging  
Pre-operative T stage; n (%)  
≤T2 132 (64.7) 
T3 58 (28.4) 
T3/4 and T4  4 (2.0) 
Tx 10 (4.9) 
Pre-operative N stage; n (%)  
N0 169 (82.8) 
N1 29 (14.2) 
N2 6 (2.9) 
Post-operative histology  
Post-operative T staging; n (%)  
≤T2 116 (56.9) 
pT3 66 (32.4) 
pT4 22 (10.8) 
Post-operative N stage; n (%)  
N0 112 (54.9) 
N1 50 (24.5) 
N2 23 (11.3) 
N3  19 (9.3) 
R0 vs. R1 resection; n (%)  
R0 149 (73.0) 
R1 39 (19.1) 
missing 16 (7.8) 
Table 2 Patient characteristics. Note: percentages may not sum to 100 due to rounding. 
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T staging 
CT staging (refer to Table 3) 
CT over-stages at least 10% of tumours pathologically staged as T1 or earlier. Patients 
staged as T1/2 on CT and ≤T1 pathologically were not considered as over-staged. CT 
over-stages 38.7% (12/31) T2 tumours. A high proportion of T3 and T4 tumours (60.7% 
(37/61) and 90.5% (19/21)) are under-staged. 
EUS staging (refer to table 4) 
65 patients underwent staging with EUS. Of 3 Tis (carcinoma in situ) lesions, 2 were over-
staged as T1. 48% (12/25) T1 lesions were over-staged and 14.3% (1/7) T2 lesions were 
over-staged. 61.9% (13/21) and 100% of T3 and T4 tumours were under-staged 
respectively. 
Best pre-operative staging (refer to table 5) 
Final pre-operative staging over-staged at least 41.7% (30/72) T1 (or earlier) tumours 
and 25.7% (9/35) T2 tumours. Overall, 22.7% (39/172) patients (T1-T3) were over-staged 
and 44.3% (54/122) patients (T2-T4) were under-staged. 53.8% (35/65) and 81.8% 
(18/22) of T3 and T4 tumours were under-staged respectively. 
 
 Pathological stage 
CT stage (n=204) ≤T1 T2 T3 T4 
≤T2 53 16 31 2 
T2 6 3 6 3 
T3 1 12 23 14 
T4 0 0 1 2 
Tx 20 5 5 1 
Totals 80 36 66  22 
Over-staged 11.7% 38.7% 1.6% 0% 
Correctly-staged 88.3% 61.3% 37.7% 9.5% 
Under-staged 0% 0% 60.7% 90.5% 
Table 3 Comparison of pre-operative T staging according to CT and post-operative pathological staging 
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 Pathological stage 
EUS stage (n=65) Tis T1 T2 T3 T4 
Tis/T0 1 2 0 0 0 
T1 2 11 0 1 0 
T2 0 10 6 12 1 
T3 0 2 1 8 1 
T4 0 0 0 0 0 
Tx 0 2 1 4 0 
Totals 3 27 8 25 2 
Over-staged 66.7% 48.0% 14.3% 0% 0% 
Correctly-staged 33.3% 44.0% 85.7% 38.1% 0% 
Under-staged 0% 8.0% 0% 61.9% 100% 
Table 4 Comparison of pre-operative T staging according to EUS and post-operative pathological staging 
 
 
 Pathological stage 
Pre-op staging 
(n=204) 
≤T1 T2 T3 T4 
Tis/T0/T1 34 1 2 0 
T1/2 8 6 8 0 
T2 26 19 25 3 
T3 4 9 30 15 
T4 0 0 0 4 
Tx 8 1 1 0 
Totals 80 36 66 22 
Over-staged 41.7% 25.7% 0% 0% 
Correctly-staged 58.3% 71.4 46.2% 18.2% 
Under-staged 0% 2.9% 53.8% 81.8% 
Table 5 Comparison of final pre-operative T staging and post-operative pathological staging 
N staging 
CT staging (refer to table 6) 
CT over-staged 9.3% (10/107) N0 patients. 1 N1 patient was over-staged and no N2 
patients were over-staged. Overall, a high proportion (87.8%; 79/90) of all node positive 
patients (N1, N2 or N3), were under-staged. 
EUS staging (refer to table 7) 
EUS over-staged 5.3% (2/38) N0 patients and 8.3% (1/12) N1 patients were over-staged. 
Overall 89.5% (17/19) patients with node positive disease were under-staged including 
all those with N2 or N3 disease. 
77 
 
PET-CT staging (refer to table 8) 
PET-CT over-staged 7.7% (4/52) N0 patients. No N1 or N2 patients were over-staged. 
Overall, 90.0% (36/40) node positive patients were under-staged including all those with 
N2 or N3 disease. 
Best pre-operative staging (refer to table 9) 
Final pre-operative stage over-staged 8.0% (9/112) N0 patients and 4.0% (2/50) N1 
patients. Overall, 88% (81/92) node positive patients were under-staged and 5.9% 
(11/185) N0-N2 patients were over-staged. 
 
 Pathological stage 
CT stage (n=204) N0 N1 N2 N3 
N0 97   40 17 9 
N1 10 8 6 7 
N2 0  1 0 2 
N3 0 0 0 0 
Nx 5 1 0 1 
Totals 112  50 23 19 
Over-staged 9.3% 2.0% 0% 0% 
Correctly-staged 90.7% 16.3% 0% 0% 
Under-staged 0% 81.6% 100% 100% 
Table 6 Comparison of pre-operative N staging according to CT and post-operative pathological stage 
 
 Pathological stage 
EUS stage (n=65) N0 N1 N2 N3 
N0 36 10 5 2 
N1 2 1 0 0 
N2 0 1 0 0 
Nx 4 1 1 2 
Totals 42 13 6 4 
Over-staged 5.3% 8.3% 0% 0% 
Correctly-staged 94.7% 8.3% 0% 0% 
Under-staged 0% 83.3% 100% 100% 
Table 7 Comparison of pre-operative N staging according to EUS and post-operative pathological stage 
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 Pathological stage 
PET-CT stage (n=99) N0 N1 N2 N3 
N0 48 17 10 3 
N1 4 4 3 3 
N2 0 0 0 0 
N3 0 0 0 0 
     
Nx 3 2 1 1 
Totals 55 23 14 7 
Over-staged 7.7% 0% 0% 0% 
Correctly-staged 92.3% 19.0% 0% 0% 
Under-staged 0% 81.0% 76.9% 100% 
Table 8 Comparison of pre-operative N staging according to PET-CT and post-operative pathological stage 
 
 Pathological stage 
Pre-op stage (n=204) N0 N1 N2 N3 
N0 103 39 17 10 
N1 8 9 6 6 
N2 1 2 0 3 
N3 0 0 0 0 
Nx 0 0 0 0 
Totals 112 50 23 19 
Over-staged 8.0% 4.0% 0% 0% 
Correctly-staged 92.0% 18.0% 0% 0% 
Under-staged 0% 78.0% 100% 100% 
Table 9 Comparison of final pre-operative N staging according to CT and post-operative pathological stage 
Staging according to neoadjuvant therapy threshold 
According to the pathological stage, 114/204 (55.9%) patients were above the threshold 
for consideration of neoadjuvant chemotherapy (locally advanced), see Table 10. The 
sensitivity for identifying this advanced stage was 51.8% (95% CI: 42.6% to 60.9%) with 
a specificity of 86.7% (95% CI: 79.6% to 93.7%). 48.2% patients with locally advanced 
tumours were under-staged and 13.3% patients with early tumours were over-staged. 
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 Pathological stage  
Pre-op stage (n=204) T2 and N0 ≥T3 or ≥N1 Totals 
T2 and N0 78 55 133 
≥T3 or ≥N1 12 59 71 
Totals 90 (44.1%) 114 (55.9%) 204 
Over-staged 13.3% (12/90) -  
Correctly-staged 86.7% 51.8%  
Under-staged - 48.2% (55/114)  
Specificity  86.7% (95% CI: 79.6% to 93.7%)  
Sensitivity    51.8% (95% CI: 42.6% to 60.9%)  
Table 10 Comparison of pre-operative and post-operative staging according to neoadjuvant therapy threshold 
Discussion 
Staging accuracy cannot directly be assessed in patients undergoing neoadjuvant 
therapy due to the therapy effect itself. Therefore, a cohort of patients going straight to 
surgery is used to estimate staging accuracy. This is necessary to ensure that any 
definition of response to neoadjuvant therapy that relies on staging would be valid. 
Specifically, evidence suggests that lymph node (N) down-staging and tumour depth (T) 
down-staging may be able to identify amongst patients considered non-responders 
according to histopathological regression, a sub-set who are partial responders and 
carry a survival benefit above the remaining non-responders. 
Of particular concern is that lower stage tumours (e.g. T1 or N0) may be systematically 
over-staged more so than higher stage tumours. This would result in an apparent down-
staging when examining the post-operative histology even in the absence of any therapy 
effect. Therefore, staging modalities that have a lower tendency to over-stage earlier 
tumours would be preferable. However, the tendency to under-stage tumours must also 
be taken into account since any under-staging will reduce the power to identifying true 
responders to therapy. I.e. if an N1 tumour is mistakenly staged as N0, then even if a 
true response to therapy resulted in pathological N0 staging, this would not be 
recognised as a response. 
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Whilst the final pre-operative staging is based on an MDT discussion of all available 
staging information, the accuracy of each individual modality was also investigated 
because these modalities may have different tendencies to over-stage disease. 
T staging 
It is generally considered that CT is unable to differentiate reliably between T1 and T2 
tumours and therefore early tumours are often staged as Tx or T1/2 on CT. It is difficult 
to comment on the over-staging of ≤T1 tumours although the data shows that 10% are 
over-staged even when the benefit of doubt is given to tumours staged as T1/2. 38.7% 
and 48.0% T2 tumours were over-staged by CT and EUS respectively. These findings are 
reflected in the final pre-operative T staging which over-stages 36.4% of T1/T2 tumours 
when grouped together. A large proportion of T3 and T4 tumours are under-staged. 
There are a number of reasons why early tumours may be over-staged. Firstly, muscle 
wall thickening caused by peri-tumour inflammation will over-stage a T1 tumour to T2 
and any irregularity of the outer muscle wall may give rise to T3 staging even if not 
representative of true tumour spread. There may also be a tendency to overcall the 
stage of T2 tumours so as not to deny patients potentially useful therapy such as 
neoadjuvant chemotherapy by under-staging. Conversely, advanced tumours (T3/4) are 
less likely to be over-staged, not least because a T4 tumour cannot be over-staged. This 
phenomenon in statistical trends has been known as regression to the mean. 
It must be remembered that this group of patients going straight to surgery differs from 
the group having neoadjuvant therapy not least because the reason for offering such 
therapy is often due to the stage of disease (≥T2 or ≥N1 disease). For this reason, staging 
accuracies will be different between the groups and the analysis must be used cautiously 
as an estimate for accuracy in the neoadjuvant group. This may explain why there are a 
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relatively low proportion of tumours staged at T3/4 pre-operatively and also why so 
many pathological T3/4 tumours are under-staged in this group. For this reason, the 
proportion of over-staging in early tumours may be an underestimate compared to the 
degree of over-staging in patients undergoing chemotherapy who have higher pre-
operative stages. The accuracy of T staging when addressed from the point of view of 
over and under-staging is poor and individual modalities appear no better than the final 
pre-operative staging. 
N staging 
Regarding N staging, CT over-staged 9.3% of node-negative (N0) tumours. Results were 
similar with EUS and PET-CT. This is reflected in the final staging which shows 8.0% N0 
tumours and 4.0% N1 tumours are over-staged. These figures compare favourably with 
a recent study in which 37.5% patients undergoing surgery alone for pN0 oesophageal 
cancer were staged as N1 pre-operatively44. A high percentage of our node-positive 
tumours were under-staged. CT staging of nodal disease is based on size criteria, which 
is known to have poor sensitivity and specificity because small nodes may contain 
metastases and large nodes may be inflammatory and benign. Although PET-CT has 
been shown in the literature to have a better specificity than CT in nodal metastasis 
detection (see Chapter 4), it performed no better than CT in this patient cohort. The 
small number of predicted node positive patients in this cohort of patients not 
undergoing neoadjuvant therapy may explain this and is also likely to be the reason for 
a high rate of under-staging in node-positive disease. 
There is no magnitude of over-staging that is considered acceptable although nodal 
over-staging of 37.5% in patients going straight to surgery has been reported by 
others44. T over-staging was 22.7% overall (41.7% in early tumours) and N over-staging 
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was 5.9% overall (8.0% in N0 patients). The significance of such over-staging is further 
examined in the next section (redefining response to neoadjuvant therapy). 
Neoadjuvant therapy treatment threshold 
It is generally accepted that patients with early tumours have less to gain from 
neoadjuvant chemotherapy since surgical resection with clear resection margins in 
patients without lymph node metastases carries a very good prognosis. Pre-operative 
staging is used to determine whether tumours are likely to be of an early stage. Patients 
staged as T2N0 or earlier (early tumours) have generally not been offered chemotherapy 
and those staged as at least T3 or N1 disease (locally advanced) are offered 
chemotherapy. There is perhaps a trend towards offering neoadjuvant therapy to earlier 
stage (T2N0) patients, perhaps because of the concern regarding possible under-staging. 
The whole basis of multimodality treatment is therefore entirely dependent on accurate 
pre-operative staging. The importance of staging in discriminating, for example, T1bN0 
tumours versus T2N0 tumours and T2N1 tumours versus T3N1 tumours is questionable 
since the management is likely to be the same with regards to neoadjuvant therapy and 
surgery. However, discriminating those early tumours where neoadjuvant 
chemotherapy would not be considered from more advanced tumours is critical. In the 
cohort of 204 patients not undergoing neoadjuvant therapy, 55.9% (114/204) were 
above this threshold on histopathological analysis. This suggests that the majority could 
have had the potential for benefit from neoadjuvant chemotherapy if given. However, 
just over half of these 114 patients with locally advanced disease appear to have been 
accurately staged with regards to this threshold and were presumably considered for 
chemotherapy but deemed not medically fit enough. Of the 204 patients, nearly 1 in 7 
patients (13.3%) with early tumours were over-staged. The clinical effect of this in all-
83 
 
comers would be an overuse of chemotherapy according to current protocol. Since this 
group of patients is likely to be of lower pre-operative stage than those over the same 
time period who underwent chemotherapy, this is likely to be an underestimate of the 
over-staging in all patients. Thus a proportion of patients are being exposed to 
chemotherapy which is associated with toxic effects and a low probability of responding 
when in fact they may have little to gain from neoadjuvant therapy. 
Perhaps even more concerning is that 48.2% of locally advanced tumours were under-
staged. Whilst this will be an over-estimate of the error in all comers for the same 
reasons as above and a proportion of these patients would not be fit for neoadjuvant 
chemotherapy, the clinical effect of this would be to deny the opportunity of 
neoadjuvant therapy for a significant proportion of those patients who have potential 
to benefit. 
Summary 
Assessment of staging accuracy is problematic now that neoadjuvant therapy forms part 
of the standard of care. Determining staging accuracy in neoadjuvant patients directly is 
not possible. The best estimation of this would be a measure of staging accuracy in a 
randomised control group going straight to surgery. Any comparison of non-randomised 
groups such as ours is a limitation. However, most ongoing randomised trials are 
currently comparing one neoadjuvant treatment with another rather than a straight to 
surgery control group, making assessment of staging accuracy impossible in these 
trials30, 91. 
With the proviso of the limitation above, this study of staging accuracy in our cohort 
uncovered a significant problem with the MDT decision making process with regards to 
neoadjuvant therapy. Treatment is considered on the basis of pre-operative staging 
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when the T stage is ≥T3 and the N stage is ≥N1. However, staging accuracy according to 
this cut-off is poor, leading to over or under-treatment. This raises the question of 
whether there is a better way to determine which patients should receive neoadjuvant 
chemotherapy. Another consideration relating to the threshold for neoadjuvant therapy 
treatment aside from the staging accuracy is exactly what constitutes the optimal cut-
off level. This will be addressed in the section on   
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Neoadjuvant therapy efficacy.  
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Redefining response to neoadjuvant therapy: Survival analysis 
Methods 
Chemotherapy regime 
Patients with tumours staged above T2N0 were considered for neoadjuvant 
chemotherapy. Chemotherapy consisted of 2 cycles of cisplatin and fluorouracil (OE02 
trial protocol); 3 cycles of ECF (MAGIC trial protocol); ECX with or without bevacizumab 
(ST03 trial protocol); or EOX. In a small number of patients, other combinations of these 
agents were used and a small number of patients underwent adjuvant therapy. After 
the completion of the final cycle of neoadjuvant chemotherapy, patients were restaged 
with a CT scan of the thorax, abdomen and pelvis for estimation of radiological response 
and operability. 
Surgery 
Patients with resectable tumours who were still fit for operation underwent surgery. 
Ivor-Lewis gastro-oesophagectomy was performed for lower oesophageal and gastro-
oesophageal junction tumours and distal, subtotal, total or extended gastrectomy were 
performed for gastric tumours depending on site and extent of the tumour. A small 
number of patients underwent left thoraco-abdominal oesophagectomy or 3 phase 
(McKeown) oesophagectomy. 
Pathological reporting 
Histopathological reporting followed the minimum dataset (recommended reporting 
guidelines) for oesophageal cancer in all cases of oesophageal and gastro-oesophageal 
junction tumours and following the minimum dataset for gastric cancers in all gastric 
cancers. Routine histopathological reporting included recording the Mandard score 
(TRG) and pathological TNM staging and was performed by a specialist gastrointestinal 
pathologist. 
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Data collection 
Data were recorded on patient demographics, histological tumour type, anatomical 
tumour location, pre-operative staging, chemotherapy regime, operative details, 
postoperative histopathology, length of stay and survival.  
Data analysis 
The Mandard scoring system was chosen over the broadly similar Becker system 
primarily because it is already used routinely in our unit and is therefore likely to benefit 
from greater reliability compared to introducing a new system. The distribution of 
tumour TRG scores was established. Kaplan-Meier estimates were used to show survival 
probabilities according to TRG scores and therefore indicate which scores represented 
histological responders. 
Tumour/Nodal down-staging analysis 
To further explore the validity of nodal down-staging, patients that were pre-operatively 
staged with disease at least as advanced as the threshold for considering neoadjuvant 
therapy (>T2 and/or >N0) were selected and patients not proceeding to resection were 
excluded. Patients were grouped according to whether they were TRG responders 
(Group Ai), non-responders (Group Aii) or had surgery only (Group B). Groups were then 
compared with respect to the apparent tumour/nodal down-staging in order to assess 
the validity of down-staging for use in defining response. 
N down-staging was defined as a lowering of the stage from pre-operative staging of 
N1/N2 to postoperative (pathological) staging of N0 which has been described 
elsewhere44. T down-staging was defined as any reduction in T stage, i.e. T3 to T2, or T2 
to T1 etc. also described previously78. 
  
88 
 
Results 
Survival according to TRG 
Of 587 patients identified in the database with a planned surgical resection, 376 
underwent neoadjuvant chemotherapy. 45 patients did not have pathological data 
available; 38 patients did not proceed to resection and 7 patients had missing/awaited 
TRG data. This left 331 patients for the analysis, see Figure 20. Patient characteristics 
are shown in Table 11. 
 
Figure 20  Patients undergoing neoadjuvant therapy and proceeding to resection with TRG data available. 
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Patient characteristics, n = 331  
Demographics  
Age, in years; mean (range) 64.5 (29.3 to 82.7)
  Male; n (%) 255 (77.0) 
Tumour characteristics  
Histological type; n (%)  
Adenocarcinoma 293 (88.5) 
Squamous cell carcinoma 35 (10.6) 
Other carcinoma 3 (0.9) 
Anatomical tumour location; n (%)  
Upper third oesophagus 2 (0.6) 
Middle third oesophagus 12 (3.6) 
Lower third oesophagus 57 (17.2) 
Gastro-oesophageal junction 216 (65.3) 
Gastric 44 (13.3) 
Pre-operative staging  
Pre-operative T stage; n (%)  
≤T2 60 (18.1) 
T3 256 (77.3) 
T3/4 and T4 15 (4.5) 
Pre-operative N stage; n (%)  
N0 133 (40.2) 
N1 167 (50.5) 
N2 31 (9.4) 
Neoadjuvant regimen; n (%)  
Cisplatin/5-FU 50 (15.1) 
ECX/ECF/EOX 245 (74.0) 
CROSS 8 (2.4) 
Carbotaxol +/- epirubicin 4 (1.2) 
Missing 24 (7.3) 
Post-operative histology  
Post-operative T staging; n (%)  
≤T2 99 (29.9) 
pT3 199 (60.1) 
pT4 32 (9.7) 
missing 1 (0.3) 
Post-operative N stage; n (%)  
N0 118 (35.6) 
N1 102 (30.8) 
N2 58 (17.5) 
N3 52 (15.7) 
Nx 1 (0.3) 
R0 resection  
R0 193 (58.3) 
R1 122 (36.8) 
R2 1 (0.003) 
missing 15 (4.5) 
Table 11 Patient characteristics. 
Abbreviations: CF; cisplatin, 5-flourouracil; ECX, epirubicin, cisplatin, capecitabine; ECF, epirubicin, cisplatin, 
capecitabine; EOX, epirubicin, oxaliplatin, capecitabine; EOF, epirubicin, oxaliplatin, capecitabine; CROSS, as per 
the CROSS trial, carboplatin, paclitaxel and concurrent radiotherapy; OEO5, as per the OEO5 study (ECX, CF); ST03, 
ECX +/- bevacizumab. Note: percentages may not sum to 100 due to rounding.  
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The distribution of TRG scores is shown in Figure 21. If patients with a TRG score of 1 or 
2 are considered as responders (as has been described elsewhere) then they account for 
13.9% of patients. 
TRG distribution 
 
Figure 21. TRG distribution in 331 patients undergoing neoadjuvant chemotherapy followed by surgical resection 
for oesophageal or gastric cancer.  
Note: percentages may not sum to 100 due to rounding. 
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Survival according to TRG score is shown in Figure 22. There appears to be a difference 
in survival according to whether patients have a TRG score of 1-3 where median values 
are not reached or a TRG score or 4 or 5 where they are reached (all mean and median 
survival times by TRG group are shown in Table 12). TRG3 patients have better survival 
than TRG 4/5 patients considered together, Log Rank (Mantel-Cox) P=0.008, Table 13 
and Figure 23. There is no difference in survival between TRG3 patients and TRG1/2 
patients considered together Log Rank (Mantel-Cox) P=0.69 (Table 14 and Figure 24). 
When response is defined by a TRG score of 1-3 (with TRG 4-5 considered non-
responders) rather than TRG 1-2, the proportion of responders increases from 13.9% 
(46/331) to 26.0% (86/331) (Figure 21). Mean survival in responders is 49.5 months 
compared to 35.7 months in non-responders, Log Rank (Mantel-Cox) P=0.0001, see 
Table 15 and Figure 25. 
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Survival according to TRG score 
 
TRG n Mean survival 
(months) 
95% confidence 
interval (months) 
Median survival 
1 26 48.0 38.6-57.4 >20.7 
2 20 53.9 45.9-61.9 >19.4 
3 40 46.9 40.3-53.6 >53.8 
4 124 37.0 32.5-41.6 37.8 
5 121 33.7 28.8-38.5 25.3 
Overall 331 39.3 36.3-42.2 51.3 
 Table 12 Mean survival according to TRG  
 
Figure 22 Kaplan-Meier estimates of survival according to TRG score. 
Log Rank (Mantel-Cox) P=0.002. 
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Survival TRG3 compared to TRG4-5 
 
TRG n Mean survival 
(months) 
95% confidence 
interval (months) 
Median survival 
3 40 46.9 40.3-53.6 >53.8 
4-5 245 35.7 32.3-39.1 35.1 
Table 13 Survival in TRG3 patients compared to TRG 4-5 
 
 
Figure 23 Kaplan-Meier estimates of survival in patients with TRG3 compared to TRG 4-5. 
Log Rank (Mantel-Cox) P=0.008. 
 
Survival TRG3 compared to TRG1/2 
 
TRG n Mean survival 
(months) 
95% confidence 
interval (months) 
Median survival 
1-2 46 51.3 44.7-57.8  
3 40 46.9 40.3-53.6 >53.8 
Table 14 Survival in TRG3 patients compared to TRG 1-2 patients 
94 
 
 
Figure 24 Kaplan-Meier estimates of survival in patients with TRG3 compared to TRG 1/2. 
Log Rank (Mantel-Cox) P=0.69. 
 
 
Survival according to TRG (TRG 1-3 responder vs. TRG 4/5 non-responder) 
TRG 
responder 
n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
Yes (TRG 1-3) 86 49.5 44.7-54.3 >53.8 
No (TRG 4-5) 245 35.7 32.3-39.1 35.1 
Table 15 Mean survival according to TRG response 
95 
 
 
Figure 25 Kaplan-Meier estimates of survival according to TRG response 
(TRG 1-3 = responder; TRG 4-5 = non-responder). Log Rank (Mantel-Cox) P=0.000.  
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Tumour/Nodal down-staging analysis 
Figure 26 shows the cohort of patients used in the analysis of T/N down-staging. Groups 
A, B, Ai and Aii and referred to in the tables and text presented below. 
 
Figure 26 Treatment groups and outcomes in patients meeting threshold for neoadjuvant therapy. 
Amongst patients who proceeded to resection and had full pathological results 
available, a comparison of lymph node down-staging in those having neoadjuvant 
therapy and those undergoing surgery alone was performed (shown in Table 16). 
Group Nodal Down-staging, 
number (% of group) 
Yes No 
Neoadjuvant therapy (Group A) n=307 58 (18.9) 249 (81.1) 
Surgery only (Group B) n=71 9 (12.7) 62 (87.3) 
Table 16 Nodal down-staging according to treatment group 
(see Figure 26 for explanation of groups), P=0.29 (chi-square) 
When the neoadjuvant therapy group is subdivided according to TRG response, 
responders (Group Aii) have a significantly higher proportion of lymph node down-
staging compared to both non-responders (Group Aii), P<0.0001 and to the surgery only 
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group (Group B), P=0.002, but there is no difference in nodal down-staging between 
non-responders (Group Aii) and the surgery only group (Bi), 13.0% and 12.7% 
respectively. 
Group Nodal Down-staging,  
number (% of group) 
Yes No 
TRG responder (Group Ai) n=78 28 (35.9) 50 (64.1) 
TRG non-responder (Group Aii) 29 (13.0) 194 (87.0) 
Surgery only (Group B) n=71 9 (12.7) 62 (87.3) 
Table 17 Nodal down-staging according to treatment group 
(see also Figure 26 shows the cohort of patients used in the analysis of T/N down-staging. 
Groups A, B, Ai and Aii and referred to in the tables and text presented below. 
), P<0.0001 (Pearson Chi square) 
The rate of T down-staging in Group A was no different from Group B, P=0.24 (Table 18). 
When patients undergoing neoadjuvant therapy were sub-divided according to therapy 
response, there was a difference in the rates of tumour down-staging between Groups 
Ai, Aii and Bi, P<0.001 (Table 19). 
In a 2x2 contingency analysis, there was no difference in down-staging rates between 
Groups Aii and B. The rate of tumour down-staging was higher in Group Ai compared to 
both Group Aii (P<0.0001) and Group B (P<0.0001). 
Group Tumour Down-staging, 
number (% of group) 
Yes No 
Neoadjuvant therapy (Group A) n=307 87 (28.3)  220 (71.7) 
Surgery only (Group B) n=71 15 (21.1)  56 (78.9) 
Table 18 Tumour down-staging according to treatment group 
(see Figure 26 for explanation of groups), P=0.28, Chi-square. 
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Group Tumour Down-staging, 
number (% of group) 
Yes No 
TRG responder (Group Ai) n=78 49 (62.8) 29 (37.2) 
TRG non-responder (Group Aii) n=223 35 (15.7) 188 (84.3) 
Surgery only (Group B) n=71 15 (21.1) 56 (78.9) 
Table 19 Tumour down-staging according to treatment group 
(see Figure 26 shows the cohort of patients used in the analysis of T/N down-staging. 
Groups A, B, Ai and Aii and referred to in the tables and text presented below. 
 for explanation of groups), P<0.0001, Pearson Chi-square. 
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Discussion 
It has become clear that responders to neoadjuvant therapy have improved survival 
compared to non-responders. Authors suggest that if non-responders can be predicted 
or identified early, then they should proceed directly to surgery to avoid excessive 
chemotherapy-associated toxicity, a delay to surgery and an unnecessary cost of 
ineffective neoadjuvant therapy86. 
The quoted proportion of patients defined as responders varies widely. This could be 
explained by differences in patients, tumour characteristics, treatments and not least by 
the existence of many methods for measuring response to neoadjuvant therapy. 
However, regardless of the method used to evaluate response, rates of response are 
low, typically 11-27%40, 44. Therefore, either 73%-89% of patients are receiving 
neoadjuvant therapy without any benefit, or the system is failing to identify all patients 
with a meaningful response.  
There is a need to re-define what constitutes an adequate response to neoadjuvant 
therapy although there have been few attempts to do this and standardise the 
definition. This section therefore has set out to achieve this. 
Firstly, a literature review was performed to identify possible methods of defining 
response. The most promising methods would then be applied to a historical patient 
cohort and survival analysed to see which method or combination provides the most 
accurate measure of response. Any proposed definition must reflect a true neoadjuvant 
therapy response and must be associated with survival. Any use of pre-operative staging 
information would depend on its accuracy. 
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The literature review provided a short-list of variables that show promise as measures 
of response to therapy. Whilst clinical and radiological features have been used, the 
methods best associated with survival are pathological. Histological regression based on 
the degree of residual tumour cells and fibrosis has the most evidence to support its use. 
The Mandard TRG score and Becker systems provide the best prognostic information 
and are broadly similar. The Mandard score is arguably the most widely used and it has 
been shown to be associated with survival in oesophageal cancer43, 44, 92 and gastric 
cancer92, 93. It has also been used routinely by our specialist GI pathologists for a number 
of years and so was chosen as the basis for defining response to therapy. 
There is evidence that combining histopathological regression and down-staging of 
primary tumour (T) or lymph node (N) stage may be associated with survival44, 78, 86. 
Specifically, it has been suggested that such down-staging may be a more sensitive or 
an additional independent measure of response that could help to identify more 
responders. It is not known if this represents a valid measure of response to neoadjuvant 
therapy, whether it should be included as part of the definition and if so, how it would 
be used alongside histopathological regression. Furthermore, there has been little 
consideration of pre-operative staging accuracy on which the validity of these 
definitions critically depends. 
The study of pre-operative staging accuracy in our cohort of patients having surgery only 
showed that pre-operative T and N staging were associated with a degree of inaccuracy, 
leaving concern over the validity of such measures. 
The issue of nodal-down-staging has been recently investigated by others. In their study, 
Noble et al acknowledged that the notion of down-staging is controversial due to 
difficulties in evaluating pre-therapy staging and specifically that apparent down-staging 
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may simply represent over-diagnosis of lymph node metastases on clinical imaging44. To 
address this, they compared the survival of patients undergoing neoadjuvant 
chemotherapy with those undergoing surgery alone, only amongst patients that were 
staged N0 in the resection specimen. Those undergoing chemotherapy had marginally 
poorer survival compared to those undergoing surgery alone. It is suggested that this 
poorer survival can be explained by and proves the existence of preoperative lymph 
node metastases. However, the neoadjuvant patients also had more advanced T stage 
(P<0.001) which could also explain the poorer survival in this group. Also of concern is 
the fact that 37.5% pN0 patients in their surgery only group had apparent nodal down-
staging, i.e. were clinically over-staged, suggesting that their neoadjuvant patients may 
also be prone to similar over-staging. 
Down-staging or T and/or N has been shown to be associated with improved survival 
after neoadjuvant chemotherapy treatment in 77 patients with oesophageal cancer78. 
Histological regression was not assessed so it is not known if these effects are 
independent of regression. Also there was no consideration of pre-operative staging 
accuracy bringing into question the validity of down-staging. 
A separate study in patients with oesophageal adenocarcinoma undergoing 
neoadjuvant chemotherapy/chemoradiotherapy, a combination of the two approaches 
above was used86. Whilst complete responders were identified by histopathological 
regression, partial responders were identified by down-staging of T and or N status. 
Response was associated with improved survival. Again, there is no consideration given 
to the validity of measuring response in this way with regards to accuracy of pre-
operative staging.  
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It is clear that histological regression (using a validated score) is likely to represent a true 
beneficial response to therapy with responders having improved survival. Our analysis 
showed that TRG scores 1, 2 and 3 (representing 26.0% patients) were associated with 
improved outcomes and could therefore be considered as responders. The issue of 
debate is amongst the histological non-responders and whether a subset of these 
patients could be considered partial responders with some survival benefit. If such a 
group exists and is represented by lymph node or tumour down-staging, then the 
proportion of down-staged patients in the neoadjuvant therapy group (and specifically 
in histological non-responders) should be greater than the proportion of apparently 
down-staged patients in the surgery only group. However, patients are selected to these 
groups on the basis of staging so an overall comparison of stage change is unreliable. 
There is a group of patients within the surgery only group in whom it can be argued 
disease stage was not used to select treatment group. These are the patients that meet 
the threshold for neoadjuvant therapy (>T2 and/or >N0) but who are unfit for or decline 
such therapy (n=76). They can be compared to a group of patients with similar staging 
undergoing neoadjuvant therapy (n=343). Figure 26 shows the broad outcomes in 
patients meeting the threshold for neoadjuvant therapy according to whether or not 
they did indeed undergo neoadjuvant therapy or had surgery only. Any patients not 
proceeding to surgery or without pathological data available were excluded, leaving 
patients in Groups Ai, Aii and B from Figure 26 in the analysis. This showed the tumour 
and nodal down-staging rates were no different between non-responders and the 
surgery only group, suggesting that the down-staging observed in non-responders is 
simply a result of clinical over-staging rather than representing a true treatment effect. 
Any true down-staging in neoadjuvant patients appears to be limited to the group of 
TRG responders (responders do express higher rates or T and N down-staging compared 
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to surgery only patients). Therefore, nodal down-staging should not be used as a method 
of identifying responders to neoadjuvant therapy in the TRG non-responder group. 
Based on the clinical review of methods used to measure response to neoadjuvant 
therapy and based on the investigation on staging accuracy above, it is suggested that 
responders are defined as those with histological regression defined by a Mandard score 
of 1 to 3. Neither T down-staging nor N down-staging are reliable enough to be included 
in the definition. 
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Neoadjuvant therapy toxicity 
From the same cohort of patients planned to undergo surgical resection, all patients 
undergoing neoadjuvant therapy were selected and therapy-associated adverse effects 
were recorded. These were graded according to the Common Terminology Criteria for 
Adverse Events v3.0 (CTCAE)94, see Table 20. 
Grade Severity 
0 No adverse event 
1 Mild adverse event 
2 Moderate adverse event 
3 Severe adverse event 
4 Life-threatening or disabling adverse event 
5 Death related to adverse event 
Table 20 CTCAE (Common Terminology Criteria for Adverse Events) grading system for 
chemotherapy/chemoradiotherapy related adverse events. 
Statistical analysis 
Survival curves were constructed using the Kaplan-Meier technique in SPSS v.21. The 
Log Rank (Mantel-Cox) method was used to assess differences in survival between 
defined groups of patients. 
Results 
Figure 27 shows the broad outcomes in patients undergoing neoadjuvant therapy 
divided according to whether they experienced therapy-associated adverse effects. 
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Figure 27 Outcomes in patients undergoing neoadjuvant therapy according to whether adverse events were 
experienced. 
Neoadjuvant therapy associated adverse effects were identified in 88 patients, 23.4% of 
those 376 undergoing therapy. The grades of severity recorded are shown below in 
Table 21. 
CTCAE 
Grade 
Severity Number 
(% of all patients undergoing therapy) 
0 No AE 288 (76.6) 
1 Mild AE 1 (0.3) 
2 Moderate AE 26 (6.9) 
3 Severe AE 25 (6.6) 
4 Life-threatening or disabling AE 31 (8.2) 
5 Death related to AE 5 (1.3) 
Table 21 Grade of adverse events, AE, (CTCAE, Common Terminology Criteria for Adverse Events). 
Of the five therapy-associated deaths, two were due to pulmonary embolism, two were 
due to myocardial infarction and one was due to gastrointestinal bleeding. 
Figure 28 shows survival curves according to the presence or absence of adverse effects. 
Survival is significantly better in patients without adverse effects (P=0.002). Median 
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survival in those with and without adverse effects was 21.1 and 52.8 months, 
respectively (Table 22). 
Chemotherapy 
morbidity 
n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
No 288 43.0 39.2-46.8 52.8 
Yes 88 28.2 23.6-32.8 21.1 
Table 22 Survival according to the presence or absence of chemotherapy morbidity 
 
Figure 28 Kaplan-Meier estimates of survival according to presence or absence of neoadjuvant therapy morbidity. 
Log Rank (Mantel-Cox) P=0.002. 
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Number of chemotherapy cycles completed 
Of the 376 patients undergoing neoadjuvant therapy, 226 (60.1%) patients had data 
available on the number of cycles of chemotherapy administered, see Table 23. 26 of 
226 patients (11.5%) did not receive the intended number of chemotherapy cycles. 15 
of these were due to documented adverse effects. In the remaining 11 patients, the 
reasons for not completing the neoadjuvant course were often not recorded but 
included poor tolerance of side-effects and signs of clinical progression, such as 
worsening dysphagia. 
In patients with adverse effects, the proportion with reduced cycles was 22.4% 
compared to 6.9% in those without adverse effects (P=0.002, chi-square). 
 Number of cycles completed  
 reduced complete missing Total 
No AE, n (%) 11 (6.9) 148 (93.1) 129 288
  
AE, n (%) 15 (22.4) 52 (77.6) 21 88 
Total, n (%) 26 (11.5) 200 (88.5) 150 376 
Table 23 Relationship between presence of adverse events, AE and number of cycles completed 
There was no survival difference between those patients completing the full course of 
neoadjuvant therapy and those with reduced cycles, Table 24 and Figure 29 (P=0.6, log-
rank). 
Cycles 
completed 
n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
Yes 200 36.3 32.7-40.0 35.2 
No 26 37.7 28.5-46.9 53.8 
Table 24 Survival in patients according to neoadjuvant course completion 
 
108 
 
 
Figure 29 Kaplan-Meier estimates of survival according to whether chemotherapy cycles were completed. 
Log Rank (Mantel-Cox) P=0.64. 
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Proportion of patients proceeding to resection 
The proportion of patients not proceeding to resection after therapy associated adverse 
events was 18/88 (20.5%); compared to 20/288 (6.9%) in those without adverse events, 
P=0.0002, chi-square (Table 25). 
 Resection status  
 No resection resection Total 
No AE 20 268 288 
AE 18 70 88 
Total 38 338 376 
Table 25 Relationship between resection status and AE 
Regardless of the presence or absence of adverse effects, it can be seen from Figure 27 
that overall, 38/376, 10% patients who undergo neoadjuvant therapy do not proceed to 
resection. 
Survival in patients proceeding to resection is greater than those failing to have a 
resection, Table 26 and Figure 30, (P<0.0001, log-rank). Median survival in those having 
a resection was 51.3 months, compared to 8.8 months in those failing to have a 
resection. 
When considering only patients having a resection, there is some evidence of improved 
survival among those who did not suffer an adverse effect on chemotherapy, compared 
to those who did, although this difference did not reach statistical significance (P=0.06, 
log-rank; Figure 31). 
Resection n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
Yes 338 42.8 39.4-46.2 37.8 
No 38 10.5 7.4-13.6 8.8 
Table 26 survival according to whether patients proceeded to resection 
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Figure 30 Kaplan-Meier estimates of survival according to whether patients proceeded to resection. 
Log Rank (Mantel-Cox) P≤0.001.  
111 
 
Neoadjuvant 
therapy 
morbidity 
n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
No 268 44.8 41.0-48.7 Not reached 
Yes 70 32.6 27.6-37.6 28.5 
Table 27 Survival according to neoadjuvant therapy toxicity in patients undergoing surgical resection 
 
Figure 31 Kaplan-Meier estimates of survival according to whether there was neoadjuvant therapy associated 
morbidity in resected patients only. 
Log Rank (Mantel-Cox) P=0.063. 
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TRG response 
The proportion of TRG responders did not differ between patients suffering therapy-
associated adverse events and those not, 16/70 (22.9%) and 70/261 (26.8%) 
respectively, P=0.6, chi-square (Table 28). 
 TRG response Total 
Responder Non-responder 
No AE 70 191 261 
AE 16 54 70 
Total 86 245 331 
Table 28 Comparison of TRG response and presence of adverse effects 
Likewise, the proportion of TRG responders did not differ between patients not receiving 
all 3 pre-operative cycles of chemotherapy (15/61; 24.6%) and those completing the 
course (35/139; 25.2%), P=1, chi-square (Table 29). 
 TRG Response Total 
Responder Non-responder 
< 3 cycles 15 46 61 
3 or more cycles 35 104 139 
Total 50 150 200 
Table 29 Comparison of TRG response and whether all 3 cycles of chemotherapy were given 
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Discussion 
Of patients undergoing neoadjuvant therapy, nearly 1 in 4 (23.4%) suffered adverse 
effects and 69% of these were graded as severe, life-threatening or fatal. There are 
perhaps a surprisingly low number of mild adverse events. The types of events that 
would be included in this category include mild, transient symptoms, such as skin rashes 
and asymptomatic anaemia, leukopenia or thrombocytopenia. It is likely that we do not 
have the pathways in place to record all such mild/moderate events. As a result, we 
probably underestimate the total number of events but overestimate the proportion of 
events that are classed a severe. The proportion of all patients undergoing neoadjuvant 
therapy that experience severe toxicity would be unchanged by the under-reporting of 
minor events. 
Only 72% patients received the full number of preoperative chemotherapy cycles and 
those with adverse effects were less likely to complete the course. Course completion 
was not associated with better survival. 
At least 1 in 5 patients with adverse effects did not proceed to resection in comparison 
to less than 1 in 15 patients without adverse effects. Not surprisingly, whether patients 
are resected or not is strongly associated with survival. 
Adverse events are associated with a failure to complete the planned neoadjuvant 
cycles, resection rate and survival. Although reduced resection is associated with 
survival, reduced number of cycles is not, suggesting that the reduced survival in those 
with adverse events is due to failure to proceed to resection rather than failure to 
complete the full course of neoadjuvant therapy. In patients undergoing resection, the 
apparent trend towards poorer survival in those with adverse events suggests that there 
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may be additional factors beyond being well enough to have a resection that have an 
ongoing negative effect on survival. 
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Neoadjuvant therapy efficacy 
Methods 
Survival according to stage and within stage groups 
Amongst the 587 patients identified in the cohort, survival across all prognostic stage 
groups was plotted and compared. To investigate whether any beneficial effects of 
neoadjuvant therapy are dependent on disease stage, each stage grouping was 
considered separately and survival compared in patients with a plan for neoadjuvant 
therapy and surgery (Group A, Figure 32) with survival in those going straight to surgery 
(Group B Figure 32). In an attempt to further characterise the patients that benefit from 
additional therapy, those undergoing neoadjuvant therapy were further sub-divided 
according to whether they were TRG responders (Group Aii) or not (Group Aiii) and 
survival curves compared to a similar group of patients having resection only (Group Bi). 
Patients not proceeding to surgical resection were excluded from both neoadjuvant 
therapy and surgery only groups in the latter analyses. 
Overall effect of neoadjuvant therapy 
To determine the overall effect of neoadjuvant therapy on survival, Kaplan-Meier 
estimates were plotted and compared across responder, non-responder or surgery only 
groups. In an attempt to reduce the natural differences in stage, the cohort was limited 
to those patients who on staging reached the threshold for neoadjuvant therapy (>T2 
and/or >N0), see Figure 32. Patient characteristics of the Groups are presented in table 
and differences between groups analysed using T-test or Chi-Square tests as appropriate 
without adjusting for multiple comparisons. The relationships between any factors 
differing between groups and survival were analysed in a Cox Regression model.  
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Results 
Survival according to stage and within stage groups 
Figure 32 shows the broad outcomes with patients divided accordingly to whether they 
underwent neoadjuvant therapy and then whether they underwent surgical resection. 
It may be helpful to refer to this diagram when interpreting the survival curves that 
follow in this results section. 
 
Figure 32 Outcomes in all according to whether or not neoadjuvant therapy was given in addition to surgery 
Named groups are referred to in the text. 
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Figure 33 and Table 30 show the survival according to the prognostic stage grouping 
(stage) based on pre-operative stage data. As stage increases, survival decreases 
significantly, P<0.0001 (Log Rank). 
 
Prognostic 
stage group 
n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
0 15 - - - 
1 125 47.7 43.5-51.9 - 
2 231 40.0 35.9-44.1 21.1 
3 216 33.6 29.9-37.3 19.4 
Table 30 Survival according to prognostic stage group. 
 
 
Figure 33 Kaplan-Meier estimates of survival in all patients according to pre-operative prognostic stage group. 
Log Rank (Mantel-Cox) P=0.000. 
Figure 34 and Table 31 include only patients in stage 1 and compare survival in patients 
undergoing neoadjuvant therapy (Group A from Figure 32, green line) and those 
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undergoing surgery alone (Group B from Figure 32, blue line). There is no difference in 
survival between the groups (P=0.81, Log-rank). 
 n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
Neoadjuvant 
therapy and surgery 
(Group A) 
21 49.1 39.4-58.8 Not 
reached 
Surgery Only 
(Group B) 
104 47.4 42.7-52.0 Not 
reached 
Table 31 Survival according to treatment plan within prognostic stage group 1 patients only 
 
Figure 34 Kaplan-Meier estimates of survival according to treatment type in prognostic stage 1 patients only 
(neoadjuvant therapy, green line or surgery only, blue line). Log Rank (Mantel-Cox) P=0.81. 
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Figure 35 and Table 32 include only patients in stage 2 and compares survival curves in 
patients undergoing neoadjuvant therapy (Group A from Figure 32, green line) and those 
undergoing surgery alone (Group B from Figure 32, blue line). There is no difference in 
survival between the groups (P=0.89, Log-rank). 
 n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
Neoadjuvant 
therapy and surgery 
(Group A) 
165 39.9 35.0-44.8 37.1 
Surgery Only 
(Group B) 
66 36.4 30.1-42.8 37.8 
Table 32 Survival according to treatment plan within prognostic stage group 2 patients only 
 
 
Figure 35 Kaplan-Meier estimates of survival according to treatment type in prognostic stage 2 patients only 
(neoadjuvant therapy, green line or surgery only, blue line). Log Rank (Mantel-Cox) P=0.91.  
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Figure 36 and Table 33 include only patients in stage 3 and compares survival curves in 
patients undergoing neoadjuvant therapy (Group A from Figure 32, green line) and those 
undergoing surgery alone (Group B from Figure 32, blue line). Survival is better in 
patients undergoing neoadjuvant therapy, P=0.015 (Log-rank). 
 n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
Neoadjuvant 
therapy and surgery 
(Group A) 
190 35.1 31.1-39.0 29.3 
Surgery Only 
(Group B) 
26 21.1 13.9-28.3 19.5 
Table 33 Survival according to treatment plan within prognostic stage group 3 patients only 
 
Figure 36 Kaplan-Meier estimates of survival according to treatment type (neoadjuvant therapy or surgery only) 
in prognostic stage 3 patients only. 
(Green line - neoadjuvant therapy; Blue line - surgery only). Log Rank (Mantel-Cox) P=0.015. 
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Figure 37 and Table 34 include only stage 1 patients who underwent surgical resection 
and compares survival in TRG responders to neoadjuvant therapy (Group Aii from Figure 
32, blue line), TRG non-responders (Group Aiii, green line) and patients undergoing 
surgery alone (Group Bi, tan line). There is no difference in survival between groups 
(P=0.92, Log-rank). 
 n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
TRG Responders 
(Group Aii) 
6 50.2 32.4-68.1 - 
TRG Non-
responders 
(Group Aiii) 
13 49.5 37.6-61.5 - 
Surgery only 
(Group Bi) 
102 48.2 43.7-52.8 - 
Table 34 Survival according to whether resected, stage 1 patients were neoadjuvant therapy responders, non-
responders or underwent surgery alone. 
 
Figure 37 Kaplan-Meier estimates of survival according to treatment type and histological response to therapy in 
prognostic stage I patients only. 
(Blue line – neoadjuvant therapy responder; green line – neoadjuvant therapy non-responder; Brown line – 
surgery only). Log Rank (Mantel-Cox) P=0.92. 
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Figure 38 includes only resected patients in stage 2 and compares survival curves in TRG 
responders to neoadjuvant therapy (Group Aii from Figure 32, blue line), TRG non-
responders (Group Aii from Figure 32, green line) and patients undergoing surgery alone 
(Group Bi from Figure 32, tan line). There is some indication of a difference in survival 
between the groups but this does not reach significance. (P=0.101, log-rank).  
 n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
TRG Responders 
(Group Aii) 
40 45.2 37.9-52.5 - 
TRG Non-
responders 
(Group Aiii) 
111 35.0 30.1-39.9 35.2 
Surgery only 
(Group Bi) 
66 36.4 30.1-42.8 37.8 
Table 35 Survival according to whether resected, stage 2 patients were neoadjuvant therapy responders, non-
responders or underwent surgery alone. 
 
Figure 38 Kaplan-Meier estimates of survival according to treatment type and histological response to therapy in 
prognostic stage II patients only. 
(Blue line – neoadjuvant therapy responder; green line – neoadjuvant therapy non-responder; Tan line – surgery 
only). Log Rank (Mantel-Cox) P=0.101.  
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Table 36 and Figure 39 includes only patients in stage 2 and compares survival curves in 
TRG responders to neoadjuvant therapy (Group Aii from Figure 32, blue line) and TRG 
non-responders (Group Aiii from Figure 32, green line). Survival is better in responders, 
Mean survival 45.2 months vs. 35.0 months, P=0.036 (Log-rank). 
 n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
TRG Responders 
(Group Aii) 
40 45.2 37.9-52.5 - 
TRG Non-
responders 
(Group Aiii) 
111 35.0 30.1-39.9 35.2 
Table 36 Survival according to whether resected, stage 2 patients were neoadjuvant therapy responders or non-
responders. 
 
Figure 39 Kaplan-Meier estimates of survival according to histological response to therapy in prognostic stage 2 
patients only. 
Blue line – TRG responders (TRG1-3); green line – TRG non-responders (TRG4/5). Log Rank (Mantel-Cox) P=0.036.  
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Table 37 and Figure 40 include only patients in stage 2 and compares survival curves in 
TRG responders to neoadjuvant therapy (Group Aii from Figure 32, blue line) and 
patients undergoing surgery only (Group Bi, tan line). There is some evidence of better 
survival in responders, mean survival 45.2 months vs. 35.9 months, P=0.074 (Log-rank). 
 n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
TRG Responders 
(Group Aii) 
40 45.2 37.9-52.5 - 
Surgery only 
(Group Bi) 
66 36.4 30.1-42.8 37.8 
Table 37 Survival according to whether resected, stage 2 patients were neoadjuvant therapy responders or 
underwent surgery alone. 
 
Figure 40 Kaplan-Meier estimates of survival in TRG responders and surgery only patients within prognostic stage 
II. 
Blue line – neoadjuvant therapy responders; Tan line – surgery only. Log Rank (Mantel-Cox) P=0.074. 
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Table 38 and Figure 41 include patients in stage 3 and compare survival in TRG 
responders to neoadjuvant therapy (Group Aii from Figure 32, blue line), TRG non-
responders (Group Aiii, green line) and patients undergoing surgery alone (Group Bi, tan 
line). Responders have a better survival than non-responders or patients having surgery 
only, P=0.001 (Log-rank). 
 n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
TRG Responders 
(Group Aii) 
40 51.4 45.6-57.1 - 
TRG Non-
responders 
(Group Aiii) 
121 34.7 29.9-39.5 29.3 
Surgery only 
(Group Bi) 
21 25.3 16.9-33.7 26.2 
Table 38 Survival according to whether resected, stage 3 patients were neoadjuvant therapy responders, non-
responders or underwent surgery alone. 
 
Figure 41 Kaplan-Meier estimates of survival according to treatment type and histological response to therapy in 
resected prognostic stage 3 patients only. 
Log Rank (Mantel-Cox) P=0.001. 
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Overall effect of neoadjuvant therapy 
Broad treatment groups and outcomes in all patients staged at or above the threshold 
for neoadjuvant therapy are shown in Figure 42, n=419. Patients not proceeding to 
resection or without post-operative pathological data available were excluded and the 
remaining 372 patients are detailed in Table 39 along with patient characteristics, 
staging information and neoadjuvant treatment details where applicable. 
 
Figure 42. Treatment groups and outcomes in patients meeting threshold for neoadjuvant therapy. 
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Patient characteristics 
n= 372 
Neoadjuvant therapy Surgery only Sig. 
Responders 
Group Aii, n=78 
Non-responders 
Group Aiii, n=223 Group Bi, n=71 Group Aiii vs. Bi 
Demographics     
Age in years; mean (range) 64.0 (31.5 to 82.7)
  
64.7 (29.3 to 80.7) 72.8 (51.3 to 85.7) P=0.000 
Male, number (%) 57 (73.1) 173 (77.6) 45 (63.4) P=0.059 
Performance score     
0 61 (78.2) 158 (70.9) 24 (33.8) P=0.000 
1 16 (20.5) 62 (27.8) 41 (57.7) 
2 1 (1.3) 3 (1.3) 4 (5.6) 
3 0 0 2 (2.8) 
Tumour characteristics     
Histological type, n (%)     
Adenocarcinoma 69 (88.5) 198 (88.8) 59 (83.1) P=0.14 
Squamous cell carcinoma 9 (11.5) 23 (10.3) 9 (12.7) 
Other carcinoma 0 2 (0.9) 3 (4.2) 
Tumour location, n (%)     
Upper third oesophagus 1 (1.3) 2 (0.9) 2 (2.8) P=0.000 
Middle third oesophagus 5 (6.4) 7 (3.1) 1 (1.4) 
Lower third oesophagus 17 (21.8) 63 (28.3) 9 (12.7) 
GO junction 47 (60.3) 124 (55.6) 29 (40.8) 
Gastric 9 (11.5) 27 (12.1) 30 (42.3) 
Pre-operative staging     
T stage, number (%)     
≤T2 5 (6.4) 25 (11.2) 8 (11.3) P=0.36 
T3 69 (88.5) 187 (83.9) 58 (81.7) 
T3/4 and T4 4 (5.1) 11 (4.9) 4 (5.6) 
Tx 0 0 1 (1.4) 
N stage, number (%)     
N0 31 (39.7) 72 (32.3) 36 (50.7) P=0.018 
N1 38 (48.7) 129 (57.8) 29 (40.8) 
N2 9 (11.5) 22 (9.9) 6 (8.5) 
Neoadjuvant regimen n 
(%) 
    
Cisplatin/5-FU 7 (9.0) 37 (16.6) n/a n/a 
ECX/ECF/EOX 62 (79.5) 162 (72.6) n/a 
CROSS style 5 (6.4) 3 (1.3) n/a 
Carbotaxol +/- epirubicin 1 (1.3) 2 (0.9) n/a 
Missing 3 (3.8) 19 (8.5) n/a 
Post-operative histology     
T stage, number (%)     
≤T2 48 (61.5) 34 (15.2) 18 (25.4) P=0.003 
pT3 30 (38.5) 156 (70.0) 33 (46.5) 
pT4 0 32 (14.3) 20 (28.2) 
pTx 0 1 (0.4) 0 
N stage, n (%)     
N0 47 (60.3) 54 (24.2) 25 (35.2) P=0.32 
N1 20 (25.6) 74 (33.2) 21 (29.6) 
N2 9 (11.5) 46 (20.6) 11 (15.5) 
N3 2 (2.6) 49 (22.0) 14 (19.7) 
Nx 0 0 1 (1.4) 
R0 status n (%)     
R0 61 (78.2) 108 (48.4) 45 (63.4) P=0.07 
R1 12 (15.4) 107 (48.0) 22 (31.0) 
R2 0 1 (0.4) 0 
missing 5 (6.4) 7 (3.1) 4 (5.6) 
Table 39 Characteristics and staging data in patients above the threshold for neoadjuvant therapy in those 
progressing to resection with pathological data available. Abbreviations: CF; cisplatin, 5-flourouracil; ECX, 
epirubicin, cisplatin, capecitabine; ECF, epirubicin, cisplatin, capecitabine; EOX, epirubicin, oxaliplatin, 
capecitabine; EOF, epirubicin, oxaliplatin, capecitabine; CROSS, as per the CROSS trial, carboplatin, paclitaxel and 
concurrent radiotherapy; OEO5, as per the OEO5 study (ECX, CF); ST03, ECX +/- bevacizumab; Sig, significance. 
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Table 40 and Figure 43 include patients above the neoadjuvant threshold, comparing 
survival in TRG responders (Group Aii from Figure 42, blue line), TRG non-responders 
(Group Aiii, green line) and patients undergoing surgery alone (Group Bi, tan line). 
Survival is better in responders compared to the other two groups, P=0.001, Log-rank. 
 n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
TRG Responders 
(Group Aii) 
78 48.6 43.7-53.4 - 
TRG Non-
responders 
(Group Aiii) 
223 35.3 31.7-38.9 34.5 
Surgery only 
(Group Bi) 
71 31.7 25.5-37.9 25.0 
Table 40 Survival according to whether resected patients above the threshold for neoadjuvant therapy were 
responders, non-responders or underwent surgery alone. 
 
Figure 43 Kaplan-Meier estimates of survival in TRG responders, TRG non-responders and patients undergoing 
surgery, limited to patients above the threshold for considering neoadjuvant therapy. 
Log Rank (Mantel-Cox) P=0.000. 
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The overall survival in patients staged above the neoadjuvant threshold was compared 
in TRG non-responders (Group Aiii from Figure 42, blue line) and patients undergoing 
surgery alone (Group Bi, green line). Results are shown in Figure 44 and Table 41. There 
is no difference in survival between the two groups (P=0.35, Log-rank).  
 n Mean survival 
(months) 
95% confidence 
interval (months) 
Median 
survival 
TRG Non-
responders 
(Group Aiii) 
223 35.3 31.7-38.9 34.5 
Surgery only 
(Group Bi) 
71 31.7 25.5-37.9 25.0 
Table 41 Survival according to whether resected patients above the threshold for neoadjuvant therapy were non-
responders, or underwent surgery alone 
 
Figure 44 Kaplan-Meier estimates of survival in TRG non-responders (blue line) and patients undergoing surgery 
only (green line), limited to patients above the threshold for considering neoadjuvant therapy. 
Log Rank (Mantel-Cox) P=0.35. 
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From Table 39 above, it can be seen that compared to non-responders (Group Aiii), 
patients undergoing surgery only (Group Bi) are older and have a higher performance 
score. They have a greater proportion of gastric tumours and have a lower proportion 
of tumours staged as N1 pre-operatively. 
To identify whether any of the above factors differing between groups are associated 
with survival, hazard ratios (HR) were estimated using a cox regression model for the 
various demographic variables. Groups Aiii and Bi are presented separately (Table 42) 
and also combined (Table 43). The only significant factor identified was age above 
median in the surgery only group (Bi) associated with improved survival. 
Variable Group Aiii 
Est. HR (95% CI) 
P 
value 
Group Bi 
Est. HR (95% CI) 
P 
value 
Performance score 1, 2 or 3 
vs. 0 
0.85 (0.53 to 
1.35) 
0.49 1.31 (0.56 to 
3.10) 
0.52 
Age (above median vs. below) 1.34 (0.88 to 
2.06) 
0.18 0.42 (0.19 to 
0.93) 
0.03 
Female vs. Male 1.22 (0.70 to 
2.10) 
0.49 0.77 (0.37 to 
1.60) 
0.48 
Pre-op N 
stage 
N0 
N1 
N2 
1.40 (0.57 to 
3.41) 
1.81 (0.78 to 
4.21) 
0.46 
0.17 
0.27 
0.64 (0.14 to 
2.89) 
0.38 (0.08 to 
1.93) 
0.56 
0.25 
0.33 
Tumour 
location 
Oesophagus 
Gastric 
Junctional 
 
0.94 (0.40 to 
2.22) 
1.48 (0.81 to 
2.70) 
0.26 
0.89 
0.21 
 
1.45 (0.51 to 
4.03) 
0.86 (0.30 to 
2.43)                                                                                                                                                                 
0.42 
0.48 
0.78 
 Table 42 Estimated hazard ratios (HR) from cox regression model, non-responder and surgery only groups 
considered separately. 
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Variable Est. HR 95% CI P value 
Performance score 1, 2 or 3 vs. 0 0.98 0.68 to 1.46 0.75 
Age (above median vs. below)  1.08 0.74 to 1.58 0.98 
Female vs. Male 1.10 0.72 to 1.68 0.75 
Pre-op N stage N0 
N1 
N2 
1.38 
1.51 
 
0.65 to 2.96 
0.72 to 3.14 
 
0.40 
0.27 
0.53 
Tumour location Oesophagus 
Gastric 
Junctional 
 
1.18 
1.23 
 
0.65 to 2.16 
0.74 to 2.03 
0.73 
0.58 
0.43 
Table 43 Estimated hazard ratios (HR) from cox regression model, non-responder and surgery only groups 
combined. 
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Discussion 
The AJCC Cancer Staging Manuals for cancers of the stomach and the 
oesophagus/oesophago-gastric junction not only describe the TNM staging system but 
specify ordered stage groupings into which any patient can be classified according to 
their individual TNM stages. These stages correspond to prognosis. There are different 
stage groupings in oesophageal/oesophago-gastric junction cancer according to 
whether histology is of adenocarcinoma or squamous cell carcinoma type and gastric 
cancer also has a separate stage grouping. 
In our cohort, prognostic stage grouping based on preoperative clinical staging is 
associated with survival which is expected and suggests some degree of accuracy in 
clinical staging. 
When patients undergoing neoadjuvant therapy and those having surgery alone are 
compared within each stage group, only stage 3 patients show a clear benefit from the 
addition of neoadjuvant therapy. However, when patients undergoing neoadjuvant 
therapy were further divided according to TRG response, not only do stage 3 patients 
benefit from neoadjuvant therapy but amongst stage 2 patients, survival was better in 
responders compared to non-responders (P=0.036). There was no significant difference 
in survival in responders compared to those undergoing surgery alone although there 
may be some association (P=0.062). In our cohort, there are few patients in stage 1 
undergoing neoadjuvant therapy, and mortality is generally very low in this group; 
therefore, a meaningful comparison of survival between responders, non-responders 
and surgery only patients in stage 1 was not possible. 
In considering the relationship between neoadjuvant therapy efficacy and stage, the 
inaccuracy of clinical pre-operative staging must be kept in mind. As shown earlier in 
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this chapter – there is a high rate of under-staging of T3N1 disease, whereby a T2/T3N0 
(stage 2) patient may actually have T3N1, and therefore stage 3 disease. 
These results together suggest that only patients with stage 3 disease stand to gain 
overall benefit from neoadjuvant therapy, however, stage 2 patients may also benefit 
on the basis that they may be under-staged and they could achieve a pathological 
response. This would support the use of neoadjuvant therapies in patients with at least 
stage 2 disease. 
The inaccuracy of clinical staging raises another issue here. The results of this study show 
quite different results according to whether a patient is clinically staged as prognostic 
group 2 or 3. However, since staging is known to be inaccurate with lower stage patients 
tending to be over-staged and more advanced stage patients tending to be under-
staged, we could be underestimating the magnitude of differences between stage 2 and 
stage 3 groups. In other words, actual stage 3 patients may have even more to gain than 
we think; however, actual stage 2 patients may have even less to gain from neoadjuvant 
therapy. If pre-operative staging accuracy was to improve and this phenomenon was 
observed, then this would provide a counter argument for using neoadjuvant therapy in 
stage 2 disease. 
These arguments for and against the use of neoadjuvant treatment apply in the current 
situation where response to therapy cannot be predicted. If it were possible to predict 
response, there is a strong argument for using neoadjuvant therapy in predicted 
responders with stage 2 and 3 disease, with insufficient data in stage 1 patients to 
comment. In predicted non-responders, any potential benefit of neoadjuvant therapy 
has to be balanced against the potential harm caused by such additional therapy in the 
event of not responding. The section above on neoadjuvant therapy toxicity highlighted 
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the incidence and significance of therapy-associated morbidity. It is therefore important 
to consider whether there is any survival difference between non-responders and 
patients undergoing surgery only. 
Survival was also analysed in patients with a pre-operative stage above the threshold 
for considering neoadjuvant therapy treatment in order to minimise stage differences 
between groups. Although responders had improved survival over non-responders and 
patients having surgery only, there was no difference in survival between non-
responders and surgery only groups (Figure 43 and Figure 44). 
This could be interpreted that that no overall harm is caused by undergoing neoadjuvant 
therapy in non-responders, implying that even if a means to predict therapy were 
available, such therapy could be given safely to predicted non-responders. Neoadjuvant 
therapy bears an additional cost, necessitates further investigations and introduces 
treatment delay. Since there is also no demonstrable benefit in non-responders; if 
response could be predicted, perhaps a stronger argument would be for predicted non-
responders to proceed directly to surgery or alternative therapies. 
The Intergroup trial reported no difference survival between non-responders and 
surgery only patients with median survival times of 1.1 years and 1.3 years 
respectively36. Although response was determined clinically using barium oesophagram, 
the findings agree with ours. In a randomised trial of neoadjuvant chemotherapy in 
patients with oesophageal squamous cell carcinoma, Ancona et al failed to show any 
overall benefit from neoadjuvant treatment. Although responders had improved 
survival compared to non-responders and surgery only groups, no difference in survival 
was shown between patients undergoing surgery only and non-responders41. 
135 
 
The major limitation of comparing neoadjuvant therapy and surgery only groups in non-
randomised groups has been touched on above. Even when doing so within stage groups 
in an attempt to reduce confounding by stage, patients may differ with respect to a 
number of variables. Factors of concern are likely to be those used to influence 
treatment decisions initially.  
A comparison of demographics and tumour details between the latter two groups 
showed that patients having surgery only tended to have older age, poorer performance 
status, a higher proportion of gastric tumours and a lower pre-operative N stage 
although there was no adjustment for multiple comparisons. Whilst it might be expected 
that these factors are associated with survival, on Cox regression modelling, the only 
significant factor was age in the surgery only group. Of 71 patients in this group, survival 
was poorer in the 21 patients of the lower age group. The reasons for this are not clear 
but may be related to different patient characteristics between the groups that are 
difficult to interpret due to small group sizes or a type I statistical error, identifying an 
effect in the sample that is not present in the population. 
The issue of neoadjuvant therapy efficacy is difficult to answer outside the context of a 
randomised trial. However, in addition to concerns which have been present for some 
time over the questionable efficacy especially in lower stage patients, there is ongoing 
concern that non-responders to therapy may suffer from poorer survival compared to 
patients having surgery alone. Given that non-responders typically make up 73-88% 
patients undergoing chemotherapy and 60-85% patients undergoing 
chemoradiotherapy, the fact that these patients may be disadvantaged by this 
treatment is of huge concern.  
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Chapter summary 
There are many ways to measure response to neoadjuvant therapy but those that 
correlate best with survival and therefore thought to be the most valid representation 
of true therapeutic response involve measurement of histological regression. The 
Mandard and Becker systems have been validated for use in oesophageal and gastric 
cancer. Whilst primary tumour and lymph node down-staging have been put forward as 
additional methods of identifying responders, these techniques are associated with 
significant limitations that have been further investigated in this chapter. Such down-
staging relies on pre-operative clinical staging accuracy which is poor, particularly in 
primary tumour (T) staging. The rate of lymph node (N) clinical over-staging was shown 
to be the same in non-responders and patients undergoing surgery only, indicating that 
this phenomenon does not represent true down-staging and is unable to identify a 
subgroup of partial responders amongst the TRG non-responders. We therefore defined 
response to neoadjuvant therapy as achieving a TRG score of 1-3 using the Mandard 
system which is in routine use in out unit. 
23.1% patients undergoing neoadjuvant therapy suffered a moderate or severe adverse 
event. Such toxicity was associated with reduced survival which is thought to be largely 
related to failure to proceed to surgical resection. Overall 10% having chemotherapy do 
not proceed to surgical resection which compares to 3.3% patients undergoing surgery 
alone.  
Whilst patients responding to therapy have the potential to benefit from it, it is not so 
clear whether the risks of chemotherapy and delay to surgery associated with its use will 
outweigh the benefits and have a negative influence on survival in patients who do not 
gain a histological response to therapy. It is also thought that the potential to benefit 
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from neoadjuvant therapy may be related to disease stage, with the risk: benefit ratio 
only in favour of neoadjuvant therapy in more advanced stages of disease. In our cohort, 
there was only a clear benefit for patients with disease stage III although it is thought 
reasonable to offer such therapy to those with stage II disease on the basis that they 
may be under-staged; they may benefit if they respond to therapy and even if they don’t 
respond, there is as yet no conclusive evidence that they will do worse than if not having 
the additional therapy. 
However, regardless of whether patients are stage 2 or 3, the most important factor 
determining outcome after neoadjuvant therapy is whether there is a histopathological 
response. It is conceivable that stage 1 patients may also stand to benefit if they respond 
to neoadjuvant therapy, particularly when considering the chance of under-estimating 
stage although small number of patients in this treatment group limits the analysis. 
The overwhelming survival advantage of histological responders together with the poor 
accuracy of clinical staging on which neoadjuvant treatment decisions are made 
indicates that if response can be predicted then this should be used in addition to or 
perhaps even instead of clinical staging in the decision whether or not to offer 
neoadjuvant therapy. 
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CHAPTER 4 - INDIVIDUALISED STAGING INVESTIGATIONS 
Introduction 
The range of treatment modalities available means that accurate staging is necessary in 
order to determine whether patients should be selected for curative treatments and if 
so, which treatments. Accurate staging also allows comparison of different treatments 
and outcomes in different units on a stage by stage basis. 
There is a now a wide range of techniques available for the staging of oesophago-gastric 
cancers including endoscopy, ultrasound, CT, PET, PET-CT, MRI, bronchoscopy, 
thoracoscopy, laparoscopy, endoscopic ultrasound, EBUS, endoscopic resection and 
many of these techniques allow the opportunity for sampling or biopsy for 
cytological/histological diagnosis. 
Clearly it is not practical or useful for all patients to have all investigations. Each carries 
a healthcare cost and has the potential to introduce a delay in starting treatment 
whether curative or palliative. Figure 45 shows the typical staging pathway used in our 
unit. Some investigations are considered mandatory in all cases such as endoscopy and 
CT. Others are useful only in specific incidences at the discretion of a specialist Upper 
Gastrointestinal MDT such as EBUS with lymph node biopsy. Other techniques have 
been widely adopted despite a lack of evidence of their importance. 
In order to standardise staging pathways, the available evidence has been reviewed and 
guidelines produced. However, these often carry only Grade C recommendations which 
are based on level IV evidence, i.e. committee reports and opinions of respected 
authorities or at best Grade B recommendations, based on non-randomised clinical 
studies12. Therefore, the evidence is weak and this type of clinical research tends to 
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consider all patients the same rather than allowing for individual factors that may be 
relevant. 
It is widely accepted that endoscopy and CT are mandatory and that specialist 
investigations such as endobronchial ultrasound, MRI, thoracoscopy and endoscopic 
mucosal resection are used for specific indications as directed by the MDT. However, 
staging laparoscopy, PET scanning and EUS are used routinely (according to tumour 
location) in many units according to the Grade B/C recommendations without any 
randomised evidence of any benefit and without consideration of individual patient 
factors. 
In the same way that there is a growing trend towards providing individualised 
treatment for patients, staging investigations should also be tailored to meet patients’ 
specific needs. 
This chapter explores the evidence for the most controversial of the routinely used 
staging investigations, staging laparoscopy and PET-CT scanning. 
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Figure 45 Flow chart showing typical staging pathway, MDT, Multidisciplinary Team. 
*all patients with primary disease below the diaphragm and selected patients with nodal disease below the 
diaphragm. 
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Staging laparoscopy 
Introduction 
Staging laparoscopy is used in patients with potentially resectable oesophago-gastric 
cancer to assess operability before committing to surgical resection with or without 
neoadjuvant therapies. Laparoscopy can identify advanced local spread (by tumour or 
nodal disease) and low volume liver/peritoneal metastases not detectable on computed 
tomography (CT) or positron emission tomography (PET) scanning12, 95-99. Laparoscopy 
can avoid the morbidity associated with unnecessary laparotomy or radical therapies in 
patients with unresectable disease. The 2002 guidelines from the Association of Upper 
Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS), the British Society of 
Gastroenterology (BSG) and the British Association of Surgical Oncology (BASO) 
suggested the routine use of laparoscopy following CT and Endoscopic Ultrasound (EUS) 
prior to consideration of radical resection in patients with gastric cancer and in gastro-
oesophageal junctional tumours where there appears to be a gastric component13. 
Updated guidelines in 2011 suggest laparoscopy should be undertaken in all gastric 
cancers and selected patients with lower oesophageal/oesophago-gastric junctional 
cancer12. The guidelines do not define how to select patients for laparoscopy and this is 
therefore open to interpretation.  
Historically, staging laparoscopy has been shown to change management in over ten per 
cent of patients with oesophago-gastric junctional cancer and over twenty per cent of 
patients with gastric cancer98. Whilst considered generally safe, laparoscopy is 
associated with complications and may delay the start of treatment in patients who go 
on to have neoadjuvant therapy or surgery98, 100. The procedure also brings an additional 
cost and is an inconvenience to the patient. 
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Advances in CT scanning technology produce higher resolution and multiplanar 
reconstructions that are able to stage oesophageal and gastric cancers more accurately. 
Consequently, studies published 10 years ago may be out of date in the context of 
staging with modern multi-detector scanners. 
The aim of the present study was to re-evaluate the role of staging laparoscopy in the 
management of oesophago-gastric cancer in the context of a modern MDT 
environment. The authors seek to validate a classification for determining the risk of 
resectability in patients with oesophago-gastric cancer. 
CT accuracy in T and N staging 
Oesophageal Cancer 
T staging 
The accuracy of CT in T staging for oesophageal cancer compared to histopathological 
stage has been reported between 43 and 92%101-105. In 2010 Umeoka et al demonstrated 
that the accuracy of CT for T staging of oesophageal carcinoma was improved by using 
dual phase imaging, particularly in early cancers which are difficult to identify on CT. 
Overall accuracy was 68% with the arterial phase compared to 51% with traditional 
venous phase imaging106.  
Ba-Ssalamah et al recently evaluated the accuracy of multi-detector CT using water as 
negative contrast in T-staging of patients with oesophageal cancer. Accurate local 
staging was achieved in 76.3% and 68.7% for the two reporters89. Sensitivity was 95% 
and positive predictive value 96%. 
N staging 
A meta-analysis of studies published prior to January 2006 demonstrated pooled 
sensitivity and specificity of CT for detection of regional lymph nodes metastases of 50% 
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and 83% respectively107. More recent papers have demonstrated accuracies in N staging 
between 27% and 86%101-103, 108. 
CT staging of lymph nodes relies on size criteria. The threshold for consideration of 
malignant involvement ranges from 5-15mm with 10mm historically being the most 
widely used. However, lymph nodes less than 10mm can harbour metastatic disease and 
indeed lymph nodes of greater than 10mm may not be metastatic. Nevertheless, the 
possibility of involved nodal disease indicates a higher risk of having inoperable disease 
which is why our high risk criteria in table 1 include any patients with lymph nodes larger 
than 10mm or with multiple (≥3) 5-10mm nodes. 
Gastric Cancer 
T staging 
The accuracy of CT T staging in gastric cancer has been reported as between 77% and 
89%109-114. Makino et al compared the T-staging by multi-detector CT with operative and 
pathologic findings in 276 patients with gastric cancer visible on CT. Overall accuracy 
was 90.9% and only 3% were under-staged90. All patients with positive cytology or 
peritoneal metastases diagnosed at laparotomy had been diagnosed as T4a or deeper, 
so would have been stratified as at increased risk using the proposed criteria. 
N staging 
The accuracy of CT staging for nodal disease in gastric cancer has been reported at 
between 63% and 80%110, 113, 114. A recent prospective validation study in 315 patients 
with gastric cancer using MDCT demonstrated overall diagnostic accuracy for N staging 
of 75.9%. It is recognised that most studies in the literature have used previous versions 
of the AJCC staging manual. CT scanning technology continues to improve along with 
greater staging accuracy. 
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Methods 
Consecutive patients diagnosed with localised oesophageal or gastric cancer over a 48-
month period between 2010 and 2013 were identified retrospectively from a database 
of all patients discussed at a regional MDT meeting. All patients undergoing staging 
laparoscopy during the time period were included in the study. The Health Research 
Authority National Research Ethics Service deemed that ethics approval was not 
required for this study. 
Predictive algorithm 
A proposed algorithm for stratifying patients according to the likely risk of having 
inoperable disease was devised. In a pragmatic approach including a literature review, 
anecdotal experience and a pilot study in 24 patients at this institution; criteria based 
on endoscopy and CT findings were identified that are thought to increase the risk of 
finding inoperable disease. These criteria are shown in Table 44. Specifically, tumour 
length was included because it provides information in addition to the T stage and has 
been shown to be an independent predictor of long-term survival115. We included 
multiple lymph nodes (5-10mm) or any lymph node with a diameter of greater than 
10mm as signs of more advanced disease that imply an increased risk of peritoneal 
disease. PET-CT criteria were not used in the algorithm because the investigation is not 
performed in most gastric cancers and the value of PET over CT is largely confined to 
more sensitive detection of distant metastases. EUS criteria were not used because in 
many centres including ours, it is being used selectively and staging is limited in 
obstructing lesions. 
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Risk of 
unresectable 
disease 
Description 
Increased  Junctional tumour >3cm length on endoscopy or not traversable 
with scope  
or 
 T3/4 on CT 
or 
 ≥3 regional lymph nodes (5-10mm) or any lymph node ≥ 1cm 
or 
 Bulky gastric tumour/>4cm ulcer 
Low  all other tumours 
Table 44 Risk of unresectable disease based on upper GI endoscopy and CT findings. 
Patient staging 
Patients underwent staging with CT of thorax, abdomen and pelvis using 64-slice multi-
detector (MD) scanners on 5 different hospital sites using the same oesophago-gastric 
staging protocol (0.625-1.25mm slices, oral water as negative contrast and intravenous 
contrast with portal venous phase imaging). Staging was reported according to the AJCC 
7th edition manuals for oesophageal and gastric cancer respectively. All CT scans were 
reviewed by at least one of four specialist upper gastrointestinal CT radiologists at a 
SMDT meeting. Tumours were staged using assessment criteria similar to that described 
by Ba-Ssalamah et al89. Specifically, T2 tumours were characterised as having thickening 
of the oesophageal wall of less than 15mm with slight/mild stenosis and outer borders 
which are smooth or show stranding for less than one third of the tumour extension. T3 
lesions were represented by thickening of greater than 15mm with mild to severe 
stenosis and marked stranding for over one third of the tumour extension or extensive 
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blurring of the outer border. T4 lesions required invasion into one of the adjacent 
structures such as pericardium, diaphragm, pleura, tracheobronchial tree or aorta. 
Gastric cancers were staged according to criteria similar to those described by Makino 
et al90. Tumours appearing as minimal thickening were staged as T2, those with more 
demonstrable thickening of the stomach wall and a smooth outer layer with preserved 
perigastric fat plane were staged as T3 and those with a nodular/irregular outer border 
of the gastric wall or infiltration of the perigastric fat or adjacent structures were staged 
as T4. 
Figure 45 shows the MDT pathway and the order of staging investigations used in the 
region. Patients underwent staging with PET-CT and EUS according to national 
guidelines12. Specifically, PET-CT was performed in all patients with potentially 
resectable oesophageal and gastro-oesophageal junction tumours but not gastric 
cancers. Operability was assessed by EUS in selective patients. 
Staging laparoscopy 
Staging laparoscopy was performed in accordance with current guidelines12. Specifically, 
laparoscopy was undertaken in all potentially resectable gastric cancers and lower 
oesophageal/GOJ cancers with a component at the level of the diaphragm. The 
technique included selective exploration of the lesser sac where unresectable nodal 
disease was suspected. Peritoneal washings for cytology were not taken due to the lack 
of consensus on how to interpret the result. 
Patient stratification 
Patients were stratified according to the risk of having unresectable disease based on 
the criteria shown in Table 44 without knowledge of the EUS findings, PET-CT result or 
staging laparoscopy outcome. Laparotomy results and the final outcome were recorded. 
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Staging laparoscopy results and patient outcomes were recorded and represented on a 
flowchart according to whether they were predicted as having a low risk or increased 
risk of finding inoperable disease at laparoscopy. Outcomes were also reported 
according to anatomical tumour location. Patients were divided into those with tumours 
of the lower oesophagus (tumour centre >5cm from the GOJ), gastro-oesophageal 
junction (component at the junction with tumour centre within 5 cm above or below the 
GOJ, i.e. Siewert I, II and III lesions) and stomach (tumour confined to stomach or centre 
>5cm below GOJ). 
Results 
227 patients were identified during the 48-month recruitment period. The mean age at 
diagnosis was 67.0 years and 74.0% were men (see Table 45). 3.1%, 59.5% and 37.4% 
tumours were located in the lower oesophagus, gastro-oesophageal junction and 
stomach respectively. Tumours staged clinically as T3 tumours made up the great 
majority of cancers. 
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Patient characteristics N=227 
Demographics  
Mean age, years (range) 67.0 (28.9-89.7) 
Male proportion, n (%) 168 (74.0) 
Histological type, number (%)  
Adenocarcinoma 218 (96.0) 
Squamous cell carcinoma 8 (3.5) 
Other 1 (0.5) 
Anatomical tumour location, number (%)  
Lower Oesophagus 7 (3.1%) 
Gastro-oesophageal junction 135 (59.5%) 
Stomach 85 (37.4%) 
Neoadjuvant chemotherapy, number (%)  
Yes 131 (57.7%) 
No 96 (42.3%) 
Staging laparoscopy result, number (%)  
Inoperable disease 33 (14.5%) 
Operable 194 (85.5%) 
T stage (clinical)  
T1/2 10 (4.4) 
j 
T2 34 (15.0) 
T3 
 
163 (71.8) 
T4a 19 (8.4) 
Tx 1 (0.4) 
N stage (clinical)  
N0 98 (43.2) 
N1 98 (43.2) 
N2 30 (13.2) 
N3  
 
1 (0.4) 
Table 45 Characteristics of patients undergoing staging laparoscopy. Note: percentages may not sum to 100 due 
to rounding. 
Overall, staging laparoscopy identified inoperable disease in 33 (14.5%) patients, Figure 
46.  
Table 46 and Figure 46 show the outcomes of patients divided into two groups according 
to the predicted risk of having inoperable disease. Of the 48 patients predicted to be at 
low risk, none had inoperable disease found on laparoscopy and none were 
subsequently found to be unresectable at operation. 45 patients underwent resection, 
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two declined resection and one patient was eventually deemed not fit for radical 
therapy. 
Within the 179 patients predicted to be at increased risk of having inoperable disease, 
laparoscopy identified inoperable disease in 33 (18.4%) patients (see figure 2 and table 
3). The breakdown by anatomical tumour location is shown in table 3. Of the 33 patients 
with inoperable disease, according to pre-operative CT, 30 were staged as T3 or T4 and 
were therefore deemed before staging laparoscopy to be at increased risk of inoperable 
disease. 20 of these patients also had lymph node burden on CT indicating higher risk of 
inoperability and 8 had advanced endoscopic findings (>3cm long or not traversable) 
suggesting increased risk. Of the 3 patients staged as T1/2, 2 had N1 disease on CT and 
the other had a fundic ulcerating lesion over 4cm in length indicating increased risk of 
inoperable disease. Therefore, all 33 patients with inoperable disease found at 
laparoscopy were identified beforehand as at increased risk of inoperability according 
the criteria in table 1. The reasons for inoperability included liver metastases; 
unresectable lymph node disease; peritoneal metastases and unresectable primary 
tumour, Table 47. These patients were referred on for palliative therapies. 
Tumour location Predicted risk of inoperability 
Low risk High risk 
Number Inoperable at 
laparoscopy 
Number Inoperable at 
laparoscopy 
Lower Oesophagus 2 0 (0%) 5 1 (20%) 
Gastro-oesophageal Junction 15 0 (0%) 120 17 (14%) 
Gastric 31 0 (0%) 54 15 (28%) 
Total 48 0 (0%) 179 33 (18%) 
Table 46 Predicted risk of inoperability and staging laparoscopy outcome according to anatomical tumour 
location. 
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Figure 46 Flow chart showing outcomes in patients after classifying according the risk of having unresectable 
disease. 
*Risk of unresectable disease is based on criteria from Table 44. 
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Reason for inoperability at staging laparoscopy 
n (%) 
Liver metastases 4 (11.8) 
Unresectable lymph node disease  3 (8.8) 
Peritoneal metastases 17 (50.0) 
Unresectable primary tumour  10 (29.4) 
Totals 34 
Table 47 Reason for inoperability at staging laparoscopy. 
Table 48 shows the pathological TNM stage of patients according to high and low risk 
groups. The large proportion of patients in the high risk group without staging data 
represents those patients not undergoing resection. 
Pathological staging Predicted risk of inoperability 
Low risk n=48 High risk n=179 
T stage T0 0 6 (3%) 
T1 17 (35%) 9 (5%) 
T2 4 (8%) 16 (9%) 
T3 19 (40%) 52 (29%) 
T4a 5 (10%) 19 (11%) 
T4b 0 8 (4%) 
Unknown 3 (6%) 68 (38%) 
N stage N0 18 (38%) 29 (16%) 
N1 16 (33%) 27 (15%) 
N2 9 (19%) 19 (11%) 
N3 2 (4%) 29 (16%) 
unknown 3 (6%) 75 (42%) 
M stage M0 45 (94%) 100 (56%) 
M1 0 52 (29%) 
unknown 3 (6%) 27 (15%) 
Table 48 Pathological TNM stage according to predicted risk of inoperability. 
Of 146 patients deemed to be at increased risk but having no sign of inoperable disease 
at laparoscopy, 116 underwent attempted resection. Of these, 105 underwent 
successful resection and 11 were found to be unresectable at laparotomy. This was due 
to direct posterior invasion into the pancreas in 5 patients, deposits on the visceral 
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pleura in two undergoing Ivor Lewis oesophagectomy, extranodal peritoneal spread in 
the lesser sac in one, direct invasion of posterior mediastinum in one, extensive direct 
invasion of the right diaphragmatic crus/overlying peritoneum in one and direct tumour 
extension into the lesser omentum in one. Outcomes in the remaining 30 patients 
deemed at increased risk with no sign of inoperable disease at laparoscopy and not 
undergoing resection are shown in Figure 46. 
The algorithm can predict inoperable disease with a sensitivity of 100% and specificity 
of 25%; i.e. of all patients deemed resectable on laparoscopy (194), 25% (48) were 
correctly predicted to be resectable and could have been spared the procedure. The 
proposed staging pathway taking into account this algorithm is shown in Figure 47. 
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Figure 47 Flow chart showing proposed staging pathway including use of staging laparoscopy depending on 
specified criteria. 
MDT, multidisciplinary team; EUS, endoscopic ultrasound; PET, positron emission tomography; CT, computed 
tomography.  
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Discussion 
Staging laparoscopy has a role in the work-up of patients with gastric and gastro-
oesophageal junction tumours, although the management of most patients will not be 
altered. A pilot study identified a number of pre-operative factors associated with 
increased risk of finding inoperable disease laparoscopy. Based on these factors, we 
proposed a classification to stratify risk of inoperability. This was investigated in a 
validation cohort and was shown to accurately predict a group of patients with low risk 
of having inoperable disease. 21.1% patients were predicted as low risk, all of whom 
underwent a staging laparoscopy showing operable disease. 
We have described a heterogeneous group of patients including those with lower 
oesophageal, junctional and gastric cancer types that behave differently and are staged 
according to two different AJCC systems. None of the gastric cancers and 86% of the 
other groups underwent PET-CT as part of staging whereas CT was performed in all 
patients. For this reason, PET-CT findings were not used in the criteria for predicting the 
risk of unresectable disease shown in Table 44. In addition, the value of PET over CT is 
largely confined to more sensitive detection of patients with distant metastases who will 
be excluded from staging laparoscopy. PET adds no additional benefit to tumour (T) or 
regional lymph node (N) staging. In a pragmatic approach, the proposed criteria have 
been kept as simple as possible and the study aims to demonstrate its validity in all 
anatomical groups so that it can be applied to all patients who would normally undergo 
staging laparoscopy. 
Richardson and Khan used a best evidence technique to answer the question of whether 
patients with radiologically-staged resectable oesophago-gastric junctional tumours 
undergoing an oesophagectomy benefit from additional useful staging information 
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provided by diagnostic laparoscopy98. They reviewed five studies, finding that 
laparoscopy appears to detect previously occult peritoneal metastases as well as liver 
metastases and lymph nodes leading to changes in management in over 10% of patients. 
They note that the procedure is associated with morbidity; complications included small 
bowel perforation, pulmonary oedema and moderate hepatic bleeding100, 116. They also 
surmise that routine PET-scanning may reduce the efficacy of routine staging 
laparoscopy. Only one of the five studies was published within the last 12 years so their 
conclusions are based on outdated CT technology. CT scanners have been replaced with 
newer multi-detector models in all of our regional units since 2007. 
In the largest study to investigate the role of staging laparoscopy, De Graaf et al reported 
on 416 patients undergoing the procedure in two UK hospitals between 1997 and 
200322. A change in treatment decision was made in 17.1%, 17.2% and 28% of patients 
with distal oesophageal, GOJ and gastric tumours respectively. Staging was performed 
with CT and/or ultrasound, the latter being very poor at predicting resectability 
therefore many of their patients may have been under-staged. With modern staging 
investigations applied, more patients with unresectable disease may have been 
identified before laparoscopy which may explain the higher proportion of patients with 
a change in management in this study compared to ours. In those that did undergo CT, 
there is no data regarding the predicted T and N staging and it is therefore impossible 
to apply the proposed classification. The other 4 studies reviewed are smaller with less 
than 80 patients in each100, 116-118. Only three directly commented on changes in 
management which were reported in 8%, 10% and 17% of patients 100, 116, 117. Changes 
in management were reported as avoiding resection due to peritoneal disease or 
unresectable lymph node disease in the majority and down-staging or altered choice of 
156 
 
operation in others. Again, no information is given on the T staging, lymph node status 
or tumour length. 
With specific regards to the use of CT in determining the presence of peritoneal disease, 
in a recent UK-based study of 46 patients with gastric cancer and no direct evidence of 
peritoneal disease according to CT, 6 (13%) were found to have peritoneal disease 
following laparoscopy96. Of these 6 patients, according to CT, one had T3 disease, one 
N1 disease, one T3N1 disease and one was a perforated tumour (T4). Therefore, at least 
4 of the 6 ‘false-negative’ cases would have been categorised as moderate/high risk in 
this study and would have gone on to have staging laparoscopy as part of our protocol. 
There is no information on the other two cases. Of 67 patients in the study without CT 
signs of peritoneal disease and no evidence of such at laparoscopy/laparotomy, it is not 
known how many would have been stratified as low risk according to the proposed 
criteria. The authors conclude that CT is not sensitive enough to directly detect early 
peritoneal disease in gastric cancer, however, they indicate that staging laparoscopy is 
likely to be of most use in tumours staged as T3 on CT which in accordance with our 
results. It should be acknowledged that transcoelomic dissemination requires breach of 
the visceral peritoneum by the tumour itself or extracapsular lymph node spread and 
therefore is dependent on T and N staging. It follows therefore that T and N staging may 
be more useful in determining the risk of peritoneal disease or unresectable lymph node 
spread than direct identification of peritoneal metastases on CT scanning. 
Studies indicate that staging laparoscopy can change management in more patients with 
gastric cancer compared to oesophageal/oesophago-gastric junctional tumours22. Our 
findings are in accord with this view (Table 50); gastric cancer has a greater propensity 
for transcoelomic spread. 
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Conclusions 
Guidelines recommend the use of staging laparoscopy in patients with potentially 
resectable gastric cancer and in oesophageal cancers with a component at the 
diaphragm level in an attempt to identify inoperable disease not identified on 
radiological staging. We have introduced a proposed classification to stratify risk of 
inoperability which can accurately predict a group of patients at a low risk of having 
inoperable disease identified at staging laparoscopy, thereby potentially avoiding 
laparoscopy in 21.1% patients. Validity has been demonstrated in our patient cohort of 
cancers affecting the lower oesophagus, gastro-oesophageal junction and stomach. 
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PET-CT 
Introduction 
Positron emission tomography (PET) and PET-CT have been used for a number of years 
in the staging of oesophageal cancer primarily to rule out metastatic disease in patients 
suitable for radical treatment. The goal of any staging modality is to differentiate 
between those patients with potentially curable disease and those without, which 
should ultimately lead to an improvement in survival and/or quality of life.  
In 2009, the Scottish National PET Advisory Group recommended the routine use of PET-
CT in staging patients with potentially operable oesophageal cancer, as it can be 
beneficial in selecting patients for curative treatment16. Recent guidelines from AUGIS, 
BSG and BASO suggest that PET-CT scanning should be used in combination with EUS 
and CT for the assessment of oesophageal and oesophago-gastric junctional cancer12. In 
2012 the Royal College of Radiologists and Royal College of Physicians published joint 
guidelines suggesting that oesophago-gastric cancer staging is a suitable indication for 
PET-CT in the UK119. 
PET-CT scanning is significantly more accurate than PET in loco-regional lymph node 
staging120 and is useful in local staging when EUS is incomplete or not tolerated121. 
Studies now tend to agree that PET-CT is superior to both PET and CT in the detection of 
distant metastases and is therefore the current modality of choice for this purpose122-
124. 
Routine PET-CT scanning has therefore become commonplace and it may have uses 
beyond staging. PET-CT is useful in identifying other incidental pathology such as 
colorectal or prostatic neoplasia. Despite guidelines and the successful uptake of PET 
scanning, controversy still exists over its impact on the staging of upper GI cancers since 
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there is a lack of data on quality of life or survival125. There is some debate over which 
isotope has the best performance, although F18-fluorodeoxyglucose (FDG) is widely 
available and has the most data supporting its use. 
Advances in multi-detector CT (MDCT) scanning technology in recent years, with 
increasingly higher resolution and multiplanar reconstructions allow for more accurate 
staging of oesophageal cancers. The role of PET therefore needs re-evaluation in the 
context of staging with modern technology. There is a rising trend to provide a tailored 
approach to the treatment of cancer patients with regards to the requirement and 
timing of neoadjuvant/adjuvant therapies44. A similar approach should be applied to 
staging investigations rather than adopting a ‘one-size fits all’ strategy. 
Compared to CT alone, PET-CT has the potential to alter the staging and change 
management in typically 12-18% patients125-128. Management in most patients is 
unaffected by the investigation. PET-CT incurs additional exposure to ionizing radiation, 
may delay definitive treatment and bears a financial cost which is significant when 
delivering a resource-limited healthcare service. 
The aim of this study was to re-evaluate the role of PET-CT in the management of 
oesophageal cancer in the context of a modern MDT environment. We have investigated 
whether a classification based on CT and endoscopy criteria can accurately predict the 
PET-CT result. 
Methods 
CT and endoscopic criteria that may be able to stratify patients’ risk of having metastatic 
disease on PET-CT were identified. The criteria encompass T and N staging, with 
additional features and are detailed in Table 49. Tumour length was included because it 
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provides information in addition to the T stage and has been shown to be an 
independent predictor of long-term survival115. The presence of multiple lymph nodes 
of 5-10mm was included because CT is increasingly able to identify sub-centimetre 
nodes that may be involved with tumour and increase the risk of metastatic disease. 
Whilst EUS can add to the accuracy of nodal (N) staging when used in addition to CT, 
EUS results were not used in the criteria to stratify risk because as an invasive 
investigation, it is usually performed after PET-CT and it is unable to fully assess patients 
with stricturing, non-traversable tumours. 
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Risk of metastatic 
disease 
Description 
Low  ≤3cm on endoscopy, traversable with scope  
and 
 ≤T2 on CT 
and 
 N0 
Increased  >3cm on endoscopy or not traversable with scope  
or 
 ≥T3 on CT (including oesophageal dilatation of >1cm 
diameter) 
or 
 N1 disease, any ≥ 1cm node or ≥3 5-10mm nodes 
or 
 Suspicion of M1 disease 
Table 49 Risk of metastatic disease based on computed tomography (CT) and endoscopy findings. 
‘T’, ‘N’ and ‘M’ refer to the tumour, node, metastasis (TNM) staging according to the American Joint Committee 
on Cancer (AJCC) 7th edition manual for oesophageal cancer. 
Patients 
Consecutive patients with localised oesophageal or gastro-oesophageal junction 
malignant tumours diagnosed over a 39-month period between 2010 and 2013 were 
identified retrospectively from a prospectively maintained database of all patients 
discussed at a specialist MDT meeting. Patients with all histological cancer types were 
included. 
Staging protocol 
After histological confirmation of the diagnosis of an oesophageal or junctional cancer 
via endoscopic biopsy, patients underwent staging with CT of the thorax, abdomen and 
pelvis using multi-detector scanners on 5 different hospital sites according to the same 
oesophago-gastric staging protocol. This included 0.625-1.25mm slices, oral water as 
negative contrast and intravenous contrast with portal venous phase imaging. Staging 
was reported according to the AJCC 7th edition manual for oesophageal cancer. All CT 
scans were reviewed by at least one of three specialist upper gastrointestinal CT 
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radiologists at a specialist MDT meeting. Tumours were staged according to criteria 
similar to that described by Ba-Ssalamah et al89. Specifically, T2 tumours were 
characterised as having thickening of the oesophageal wall of less than 15mm with 
slight/mild stenosis and outer borders which are smooth or show stranding for less than 
one third of the tumour extension. T3 lesions were represented by thickening of greater 
then 15mm with mild to severe stenosis and marked stranding for over one third of the 
tumour extension or extensive blurring of the outer border. T4 lesions required invasion 
into one of the adjacent structures such as pericardium, diaphragm, pleura, 
tracheobronchial tree or aorta. 
Figure 47 shows the MDT pathway and the order of staging investigations used in the 
region. EUS was used in traversable tumours to further assess T and N stage which helps 
determine resectability and the need for neoadjuvant therapy. PET-CT was performed 
in all patients with the potential for radical treatment and curative intent in accordance 
with current guidelines12. All patients undergoing PET-CT were included in the study. 
Data recording and analysis 
Data were recorded on dates and results of all staging investigations. Time intervals from 
diagnosis to CT scan and from diagnosis to PET-CT were calculated. Data were captured 
on any incidental pathology identified by PET-CT. 
Patients were stratified according to the risk of finding inoperable disease on PET-CT 
based on the criteria shown in without knowledge of the EUS or PET-CT results. The 
results of the PET-CT scan results and patient outcomes were recorded. 
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It is not possible to calculate sensitivity or specificity of PET-CT for detection of distant 
metastases since the true positive and true negative numbers are impossible to define 
for any study such as this. 
Results 
Patients and demographics 
383 patients undergoing PET-CT were identified. Mean age at diagnosis was 66 years 
and 74% were male. Patient characteristics are shown in Table 50. 
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Patient characteristics n=383 
Demographics  
Age, in years; mean (range) 66.4 (31.2 to 85.4) 
Male; n (%) 285 (74.4) 
Histological type; n (%)  
Adenocarcinoma 305 (79.6) 
Squamous cell carcinoma 75 (19.6) 
Adenosquamous carcinoma 3 (0.8) 
Anatomical tumour location; n (%)  
Upper third oesophagus 7 (1.8) 
Middle third oesophagus 43 (11.2) 
Lower third oesophagus 163 (42.6) 
Gastro-oesophageal junction 170 (44.4) 
Treatments  
Curative - Surgery only; n (%) 74 (19.3) 
 Resected 69 
 Inoperable 5 
Curative - Neoadjuvant therapy and surgery; n (%) 187 (48.8) 
 Progressed/inoperable after chemotherapy 20 
 Chemotherapy morbidity preventing surgery 7 
 Resected 158 
 Unknown 2 
Curative – Chemoradiotherapy; n (%) 26 (6.8) 
Not fit for radical therapy; n (%) 14 (3.7) 
Declined radical treatment; n (%) 8 (2.1) 
Palliative; n (%) 68 (17.8) 
Local therapies; n (%) 6 (1.6) 
T Stage (on staging CT)*; n (%)  
≤T2 140 (36.6) 
T3 220 (57.4) 
T3/4 and T4 19 (5.0) 
Tx 4 (1.0) 
PET-CT result; n (%)  
Metastatic disease 52 (13.6) 
No metastatic disease 331 (86.4) 
Table 50 Characteristics of all patients undergoing positron emission tomography-computed tomography (PET-CT) 
scan. 
*‘T’ refers to tumour staging according to the American Joint Committee on Cancer (AJCC) staging manual 7th 
edition for oesophageal cancer. 
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Outcomes according to PET-CT result 
Overall, PET-CT identified possible metastatic disease in 71 (18.5%) patients. Table 51 
shows the anatomical distribution of metastases and Table 52 shows the outcomes 
according to PET-CT result. 52 patients had metastases that were unequivocal or 
confirmed on biopsy. They were not offered radical treatment (surgery or 
chemoradiotherapy) and were referred for palliative options. Of these patients, 
according to pre-operative CT, 51 of these patients were staged with at least T3 or N1 
disease. The remaining patient had a long stricturing lesion on endoscopy. Therefore, all 
52 patients with metastatic disease on PET-CT were identified as being at increased risk 
according to the criteria in Table 49. 
Whilst metastases were unequivocal in some, others underwent further investigation to 
confirm or refute the presence of metastases. M1 disease was disproven in 19 patients. 
Of these, 3 progressed on neoadjuvant therapy; 4 had unresectable disease diagnosed 
on other investigations (staging laparoscopy/EUS); 7 were not fit for radical therapy; 4 
had radical treatment (2 chemoradiotherapy and 2 surgery); and 1 patient declined 
radical treatment. 
Of the 312 patients without suspicion of metastatic disease on PET-CT, 22 underwent 
radical chemoradiotherapy; 8 declined radical treatment; 6 underwent local therapies; 
9 had unresectable disease diagnosed by other means (staging laparoscopy (7), EUS (1), 
CT (1)); 20 were not fit for radical therapy; 225 underwent resection; 13 had inoperable 
disease at the time of surgery and 9 patients had progression of disease on neoadjuvant 
therapy (Table 52). 
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Distribution of Metastases 
M1 disease suspected 
M1 
confirmed 
M1 
disproven 
Lymph nodes  31 9 
Bone 11 3 
Liver 6 1 
Adrenal 2 2 
Other 2 4 
Totals 52 19 
Table 51 Distribution of metastases and PET-CT results. 
Main outcome 
PET-CT result 
Totals 
M0 
M1 
M1 
confirmed 
M1 
disproven 
Surgical resection 225 0 2 225 
Planned resection - inoperable 13 0 0 13 
Declined radical therapy 8 0 1 9 
Radical chemoradiotherapy  22 0 2 23 
Local therapies 6 0 0 6 
Not fit for radical therapy 20 0 7 26 
Progression of disease on neoadjuvant 
therapy 
9 0 3 12 
Unresectable disease diagnosed by other 
means  
(CT, laparoscopy or EUS) 
9 0 4 13 
Palliative options 0 52 0 52 
Totals 312 52 19 383 
 Table 52 Patient outcomes according to initial PET-CT results. 
Outcomes according to predicted risk of metastatic disease 
83 (21.7%) patients were predicted as low risk and 300 (78.3%) as increased risk (Figure 
48). Table 53 shows the breakdown according to anatomical location. Within the low 
risk group, none had metastatic disease on PET-CT. Within the high risk group, 52 (17%) 
patients had metastatic disease on PET-CT. A further 46 (15%) patients developed 
progression of disease during neoadjuvant treatment or went on to have a failed 
resection due to inoperable disease (see Figure 48). 
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Lymph node staging and neoadjuvant therapy decision making 
Nodal involvement was identified by PET-CT in 127 of 383 patients. 34 of these patients 
did not have enlarged lymph nodes on CT. Management in these patients were analysed 
further to identify whether PET-CT contributed to decision making regarding 
chemotherapy. Of the 34 patients (N0 on CT and N1 on PET-CT), 25 were categorised as 
at increased risk of metastatic disease on the basis of the primary tumour size or 
endoscopy criteria and would therefore have had PET-CT under the criteria anyway. Of 
the remaining 9 patients, 5 did not undergo chemotherapy despite PET-CT suggesting 
N1 disease, one underwent radical chemoradiotherapy and the remaining 3 had 
chemotherapy based on EUS findings. 
Time to PET-CT 
Median time from diagnosis to CT scan was 11.5 days and from diagnosis to PET-CT was 
23.6 days. 
Patients not proceeding to radical therapy 
Overall, in patients not undergoing radical therapy after PET-CT (130), this was due to 
inoperable disease seen on the PET-CT in 40% (n=52). 20% (n=26) were unfit for surgery 
or declined surgery; 35% (n=46) had inoperable disease or progressed on neoadjuvant 
therapy and 5% (n=6) underwent local therapies. 
PET-CT identification of incidental pathology 
PET-CT identified possible incidental pathology in 43 (11.2%) patients (data not shown 
in tables or figures). These patients underwent further examination or investigation 
leading to benign or normal findings in 39 and to neoplastic diagnoses in 4 (1.0%). In two 
of these patients, a colonic adenomatous polyp was removed. In one patient, a sigmoid 
colon cancer was identified and simultaneous Ivor-Lewis oesophago-gastrectomy and 
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sigmoid colectomy were performed. One patient had a PET-avid pelvic lymph node 
which was excised and proved to contain metastatic prostate adenocarcinoma. 
Tumour location Predicted risk of metastatic disease 
Low risk Increased risk 
 
Number Metastatic 
disease on PET-
CT 
Number Metastatic disease 
on PET-CT, number 
(%) 
Upper third 
oesophagus 
0 0 7 3 (43) 
Middle third 
oesophagus 
8 0 35 9 (26) 
Lower third 
oesophagus 
45 0 118 19 (16) 
Junctional 
tumours 
30 0 140 21 (15) 
Total 83 0 300 52 (17) 
Table 53 Predicted risk of metastatic disease and positron emission tomography-computed tomography (PET-CT) 
outcome according to anatomical tumour location. 
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Figure 48 Flow chart showing outcomes in patients after classifying according to the risk of having metastatic 
disease. 
PET, positron emission tomography; CT, computed tomography. *Risk of metastatic disease predicted according 
to criteria in Table 49. Outcomes are numbered i to x for reference in the text. 
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Discussion 
PET-CT has an important role in the staging of patients with oesophageal cancer, 
however, only a minority will benefit. We review the evidence for use of PET-CT in the 
management of oesophageal cancer within a modern MDT environment and seek to 
validate a proposed classification for stratifying patients according to the risk of having 
metastatic disease. 
A multicentre, prospective, UK study examined the role of PET-CT in the staging of 191 
patients with oesophageal cancer126. Metastatic disease was identified by PET-CT and 
confirmed in 9.4% patients overall which included 13% patients undergoing selective 
PET-CT. The criteria for selective PET-CT were not reported. In the 85% patients 
undergoing PET-CT routinely, metastatic disease was confirmed in 5%. When subdivided 
by CT/EUS staging, metastatic disease was found in 13%, 0%, 6% and 0% of patients with 
stage 3/4, stage 2b, stage 2a and stage 1 disease respectively. Results concur with ours 
demonstrating that early tumours infrequently show evidence of metastasis on PET-CT. 
The authors suggest further data are required to determine in which patients PET-CT 
has no additional value. 
Berrisford et al assessed the role of PET-CT in staging 50 patients with 
oesophageal/oesophago-gastric junctional tumours127. Patients were assigned to one of 
two groups according to CT and EUS staging (group A CT N0M0, group B CT N1 and/or 
borderline M1). PET-CT re-categorised 6 (12%) patients as inoperable based on the 
presence of distant metastases. Four of these patients were from the group without 
confirmed nodal or suspected metastatic disease. It is not known whether these patients 
had any characteristics that could have predicted the likelihood of metastatic disease. 
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In a study of 199 patients with oesophageal cancer from the Netherlands, the addition 
of PET to staging investigation led to surgery being avoided in only 6 (3%) patients, all of 
whom had clinical stage III-IV disease before PET. No patients with stage I-II disease went 
on to have distant metastases on PET scanning129. These results support the notion that 
early tumours rarely demonstrate metastatic disease on PET scan and casts doubt over 
the suggestion that all patients should undergo PET scan as part of staging. 
A recent study from Bristol by Blencowe et al, 128 investigated the influence of PET-CT 
on decision making in MDTs. M1 disease was identified in 43 of 238 (18%) patients. 
Tumour stage was not reported so it is not known whether patients upstaged on PET-CT 
would have been identified as at high risk according to our criteria. Whilst MDT 
recommendations were said to be changed in 91 patients, 23 of these were due to 
incidental findings which were of minimal consequence and 25 were due to refuting CT 
suspicion of M1 disease which arguably may not have altered the key management 
decisions. This study was not designed to investigate which patients stood to gain the 
most from PET-CT scanning. It did raise the important issue of how to evaluate the 
influence of PET-CT on decision making. The authors correctly recognise that many 
studies do not define what a change in management constitutes. The majority of studies 
do report the frequency of finding previously undetected metastases which is the most 
important factor in determining suitability for radical therapy. The authors also suggest 
calculating survival in patients assigned to groups according to the influence of PET-CT 
but this will not answer the question of whether PET-CT improves outcomes.  
None of the above studies recognise that the ultimate aim of improving survival/quality 
of life can only be demonstrated by comparing patients that undergo PET-CT as part of 
staging with control patients that don’t and few have attempted to address this. The 
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increase in PET/PET-CT scanning has been supported with guidelines now 
recommending routine use so there may be a reluctance to perform controlled trials. 
There have been no randomised studies to date. A good example of such study is the 
pragmatic randomised EUS trial, COGNATE (Cancer of Oesophagus or Gastricus - New 
Assessment of Technology of Endosonography) which showed that EUS improves 
survival and has the potential to reduce health-care resources17. This demonstrates that 
randomised study designs can be performed in a modern MDT environment. 
An important study from the Three-Counties Cancer Network used a control group to 
investigate whether integrated PET-CT improved staging, reduced early recurrence or 
increased survival in oesophageal cancer130. Patients were retrospectively divided into 
two groups according to whether they had undergone PET-CT or not. Early recurrence 
and survival rates were the same despite more patients in the PET-CT group undergoing 
neoadjuvant chemotherapy (as a result of change in routine practice over time). PET-CT 
was responsible for upstaging only 4% patients and down-staging 5.5%. In the 5.5% 
patients down-staged, it is not clear whether the suggestion of metastatic disease on CT 
was clear enough to deny patients radical treatment if PET-CT were not performed but 
regardless this seems a good indication for the use of PET scanning. Inaccurate 
identification of occult metastatic disease prior to the introduction of PET-CT did not 
appear to be the primary cause of early recurrence in their patients. The study compared 
two patient groups treated over different time periods. Although multiple potential 
confounding factors make comparison unreliable, if the findings are realistic then doubt 
is cast over the true influence of PET-CT on early recurrence and survival. 
When comparing the pre-PET-CT MDT recommendation with the post-PET-CT 
recommendation, (a recognised method of evaluating the influence of PET-CT128, our 
173 
 
MDT recognised a problem common to all studies above but not addressed by any. The 
recommendation before PET-CT may be influenced by the knowledge that a PET-CT is 
planned. Specifically, if it is known that a PET-CT will be performed, the MDT may be 
more likely to suggest a patient is suitable for radical treatment. In one study, three 
quarters of the advanced disease found on PET-CT had already been identified by other 
staging investigations even though PET-CT was said to be restricted to those without 
metastatic disease130. 
Furthermore, patients who are not fit for surgery or who have signs of advanced disease 
on other staging modalities may be undergoing PET unnecessarily. This is implied by the 
high percentage of patients that have a negative PET-CT but do not proceed to surgical 
resection or radical therapy, 24% (78 of 331 patients) in our study (represented by 
outcome groups ii, iv, vi and vii from Figure 48. This compares to 26-28% in the Bristol 
study128 and 35% in the study by Noble et al126. When considering all patients not 
undergoing curative therapy (surgery/CRT) after PET-CT scan (groups ii, iv, vi, vii and x 
from Figure 48), the reason for this was due to advanced disease seen on PET-CT in only 
39.4% in our study (represented by group x from Figure 48) and 23% to 35% in others126, 
130. The remainder of patients not undergoing surgery in our study were unfit for 
surgery, declined surgery, underwent local therapies, had inoperable disease identified 
through other investigations or progressed on neoadjuvant therapy. The main intended 
use of PET-CT is to rule out incurable disease in patients suitable for radical therapy, 
however, many patients deemed curable do not end up undergoing radical therapy. A 
positive PET-CT can make decision making easier for patients with borderline fitness for 
surgery and if all patients were to undergo formal cardiopulmonary 
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investigations/exercise testing before PET-CT scanning, staging and treatment could be 
delayed, however, a negative PET-CT at this time is frequent (86.4%) and unhelpful. 
In our study, the median time from diagnosis to CT was 11.5 days and from diagnosis to 
PET-CT was 24 days. This compares to median times of 11 days and 35 days in patients 
from the Three-Counties Cancer Network study130. A concern is that having a PET-CT 
scan will risk a delay in definitive treatment. 
False positive rates for PET-CT have been reported at between 1.5% and 7.5%126, 129-131. 
In these cases, metastatic disease suggested by PET-CT has been subsequently disproved 
after further investigations or MDT discussion. This limitation of PET-CT is sometimes 
poorly quantified and the true false positive rate often unknown since positive PET-CT 
results are not always challenged128. This may lead to over-staging and withholding 
potentially curative treatments. Biopsy-confirmation of metastases identified by PET-CT 
in selected/all cases has been discussed without consensus128, 131, 132. A balance may 
need to be struck between avoiding unnecessary confirmatory investigations and 
ensuring that patients are not over-staged. 
PET-CT offers the potential to identify incidental pathology that may change the 
management with regards to the oesophageal cancer or the patient in general. In our 
cohort, 11.2% (43/383) had uptake in other organs and 1.0% (4/383) of patients had 
incidental neoplastic disease confirmed. This compares to 6.6% and 1.6% respectively in 
the study by Noble et al126. In the three-counties study, 8% patients had uptake in other 
organs all of whom were shown to have benign conditions not requiring treatment130. 
Therefore, although incidental neoplastic disease can be identified in a small percentage 
of patients and other treatments are occasionally undertaken, the poor prognosis of 
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oesophageal cancer is such that this dictates outcome (survival) rather than any 
incidental disease. 
PET usage is commonplace; however, as part of routine staging, its influence on 
management may be minimal and restricted to those patients with advanced stages of 
disease. Whilst it is becoming clear that patients with less advanced cancers may not 
benefit from undergoing a PET scan, no method for accurately identifying such patients 
is currently available. The authors have developed criteria based on endoscopy and CT 
findings that can accurately identify a proportion of patients (22%) in whom PET scan 
will be negative for metastatic disease and could be spared this investigation. Of the 52 
patients with metastatic disease demonstrated on PET, none were categorised as having 
a low probability of metastatic disease. 
It may be argued that PET can identify nodal disease not reaching CT criteria for lymph 
node metastases. This could impact on the decision to give neoadjuvant therapy. 
However, in our series none of the patients that were upstaged on PET and would not 
have had a PET under the new criteria had a decision to give chemotherapy based on 
the PET result. Therefore, limiting the use of PET-CT in this series would not have 
changed the decision making process regarding neoadjuvant chemotherapy. 
Financial implications must be considered with the routine use of PET-CT in the staging 
of patients with oesophageal cancer. Whilst a reduction in unnecessary operations as a 
result of identifying occult metastatic disease may lead to cost savings, the investigation 
itself bears a cost which could be reduced by restricting its use to those with a realistic 
chance of benefit. 
176 
 
This study is limited by its retrospective design. A digital, centralised radiology package 
gave us reliable CT reports, but endoscopy results were only recorded on local systems 
leading to some missing data. It can be difficult to determine the true treatment intent 
and MDT recommendation before PET-CT scan in an era when the investigation is used 
routinely. In our study, as in others, the false positive rate/specificity of PET-CT has not 
been quantified since biopsy confirmation of positive lesions is not performed in all 
cases. Likewise, it is not possible to calculate sensitivity of PET-CT in detecting metastatic 
disease but the treatment outcomes in patients are shown in order to give an idea of 
the influence of PET-CT results on patient management. 
In order to demonstrate its external validity, this classification needs to be applied in 
other institutions to be sure that similar results can be achieved in the presence of locally 
variable factors such as radiologist reporting and CT technology. 
Conclusions 
PET-CT undoubtedly makes a contribution to the staging of patients with oesophageal 
cancer and guidelines recommend its routine use in patients with potentially curable 
disease. The investigation is useful to confirm suspected sites of metastases and in 
localising the most suitable sites for biopsy. Unfortunately, only a small proportion of 
patients benefit from the information provided by PET-CT. In the largest study of this 
kind to date, the authors re-evaluate the use of PET-CT in the staging of oesophageal 
cancer and introduce a classification based on endoscopy and CT findings that can 
predict a group of patients who will not benefit from PET-CT scanning and could be 
spared this investigation. 
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Summary 
The risk-stratification criteria and results above were presented to the MDT business 
meeting on 24th July 2014. The criteria will now be applied to patients discussed at the 
forthcoming MDT meetings and decisions regarding whether to perform staging 
laparoscopy or PET scan will be made accordingly. Results will be monitored over the 
next 12 months to audit the adoption of this service improvement tool and to ensure its 
safety.  
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CHAPTER 5 - PREDICTION OF NEOADJUVANT THERAPY 
RESPONSE: CLINICAL REVIEW 
Introduction 
In Chapter 1 it was shown that outcomes in oesophago-gastric cancer are poor. 
Neoadjuvant therapy has been used in an attempt to improve survival. The widespread 
adoption of neoadjuvant treatments was initially hampered by conflicting results of 
randomised trials26, 27. A large US trial36 and an updated Cochrane review29 failed to 
demonstrate any significant benefit from the use of pre-operative chemotherapy. 
However, two important trials, the MRC OEO2 study28 and the MAGIC trial25, have 
demonstrated a benefit associated with the use of pre-operative chemotherapy. The 
lack of benefit in non-responders may explain why initial trials failed to demonstrate any 
overall benefit26, 36. Trials in chemoradiotherapy have suffered from similar limitations 
but again recent reports indicate that pre-operative chemotherapy is likely to be 
associated with a benefit in patients with oesophageal cancer31-33. As a result of the 
more recent studies above, guidelines now suggest using neoadjuvant 
chemotherapy/chemoradiotherapy in patients with oesophageal cancer and 
chemotherapy in patients with gastric cancer12. As a result, these multimodality 
treatments have become the standard of care in the UK. 
Whilst neoadjuvant treatment has been shown to improve outcomes, typical 5-year 
survival rates of 23%-47% are still poor12, 25, 34. The findings shown in Chapter 3 that only 
responders to neoadjuvant therapy gain any benefit may be partly responsible for this36, 
40, 41. A wide range of response rates is quoted in the literature with complete response 
rates of 0-13% 40-44, 78 and complete/near-complete responses of 11-40%36, 40, 44. Poor 
overall survival in patients despite the use of neoadjuvant therapy may be due to poor 
survival in non-responders that make up the majority. The wide range in reported 
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response rates may be due to patient factors or differences in treatment but could also 
result from the varying methods of defining response. The latter was addressed in the 
previous chapter and response has been re-defined in our population. Though there are 
many ways to measure response to therapy, it must be remembered during this review 
that those methods relying on histological analysis have been shown to be the most 
reliable and correlate best with survival. 
Despite not gaining any benefit from neoadjuvant therapy, non-responders are still 
exposed to the risks of therapy and face a delay to potentially curative surgery. These 
factors together with the observations above have led to a number of authors calling for 
research into how the response to neoadjuvant chemotherapy/chemoradiotherapy can 
be predicted in patients with oesophageal and gastric cancer24, 38, 41, 49, 51, 54, 56, 133, 134. 
Predicting response 
The earlier in a patient’s treatment pathway that response can be predicted, the greater 
the potential to influence changes in management. Any factors identifiable before 
starting neoadjuvant therapy are truly predictive. These could be used to change 
management in predicted non-responders by directing clinicians towards second-line 
chemotherapy regimens or by avoiding potentially harmful neoadjuvant treatment 
altogether and proceeding directly to surgery. Patients predicted to respond may even 
be considered for having all ‘peri-operative’ cycles of chemotherapy up front, before 
surgery although there is no evidence to support this as yet. 
Early assessment of response 
Early assessment of the response to neoadjuvant treatment (after treatment has been 
started) can be thought of as an in vivo way of assessing chemo-sensitivity and could 
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also influence a change in treatment at this stage although it would not have all the 
benefits of pre-therapy prediction135. 
Measuring response after treatment 
Finally, response can be assessed after completion of neoadjuvant treatment. Although 
too late to influence chemotherapy, it may give valuable information on prognosis and 
influence whether or not to proceed with attempted curative resection. 
Biomarker research 
What is a biomarker? 
The National Institute of Health Biomarkers Definition Working Group defined a 
biomarker as a “characteristic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes or pharmacological responses to a 
therapeutic intervention”136. Matuszcak et al go further to suggest this definition implies 
it should be easily detectable and measurable in the relevant patient samples; be 
consistently expressed and refractory to degradation in these samples in order to allow 
proper analysis on clinical samples137. 
What are the ideal properties of a biomarker? 
Fareed et al state that the ideal predictive marker should be reliable, readily available 
and detectable by reasonably acceptable laboratory techniques57. In a commentary for 
the Journal of the National Cancer Institute, Pepe et al suggest that the ideal marker 
should be sensitive, specific and cost-effective138. 
Biomarker development 
In order to define the process of biomarker development; to set standards for 
development and to standardise development, organisations have described the 
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process using a number of phases. In 2001, The Early Detection Research Network 
(EDRN) backed by the National Cancer Institute established a development sequence of 
five phases of biomarker development for cancer diagnosis/screening138, see Table 54. 
Phase Description 
I Preclinical exploratory studies 
II Clinical assay development for clinical disease 
III Retrospective longitudinal repository studies 
IV Prospective screening studies 
V Cancer control studies 
Table 54 Phases of biomarker development according to the Early Detection Research Network (EDRN). 
In a further news article published in the Journal of the National Cancer Institute in 2004, 
it was acknowledged that development of biomarkers used as prognostic indicators is 
much more complicated than for markers used strictly for detection because there is an 
additional step in the validation where the relationship between biomarker and 
outcome has to be investigated139. Not only is the association important, but the issue 
of causation and a true biological effect has to addressed. A separate process was 
described by the American Society of Clinical Oncology’s tumour marker guideline 
committee which includes three phases and is more relevant to prognostic/predictive 
markers140, see Table 55: 
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Phase Description 
I Identification of potential association between marker and outcome 
II Measurement of association between marker and outcome 
III Randomized marker validation trial 
Table 55. Phases of biomarker development according to the American Society of Clinical Oncology140. 
Whilst the process of biomarker development has been described in phases as above, 
put simply, it is clear that there are two main aspects of development, namely biomarker 
discovery and biomarker validation. Discovery aims to identify potential candidate 
markers and validation aims to independently establish accuracy and clinical usefulness. 
Biomarker discovery 
There are multiple approaches being used to identify potentially useful biomarkers. 
These approaches can be classified into two groups: 
Hypothesis-driven approaches 
Firstly, knowledge-based methodologies focus on specific markers or pathways and can 
include seeking novel applications of existing biomarkers; investigating new biomarkers 
and hypothesis-driven immunohistochemical techniques134.  
Examples of existing markers include routine haematological/biochemical parameters 
measured in peripheral blood such as white cell count or alkaline phosphatase, which 
have recently been examined for their predictive and prognostic potential. 
Biochemical research frequently identifies new factors such as cell surface antigens, 
receptors or intracellular enzymes. If these are differentially expressed in cancer 
patients or tissues compared to controls this will stimulate interest in them as potential 
screening or prognostic markers. Any molecular factors identified from pathways 
involved in carcinogenesis will be subject to interest as potential diagnostic/prognostic 
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markers or targets for therapy. Similarly, with specific regards to potential markers of 
chemosensitivity/chemoresistance, molecular cancer research has identified a large 
number of markers that function in pathways related to the mechanism of action of anti-
cancer therapies. Such markers are often seen as having predictive potential and are 
investigated accordingly. 
Therapeutic trials are often used as a means of retrospectively investigating the value of 
such potential markers since issues of ethical approval, consent, sample acquisition and 
data collection are already covered. 
Mass discovery approaches 
Secondly, high-throughput or ‘fishing’ approaches such as gene expression RNA 
profiling, single nucleotide polymorphism (SNP) array analysis, microRNA expression 
analysis and proteomics have been used to screen for potentially predictive 
biomarkers80, 134, 141-145. 
Biomarker validation 
Biomarker development can be lengthy, costly and complex. The key to successful 
biomarker development is validation and although the term is used frequently and there 
are much written on the subject, it is poorly understood139. It is beyond the scope of this 
chapter to enter a lengthy discussion on the concept of validation, however, it is 
important to understand that once the relationship between a biomarker and outcome 
has been investigated and normal marker ranges/thresholds set as necessary, the 
marker needs to be tested in a further prospective validation cohort. Whether a 
predictive marker can achieve a difference in outcome by changes in management can 
then only be identified as part of a randomised trial. The process of biomarker 
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development requires collaboration between clinicians, biologists and statisticians 
which to date has been limited138 
Aims 
This chapter aims to provide an up to date summary of the published literature on 
predicting response to neoadjuvant therapy in oesophago-gastric cancer. This is 
separated into two distinct parts. Firstly, in Part 1, a review of clinicopathological and 
radiological predictors is presented. In Part 2, molecular biomarkers derived from blood 
serum/plasma (known as circulating biomarkers) and those derived from tumour tissue 
and are summarised. 
Part 1: Clinical, pathological and radiological markers 
Methods 
A MEDLINE search using the PubMed service was performed using the terms esophageal 
cancer, oesophageal cancer, gastric cancer and predicting response to neoadjuvant 
therapy, chemotherapy or chemoradiotherapy. Papers including clinical, pathological 
and radiological criteria were reviewed. Summaries of potential clinicopathological and 
radiological predictors are presented, the latter presented according to radiological 
modality. 
Results 
Clinicopathological markers 
Ajani et al devised a model based on clinicopathological parameters to predict 
pathological response in 322 patients undergoing preoperative chemoradiation for 
oesophageal cancer49. The following parameters were identified as contributing to the 
model: the post-chemoradiation biopsy, post-chemoradiation PET, sex, histologic 
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tumour grade and baseline T stage (Endoscopic Ultrasound). The area under the 
receiver-operating characteristic curve was 0.70; however, they admit that other 
parameters (biomarkers) would be required to accurately predict response. 3 of the 5 
parameters were measured after chemoradiation treatment which limits its predictive 
nature and clinical usefulness.  
A further study identified nutritional status, T stage, M stage and alkaline phosphatase 
(also considered as a circulating molecular marker, see below) as significant factors that 
contributed independently to the response of oesophageal cancer to 
chemoradiotherapy146. Other factors were associated with response on univariate 
analysis but lost significance on multivariate analysis including body mass index, N stage, 
and tumour length. Odds ratios of the four independently predictive factors were 
approximated and scored. The overall response score was able to differentiate between 
responders and non-responders and a high score was associated with a greater chance 
of complete response (72.7% vs. 14.8%, P<0.001). In this study chemoradiotherapy was 
with palliative/curative intent rather than neoadjuvant and no patients went on to 
resection. Response was measured radiologically using the WHO criteria. 
MacGuill et al investigated a wide range of pre-treatment clinicopathologic factors in 
176 patients undergoing neoadjuvant chemoradiotherapy for oesophageal cancer in 
Dublin and showed that only tumour length differed significantly between responders 
and non-responders to chemotherapy147. A smaller tumour length was predictive of a 
greater response to chemotherapy (p<0.05). They concede that results may indicate 
existing dose and treatment schedule are inadequate in larger tumours rather than 
representing different tumour biology and a true increased responsiveness to therapy 
in smaller tumours. 
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Improvement in dysphagia has been investigated by two studies regarding its potential 
to predict the pathological response to chemotherapy/chemoradiotherapy. Neither 
study demonstrated significant predictive ability60, 148. 
The National Centre of Tumor Diseases in Heidelberg evaluated the prognostic 
significance of various clinicopathological parameters in 410 gastric cancer patients 
treated with neoadjuvant chemotherapy149. Multivariate analysis identified three 
parameters associated with improved response to therapy and prognosis. These were 
tumour localization in the middle third of the stomach (P=0.001), well-differentiated 
tumours (P=0.001) and intestinal tumour type (P=0.001). A scoring system was 
developed from these parameters separating patients into low, medium and high risk 
groups. Suggestions of how this information should be used to alter management are 
not given only to suggest the system needs to be prospectively validated in another 
cohort. Even if patients deemed at high risk were considered for alternative strategies, 
this group only accounts for 15.4% patients. Even in the intermediate and low risk 
groups, 75% and 67% patients respectively did not respond to chemotherapy indicating 
that the system is not sensitive in identifying non-responders.  
Other authors have suggested that tumour subtypes based on anatomical location may 
behave differently in many ways including response to therapy, however, it is suggested 
that these subtypes may have less relevance to systemic chemotherapy treatment 
compared to for example surgical approach and pattern of recurrence38. A study in 1775 
patients with cancers of gastric, junctional and oesophageal subtypes demonstrated no 
significant difference in response rate to palliative chemotherapy between the three 
types150. 
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Brown et al investigated the value of endoscopic assessment of tumour regression after 
neoadjuvant chemoradiotherapy in patients with oesophageal cancer. Endoscopy can 
predict some complete responders but it is not sufficiently accurate to be used for 
excluding patients from further treatment on the basis of inadequate response151. 
Radiological criteria 
CT 
Westerterp et al published a systematic review on the use of CT (and EUS/PET, see 
below) to assess response to neoadjuvant therapy using histopathological response as 
the reference standard58. CT has limited sensitivity (33%-55%) and specificity (50%-71%), 
the authors concluding that CT has poor accuracy for assessment of response when 
compared to EUS or PET. 
More recently, Motoori et al assessed the use of CT in the early evaluation of tumour 
response to neoadjuvant chemotherapy (after completion of the first cycle of 
neoadjuvant chemotherapy)152. Patients with a >20% decrease in the size of the primary 
tumour were defined as early responders and the remainder as non-responders. 20% 
patients were classified as responders. The progression-free survival and response to 2nd 
chemotherapy cycle were poorer in the non-responder group. In addition to non-
responder status, clinical T3 stage was an independent predictor or poor survival. In non-
responders with T3 disease survival was poor and no difference was observed between 
those undergoing one or two cycles of neoadjuvant chemotherapy therefore authors 
suggest discontinuation of neoadjuvant chemotherapy in early non-responders with T3 
disease according to CT. 
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To summarise the use of CT in assessment of chemotherapy response, it is becoming 
clear that progression of disease on CT after completion of neoadjuvant chemotherapy 
is usually associated with a very poor histopathological response and overall prognosis 
which presents a strong argument in such cases for considering avoidance of surgery38. 
However, the value of CT in early assessment of response and determining whether 
patients should continue neoadjuvant chemotherapy is not proven. 
Endoscopic ultrasound 
The main role of EUS before commencing neoadjuvant chemotherapy is in accurate 
determination of the T-stage and this may be used in part to determine whether a 
patient is offered neoadjuvant chemotherapy although not on the basis of whether or 
not a patient is likely to respond but rather whether it is required at all. 
In Westerterp’s systematic review, EUS was show to be more accurate than CT in the 
assessment of response to chemotherapy, with sensitivities of 50%-100% and 
specificities of 36%-100%58.  
EUS is an invasive procedure, its use is not as widespread at CT and it is not possible to 
pass the tumour in a proportion of cases, limiting its usefulness. As with endoscopy and 
CT, at best EUS could be used in the early assessment of response to therapy which has 
already started rather than acting as a predictive test before initiation of treatment. 
Metabolic criteria (FDG-PET) 
Metabolic imaging (FDG-PET) currently provides the most promising data in the 
prediction of histopathological response to neoadjuvant therapy using radiological 
means. 
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Single scan 
The ability of absolute pre-treatment PET to predict response is unclear. Studies have 
shown that initial maximum standardized uptake value (SUVmax) is unable to predict 
response to chemotherapy153-155. In a study of patients with oesophago-gastric 
junctional adenocarcinoma undergoing neoadjuvant chemotherapy absolute SUVmax 
levels from scans performed 2 weeks after initiation of therapy and preoperatively did 
not demonstrate a significant correlation with histopathological response or survival.155 
One study suggests that the number of PET abnormalities (reflecting the regional nodal 
metastases) correlates with overall survival but not pathologic response156. 
Serial scans 
A number a reports have investigated the use of serial FDG-PET measurements in 
predicting the pathological response to chemotherapy. These have been reviewed by 
Bain and Petty in 201038.  
The strongest evidence supporting serial PET in the predicting histological response 
comes from the Munich group. A reduction in metabolic activity (SUV decrease ≥35%) 
14 days after initiation of chemotherapy was shown to correlate with histopathological 
tumour regression, a higher rate of curative resections and longer survival157, 158.  
The Metabolic response evalUatioN for Individualisation of neoadjuvant Chemotherapy 
in esOphageal and esophagogastric adeNocarcinoma trial (MUNICON) assessed the 
feasibility of an algorithm based on PET response159. Metabolic responders underwent 
further chemotherapy and non-responders went straight to surgery after the initial 2 
weeks’ chemotherapy. The metabolic responders did have a higher histopathological 
response rate, however 50% of those predicted to respond did not and therefore did 
not receive any clinical benefit from neoadjuvant therapy. The hazard ratio for survival 
between those with a PET response and histopathological response and those with a 
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PET response but no histopathological response was 4.55 (95% CI, 1.37-15.04; p=0.004). 
This demonstrates clearly that the histopathological response is still a stronger indicator 
of clinical outcome and that PET is only partly able to predict this. 
In the protocols above, chemotherapy has to be given for two weeks before any 
predictive value is gained. One study performed PET on day 7 after initiating 
chemotherapy and found no correlation between the change in SUV from baseline and 
the TRG160. Delaying the PET until 3 months after starting chemotherapy or after 
completion does not result in a better correlation with histological response suggesting 
that 14 days is the optimal period155. The optimal timing may be dependent on the type 
of chemotherapy regime used. 
It has been hoped that similar results could be achieved with the use of neoadjuvant 
chemoradiotherapy rather than chemotherapy. The Munich group showed similar 
results with chemoradiotherapy using a threshold of 30% reduction in SUVmax for 
patients with oesophageal squamous cell cancer161. In a study from the Netherlands, 
SUV decrease at 14 days was associated with histopathological tumour response but the 
accuracy in detecting non-responders was too low to justify the use of PET for early 
discontinuity of chemoradiotherapy162. Other centres have failed to demonstrate any 
positive results163, 164. In the study by Malik et al from Dublin, the negative results may 
have been due to differences in the chemotherapy part of the regime which ceased at 
day 6, allowing time for an inflammatory radiation response to develop in the 
oesophagus and obliterating any potential reduction in SUV values by the time of the 
PET scans at day 9-14163. This study included only adenocarcinoma whereas the Munich 
study included only squamous cell cancer which could also explain the differing results. 
However, a further study including both histological types demonstrated a higher 
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metabolic response to chemoradiotherapy in adenocarcinoma compared to squamous 
cell carcinoma and different optimal threshold values165. This adds further complexity 
to interpretation of studies that include differing cancer subtypes and typifies the 
difficulties in appraising such literature. 
A systematic review and meta-analysis of prediction of tumour response to neoadjuvant 
chemotherapy/chemoradiotherapy in patients with oesophageal cancer using PET was 
published in 2010166. It reviewed 20 studies totalling 849 patients including both 
adenocarcinoma and squamous carcinoma types. Pooled sensitivity and specificity were 
67% and 68% respectively. The area under the ROC curve was 0.7815. They concluded 
that PET should not be used to guide neoadjuvant therapy decision in patients with 
oesophageal cancer. 
PET Parameters 
Rather, than simply the maximal tumour SUV, other parameters have been considered 
as potentially more useful in prognostic scoring and may be more powerful predictors 
of chemotherapy response. The number of baseline PET abnormalities (reflecting the 
regional nodal metastases) was significantly associated with overall survival156. A 
separate study showed that post-chemoradiotherapy uptake in a focal distribution 
compared to diffuse uptake predicted residual disease when maximal tumour SUV and 
length of uptake did not suggesting that this qualitative measure may be a more 
accurate predictor of response to therapy167. A recent paper found the post-
chemoradiotherapy metabolic tumour volume correlated with the TRG score but that 
the maximum tumour SUV did not153. 
Although PET shows some promise in predicting the response to neoadjuvant therapy, 
there are clearly outstanding issues that need to be overcome before it could be used 
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reliably in the clinical setting to make treatment decisions. Many issues relate to 
heterogeneity between studies and these would need to be addressed with 
standardisation of various factors including PET acquisition, image analysis, optimal PET 
parameter, chemotherapy/radiotherapy regime and tumour subtype. These could be 
overcome with a well-designed multicentre study and followed by randomised trials in 
order to prove that outcomes could be improved by using PET as a predictor of 
response166, 168.  
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Part 2: Molecular biomarkers 
Methods 
A systematic search of the MEDLINE, Embase, and Cinharl databases was performed 
using the NICE Healthcare Databases Advanced Search facility by combining the search 
terms “oesophageal cancer” or “esophageal cancer” or “gastric cancer” and “therapy”, 
“chemotherapy” or “chemoradiotherapy” and “predict” and “response”. Publications 
up to and including December 2014 were included. Titles were reviewed for suitability 
and after excluding irrelevant papers, the remaining abstracts/full-texts were reviewed 
as necessary. Additional studies were identified through reference lists, by a PubMed 
search and using the PubMed related articles feature. Only clinical studies were included 
rather than those using in-vitro methods. Studies using adjuvant therapy (after surgery) 
only were excluded. Only markers demonstrating a statistically significant relationship 
to therapy response were included.  
Search criteria - tissue markers 
Biomarker discovery is far more advanced in the case of tumour tissue markers 
compared to serum/plasma markers and the great number of publications relating to 
tissue biomarkers reflects this. It was therefore possible to be much more selective in 
the review of tissue biomarkers. Only studies in patients undergoing neoadjuvant 
chemotherapy/chemoradiotherapy and those measuring response using histological 
means were included. Studies using palliative treatments and those only reporting 
clinical response were excluded. Negative studies, studies in palliative/adjuvant therapy 
and those measuring only clinical response although not included in the main results, 
are referred to in the discussion where the additional information is helpful. 
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Search criteria - serum/plasma markers 
In contrast, for serum/plasma biomarkers, there are far fewer studies published and 
limiting the search to neoadjuvant therapies and those studies measuring histological 
response would risk excluding potentially useful studies with biomarkers that are yet to 
be investigated in the neoadjuvant role. Therefore, studies in palliative patients and 
those measuring only clinical responses were included. Once again, negative studies 
whilst not reported in the results section are referred to in the discussion where 
necessary. 
Presentation of results 
It was helpful to divide the large number of candidate markers identified into groups 
according to the function of the marker and the predominant cellular pathway in which 
it acts. 
A table including all studies on tissue markers was compiled and included data on 
anatomical tumour location, histological type, type of therapy 
(chemoradiotherapy/chemotherapy), number of subjects, the type of histological 
response assessment used, the biomarker of interest and the direction of correlation 
between biomarker level and response. Any systematic reviews/meta-analyses of 
specific markers are discussed separately in the text. 
A separate table was compiled for studies on plasma/serum marker which also included 
whether therapy was neoadjuvant or palliative. Again, systematic reviews/meta-
analyses are discussed separately in the text. 
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Results  
Search results 
The initial search identified 542 articles (see Figure 49). 479 were excluded on the basis 
of title alone. Abstracts and full texts were reviewed with further exclusion of 35 papers. 
28 studies were therefore included. A further 53 studies were identified through 
reference lists, a PubMed search and by using the PubMed related articles feature. Of 
the 81 studies identified in total, 51 investigated tissue markers and 30 investigated 
plasma/serum markers. 
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Figure 49 Flow chart of biomarker search 
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Tissue Biomarkers 
Growth factor receptors 
Epidermal growth factor receptor (EGFR), is also known as ErB-1 or HER-1 and is a 
member of the ErbB family of receptors. EGFR mutations are known to be associated 
with cancers and may form a heterodimer by pairing with another ErbB family receptor 
such as human epidermal growth factor receptor 2 (HER-2).  HER-2 has a direct activating 
ligand and its activity may be dependent on this EGFR pairing. Proliferating cell nuclear 
antigen (PCNA) is essential for DNA replication and repair. In a small study, Hickey et al 
showed that EGFR and or PNCA activity were associated with increased pathological 
response (P < 0.05). 
The search identified 4 studies demonstrating a relationship between HER-2 expression 
and histopathological response to chemotherapy/chemoradiotherapy. One study 
measured HER-2 mRNA using polymerase chain reaction (PCR) and the other 3 
measured protein using IHC. In 3 of the 4 studies, increased mRNA/protein levels were 
associated with reduced response53, 54, 169. In the other study, increased HER-2 levels 
were associated with increased response170. The latter study included only AC, 2 of the 
other 3 included only SCC and the final paper (Miyazono et al) included both AC and SCC 
types. Interestingly when Miyazono performed a subgroup analysis according to tumour 
type, HER-2 was associated with response in SCC but no significant relationship was 
found in patients with AC. This suggests that whilst the majority of positive studies 
looking at HER-2 show a relationship to response in SCC patients, the situation in AC is 
less clear with one study showing the opposite relationship and the other showing none. 
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Angiogenic factors 
Vascular endothelial growth factor (VEGF) is a signal protein that stimulates 
vasculogenesis/angiogenesis necessary for tumour growth. Imdahl et al showed lower 
levels of VEGF expression in patients was associated with a complete pathological 
response (P=0.035) and better long term survival (P=0.0205). 
Tumour suppressor genes 
p53 is a protein encoded by the TP53 gene, known as a tumour suppressor gene. TP53 
is frequently mutated in human cancers with mutations occurring in at least 40% 
oesophageal cancers171. Mutated p53 is more resistant to degradation and p53 levels 
are considered as a marker of mutation. It is a critical transcription factor and involved 
in cell functions that are key to cancer growth such as cell cycle regulation, apoptosis 
and DNA repair. It is not surprising then that its status is related to prognosis and it has 
been considered as an important potential predictive marker of response to therapy. 
In all 9 studies identified in this review, the wild-type TP53I or low p53 expression was 
associated with better pathological response. 
p21 is a cyclin-dependent kinase inhibitor that operates downstream of p53-dependent 
cell cycle regulation. One study has shown that increased p21 expression is associated 
with greater pathological response to hyperthermochemoradiotherapy in SCC 
oesophageal cancer(P=0.0213)172. 
DNA repair system/DNA synthesis 
Oesophageal and gastric cancers are commonly treated with 5-FU and platinum-based 
agent as part of multimodality therapy. Recently other agents such as epirubicin have 
been added to these regimes. 5-FU drugs are known as antimetabolites and act by 
inhibiting DNA and RNA synthesis. There are a number of proteins involved in the 
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metabolism of 5-FU products that affect chemotherapy sensitivity and protein levels, 
mRNA levels and polymorphisms of such enzymes have all been investigated as potential 
markers of chemosensitivity. Thymidylate synthase (TS) catalyzes the conversion of 
deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) 
necessary for the production of thymine which DNA synthesis is dependent upon. 5-FU 
metabolites compete with endogenous 5-dUMP for TS binding reducing its endogenous 
activity and therefore inhibiting DNA synthesis. This review identified 6 studies all 
showing that increased levels of TS protein or mRNA are associated with poorer 
response to chemotherapy presumably by overcoming the actions of 5-FU-based 
chemotherapy. 
Platinum-based drugs such as cisplatin and oxaliplatin act by binding DNA, producing 
cross-links and by free radical production. Therefore, the DNA repair pathway is 
important in resistance to platinum-based chemotherapy. Several genes and gene 
products acting in DNA repair pathways have been identified as potential markers for 
response to therapy. ERCC1 is involved in nucleotide excision repair of damaged DNA. 
This review identified 5 studies showing a significant association with response to 
platinum-based neoadjuvant therapy. Reduced ERCC1 levels and reduced mRNA levels 
were linked to increased response in 2 studies and 1 study respectively and two studies 
from the same research group, polymorphisms of the ERCC1 gene was associated with 
response. 
High levels of the DNA double-strand break repair enzyme DNA-PKcs have been shown 
to correlate with increased response to chemoradiotherapy (P=0.0149). 
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The XRCC1 gene is involved in base excision repair and a polymorphism of this gene has 
been shown to correlate with response to chemoradiotherapy in oesophageal cancer 
(P=0.002)173. 
p53R2 is a ribonucleotide reductase regulated by p53 and supplies nucleotides to repair 
damaged DNA. Lower p53R2 expression was associated with better pathological 
response (P=0.0018)174. 
A study in 79 patients undergoing neoadjuvant chemoradiotherapy for oesophageal 
cancer created tissue micro arrays from tumour tissue and evaluated expression of a 
number of proteins involved DNA repair pathways175. Higher scores for MLH1 (P=0.018) 
and lower scores for FANCD2 (P=0.037) were associated with pathological response to 
chemoradiotherapy on multivariate analysis. 
Apoptotic factors 
Regardless of the precise upstream mechanism of toxicity, chemotherapy and radiation 
induce apoptosis through the intrinsic (mitochondrial) pathway. Therefore, inhibitors of 
apoptosis (e.g. survivin) and pro-apoptotic factors (e.g. Bax) have been investigated as 
potential markers for response to chemotherapy and radiotherapy. Reduced survivin 
expression is associated with increased pathological response (P=0.043) and survival 
(P=0.0023)176. 
Cox-2 may also be associated with resistance to apoptosis as well as mediating 
angiogenesis, tumour growth and tumour invasion57, 177. Both Cox-2 expression (P=0.01) 
and Cox-2 mRNA (P=<0.05) levels are associated with reduced pathological response178, 
179. 
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DNA transcription factors 
Nuclear factor kappa B (NF-B) controls transcription of DNA and high levels have been 
associated with reduced pathological response to neoadjuvant chemoradiotherapy in 
three studies (two from the same institution) that include patients with oesophageal 
cancer of both AC and SCC types. 
Cell cycle regulators 
Normal cell cycle function is a requirement for dividing cancer cells and cell cycle 
regulatory factors have therefore been suggested as targets for response to therapy. 
Three studies have demonstrated an inverse relationship between cyclin D1 levels and 
pathological response with 2 of those demonstrating an associated survival 
advantage180, 181. High CDC25B levels have been shown to correlate with increased 
response in two studies from the same group 182, 183. 14-3-3sigma is a conserved 
regulatory protein of the p53 family and is associated with increased response to 
chemoradiotherapy184. 
Chemotherapy/pyrimidine degradation 
Dihydropyrimidine dehydrogenase (DPD) inactivates 5-FU and not surprisingly, 
increased levels of the protein or mRNA are associated with reduced response to 5-FU 
based chemotherapy185-187. 
Proliferation index 
Ki-67 is a protein that is associated with and may be necessary for cellular proliferation. 
To date, 3 separate studies have shown an association between higher Ki-67 expression 
(one using the MIB-1 antibody) and increased pathological response to 
chemoradiotherapy188-190. 
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Other markers associated with chemotherapy resistance 
There are a number of other individual markers that that are involved in various 
pathways thought to influence sensitivity to chemotherapy/radiotherapy. Some of these 
have been shown to correlate with pathological response to therapy and are included in 
Table 56 below. Results from all the relevant studies are summarised in Table 56 below. 
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Mechanism/
pathway 
Marker and direction 
of change 
Site n T type Therapy Analytical method Outcome 
measures  
P value Author 
Growth factor 
receptors 
EGFR and/or PCNA -ve OC 14 SC CRT IHC PR 
OS 
<0.05 
0.0003 
Hickey et al. 1994191 
HER-2 OC 36 AC/SC CRT PCR PR(Junker) 0.015 Miyazono et al. 200453 
HER-2  OC 34 SC CRT IHC PR 0.02 Akamatsu et al. 2003169 
HER-2  OC 51 SC CRT IHC PR unknown Predescu et al.201254 
HER-2  OC/ 
OGJ 
42 AC CRT IHC PR 
OS 
<0.05 
0.010 
Duhaylongsod et al. 1995170 
Angiogenic 
factors 
VEGF  OC 56 AC/SC CRT IHC PR 
S 
0.035 
0.021 
Imdahl et al. 2002192 
Tumour 
suppressor 
genes 
p53  OC 59 SC CT IHC PR 0.032 Shimada et al. 2000193 
p53  OC 47 SC RT IHC PR <0.0001 Miyata et al. 2000182 
p53  OC 62 SC CRT IHC PR 
Clinical 
survival 
0.0001 
0.016 
0.0011 
Okumura et al. 2005174 
p53  OC 77 SC CRT IHC PR 0.005 Kishi et al 2002183 
p53  OC 48 AC/SC CRT/CT IHC PR 0.024 Beardsmore et al. 2003194 
p53  OC 28 SC CRT IHC PR 0.08 Sobajima et al. 2012195 
p53 mutation 
p53  
OC 64 SC CRT PCR 
IHC 
PR 
PR 
0.004 
0.042 
Makino et al. 2010196 
p53  OC OGJ 42 AC CRT IHC PR 
OS 
0.01 
n/s 
Duhaylongsod et al. 1995170 
p53  
p21  
OC 30 SC NACT IHC PR 
PR 
<0.01 
<0.01 
Nakashima et al 2000197 
p21 OC 32 SC NACRT IHC PR 0.0213 Ishida et al2007172 
DNA repair ERCC1  OC 129 SC CRT IHC PR 
OS  
<0.001 
ns 
Kim et al. 2008198 
ERCC1mRNA GC 38 AC CT PCR PR 
OS 
0.003 
0.034 
Metzger et al 1998199 
ERCC1  OC 36 AC/SC CRT PCR PR, Junker  <0.001 Warnecke-Eberz et al. 
2004200 
ERCC1 (rs11615) CT OC 153 AC CRT PCR PR <0.001 Metzger et al.2012201 
ERCC1 C118T OC 52 AC/SC CRT PCR  PR <0.003 Warnecke-Eberz et al. 
2009202 
DNA-PKcs  (protein) OC 67 SC/AC CRT IHC PR 0.0149 Noguchi et al 2002203 
XRCC1 Arg399Gln  GG 
type 
OC 210 SC CRT PCR PR 
 
 
MST 
OR 2.75 
(CI 1.14-
6.12) 
0.0002 
Wu et al 2006173 
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p53R2- OC 62 SC CRT IHC PR 
CR 
OS 
0.0018 
0.041 
0.0057 
Okumura et al. 2005174 
MLH1 
FANCD2 
OC 79 AC/SC CRT TMA PR 
PR 
0.018 
0.037 
Alexander et al2012175 
DNA 
synthesis/5-
FU 
metabolism 
TS protein OC 129 SC CRT IHC PR 0.04 Kim et al 2008198 
TS protein GC/ GOJ 22 AC CT Western Blot PR 0.03 Alexander et al 1995204 
TS GC 62 AC CT IHC PR <0.05 Fukuda et al 2006185 
TS  OC 99 AC/SC
C 
CRT PCR PR 
Survival  
<0.001 
0.003 
Joshi et al. 2005205 
TS mRNA GC 38 AC CT PCR PR 0.024 Metzger et al 1998199 
TS mRNA GC 65 AC CT PCR PR 
OS 
<0.001 
0.003 
Lenz et al1996206 
TP  OC 21 AC CT PCR PR(Becker) 0.013 Langer et al. 2007186 
Apoptotic 
factors 
Survivin  OC 51 AC/SC CT PCR PR 
survival 
0.043 
0.0023 
Kato et a.l 2001176 
COX-2  OC 18 SC/AC CRT IHC PR 0.01 Kulke et al 2004178 
COX-2 mRNA OC 29 SC CRT PCR PR <0.05 Takatori et al 2005179 
DNA 
Transcription 
factors 
NF-B -ve OC 58 AC CRT IHC, Western blot PR 
survival  
0.0001 
<0.05 
Abdel-Latif et al. 2004207 
NF-B +ve OC 43 AC/SC CRT IHC PR 
OS 
0.05 
0.06 (ns) 
Izzo et al. 2006208 
NF-B +ve OC 80 AC/SC CRT IHC PR 
OS 
0.006 
0.009 
Izzo et al. 2006209 
Cell cycle 
regulators 
Cyclin D1  OC 38 SC CRT IHC PR 
Survival ns 
0.026 Sarbia et al.1999210 
Cyclin D1  OC 34 SC CRT IHC PR/CR 
OS 
0.0025 
0.038 
Samejima et al.1999180 
Cyclin D1 OC 26 SC CRT PCR PR 
survival 
0.047 
0.02 
Brucher et al 2009181 
CDC25B  OC 47 SC CRT IHC PR 0.0168 Miyata et al 182 
CDC25B  OC 77 SC CRT IHC PR 
Survival ns 
0.038 
ns 
Kishi et al.2002183 
14-3-3sigma OC 36 SC CRT IHC PR 0.01 Okumura et al 2005184 
Chemo-
therapy/ 
pyrimidine 
degradation  
DPD GC 62 AC CT IHC PR <0.01 Fukuda et al 2006185 
DPD  OC 21 AC CT PCR PR Becker  0.032 Langer et al. 2007186 
DPD mRNA  GC 61 AC CT PCR PR 
OS  
0.006 
ns 
Napieralski et al 2005187 
Proliferation 
index 
MIB-1  OC 42 AC/SC CRT IHC PR 
S 
0.018 
0.0149 
Imdahl et al. 2000188 
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Ki-67  & p53- OC 95 AC/SC CRT IHC PR 0.0013 Kitamura et al. 2000189 
Ki-67 OC 41 SC CRT IHC PR 0.033 Takeuchi et al2003190 
Other 
genes/protein
s associated 
with 
chemotherap
y resistance 
ABCB1 C3435T 
(rs1045642) 
OC 262 AC/SC CRT Real-time PCR Lymph node 
formation 
0.012 Narumiya et al. 2011211 
 
CHK2  OC 94 SC CRT IHC PRBecker 0.0011 Sarbia et al 2007212 
Caldesmon  OC 38 AC CT PCR PR, Becker 0.016 Langer et al. 2005213 
MTHFR  OC 38 AC CT PCR PR, Becker 
Survival  
0.012 
0.015 
Langer et al. 2005213 
MRP1 OC 38 AC CT PCR PR, Becker 
survival 
0.007 
0.017 
Langer et al. 2005213 
MT OC 30 SC CRT IHC PR 
Survival ns 
0.0024 Yamamoto et al 1999214 
MT OC 77 SCC CRT IHC PR  0.033 Kishi et al 2002183 
ALDH-1 OC/GOJ 167 SC/AC CRT IHC PR <0.001 Ajani et al 2014215 
hsa-miR-296 
HS-240 
hsa-miR-141 
hsa-miR-31 
HS-217 
OC 25 SC/AC NACRT PCR PR 0.007 
0.040 
0.019 
0.018 
0.048 
Ko et al.2012144 
let-7b 
 
let-7c 
OC 74 SC NACT PCR PR 
OS ns 
PR 
OS 
0.014 
ns 
0.032 
0.032 
Sugimura et al 2012216 
Lin28 GC 47 AC NACT IHC PR 0.006 Teng et al2013217 
c-MYC 
PSEN1 
GC 
 
69 
 
AC NACT PCR PR 
PR 
0.013 
0.033 
Munzig et al 2014218 
Table 56 Tumour tissue biomarkers demonstrating potential in prediction of the response to chemotherapy/chemoradiotherapy. 
EGFR, epidermal growth factor receptor; HER-2, Human epidermal growth factor receptor 2; VEGF, vascular endothelial growth factor; NF-B nuclear factor kappa-light-chain-
enhancer of activated B cells; MRP1, multidrug resistance protein 1; GST, glutathione-S-transferase; GC, gastric cancer; OC, oesophageal cancer; AC, adenocarcinoma; SC, squamous 
carcinoma; CRT, chemoradiotherapy; CT, Chemotherapy; IHC, immunohistochemistry; PCR, polymerase chain reaction; OS, overall survival; PFS, progression-free survival; PR, 
pathological response; PCNA, Proliferating cell nuclear antigen; TP, Thymidine phosphorylase; DPD, Dihydropyrimidine dehydrogenase; MT, Metallothionein; TS Thymidylate 
synthetase; MTHFR Methylene-tetrahydrofolate reductase; CHK2, Checkpoint kinase 2. MST, Median survival time; ALDH-1, aldehyde dehydrogenase-1; TMA, tissue microarray
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Plasma/Serum Biomarkers 
Liver function tests 
In one analysis, a higher level of pre-therapy serum alkaline phosphatase was shown to 
be associated with poorer clinical response to chemoradiotherapy in patients with 
oesophageal cancer (univariate, P=0.009, multivariate P=0.014)146. Alkaline 
phosphatase is found in all human tissues can be seen as a general, non-specific marker 
of malignancy and the authors found that higher pre-therapy T and M stage were 
associated with poorer response to chemoradiotherapy. It is therefore expected that 
alkaline phosphatase may simply be acting as a marker of more advanced disease but 
the multivariate analysis suggests there may be an independent association. 
Serum albumin can be seen as a marker of nutrition which is thought to affect sensitivity 
to and tolerance of neoadjuvant therapy. In the study by Kogo et al, low albumin was 
found to be a predictor of poor clinical response on univariate analysis but not 
multivariate analysis146. In a retrospective analysis of 105 patients undergoing definitive 
chemoradiotherapy, a serum albumin level of >35g/l was shown in a multivariate 
analysis to be an independent predictive factor of complete pathological response219. A 
more recent and larger retrospective study on 246 patients showed that amongst a 
panel of baseline nutritional biomarkers, only serum albumin levels predicted 
pathological response to neoadjuvant chemotherapy on multivariate analysis 
(P=0.029)220. 
A lower alanine transaminase (ALT) was associated with a greater chance of clinical 
response to neoadjuvant chemotherapy in a study of 38 patients with locally advanced 
oesophageal squamous cell cancer221. 
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Haematological markers 
In a retrospective study of 123 patients undergoing neoadjuvant chemoradiotherapy for 
oesophageal cancer, pre-treatment haemoglobin (Hb) level was shown to be the sole 
independent predictive factor of a good pathological response222. Yi et al also found that 
Hb levels correlated with response to chemoradiotherapy(P=0.005)223. Hb levels of 12.0 
to 14.0 g/dl were associated with the best response and patients with levels of >14.0 or 
<12.0 had poorer response rates.  
In a 38 patients with oesophageal squamous cell cancer undergoing neoadjuvant 
chemotherapy, those with higher white blood cell counts, lymphocyte percentages, 
mononuclear cell counts, neutrophil counts, and eosinophil counts had a significantly 
greater chance of having an effective clinical response221. Elevated pre-treatment 
neutrophil to lymphocyte ratio predicts poor clinical response to palliative 
chemoradiotherapy in patients with metastatic gastric cancer(P=0.034)224. 
Pre-therapeutic d-dimer levels have been shown to be significantly lower in responders 
to neoadjuvant chemotherapy when response was measured clinically and 
pathologically225. 
Tumour cell antigens 
In a study of 73 patients with advanced upper gastrointestinal adenocarcinoma 
undergoing palliative chemotherapy, baseline normal levels of CEA, TPA, CA19-9 and 
CA242 were associated with more clinical responses compared to elevated levels226. A 
model combining baseline levels with the change in levels after initiation of therapy 
provided a marginally but not significantly better prediction of outcome. 
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Yi et al demonstrated that CEA and CYFRA 21-1 may be helpful in predicting the 
responsiveness of oesophageal squamous cell carcinoma to chemoradiotherapy227. 
In 96 patients with SCC of the oesophagus, pre-treatment levels of Cyfra 21-1 correlated 
with histological response228.   
Complement 
A study in 31 patients with oesophageal cancer, serum samples were analysed using 
surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and 
ELISA143. Samples were analysed before chemoradiotherapy treatment and at 24-hour 
and 48-hour time points. Peaks relating to complement C4a and C3a had different 
intensity in pathological responders compared to non-responders. These were then 
quantified using an ELISA technique. Pre-treatment serum levels of C4a (P=0.002) and 
C3a (P=0.035) were significantly higher in poor responders compared to non-
responders. A leave-one-out analysis was used to determine that these proteins could 
predict response with a specificity and specificity of 78.6% and 83.3% respectively. In 
this proteomic profiling approach to biomarker discovery, these complement markers 
were not selected based on known mechanism relating to therapeutic sensitivity, 
however, as part of the complement family, they are linked to the inflammatory 
responses. Inflammation is known to drive the development of oesophageal cancer and 
a separate gene expression analysis by the same author has identified genes mediating 
inflammatory pathways that are differentially expressed in responders and non-
responders142, 143. 
DNA repair/platinum dug action 
Polymorphisms of the XRCC3 gene have been shown to predict clinical response to 
chemotherapy in gastric cancer but not histopathological response229. 
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Gusella et al identified a polymorphism of the XRCC1 gene that is associated with 
pathological response in patients with oesophageal cancer230. 
Two separate ERCC1 polymorphisms have been associated with clinical response to 5-
FU/oxaliplatin-based chemotherapy in a large study on 447 patients with advanced 
gastric cancer231. 
ERCC1 RNA levels can be measured in peripheral blood and have been shown to predict 
minor histopathological response to neoadjuvant chemoradiotherapy in patients with 
locally advanced cancer of the oesophagus232. 
A study in 89 patients with advanced gastric cancer showed that polymorphisms of the 
glutathione S-transferase P1 (GSTP1) gene was associated with clinical response to 
oxaliplatin/5-FU-based chemotherapy (P=0.026) and median overall survival 
(P=0.002)233. 
DNA synthesis/5-FU metabolism 
In a multivariate analysis, a 6-bp deletion in TS-3’UTR was associated with a significantly 
higher clinical response rate to 5-FU/oxaliplatin-based palliative chemotherapy in 73 
patients with advanced gastric cancer234. 
Increased levels of TS RNA measured in peripheral blood of 29 patients undergoing 
neoadjuvant chemoradiotherapy for oesophageal cancer. A high expression level of TS 
was associated with minor histopathological response235. 
DPD expression and mRNA levels measured tumour tissue were identified as promising 
markers of response to 5-FU therapy. One study investigated the predictive potential of 
4 DPYD gene polymorphisms in 362 patients with gastric cancer undergoing 5-FU-based 
chemotherapy as neoadjuvant or palliative therapy with response measured 
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pathologically and clinically respectively236. The rs1801159A/A polymorphism was over-
represented in responders (P=0.012). 
Angiogenic factors 
VEGF expression in tumour tissue was shown to act as a predictive biomarker of 
response to neoadjuvant chemotherapy in oesophageal cancer192.  Polymorphisms of 
the gene can be identified from peripheral blood DNA. Oh et al demonstrated that the 
G/G genotype of VEGF-634G/C polymorphism is related to higher serum levels of VEGF 
and is predictive of the response to 5-FU/oxaliplatin-based chemotherapy in patients 
with advanced gastric cancer237. 
The predictive value of serum VEGF-A levels was investigated in 103 patients with 
oesophageal SCC undergoing neoadjuvant chemoradiotherapy238. Higher pre-therapy 
VEGF levels correlated with lower pathological response to treatment (P=0.042), poorer 
disease-free survival (0.009) and poorer overall survival (P=0.07). 
Micro RNAs 
There is increasing evidence that microRNA (miRNA) expression in cancer tissue can help 
to predict the prognosis in cancer patients. The relationship between a number of 
circulating miRNAs and response to neoadjuvant chemotherapy in oesophageal cancer 
has been investigated239. High levels of miR-200c levels were shown to correlate with 
poor response to chemotherapy (P=0.0211) and poor progression-free survival 
(P=0.0076). 
Other markers 
Germline polymorphisms have been identified in genes that are less well known and 
single studies have shown associations with response to therapy. These genes include 
the LRP5 and STK15 genes240, 241. 
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Chen et al used genotyping arrays and mass spectrometry sequentially to determine 
germline polymorphisms that were associated with response to concurrent neoadjuvant 
chemoradiotherapy in patients with oesophageal cancer145. 2 SNPs were identified with 
a high accuracy for predicting response. 
Huang et al used a mass spectrometry technique to identify potential predictive markers 
of response to palliative paclitaxel/capecitabine chemotherapy in patients with 
advanced gastric cancer242. 17 proteins were identified that were differentially 
expressed in responders and non-responders. These were investigated in a validation 
cohort of 24 patients and (Alpha-1-Microglobulin/Bikunin Precursor (AMBP) was 
identified as being higher in patients with progressive disease compared to those with 
partial response when measured using ELISA(P=0.06) and Western blotting (P=0.03). 
Table 57 below includes all the serum/plasma biomarkers shown to be associated with 
response to chemotherapy/chemoradiotherapy in oesophago-gastric cancer. 
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Type of 
biomarker 
Marker  n Site Tumour 
type 
Therapy Outcome measure P value Author 
Liver function 
tests 
Albumin  105 OC AC/SC DefCRT CR 0.009 Di Fiore et al. 2007219 
Albumin  246 OC/ 
GOJ 
AC/SC NACT PR (Mandard) 0.037 Noble et al. 2013220 
ALT  38 OC SC NACT CR (WHO) 0.003 Liu et al. 2014221 
Alk phos 108 OC AC/SC CRT CR (WHO) <0.05 Kogo et al. 2008146 
Haematological 
markers 
Hb  123 OC SC CRT PR (JSED243) 0.02 Hamai et al. 2014222 
Hb (12-14g/dl) 181 OC SC DefCRT CR   0.005 Yi et al. 2010223 
WBC 
Lymp% 
Mon 
Eos 
Neut 
38 OC SC NACT CR (WHO) 0.003 
0.047 
0.027 
0.038 
0.005 
Liu et al. 2014221 
D-dimer  71 OC SC NACT CR 
PR 
0.0491 
0.0107 
Tomimaru et al 2008225 
NLR 269 GC AC Pall CT CR 
PFS 
OS 
0.034 
0.001 
0.001 
Cho et al 2012224 
Tumour cell 
antigens 
TPS 
CA19-9 
TPA  
CA242 
73 
 
UGI
* 
AC 
 
Pall CT 
 
CR  
CR  
CR 
CR 
0.007 
0.001 
0.036 
0.002 
Bystrom et al. 2010226 
 
CEA  
CYFRA21-1  
181 OC SC DefCRT CR 0.000 
0.000 
Yi et al. 2010223 
 
CYFRA21-1  96 OC SC NACRT PR 0.03 Quillien et al. 1998228 
Complement C3a  31 OC AC/SC NACRT PR (Mandard) 0.035 Maher et al. 2011143 
C4a  31 OC AC/SC NACRT PR (Mandard) 0.002 Maher et al. 2011143 
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DNA repair/ 
platinum drug 
action 
GSTP1-105VL or VV 89 GC AC PallCT CR 0.026 Li et al 2010233 
XRCC1 
XPA 
105 OC AC/SC NACRT PR  Gusella et al 2012230 
XRCC3 rs861539 
XRCC3 rs861530 
144 GC AC NACT CR 
 
PR 
0.02 
0.05 
ns 
Ott et al 2011229 
ERCC1 rs11615 TT/T 
 
ERCC1 rs2298881CC /C 
447 GC AC PallCT CR(WHO) 
OS 
CR(WHO) 
OS 
0.015 
0.018 
0.03 
0.02 
Lu et al 2014231 
ERCC1 RNA 29 OC AC/SC NACRT PR  0.004 Brabender et al.2008 232 
DNA synthesis/ 
5-FU 
Metabolism 
TS RNA 29 OC AC/SC NACRT PR 0.046 Grimminger 2009 et al235 
TS-3’UTR-6bp/-6bp 
XPD156 CA/AA 
73 GC AC PallCT CR 0.034 
0.038 
Keam et al 2008234 
DPYD rs1801159A/A 362 GC AC PallCT/NACT CR(WHO)/PR(Becker) 0.012 Zhang et al2012236 
microRNA miR-200c  (micro RNA) 64 OC SC NACT PR 
PFS 
0.0211 
0.0076 
Tanaka et al. 2013239 
Angiogenic 
factors 
VEGF-A 103 OC SC NACRT PR 0.042 Chiang et al238 
VEGF -634 GC or CC 190 GC AC PallCT CR 
PFS 
0.034 
0.043 
Oh et al2013237 
Other markers AMBP 17 GC AC PallCT CR 0.06 Huang et al242 
LRP5 rs3736228 CC 107 GC AC PallCT CR(RECIST) 
PFS 
OS 
<0.001 
<0.001 
<0.001 
Liu et al 2014240 
rs16863886 (SGPP2) 
rs4954256 (ZRANB3) 
116 OC SC NACRT PR 0.0006 
0.002 
Chen et al. 2012145 
STK15-T91A (Phe31Ile) 134 OC AC/SC NACRT PR  0.048 Pan et al. 2012241 
Table 57 Serum/plasma markers demonstrating potential in predicting the response to chemotherapy/chemoradiotherapy. 
Abbreviations: ALT, Alanine transaminase; CEA, Carcinoembryonic antigen; TPA, tissue plasminogen activator; SNPs, single nucleotide polymorphisms; AC, adenocarcinoma; SC, 
Squamous cell carcinoma; NACRT neoadjuvant chemoradiotherapy; PallCT, palliative chemoradiotherapy; CRT, chemoradiotherapy; CT, chemotherapy; TPS, Tissue polypeptide-
specific antigen; PR Pathological response; CR, Clinical response; UGI*, upper GI cancers including gastric, pancreatic and biliary. GST, glutathione S-transferase; VEGF-A, vascular 
endothelial growth factor A; NLR, neutrophil lymphocyte ratio; TS, thymidylate synthase; AMBP, Alpha-1-Microglobulin/Bikunin Precursor.
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Discussion 
A number of authors have recognised the need to predict the response to neoadjuvant 
therapy in the treatment of oesophago-gastric cancer and recognise the need for 
research in this area38, 44, 49-58. 
This chapter has reviewed the published literature on prediction of response to 
neoadjuvant therapy in patients with oesophago-gastric cancer. A summary of the 
literature relating to clinical, pathological and radiological markers has been presented 
and a detailed review of molecular biomarkers has been undertaken. 
Clinical, pathological and radiological markers 
Clinical, pathological and radiological markers are not the focus of the thesis but a 
summary of the published literature was presented in order to provide the background 
and historic context within which the field of molecular biomarkers has emerged. The 
most accurate model of prediction would take into account any factors that are shown 
to contribute to prediction in a multivariate analysis whether they are clinical, 
pathological, radiological or molecular and therefore any strong candidate variables 
should be further investigated. 
Of the clinicopathological markers identified in the reviewed literature, the following 
were shown to be significantly associated with response to therapy: gender, T stage, 
nutritional status, M stage, tumour length, tumour localization in the middle third of the 
stomach, well differentiated tumours and intestinal tumour type. Of these factors, only 
T stage appeared in more than study. 
The literature is limited by heterogeneity of subjects with regards to many variables 
including treatments, anatomical tumour locations, tumour types, tumour stage and the 
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means by which response to therapy was measured. The timescale over which studies 
are published adds further complexity as not only do patient selection and treatments 
change with time but staging criteria have also changed so the relevance of these studies 
to current practice remains uncertain. 
Many of the clinicopathological factors identified are amongst those routinely measured 
during assessment and staging and could therefore be investigated in a retrospective 
patient group. 
Molecular biomarkers 
The field of molecular biomarkers in oesophageal and gastric cancer is relatively new 
and rapidly expanding. A simple plot of the publication trends when searching for 
“gastric cancer biomarker” and “oesophageal cancer biomarker” shows the rate of 
growth in publications, see Figure 50. The combined number of publications per year 
has doubled in less than 4 years. An up to date search is vital in order to keep up with 
the pace of research. A number of authors have suggested that molecular biomarkers 
are likely to provide to provide the solution to the problem of predicting response to 
neoadjuvant therapy, see 24, 38, 52-55, 57. 
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Figure 50. Publication trends for "oesophageal cancer biomarker" and “gastric cancer biomarker” 
from PubMed.gov, US National Library of Medicine National Institutes of Health. 
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Figure 51 Authors suggesting that the solution to the problem of finding a means to predict response to 
neoadjuvant therapy is likely to be provided by molecular biomarkers. 
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Tissue markers 
A review of the literature on the role of molecular biomarkers in predicting the response 
to chemotherapy/chemoradiotherapy was performed. For this part of the review only 
those markers measured in tumour tissue were included. There are a huge number of 
potential biomarkers measurable in tissue and most will have no role in the prediction 
of response so only markers demonstrating statistically significant associations with 
response to therapy were included. Whilst there are a number of published biomarker 
discovery studies evaluating the predictive value of tissue markers for response to 
adjuvant or palliative therapy and these may be useful in identifying potential candidate 
markers for predicting response to neoadjuvant therapy, these were not included for 
two reasons. Firstly, the patients undergoing palliative therapies often have metastatic 
disease and therefore tumour biology may not reflect that in the less advanced tumours 
undergoing neoadjuvant chemotherapy. Secondly, in adjuvant and palliative therapy 
response can only be measured clinically which is known to be a poor surrogate marker 
of histopathological response. For the same reason, neoadjuvant studies where 
response was only measured clinically were also excluded. 
Growth factor receptors 
HER-2 is one of the first biomarkers to have been used successfully in the clinical 
management of solid tumours. It is used to determine sensitivity to trastuzumab in 
breast cancers over-expressing the receptor protein. There is in vitro evidence already 
reviewed by Miyazono et al53 suggesting that sensitivity to several chemotherapeutic 
agents and radiotherapy may be dependent on ErbB receptor status. The evidence 
suggests that HER-2 is able to predict sensitivity to cisplatin/5FU-based 
chemoradiotherapy in SCC of the oesophagus, however evidence in AC suggest either 
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no association or perhaps even an opposite relationship. Whilst in vitro evidence has 
suggested c-erB-1 may also determine chemotherapy/radiotherapy sensitivity, the 
evidence is mixed. One study demonstrated an association between marker levels and 
response for HER-2 but not c-erbB-153 and another demonstrated increase in response 
when either c-erbB-1 or PCNA were positive191. 
Angiogenic factors 
One study was identified supporting VEGF as a predictive biomarker and other authors 
have demonstrated associations with clinical response in patients undergoing NACRT or 
definitive CRT244, however, other studies have failed to identify a significant 
relationship178, 185. 
Tumour suppressor genes 
p53 is the most research biomarker for use in predicting response to therapy in 
oesophago-gastric cancer. All 9 studies identified in this review demonstrated an inverse 
relationship between p53 level/mutant form and histological response to therapy. 
However, other studies have not shown any such significant relationship212, 244, 245. 
A meta-analysis published in 2013 investigated the value of p53 status for predicting the 
response to chemotherapy/chemoradiotherapy in patients with oesophageal cancer171. 
A total of 28 studies with 1497 cases were included. Wild-type p53 (wild-type p53 gene 
and/or low p53 protein expression) was associated with a high rate of major pathological 
response to chemotherapy, risk ratio 1.15, CI 1.06-1.25, P=0.001. The authors concluded 
that p53 status might be a predictive biomarker for response to chemotherapy-based 
treatments in oesophageal cancer. The conflicting results in the literature were due to a 
lack of large-scale studies, no standardised evaluation of response, heterogeneity of 
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chemotherapy-based treatment and different methods of measuring p53 status which 
lack high sensitivity and specificity. 
Regarding p21, in addition to the one study showing an association between increased 
expression and greater pathological response, a further study showed that the 
combination of HIF-1 levels, p21 levels and p53 type (mutant vs wild) is a powerful 
indicator of clinical response to CRT246. Patients with high p21 expression had high 
sensitivity to CRT but only compared to those with low p21 and mutant p53. The detailed 
underlying mechanisms are beyond the scope of this report suffice to say that p21 
operates downstream of p53 and HIF-1 so it is perhaps not surprising that if p21 is 
looked at in isolation, results can be unpredictable and misleading. 
DNA repair system & DNA synthesis 
5-FU-based drugs predominantly act by inhibiting DNA synthesis and platinum-based 
drugs act by damaging DNA. Therefore, DNA synthesis and repair pathways encompass 
many markers that have the potential to influence sensitivity to these two drug types 
which form the basis of chemotherapy directed towards oesophago-gastric cancer. 
High TS protein and mRNA levels were identified as being associated with fewer 
pathological responses. ERCC1 protein and mRNA levels also correlated with lower 
pathological response rates.  
Hu et al published a systematic review in 2012 on the predictive value of TS in gastric 
cancer247. They analysed 24 studies including a total of 2,079 patients. 15 of the studies 
were in advanced gastric cancer undergoing palliative therapy and 9 were in localised 
cancers undergoing adjuvant therapy. They showed that high TS levels predicted poor 
response rates. They concluded that additional studies adhering to consistent 
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methodology would be needed to define the precise value of TS in these patients. 
Extrapolation to neoadjuvant therapy represents one further leap and therefore more 
studies in this defined population are needed. 
The promising results here have led to a search for polymorphisms in the genes involved 
in DNA synthesis/repair in the hope that they may be predictive of response. Although 
individual studies have identified polymorphisms that appear to achieve this, a 
systematic review analysing 5 studies for TS and 4 studies for ERCC1 failed to 
demonstrate any overall significant predictive ability248. However, in an analysis of 6 
studies investigating glutathione -S transferases (GSTs), they did find higher response 
rates in patients with the GSTT+ phenotype compared with the GSTT- phenotype 
including in a neo-adjuvant subgroup248. 
Whilst DNA-PKcs, XRCC1 polymorphism, p53R2, MLH1 and FANCD2 have been linked 
with response to therapy in isolated biomarker discovery projects, further studies will 
be required to substantiate their results. 
Polymorphisms of other genes relating to chemotherapeutic sensitivity and DNA 
synthesis/repair pathways have been identified from other studies in patients with 
advanced cancers undergoing palliative chemotherapy. Although results cannot be 
directly extrapolated to neoadjuvant treatment, they are useful in identifying potentially 
predictive markers for further investigation. On such study by Goekkurt et al identified 
polymorphisms of the TS gene and GSTP1 gene that were associated with clinical 
response to 5-FU and cisplatin-based palliative chemotherapy249. 
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Apoptotic factors 
Although survivin has been shown in one study to predict pathological response to 
chemotherapy and it may act as an independent indicator of overall prognosis, another 
study did not demonstrate a relationship with response to therapy250. 
Cox-2 has been shown to inhibit chemotherapy and radiotherapy induced apoptosis in 
vitro and therefore has been considered as a potential clinical predictive marker251. It 
has not been extensively investigated as yet but two studies have demonstrated a 
relationship between increased levels and reduced response to neoadjuvant 
chemoradiotherapy. A further study failed to show a relationship between pre-therapy 
COX-2 mRNA or protein levels and response to neoadjuvant chemoradiotherapy in a 
cohort containing 38.5% AC 251. The discrepancy in results cannot easily be explained by 
differences in tumour type or therapy regime, however, as is often the case, there were 
differences in techniques used to quantify of Cox-2 protein including the primary 
antibody. This illustrates a common and frustrating feature of biomarker discovery and 
development. 
DNA transcription factors 
NF-B control the transcriptional regulation of target genes involved in cell survival. NF-
B activation is a highly regulated process which can be initiated by a range of stimuli 
and has been associated with cancer209. It suppresses apoptosis when cancer cells are 
exposed to radiotherapy or chemotherapy and therefore has been investigated as a 
predictor of response to neoadjuvant therapy. Two studies from one centre and a 
further study have all shown that NF-B levels can predict pathological response to 
chemoradiotherapy. 
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Cell cycle regulators 
Amongst isolated reports of individually promising markers, Cyclin D1 is emerging as the 
strongest candidate biomarker acting through cell cycle regulation 3 studies have shown 
a significant relationship with pathological response to therapy however, there are also 
two published studies that fail to show any relationship182, 252. All studies were in 
patients with SCC undergoing chemoradiotherapy. One of the negative studies assesses 
clinical rather than pathological response252. 
Chemotherapy degradation 
Three studies have shown a correlation between DPD levels and the response to 5FU-
based chemotherapy. In one study using chemoradiotherapy, DPD above the median 
correlated with pathological response (P=0.014) however on ROC analysis, the result did 
not reach significance181. DPD is also often considered in the DNA synthesis group due 
to the mechanism of action of 5-FU which is inactivated by DPD. 
Proliferation index 
Ki-67 is a marker of cell proliferation, may be a necessary for cells to continue 
proliferating and has been shown to correlate with increased pathological response 
rates. Three further studies have failed to report and significant association 180, 182, 252. 
All these studies were in SCC whereas the positive studies all included AC except for one 
in which the P value was highest (0.033). This suggests Ki-67 may be better at predicting 
response in patients with AC compared to SCC. 
Micro RNAs 
The other group of markers worthy of discussion at this stage is microRNAs (miRNAs). 
These are short, non-coding RNAs that have a key role in post-transcriptional regulation 
of gene expression144. They are involved in cancer initiation and progression and there 
224 
 
is evidence that they impact on resistance towards various chemotherapeutics137. Since 
miRNAs are small, they are not easily degraded and can be extracted from formalin-
fixed, paraffin-embedded (FFPE) tissue blocks, a process which is considered unsuitable 
for mRNA profiling144. Identification of example miRNAs that differ between 
pathological responders and non-responders to neoadjuvant chemoradiotherapy for 
oesophageal cancer has been attempted through expression profiling in a study by Ko 
et al144. This study identified 5 miRNAs from tumour tissue that had greater than 2-fold 
differences between responder and non-responder groups and are worthy of further 
investigation in external cohorts. A further study in 90 gastric cancer patients was not 
including in the main results table because therapy was palliative and time to 
progression was used as a measure of benefit from chemotherapy253. A 58-miRNA gene 
expression signature was able to differentiate between those with delayed time to 
progression and those with rapid time to progression. A review paper reported on 9 
miRNAs identified from 7 in vitro studies that were associated with chemoresistance in 
gastric cancer and are worthy of further clinical evaluation. 
Other markers associated with resistance 
Of the other markers that have been liked to chemotherapy/chemoradiotherapy 
resistance, Metallothionein (MT) has the best evidence supporting is predictive 
properties. MTs are intracellular metal-binding proteins involved in zinc homeostasis 
and detoxification of heavy metals. They are thought to affect cisplatin-induced 
apoptosis. 3 studies have shown an inverse relationship between levels of the marker 
and response to chemoradiotherapy. There are no published reports of negative studies 
as yet, however, this may represent publication bias and reflect the small number of 
studies published on this marker (type I error). 
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Limitations 
Interpretation of research into tissue biomarkers is made difficult by a number of 
factors. There is heterogeneity in many aspects making comparison of studies difficult. 
Patient factors include disease stage, staging classification used, anatomical tumour 
location and of course histological tumour type. Whilst mechanisms behind sensitivity 
to chemotherapeutic agents in AC and SCC are similar, it remains unclear whether there 
is a variation in clinical and histological responses between tumour types143. Not only do 
similar uncertainties exist in the potential differences between gastric tumours, 
oesophageal tumour and gastro-oesophageal junctional tumours with regards to 
sensitivity/resistance to therapeutic agents, but the treatments offered to such tumours 
are often different. Multimodal therapies now include a wide range of possible 
treatments that are all likely to have different molecular resistance mechanisms, some 
of which have been discussed above.  
Most of the studies published to date are small including typically less than 100 subjects 
with sample sizes being determined by availability of tumour samples rather than being 
statistically powered. The studies are retrospective and often are of a discovery nature 
with no validation cohort. Whilst some of the markers above have been investigated 
with meta-analyses, these reviews are subject to the limitations above and none of the 
markers above have reached randomised trial phase. 
As with any biomarker studies, publication bias is likely to be significant. The more 
factors are investigated, the more type I statistical errors will be made, generating 
associations which occur by chance rather than representing true biological effects. 
Overcoming this requires validation in other cohorts. It would be naïve to expect the 
publication of many negative biomarker studies but a step towards more openness 
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could involve compulsory registration of all biomarker studies on a public database. All 
studies being granted ethical approval in the UK are now required to be registered on 
such a database. 
As we have seen in the previous chapter, there are a number of different methods used 
to define response to chemotherapy/chemoradiotherapy. An accurate measure of 
response is critical when making associations with biomarker levels since it is important 
that biomarkers are truly predicting what we think they are rather than representing a 
surrogate for other factors such as disease stage. If the measure is poor, then the 
prediction will be poor. 
The major drawback of tissue markers is the reliance upon biopsy specimens which 
require invasive procedures and in general are not suitable for serial measurements. 
Many of the laboratory analytical techniques are not widely available yet although 
techniques such as PCR will become more commonplace. 
Analytical techniques such as immunohistochemistry have a subjective, observer-
dependent aspect to them and only give semi-quantitative results. There is often 
heterogeneity of expression within tumour tissue which may represent different clonal 
groups. These factors introduce problems with accuracy, repeatability and inter-
observer/inter-unit agreement. Whilst different studies may use broadly similar 
techniques, each biomarker can often be targeted by different antibodies that exhibit 
different specificities for the marker in question. 
Circulating markers 
A systematic review of the published literature on biomarkers measured in blood 
plasma/serum was performed. The review on tissue markers was restricted to reports 
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in patients undergoing neoadjuvant chemotherapy and with response measured by 
histopathological regression. Due to the limited number of publications on circulating 
markers, this would have resulted in a very low yield and would have excluded reports 
on emerging biomarkers that may prove useful in the prediction of response in future 
studies, therefore in this section, reports in palliative therapy and those measuring 
clinical response to therapy were included.  
Liver function tests 
Whilst there have been a small number of studies published suggesting a relationship 
between liver function tests (alkaline phosphatase, albumin and ALT), these markers 
have been routinely measured for many years and if the results were reliable, one would 
expect numerous publications confirming similar results. However, since these tests are 
routinely performed, they can be readily investigated in retrospective studies. 
In the case of alkaline phosphatase, it is found in all human tissues can be seen as a 
general, non-specific marker of malignancy. In the study by Kogo et al, in addition to 
alkaline phosphatase, pre-therapy T and M stage were associated with poorer response 
to CRT. Alkaline phosphatase may therefore simply be acting as a marker of more 
advanced disease although the multivariate analysis suggested there may be an 
independent association. 
Although albumin has also been shown to correlate with response to therapy it may also 
be acting as a surrogate for poor nutritional health and more advanced tumour biology 
thereby acting as a prognostic marker rather than predictor of response. Prognosis is 
likely to be poor in patients predicted to respond poorly to therapy regardless of 
whether they undergo this or an alternative treatment plan.  
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Haematological markers 
Although there were two reports suggesting a link between serum Hb level and 
response, there was a discrepancy in what levels are beneficial with one paper 
suggesting benefit over a cut-off at 13.0g/dl and the other suggesting a benefit within a 
range of 12.0-14.0g/dl. 
Differential white cell counts, white cell differential proportions/ratios, total white cell 
counts and d-dimer levels have all been shown in single papers to be associated with 
response to therapy. Differential white cell counts and ratios were investigated in a 
recent study by Noble et al and not found to correlate with response to neoadjuvant 
chemotherapy in patients with oesophago-gastric cancer220. 
As with liver function tests, these haematological markers may simply represent poor 
nutritional status or advanced tumour biology which may explain why no link to 
histological response was shown in the above, latter study. 
Tumour cell antigens 
The markers CEA, TPA, CA19-9 and CA242 were significantly associated with clinical 
responses in patients undergoing palliative chemotherapy226. However, a separate study 
in patients with gastric cancer receiving palliative chemotherapy found no correlation 
between initial CEA, CA19-9 or CA-50 levels and radiological response to chemotherapy 
although there was a trend towards lower levels having a more favourable outcome254. 
Shimada et al reviewed the literature on the value of CEA, CA19-9 and CA72-4 in staging, 
evaluation of response to therapy and detection of recurrence in patients with gastric 
cancer although they did not specifically review the roles in predicting therapy 
response255. They conclude that a prospective trial is required to evaluate the clinical 
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significance of these markers and that a model combining these markers is likely to be 
the most effective way of staging before chemotherapy and that this could be used in 
the early evaluation of response to chemotherapy. 
Complement 
The findings of one study identifying through serum protein profiling C3a and C4a as 
predictive of response to chemoradiotherapy in oesophageal cancer are promising. 
Although these proteins were identified through a mass discovery approach, they are 
involved in inflammatory pathways and it has been hypothesised that these 
complement factors could alter the immune microenvironment of oesophageal tumours 
promoting differential responses to chemoradiotherapy143. C3a and C4a are therefore 
worthy of further study in other centres to externally validate results. 
DNA repair/platinum-drug action 
As outlined above platinum-based drugs work by damaging DNA, therefore DNA repair 
pathways are important in drug resistance mechanisms. The ERCC genes are involved in 
nucleotide excision repair and the XRCC genes are involved in base excision repair. 
Polymorphisms of both have been associated with clinical responses to chemotherapy 
in gastric cancer. 
GSTP1 also directly participates in the detoxification of platinum compounds and 
polymorphisms of this gene are associated with clinical response to oxaliplatin-based 
chemotherapy. 
A small study in 28 patients, Font et al investigated the relationship between 
polymorphisms of genes featuring in DNA repair pathways (XPD and XRCC3)256. The 
XRCC3 241M/T polymorphism showed a trend towards association with response to 
230 
 
CPT-11/docetaxel/cisplatin chemotherapy in patients with oesophago-gastric cancer 
(P=0.06). This finding merits further investigation in a larger patient cohort. 
DNA synthesis/5-FU metabolism 
As outlined above, 5-FU-based drugs can inhibit DNA synthesis and there are a number 
of pathways involved that could determine the sensitivity to this chemotherapy. In the 
case of tissue markers, thymidylate synthase was one of the most investigated factors 
from these pathways and not surprisingly authors have been interested in whether any 
markers relating to this enzyme can be identified in peripheral blood. Cellular tumour 
RNA has been extracted from peripheral blood and TS RNA levels were shown to be 
associated with a minor histopathological response to neoadjuvant 
chemoradiotherapy235. Although a review DNA synthesis/repair pathway 
polymorphisms identified from tumour DNA revealed limited association with response, 
there is interest in investigating the predictive value of polymorphisms in germline DNA 
which can be sampled peripherally. Of ten polymorphisms within 5 genes examined in 
genomic DNA from peripheral blood, a single TS polymorphism was found to be 
associated with a higher response rate to 5-FU/platinum-based palliative 
chemotherapy234. 
DPD expression measured in tumour tissue was another marker showing promise and 
one study has identified a genomic DPD polymorphism in DNA extracted from peripheral 
blood that was associated with better response to 5-FU-based chemotherapy. 
Angiogenic factors 
Not only does VEGF promote the neovascularisation require for tumour growth, but it 
increases the vascular permeability and capillary leakage. It has been suggested that this 
leads to elevated interstitial fluid pressure preventing effective transport of therapeutic 
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drugs into tumours and thereby reducing the efficacy of treatment237. Therefore, VEGF-
A expression levels or polymorphisms that are known to alter the expression level could 
determine chemosensitivity. Lower serum VEGF-A levels have been associated with a 
greater histopathological response to neoadjuvant chemoradiotherapy and a 
polymorphism of the VEGF gene isolated from peripheral blood genomic DNA which is 
known to reduce expression of VEGF has been linked with clinical response to palliative 
chemotherapy237, 238. 
Micro RNAs 
The role of micro RNAs in tumour growth and their potential association with 
chemosensitivity has been introduced above. They represent an area of rapidly 
developing research and there is particular interest in their ability to predict response 
to chemotherapy partly because of the discovery that they can either promote tumour 
development and growth or inhibit tumour progression through key processes such as 
cell proliferation, differentiation and apoptosis144. This is achieved by controlling 
translation and stability of mRNAs in a process downstream of transcription137, 144. 
MiRNAs are known to regulate the same genes that are targeted by chemotherapy 
agents257. MiRNA action is discreet from genetic polymorphism, DNA transcription or 
measurement of discreet protein levels but in a similar way to DNA/RNA analysis, miRNA 
expression patterns can be compared in different clinical subject groups – e.g. cancer 
patients vs. controls or responders vs. non-responders137. 
Not only can miRNAs be extracted from fixed tumour tissue but they can be identified 
in body fluids where they are known as circulating miRNAs137, 239. High levels of miR-200c 
in blood serum were shown to be associated with poor response to chemotherapy and 
shorter progression-free survival in patients with oesophageal cancer undergoing 
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neoadjuvant chemotherapy239. Whilst this is the only in vivo report describing a 
relationship between circulating miRNAs and response to therapy, there is background 
evidence that suggests this area warrants further study. A review of 22 studies has 
identified 35 circulating miRNAs that are differentially expressed in patients with gastric 
cancer and controls. Of these candidate markers, six (including miR-200c investigated 
above) have been shown to be deregulated in chemotherapy resistant gastric cancer cell 
lines adding further suggestion that they are implicated in drug resistance137. 
Other markers 
Germline polymorphisms remain stable throughout disease progression unlike somatic 
mutations from tumour tissues and represent variations in genotype that may 
determine individual sensitivity to therapeutic agents. It is a relatively new field of 
exploration; however, it is rapidly expanding especially in the area of serum/plasma 
analysis because genomic DNA is so readily obtained from sampling peripheral blood. 
Studies aimed at investigating germline polymorphisms using a range of methods 
including genotyping arrays and more direct SNP genotyping have identified a number 
of polymorphisms that show potential in predicting response to chemotherapy. Like 
miRNAs, germline DNA is readily extractable from peripheral blood and this research in 
area is likely to expand. 
Limitations 
Circulating biomarkers are subject to many of the same limitations as tissue biomarkers 
with respect to the heterogeneity between studies and therefore the difficulty 
comparing them. Whilst they don’t require invasive testing and histological analysis, 
plasma and serum acquisition and analysis have their own limitations. Biomarker levels 
will depend on whether they are tested in plasma or serum which also affects marker 
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stability. The same applies to the different anti-coagulants used in plasma samples (e.g. 
EDTA, citrate, lithium-heparin). Biomarker levels in blood can depend on circadian 
timing, patient fasting status. Stability of markers in samples tubes also depends on 
handling issues such as ambient temperature, storage temperature, time to 
centrifuge/separation and time to freezing. 
Research into circulating biomarkers is a rapidly expanding field highlighted by the fact 
that most of the key studies in the results section were published within the past few 
years. Reviews therefore need to take advantage of the most up to date literature and 
may need to be repeated a frequent intervals as new information becomes available. 
Many serum/plasma assays like immunohistochemistry rely on immune techniques such 
as ELISA that are prone to the same issues of antibody specificity. Due to differences in 
sample handling and laboratory techniques, threshold values from one unit may not be 
valid in others even when using the same antibodies/kits. Cut-offs may need to be re-
defined in separate validation studies 
Interest in DNA/RNA extraction from peripheral blood has increased recently and 
techniques for achieving this are likely to become more commonplace. There are 
variations in these techniques with respect to probes, primers and cycling conditions. 
When measuring a biomarker in peripheral blood, researchers need to be clear what 
exactly they are measuring. Is it a protein marker expressed and secreted by tumour 
cells or even host cells such as neutrophils or lymphocytes? Do circulating levels of the 
marker reflect expression levels? If it is a tumour marker, is it specific to the primary 
tumour in question and what is the relationship to secondary lesions? Secondary lesions 
may express clonal differences compared to primary lesions and will this affect the 
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circulating biomarker level. In DNA analysis, is it genomic DNA that is the desired target 
or circulating tumour DNA? 
Summary 
Some of the biomarkers identified in this review are promising but further studies are 
needed to validate and confirm the results in separate patient cohorts. 
It is becoming clear that the most predictive pre-therapy markers are likely to be 
biomarkers38, 54, 55. Functional imaging (FDG-PET) is likely to be most useful when used 
after initiation of chemotherapy (early assessment of response)166, 168. There have been 
a number of promising tissue biomarkers identified but these rely on an invasive test 
and laboratory methods that may not be widely available38, 55. 
The potential role of serum/plasma biomarkers is under-investigated but offers exciting 
potential for many reasons143, 146. The technique relies only on a minimally invasive test, 
regularly undertaken in the routine management of cancer patients and universally 
available. Most laboratory analyses for circulating biomarkers rely on relatively low-cost 
techniques. Biomarker levels can be measured before neoadjuvant treatment when 
they offer the potential to be truly predictive. Serial measurements can also be recorded 
throughout treatment to monitor response to therapy in vivo. 
No single biomarker or technique appears to be able to predict with sufficient accuracy 
the response to neoadjuvant therapy. The complexity of molecular carcinogenesis, the 
uniquity of individual cancers and the multiple mechanisms of chemoresistance mean 
that the ultimate model for accurately predicting response to chemotherapy is likely to 
require a combination of several predictive biomarkers38, 51, 54, 133. This will depend on 
having a panel of biomarkers validated in prospective trials showing in multivariate 
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analysis that they are independently associated with response. The goal should be to 
predict sensitivity/resistance to each and every potential therapeutic agent available. If 
in-vivo monitoring with the use of serial measurements alongside therapy could be 
shown to reflect changes in tumour biology during treatment, then this would be 
desirable. 
There are a number of candidate biomarkers expressing potential to predict response 
to neoadjuvant therapy in oesophago-gastric cancer that are not included in this review. 
Whilst they may be involved in key cancer-cell pathways or have been studied in the in-
vitro environment, they have not been subject to clinical investigation as yet. One such 
biomarker is the glycolytic enzyme M2-pyruvate kinase (M2-PK). M2-PK is known to be 
expressed by tumour cells and can be detected in peripheral blood. Although levels vary 
amongst patients with cancer, the significance of this is not known. There is in vitro 
evidence and a very limited amount of clinical evidence suggesting that M2-PK and in 
particular, the dimeric, tumour-specific form may be linked to chemotherapy resistance. 
Chapter 6 describes this in further detail. 
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CHAPTER 6 – M2-PYRUVATE KINASE 
Introduction 
In the search for a means to predict the response to neoadjuvant therapy in oesophago-
gastric cancer, Chapter 5 demonstrated that molecular biomarkers have so far shown 
the most promise.  
Pyruvate kinase (PK) catalyses the final step in the glycolysis pathway and is therefore 
common to cells of almost all living organisms.  This action involves the 
dephosphorylation of phosphoenolpyruvate, yielding pyruvate and the production of 
ATP from ADP.  Importantly, it is in independent of oxygen supply. 
The Warburg effect 
It has long been known that tumour cells have a different metabolism to that of normal 
cells particularly with regard to glycolysis258.  In cancers, glucose is readily converted into 
lactate even in the presence of oxygen. This phenomenon is known as aerobic glycolysis 
or the Warburg effect and was first described in 1924. However, for many years the 
molecular basis behind this was poorly understood.  It is now known that PK is a key 
regulator of this mechanism and it is this realisation that has prompted a wave of 
research into the molecular functions and interactions of PK259.  In particular, the role of 
PK as potential target for chemotherapy is an area rapidly building momentum260-265. 
Pyruvate kinase isoforms 
PK occurs in different isoforms according to tissue type266.  The characteristics of each 
isoform depend on the needs of the tissues expressing them.  Type L and type R isoforms 
are expressed in liver and red blood cells respectively and the M1 isoform is expressed 
in tissues requiring production of large amounts of energy such as brain and muscle266, 
267.  The type M2 isoform (M2-PK) is a splice variant of the M1 form266. It is an embryonic 
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form present during development and in most tissues is eventually replaced by other 
isoforms. M2-PK is found in some differentiated tissues and is characteristic of cells with 
a high rate of nucleic acid synthesis including many proliferating cell types and 
significantly, tumour cells5, 268-272. The PK isoenzymes are tetramers containing four 
identical subunits, however, M2-PK is unique in that it can exist both as a tetramer or 
dimer giving it exclusive properties266, 273-277. 
Pyruvate kinase and cancer cell metabolism 
Other than its mere presence in cancer tissues which indicate that it may at least stand 
as a marker for cancer, several observations outlined below have led to the hypothesis 
that M2-PK and particularly its ability to exist in the dimeric form have a key role in the 
metabolic and genetic aspects of cancer cell survival and tumour growth. 
Dimeric M2-PK has been demonstrated in metastatic cancer cells but not in adjacent 
lung tissue suggesting it is a tumour-specific form273, 278, 279.  However, since this 
discovery, the dimeric form has been also been identified in non-cancerous proliferating 
tissues270, 271. Nevertheless, it is thought to be the predominant form in cancer cells and 
has therefore been termed tumour M2 pyruvate kinase270, 280.  This terminology causes 
confusion in the literature whereby when total M2-PK (dimeric + tetrameric) is 
measured, it is sometimes referred to as tumour M2 pyruvate kinase due do it having 
the potential to exist in dimeric form rather than it actually occurring in the dimeric 
form. 
The dimeric form has significantly lower affinity for the substrate phosphoenolpyruvate 
and therefore has much lower enzyme activity compared to the tetrameric form273, 274, 
281, 282. Importantly, this allows glucose to be channelled into the synthesis of nucleic 
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acids, amino acids and phospholipids via the build-up of glycolytic intermediates which 
is thought to be essential for the proliferation of tumour cells274, 282. 
Tissues which do not normally express M2-PK start expressing it during tumorigenesis283-
285.  Cristofk et al’s work showed that M2PK expression was associated with increased 
glucose uptake and lactate production but decreased oxygen consumption in cancer 
cells, supporting its role in the aerobic glycolysis and was published in Nature285. Genetic 
manipulation used to switch M2-PK to M1-PK reverses the Warburg effect in cancer cells 
and M2-PK but not M1-PK induces tumour xenograft growth in mice285.     
In addition to its role in glycolysis, M2-PK is thought to have other cytosolic and nuclear 
actions which may encourage the survival and proliferation of cancer cells.  These are 
diverse, complex and may be equally if not more important to tumour cells than simply 
the role of PK in glycolysis286-291. The observation that cancer cells typically fail to 
respond to apoptotic stimuli and their ability to adapt to hypoxia by increasing the 
glycolytic rate via M2-PK has led to investigation of the relationship between M2-PK and 
apoptosis291. Agents that induce apoptosis interact with M2-PK which is then 
translocated to the nucleus. This is sufficient to induce cell death in a way that is 
independent of its enzyme activity and isoform specific291. 
Tissue pyruvate kinase expression in oesophago-gastric cancer 
The majority of published research on M2-PK in humans has focussed on its role in 
disease screening, particularly for cancers, using blood plasma and faecal enzyme 
assays. Despite this, although there has been some quantification of M2-PK expression 
in colon cancer270, pancreatic cell lines272, 292, lung cancer293, 294 and breast cancer5, 294, 
there has been relatively little in oesophago-gastric cancers. The work that has been 
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done suggests that compared to established tumour markers, plasma M2-PK has similar 
or better sensitivity and specificity for oesophageal and gastric cancer295-297. 
Two recently published studies have compared M2-PK levels in gastric cancers to 
adjacent normal tissue288, 298. Kwon et al demonstrated an increased expression in tissue 
microarrays (semi-quantitative) of cancer tissues using an antibody recognising total 
M2-PK protein288.  M2-PK expression correlated with reduced survival and tumour size 
suggesting it may have a prognostic value.  Lim et al showed increased levels of M2-PK 
mRNA in gastric cancer compared to normal gastric epithelium298.  Their results suggest 
higher total M2-PK levels are associated with poorer survival in signet cell cancers.  
Neither study quantified dimeric M2-PK protein. 
Two published reports have measured total M2-PK in squamous oesophageal cancer 
using a range of techniques269, 294.  These reports did not measure dimeric M2-PK and 
they did not examine adenocarcinoma, which is the predominant subtype in the UK. 
Koss et al used immunohistochemical staining to identify dimeric M2-PK expression in 
oesophageal adenocarcinoma and Barrett’s oesophagus271. They demonstrated an 
increase in expression through the metaplasia-dysplasia-carcinoma sequence and they 
also identified M2-PK expression in reflux oesophagitis. They did not measure M2-PK in 
blood sera/plasma and did not analyse normal oesophageal mucosa for the presence of 
M2-PK. 
Pyruvate kinase and pharmacological manipulation 
Small molecule M2-PK activators have been identified that promote the formation of 
the tetramer thereby suppressing tumorigenesis in xenograft tumours265, 299.  Another 
agent (TLN-232/CAP-232) has been used in phase II trials for patients with metastatic 
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renal cell carcinoma with encouraging results264.  Shikonin is an extract from the root of 
Lithospermum erythrorhizon used in traditional Chinese medicine for its various anti-
inflammatory properties.  It is now understood to act via M2-PK and has previously been 
used in effectively in patients with late-stage lung cancer300, 301. However, despite the 
obvious potential M2-PK has as a target for chemotherapy, further work is needed to 
develop new agents and further evaluate established compounds. 
Pyruvate kinase and disease monitoring 
In a cohort of lung cancer patients undergoing chemotherapy, tumour remission and 
progression correlated appropriately with M2-PK expression, demonstrating that M2-
PK could be valuable as a diagnostic aid for therapy control and may be able to detect 
tumour relapse after treatment278. 
M2-PK and chemotherapy response 
The majority of research measuring M2-PK in the blood plasma of cancer patients has 
been to investigate its role in screening295. Therefore, whilst preoperative/pre-
chemotherapy re-therapy plasma M2-PK levels in cancer patients and controls have 
been established, much less is known about the relationship between disease activity or 
response to neoadjuvant therapy and M2-PK. 
Platinum-based chemotherapy 
Yoo et al undertook in vitro studies showing that cisplatin-resistant gastric cell lines have 
decreased total M2-PK protein levels and lower PK activity. In addition, suppression of 
M2-PK activity results in acquired cisplatin resistance262. 
Likewise, in colorectal cancer cell lines, using a proteomic approach, decreased M2-PK 
mRNA was associated with oxaliplatin resistance in human colorectal cancer cell lines 
and patients with colorectal cancer261. 
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A further proteomic approach was used in an effort to understand the molecular 
mechanisms of multidrug resistance in ovarian cancer302. M2-PK was differentially 
expressed in cisplatin-resistant cell lines compared to parent cell lines and further 
analysis showed that M2-PK along with another marker (HSPD1) could contribute to the 
cisplatin resistance in the ovarian cell line. 
The mechanism(s) behind platinum chemotherapy-resistance caused by low M2-PK 
activity is not clearly understood, however, Yoo et al offer a possible explanation262. M2-
PK in its dimeric form has low enzyme activity leading to accumulation of upstream 
metabolites necessary for cell proliferation. As a result, glycolytic carbons are directed 
to the pentose phosphate pathway where they can be used in nucleic acid synthesis. 
Tumour cells with low M2-PK activity rely on glutaminolysis for energy production but 
may also have increased NADPH production from the oxidative pentose phosphate 
pathway. NADPH is a cofactor of GSH reductase, necessary for reduction of oxidised GSH 
(GSSH) back to GSH (2 molecules). It is known that cisplatin is inactivated by GSH-linking 
which could explain the mechanism of resistance in conditions with reduced M2-PK 
activity, such as the presence of the dimeric, tumour-form262. Activation of the 
Thioredoxin (Trx) system by NADPH may also be responsible for cellular resistance to 
cisplatin by scavenging intracellular toxic oxidants generated by cisplatin303-305. It is 
possible, therefore, that low M2-PK activity as a result of increased proportion of the 
dimeric form may lead to increased NADPH production via the pentose phosphate 
pathway and glutaminolysis262. Higher NADPH levels may lead to platinum-compound 
resistance via GSH reductase and the Trx system. 
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5-FU-based chemotherapy 
In one study, Shin et al attempted to identify markers of 5-FU resistance in human colon 
cancer cell lines260. They identified secreted proteins that were up- or down-regulated 
in resistant cell lines compared to non-resistant parent cell lines. M2-PK was one of a 
number of glycolytic enzymes shown to be upregulated in the resistant cells. A separate 
study has also shown that inhibition of glycolysis can overcome drug resistance in colon 
cancer cells and lymphoma cells under hypoxic conditions in which cells exhibit high 
glycolytic activity306. Since the rate of glycolysis is known to be dependent on M2-PK 
effects, Shin et al investigated the effects of M2-PK substrate and product on 
proliferation of 5-FU resistant cells. They found a differential effect of addition of these 
intermediaries depending on the presence or absence of 5-FU. In the absence of 5-FU, 
intermediaries allowed increased proliferation but in its presence, intermediaries had 
no such effect. This suggests that M2-PK activity is perhaps sensitive to 5-FU and it is 
suggested that this biomarker could be a potential target for therapy in 5-FU resistant 
cancer. It would have interesting to known whether this effect is mirrored in 5-FU 
sensitive cells. The same authors demonstrated a trend towards increasing levels of M2-
PK in sera (p=0.23) and tissues (p=0.34) from colorectal cancer patients responding 
poorly to 5-FU-based neoadjuvant chemotherapy compared to partial and complete 
responders260. Serum M2-PK was measured using a semi-quantitative western blot 
technique recognising total (rather than dimeric) protein which is thought to be less 
specific to cancer cell metabolism. Response to therapy was measured by CT scanning 
which is known to be an inaccurate predictor of histopathological response and clinical 
outcome. 
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Other agents 
One study in 4 patients with lung cancer measured blood M2-PK, CEA and CYFRA-21 
levels throughout the course of poly-chemotherapy treatment278. In two patients, 
radiological remission due to successful chemotherapy was associated with a fall in M2-
PK levels. In one patient, surgical resection was associated with a fall in levels and in the 
final patient, progression of disease despite chemotherapy was associated with a rise in 
levels. M2-PK appeared to follow disease remission/progression more accurately than 
either of the other two biomarkers. No statistical analysis was possible in such a small 
number of patients. 
DNA damaging agents such as H2O2 and UV radiation are associated with isoform-
specific M2-PK translocation to the nucleus which is sufficient and necessary for 
programmed cell death291. Importantly, overexpression of an inactive form of the 
enzyme decreases the overall metabolic rate of cells but without triggering apoptosis291. 
However, it would be interesting to know specifically whether M2-PK dimers are as 
effective as M2-PK tetramers in stimulating apoptosis. 
Whilst the studies above provide some evidence that M2-PK may be inked with 
sensitivity to chemotherapy, there are obvious limitations and further work has been 
called for 260-263, 266, 302. Whilst it is known that the dimeric form of M2-PK carries its 
tumour-specific metabolic properties, most studies have examined total M2-PK m-RNA 
or protein levels. Much of the work has been in vitro with very little in human subjects. 
The association between chemotherapy resistance and M2-PK has been explored to an 
extent in colorectal, ovarian and lung cancer but there has been no work in oesophago-
gastric cancers. Specifically, there is a need to investigate the relationship between pre-
treatment dimeric M2-PK levels and response to neoadjuvant chemotherapy in patients 
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with oesophago-gastric cancer. Similarly, to establish the use of M2-PK in early 
assessment of response to neoadjuvant therapy, the relationship between M2-PK levels 
after initiation of treatment and response to therapy would be useful. 
Summary 
M2-PK is an isomer of the glycolytic enzyme pyruvate kinase. It can exist as a dimeric 
form which is over-expressed in tumour cells and is detectable in peripheral blood. 
There is evidence that M2-PK and PK activity may be linked to chemotherapy resistance 
although there have been few clinical studies in this area and none have been conducted 
in oesophago-gastric cancer patients. 
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CHAPTER 7 - PREDICTING RESPONSE TO NEOADJUVANT 
THERAPY 
Background 
The high proportion of patients with oesophago-gastric cancer who do not respond to 
neoadjuvant chemotherapy/chemoradiotherapy is concerning and leads to adverse 
outcomes. Currently there are no reliable methods of predicting the response to 
neoadjuvant therapy in clinical use. Early assessment of the response, or better still pre-
therapy prediction would enable non-responders to proceed directly to surgery or be 
considered for alternative therapies, avoiding unnecessary toxicity and a delay to 
surgery. 
The use of biomarkers in predicting response is promising, but there is a need to 
evaluate new markers and investigate the potential of established markers. Such 
biomarkers need to be safe, readily available, cost effective and acceptable to patients. 
M2-PK is a novel biomarker involved in cancer cell metabolism. It has been investigated 
from a screening point of view and has shown good accuracy in detection of oesophago-
gastric cancer compared to other makers. It can be quantified in tumour tissue, faeces 
and peripheral blood. A small number of studies have suggested links between M2-PK 
and sensitivity to chemotherapy, through the pentose phosphate pathway, the Trx 
pathway and via nuclear translocation/apoptosis. This is an under-researched area and 
to date there have been no clinical studies investigating the potential of M2-PK in 
predicting response to therapy in patients with oesophago-gastric cancer. 
Biomarkers with established uses that have recently been shown to demonstrate 
potential to predict response to chemotherapy are attractive subjects for further 
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investigation because analysis is usually low-cost and widely available. Existing markers 
showing promise in oesophageal and gastric cancers are CEA, CA 19-9 and CA 72-4. 
A number of clinicopathological radiological markers have been identified as having 
potential to predict response to neoadjuvant therapy and a model combining these with 
molecular biomarkers may offer the best prediction of response to therapy. 
There are many methods available for defining the response to neoadjuvant therapy, 
which include measures of histopathological regression and tumour/lymph node down-
staging. Such methods must be validated in the relevant population, must be associated 
with survival benefit and must reflect a true therapy effect, or they are of no clinical use 
in this setting. In Chapter 3 it was established that in our population, response is defined 
by a Mandard TRG score of 1-3. 
Chapter outline 
To investigate whether plasma M2-PK levels can be used as a biomarker alone or in 
combination with other biomarkers, imaging or clinicopathological parameters to 
predict the response to neoadjuvant chemotherapy/chemoradiotherapy, a number of 
project designs were considered. 
The basic methodology involves biomarker analysis from blood tests taken before 
starting neoadjuvant treatment and investigating the relationship between these levels 
and the histological response. The background literature review also suggested that 
biomarkers may be useful in monitoring/early assessment of the response to therapy. 
Measurement of biomarker levels at a time point after initiation of therapy would be 
necessary to investigate this further. 
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Study designs can be classified as retrospective or prospective and are detailed below. 
Following this, preliminary studies were undertaken and are described in their own 
section. Finally, the main study is presented making the greatest contribution to this 
final thesis Chapter. 
Retrospective study designs 
Retrospective studies have the advantage of being able to immediately access readily 
available data without needing to recruit new patients and await sample collection. The 
number of available subjects could be identified at the start of the study. It was noted 
that blood tests are routinely taken during the management of potentially curable 
oesophago-gastric cancer before induction of chemotherapy and after completion of 
each cycle. 
This type of study has the disadvantages of relying upon saved samples, not knowing 
how samples have been stored and being unable to control the timing of samples. Tissue 
biopsy and resection samples are routinely stored for clinical use but serum/plasma 
samples may not have been placed in long term storage.  
Peninsula oesophago-gastric cancer database 
The Peninsula Oesophago-gastric Surgery Unit is the tertiary referral centre for the 
Peninsula region. It has been responsible for undertaking all oesophageal and gastric 
cancer resections since 2010 and has kept an electronic database of all cancer patients 
since this time. This contains data on basic patient demographics, clinical history, 
tumour characteristics, investigations, regional hospital location, treatments, operative 
details and histopathology results. 
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Some of the haematological and biochemical markers identified in Chapter 5 as having 
potential to predict response to therapy would have been routinely measured in 
patients registered in the database before they commenced neoadjuvant therapy. This 
is done for reasons other than response prediction such as ensuring adequate 
hepatic/renal function, immune-nutritional assessment and to act as a baseline for 
comparing with subsequent tests. Likewise, clinicopathological and radiological factors 
identified as potential predictors of response are held in the database. An analysis of 
this historical data with relation to the subsequent histological response is possible and 
may be able to confirm or deny whether these markers have any useful predictive value. 
Tissue specimens from cancer resections are routinely stored in the Derriford 
Laboratory. These may be useful in identifying additional novel biomarkers, however, it 
was found that plasma/serum samples taken from patients are not currently saved 
beyond 3-5 days and there is no biobank facility currently in place for blood samples. A 
retrospective study design utilising the general cohort of historic oesophago-gastric 
cancer patients would therefore not be feasible for investigation of novel blood markers. 
Screening project data 
The Peninsula oesophago-gastric centre recently undertook a feasibility study into the 
potential of faecal and blood biomarkers as a means of screening for oesophageal and 
gastric cancer. Data on demographics, history, tumour characteristics, treatment, and 
faecal/peripheral blood biomarker levels were available as a pilot study. 
Prospective study design 
A prospective study would ensure that the correct samples could be taken at the optimal 
time points and processed in the correct way. Consent could be taken to include storage 
of samples which could be used for future research pending further ethics approval. A 
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prospective study would also ensure that accurate and detailed demographic and 
clinical data could be taken at the time of recruitment. A prospective study, however, 
can be a lengthy process, slow to recruit participants and acquire data.  This also involves 
an inbuilt delay in obtaining the necessary data (response to neoadjuvant therapy). 
When the anticipated low proportion of responders is taken into account, there is 
concern that it may take a long time to recruit the required sample size. 
Preliminary studies 
Screening project database 
An examination of the screening project data provided pilot data on pre-therapy 
biomarker levels and the TRG in patients with oesophageal and gastric cancer. This was 
done as a pilot study in an attempt to demonstrate basic proof of concept that a formal 
biomarker discovery project was worthy of undertaking. 
A group of 53 cancer patients had pre-therapy biomarker data available (plasma M2-PK, 
serum CA19-9, serum CA72-4 and faecal M2-PK). It was made up of a heterogeneous 
group of patients. 22 of these were not suitable for surgery either due to advanced stage 
or medical co-morbidity. Of the 31 patients undergoing surgery, nine did not receive 
neoadjuvant chemotherapy. Four patients had missing data on the TRG, leaving a total 
of 18 patients with data available on biomarker levels and TRG. It should be noted that 
at the time of this analysis, before starting the 2-year project, a clinically significant 
histopathological response was thought to be defined by a TRG score of 1-2. Two of the 
18 patients were TRG 1-2. When the patients were plotted on a scatter diagram, it 
appeared that the responders had relatively low plasma M2-PK, CA19-9 and CA72-4 
levels compared with non-responders (see Figure 52, Figure 53 and Figure 54). Serum 
CA19-9 levels were plotted on a logarithmic scale due to left-skewed data. 
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Figure 52 Plasma M2-PK levels in responders and non-responders to neoadjuvant therapy 
 
Figure 53 Log10 Serum CA 19-9 levels in responders and non-responders 
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Figure 54 Serum CA 72-4 in responders and non-responders 
Mean, median and range of biomarker levels are shown according to whether patients 
were neoadjuvant therapy responders or not (see Table 58). Average biomarkers levels 
appeared to be higher in responders compared to non-responders for all biomarkers. 
With only two patients in the responder group, this was felt too small for statistical 
analysis. 
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Marker n Mean Median (range) 
Resp. Non-resp Resp. Non-resp. Resp. Non-resp. 
M2-PK 2 16 22.0 46.0 22.0 (11.1-33.0) 39.2 (27.6-101.29) 
CA 19-9 2 16 4.0 124.5 4.0 (2.0-6.0) 17.5 (1-1240) 
CA 72-4 2 15 1.3 4.9 1.3 (1.1-1.5) 3.3 (0.9-16.5) 
Table 58 Mean, median and range of biomarker levels are shown according to whether patients were 
neoadjuvant therapy responders or not. 
Abbreviations: Resp, TRG responder; Non-resp, TRG non-responder 
This limited amount of information adds support to the theory that it would be worth 
investigating the role of plasma and serum biomarkers in predicting the response to 
chemotherapy. 
Historical data 
Pre-treatment clinicopathological factors identified in the literature review (Chapter 5) 
as having potential to predict response to therapy in patients suitable for curative 
treatments included sex, T-stage, tumour grade, tumour length and tumour type 
(intestinal/diffuse). 
Pre-treatment biochemical markers showing promise included alkaline phosphatase, 
albumin and alanine transaminase. Haematological markers identified included 
haemoglobin and white blood cell parameters including the neutrophil/lymphocyte 
ratio. 
Methods 
From the Peninsula Oesophago-gastric database, patients undergoing neoadjuvant 
therapy for oesophageal or gastric cancer and proceeding to resection over a five-year 
period from 2010 to 2014 inclusive were identified. 
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Clinicopathological markers 
Demographics, tumour details, clinical staging information and treatments for all 
patients were recorded. The relationships between various pre-therapy clinical variables 
and TRG response were investigated to identify any factors displaying potential to 
predict response. 
Blood biomarkers 
From this 5-year cohort, pre-treatment blood biomarker data were available only in 
patients on the Plymouth site (PHNT). Levels of haematological and biochemical markers 
in these patients were identified from the electronic laboratory results system and the 
relationship between marker levels and TRG response investigated. 
Results 
376 patients had planned to undergo neoadjuvant therapy. 38 patients did not proceed 
to resection and 338 were resected. 7 patients did not have TRG data available leaving 
331 patients for the analysis, see Figure 55. Demographic, tumour, staging and 
treatment details of these patients are shown in Table 59. 86 of the 331 (26.0%) patients 
responded to neoadjuvant therapy using the TRG 1-3 definition. 
Clinicopathological markers 
None of the clinicopathological variables were associated with TRG response (Table 60). 
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Figure 55 Patients identified from the database  
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Patient characteristics 
N=331 
Non-responders 
N=245 (74.0 %) 
Responders 
N=86 (26.0%) 
Significance 
Demographics    
Age, in years; mean (range) 64.7 (29.3-80.7) 63.9 (31.5-82.7) 0.89 (MWU) 
Male, number (%) 190 (74.5) 65 (25.5) 
0.82 (chi-sq) 
Female 55 (72.4) 21 (27.6) 
Performance score, n (%)    
0 171 (72.2) 66 (27.8) 0.44 (chi-sq 
trend) 1 64 (79.0) 17 (21.0) 
2 3 (60.0) 2 (40.0) 
missing 7 (87.5) 1 (12.5) 
Referring Unit    
PHNT 68 (80.0) 17 (20.0) 
0.73 (FE) 
RCHT 55 (72.4) 21 (27.6) 
RDE 53 (70.7) 22 (29.3) 
SDHT 47 (73.4) 17 (26.6) 
NDDH 21 (70.0) 9 (30.0) 
Other 1 (100) 0 (0) 
Tumour characteristics    
Histological type, n (%)    
Adenocarcinoma 219 (74.0) 77 (26.0) 
0.91 (FE) Squamous cell carcinoma 24 (72.7) 9 (27.3) 
Other carcinoma 2 (100.0) 0 (0) 
Tumour location, n (%)    
Oesophagus 48 (67.6) 23 (32.4) 
0.34 (chi-sq) Gastro-oesophageal junction 165 (76.4) 51 (23.6) 
Gastric 32 (72.7) 12 (27.3) 
Tumour length, in cm median (range)    
Length, in cm, median (range) 5 (1-17) 5 (2-12) 0.56 (MWU) 
Missing, n (%) 158 (64.5) 56 (65.1)  
Histological pattern    
Intestinal 140 (74.5) 48 (25.5) 
0.94 (FE) Diffuse/Mixed 10 (71.4) 4 (28.6) 
Diffuse/Signet ring 48 (75.0) 16 (25.0) 
unknown 47 (72.3) 18 (27.7)  
Differentiation grade    
Well 4 (100.0) 0 (0) 
0.55 (chi-sq 
trend) Moderate 89 (74.8) 30 (25.2) 
Poor 118 (73.8) 42 (26.3) 
unknown 34 (70.8) 14 (29.2)  
Pre-operative staging    
Pre-operative T stage, n (%)    
≤T2 47 (78.3) 13 (21.7) 
0.46 (chi-sq 
trend) T3 187 (73.0) 69 (27.0) 
T4 11 (73.3) 4 (26.7) 
Pre-operative N stage, n (%)    
N0 94 (70.7) 39 (29.3) 
0.49 (chi-sq 
trend) N1 129 (77.2) 38 (22.8) 
N2 22 (71.0) 9 (29.0) 
Neoadjuvant regimen, n (%)    
Cisplatin+5-FU/capecitabine 41 (82.0) 9 (18.0) 
0.06 (FE) ECX/ECF/EOX (+/- bevacizumab) 177 (72.2) 68 (27.8) 
CROSS style 3 (37.5) 5 (62.5) 
Carbotaxol +/- epirubicin/etoposide 3 (75.0) 1 (25.0) 
Missing 21 (87.5) 3 (12.5)  
Neoadjuvant therapy cycles, n (%)    
1 11 (91.7) 1 (8.3) 
0.54 (chi-sq 
trend) 2 35 (71.4) 14 (28.6) 
≥3 104 (74.8) 35 (25.2) 
missing 95 (72.5) 36 (27.5)  
Table 59 Demographic, tumour, staging and treatment details of patients undergoing neoadjuvant therapy and 
surgery. 
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Blood biomarkers 
Of 85 patients from PHNT, 84 had data available on blood markers (see Table 60). None 
of the haematological or biochemical biomarkers were associated with response to 
neoadjuvant therapy. 
Patient characteristics 
Non-responders 
(n=67) 
Responders 
(n=17) 
Significance 
MWU Ex 2-tailed 
Haematological Markers, median (range) 
(%) 
 
 
 
Haemoglobin 138 (75-166) 135 (117-164) 0.99 
Platelets 289 (105-838) 282 (133-442) 0.50 
Haematocrit 0.41 (0.26-0.49) 0.41 (0.35-0.47) 0.62 
Total White cell count 8.1 (3.6-20.8) 8.3 (5.1-15.2) 0.52 
Neutrophils 4.9 (1.4-15.9) 6.0 (3.2-11.8) 0.46 
Lymphocytes 2.1 (0.7-3.8) 1.9 (0.7-3.1) 0.77 
Neutrophil: Lymphocyte ratio 2.55 (0.82-7.67) 2.47 (1.19-16.86) 0.51 
Biochemical Markers, Median (range)    
Alkaline phosphatase 78 (75-166) 67 (117-164) 0.28 
Alanine aminotransferase (ALT) 18 (10-40) 20 (11-43) 0.26 
Albumin 43 (36-53) 44 (40-47) 0.60 
Table 60 Haematological and biochemical biomarker levels in histological responders and non-responders. 
Abbreviations. MWU, Mann-Whitney U test 
 
Preliminary studies summary 
A striking feature of this preliminary work, as also identified in Chapter 3, is the low 
proportion of patients that respond to chemotherapy - only 12.9% using the old 
definition (TRG 1-2) and 26.0% when considering the updated definition (TRG 1-3). This 
indicates the magnitude of the problem, with the great majority of patients not 
responding to neoadjuvant therapy and not expected to benefit. This makes it difficult 
to interpret results of the preliminary study. In the pilot study from the screening project 
data, only 2 of the 18 patients with complete TRG and biomarker data available were 
classified as responders to treatment using the definition at the time. These unequal 
sample sizes and in particular the small number of patients in the responder group limits 
the statistical analysis that can be performed. 
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From a research perspective, it is interesting to note that patients do undergo blood 
tests as part of routine treatment at the time periods at which blood samples would 
need to be taken as part of a prospective study. Currently there is no system in place to 
store such samples for use in future research. This appears to represent an underutilised 
resource and Plymouth Hospital NHS Trust Research & Development Department is 
investigating the feasibility of setting up a research bank which could include the storage 
of such samples. This would be a big step forward in maximising the potential of 
biological material taken (through routine diagnostic purposes) for use in future 
research. 
Despite literature reports suggesting a link between routine 
haematological/biochemical parameters measured in peripheral blood and response to 
chemotherapy, data here do not support this. This may be because better patient 
selection means patients have better pre-therapy nutritional status and therefore less 
variation in levels of nutritional markers. It may be that there is a link between poor 
nutritional status and response but that this is not relevant in the context of modern 
patient selection. 
Without any long-term storage of blood samples, a retrospective study design for 
investigating the use of novel biomarkers in prediction of response to neoadjuvant 
therapy was impossible, necessitating a prospective study. 
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Prospective study 
Aims and objectives 
The study aimed to investigate whether pre-therapy plasma/serum levels of the 
biomarkers M2-PK, CEA, CA19-9 and CA72-4 can be used to predict the response to 
neoadjuvant therapy in patients with oesophageal and gastric carcinoma as part of a 
curative treatment plan. Secondary aims were to investigate the performance of 
biomarkers in early assessment of response to neoadjuvant therapy. 
Methods 
Overview 
A multi-centre, prospective study was set up to recruit patients with oesophageal and 
gastric adenocarcinoma before starting neoadjuvant therapy. Patients referred to the 
tertiary Peninsula Oesophago-gastric Surgery Unit from the locality and 3 other regional 
NHS Trusts were included in this part of the study. After collaboration with external 
research organisations (detailed below), further clinical patient data and samples were 
acquired to contribute to the sample size. 
The methods of each part of the study need to be explained separately and for clarity, 
the local/regional and collaborative parts of the study will be simply referred to as the 
‘regional’ study and the ‘collaborative’ study respectively. 
Analysis of biomarker levels was performed on peripheral blood samples taken before 
starting neoadjuvant therapy (regional study and collaborative study) and after 
completion of the first cycle (regional study). Clinicopathological, demographic and 
radiological data were recorded in all patients and the ability of biomarkers to predict 
histological response to therapy was investigated. 
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Collaborations 
Oesophageal Cancer Clinical and Molecular Stratification Study 
Derriford Hospital is participating in the multicentre Oesophageal Cancer Clinical and 
Molecular Stratification Study (OCCAMS). This is a multicentre study established to 
determine predictive and prognostic biomarkers and therapeutic targets for 
oesophageal and junctional adenocarcinoma including whole genome sequencing. 
Patients from a number of UK sites are locally recruited to the study and consented. The 
study involves the collecting of demographic data, clinicopathological data, blood 
samples and resected tissue samples. These are being used to identify predictive and 
prognostic biomarkers alongside validating a molecular staging system and completing 
a DNA sequencing project as part of the International Cancer Genome Consortium 
(ICGC). 
In 2013, the OCCAMS collaboration offered all participating centres the opportunity to 
set up collaborative sub-studies. As part of this arrangement, local centres could benefit 
from sharing centrally collected clinical data and laboratory samples for use in their own 
sub-studies. An application for a collaborative study was submitted and approved in 
August 2013. Access to plasma samples and clinicopathological data has been granted 
pending ethics approval which was subsequently obtained. This was the first such 
OCCAMS sub-study to be supported by the group. 
Scottish Academic Health Sciences Collaboration 
Edinburgh is one of the centres contributing to the OCCAMS study. The unit 
independently collects and stores blood samples for research purposes from patients 
with oesophago-gastric cancer as part of the Scottish Academic Health Sciences 
Collaboration (SAHSC) BioResource. The Edinburgh study team agreed to collaborate 
separately, providing anonymised plasma samples and data for this study. 
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Sponsorship 
The project was reviewed, approved and sponsored by Plymouth Hospitals NHS 
Foundation Trust Research & Development Department.  
Ethics 
Ethical considerations 
This study did not introduce an intervention or test result that altered patient 
management. The treating physicians did not need access to participants’ research data.  
The study protocol involved the taking of an additional 4ml venous blood via EDTA 
Vacutainer  before and after the first chemotherapy cycle. In most cases it is expected 
that these would be performed alongside routine blood tests and would not involve 
additional skin puncture, however, approval was sought for phlebotomy specifically for 
the purposes of this study. 
There were no specific reasons related to the study protocol that would have expected 
to result in informed consent not being granted. 
Ethics approval 
Regional study 
The main protocol received a favourable ethical opinion from the Bristol Research Ethics 
Committee on 4th September 2013. 
Study title: Predicting the response to neoadjuvant therapy in patients with 
oesophago-gastric cancer 
REC Reference: 13/SW/0208 
Protocol number: 13/P/062 
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IRAS project ID: 132595 
Collaborative study proportionate review 
The protocol for the receipt and analysis of anonymised samples and clinical data from 
the OCCAMS and SAHSC collaborations received a favourable ethical opinion from the 
Nottingham 1 NRES Committee, East Midlands on 13th November 2013. 
Study title: Predicting the response to neoadjuvant therapy in patients with 
oesophageal cancer– collaboration with the OCCAMS/Edinburgh 
studies 
REC Reference: 13/EM/0437 
Protocol number: 13/P/157 
IRAS project ID: 139550 
Sample size and recruitment planning 
It was necessary to perform a sample size calculation at an early stage along with a 
review of the patient numbers treated in the unit to understand how long it would take 
to recruit patients and how many sites would need to be involved in recruitment. 
Sample size 
An initial sample size calculation was performed using the G*Power application based 
on an independent two-sided t-test with an effect size of 0.75 and a power of 0.8. 
Anticipating that 25% of patients would respond to treatment (TRG 1-3) and 75% would 
not respond, this generated a total sample size of 78 (19 responders and 59 non-
responders). 
A more sophisticated power analysis according to the proportion of patients from each 
group (responder/non-responder) falling above or below a range of biomarker 
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thresholds indicated that a sample size of 92 (estimated responder to non-responder 
ratio of 3:1) would identify responders with a sensitivity of 90% and a specificity of 40% 
for a single biomarker, equivalent to an effect size of 1.0 at a power of 0.99 and 
significance level of 0.05. The addition of further discriminatory 
biomarkers/clinicopathological features would increase the predictive accuracy of the 
test. 
Hospital Sites 
The Peninsula Oesophago-gastric Surgery Unit, based within Plymouth Hospitals NHS 
Trust (PHNT) at Derriford Hospital receives tertiary referrals from the Royal Devon & 
Exeter Hospitals NHS Foundation Trust (RDE), the Royal Cornwall Hospitals NHS Trust 
(RCHT), the South Devon Healthcare NHS Foundation Trust (SDHT) and the North Devon 
District Hospital NHS Trust (NDDH). 
The Collaborative studies pledged to contribute a total of 50 patient samples. With an 
estimated 25% drop out rate for lack of suitability for laboratory testing or incomplete 
histological data, this would total 38 valid patient samples. This would leave 54 patients 
needing inclusion from the regional study. Data from the pilot study were available on 
18 patients, leaving data from 36 patients needed from the regional study. Allowing for 
a 30% drop out of patients not proceeding to surgical resection after neoadjuvant 
treatment this would require recruitment of 51 patients in the regional study bringing 
the total recruitment number to 119 patients.  
Over the past 2 years, The Peninsula Unit has treated on average 4.83 typically eligible 
patients per month. A recruitment rate of 70% total eligible patients predicts it would 
take 15 months (64 weeks) to recruit the required 51 patients. The recruitment period 
was established as October 2013 to December 2014 inclusive. It was predicted that the 
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70% recruitment target could be reached by recruiting mainly from the PHNT site, but 
also from RDE, RCHT and SDHT sites. NDDH refers very few patients each year (<5) and 
it was felt that the potential benefit of reaching this small number of patients would be 
outweighed by the significant additional burden of setting up on this site together with 
lengthy journeys necessary for site visits and sample transfers, therefore, NDDH was not 
included in the regional study. Some peripheral site patients (RCHT/RDE/SDHT) could be 
recruited on the local site (PHNT) when visiting for staging investigations. Other 
peripheral patients would need to be recruited at their local sites. 
Participants, Regional Study 
Patient pathway and recruitment 
Patients with newly diagnosed, histologically proven oesophageal and gastric cancer 
were identified though multidisciplinary team meetings at Derriford Hospital and 
recruited after histological diagnosis had been confirmed. 
As part of the usual patient management, the multidisciplinary meeting establishes the 
diagnosis and staging and a treatment plan is made that will include whether or not a 
patient is suitable for surgery. This may be after a planned course of chemotherapy with 
reassessment of surgical suitability after completion or without preoperative 
chemotherapy. Patients are normally then invited to the surgical outpatient clinic where 
the diagnosis and treatment options are discussed including surgery. If they wish to 
pursue a radical treatment plan including surgery and are offered neoadjuvant therapy 
they are also seen by a Consultant oncologist in the oncology clinic. 
At this time, if felt appropriate, patients due to embark on a radical treatment plan 
including neoadjuvant chemotherapy and surgery were approached by either a 
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Consultant Oncologist or Consultant Surgeon and invited to discuss participating in the 
study. If the patient agreed to discuss it further then they were introduced to the 
Principal Investigator, Mr Bunting who counselled the patient regarding the study, 
formally offered them the opportunity to participate, gave them a patient information 
leaflet (see Appendix I) and took informed consent (see Appendix II). 
Eligibility assessment 
Inclusion criteria 
 Participant diagnosed with histologically proven gastric or oesophageal cancer 
 Participant willing and able to give consent to participate in the study 
 Able to comply with all study requirements 
 Agrees to involvement in the study being known to the study management 
group, treating clinicians and patient’s general practitioner 
 Patient planned to undergo surgical resection 
Exclusion criteria 
 Participant unable or unwilling to give consent 
 Participant under the age of 18 years 
Withdrawal criteria 
 Participant withdrawing consent 
 Significant deviation from the study protocol 
 Adverse event effecting ability to comply with study requirements 
 Participant lost to follow up 
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Participant involvement 
After treatment decisions were made in the clinic, patients underwent routine 
venepuncture prior to commencing any chemotherapy or surgery.  Recruited study 
participants would need to give two additional 4ml blood tubes for the study. It was 
expected that in most cases this would be done alongside the usual tests at this time. If 
undergoing chemotherapy prior to surgery, then blood tests were also performed after 
each cycle. Similarly, an additional sample was taken for purposes of the study at time.  
Venepuncture was carried out by trained phlebotomy staff/the Chief Investigator.   
There was no requirement for participants to make additional hospital attendances for 
venepuncture, clinic appointments, follow-up, investigation, procedures or operations 
over and above those normally required in the usual course of management of their 
condition outside the study. 
Blood tests at peripheral sites 
The first blood test taken after recruitment would be performed at the local hospital 
either by the Chief Investigator or the Phlebotomy Department. The second blood test 
(after first chemotherapy cycle) would be taken by the local hospital Phlebotomy 
department who would routinely be taking a test at this time. 
Participants, Collaborative study 
Participants recruited through the OCCAMS and SAHSC had consented to the future 
analysis of stored peripheral blood samples (see Appendices III and IV). In the OCCAMS 
study, blood samples had been taken at local sites and transported to the storage facility 
in Cambridge. In the SAHSC study, blood samples were stored in the SAHSC BioResource.  
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Data Collection 
Regional study 
Patient demographic details; medical history; tumour details (including anatomical 
location, subtype and stage); neoadjuvant treatment details; operative details and post-
operative pathological detail were recorded. Radiological response to chemotherapy 
was assessed by Consultant radiologists with a special interest in Upper GI radiology 
according to the RECIST criteria62. Pathological details were reported by Consultant 
histopathologists with a special interest in Upper GI pathology. Histopathological 
response to therapy was reported according to the Mandard TRG Score.  
Collaborative Study 
Demographic details, medical history, cancer location, subtype and stage, radiological 
response to therapy and histopathological response to therapy were recorded as part 
of the OCCAMS and Edinburgh studies. Mr Bunting was given access to these data in 
anonymised form for use in this this study. 
Sample handling 
Regional study 
Blood samples were taken to specimen reception at Derriford Combined Laboratories 
within 1 hour of taking. Samples were processed in the laboratory within 30 minutes. 
This consisted of centrifuging samples for 3 minutes at 3400rpm, then aspirating the 
serum/plasma supernatant and transferring to separate barcoded tubes. Serum samples 
were immediately used for alkaline phosphatase and CEA analysis. CA 19-9 tests were 
run twice weekly from refrigerated samples. The remaining serum was frozen at -20 
degrees centigrade for subsequent analyses. Plasma samples were frozen for 
subsequent ELISA M2-PK batch-analysis. Serum samples were frozen for subsequent 
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CA72-4 batch analysis. All stored serum/plasma samples were labelled with a unique 
sample number, trial number and whether they contained EDTA plasma or serum. 
Collaborative study 
Initial blood sample handling occurred at each local centre. They were centrifuged and 
the plasma component separated then placed in frozen storage locally. In the OCCAMS 
study, samples were then transferred to a central storage facility in Cambridge where 
they are subjected to analysis as part of the OCCAMS study. In the Edinburgh study, 
samples were stored in a laboratory facility in Edinburgh. A sample of each patient’s 
plasma was sent in anonymised form under a material transfer agreement (MTA) to 
Derriford Hospital for analysis in the present study. Biomarker levels were measured in 
plasma samples at the Clinical Biochemistry laboratory, Derriford Hospital.  
Temporary sample storage 
Samples were kept in frozen storage at -20 degrees centigrade. 
Long-term sample storage 
Plasma and serum samples remaining after analysis were kept in a storage facility frozen 
at 80C for 5 years. 
Sample transport 
The full panel of laboratory tests required for the study were only available at the 
Derriford site therefore all samples taken at local sites needed to be locally processed, 
temporarily stored, then transferred to Derriford for analysis. Initial local processing of 
samples followed the same procedure as above. Samples were transferred back to 
Derriford in insulated ice-packs. 
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Biochemistry laboratory biomarker analyses 
M2-PK assay 
Plasma samples were analysed using the dimeric M2-PK enzyme linked immunosorbent 
assay (ELISA) manufactured by ScheBo Biotech, Giessen, Germany (‘ELISA EDTA-Plasma 
Test’), see Figure 56 and Figure 57. This is a CE-marked, highly sensitive ELISA which 
allows the quantitative measurement of dimeric (‘Tumour’) M2-PK in EDTA-plasma. The 
test is based on two monoclonal antibodies which specifically react with the dimeric 
form of M2-PK and do not cross react with the other isoforms of pyruvate kinase (Type 
L, R, M1 and tetrameric M2). Dimeric M2-PK levels are stable in blood plasma kept at 
room temperature for up to 24 hours, refrigerated for 7 days and frozen for at least 6 
months.  
 
Figure 56 ScheBo Tumour M2-PK EDTA-Plasma Test kit. 
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Figure 57 ScheBo Tumour M2-PK EDTA-Plasma Test kit. 
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Principle of assay 
The ELISA plate is coated with a monoclonal antibody only recognising dimeric M2-PK. 
M2-PK protein in EDTA plasma samples and calibration standards binds to the antibody 
and is immobilised to the plate. A second monoclonal antibody binds to the M2-PK 
during the next incubation. The conjugate of POD (peroxidase) and streptavidin binds to 
the biotin moiety. The peroxidase oxidizes 3,3’5,5’-tetra-methyl benzidine. The 
concentration of oxidized TMB is then determined photometrically. 
The manufacturers’ instructions for the assay were followed precisely. Samples, 
standards and controls were pipetted in duplicate and the plates were read using a 
microplate reader, Multiskan EX, Thermo Electron Corporation (see Figure 60). Optical 
densities of 450nm and 620nm are used to take measurements between 5 minutes and 
30 minutes after addition of the stop solution which changes the colour of the well fluid 
from blue to yellow. The M2-PK level is then calculated by using a calibration standard 
curve based on the average values of duplicate wells. The control has to read within 15% 
of its expected value for the assay to be valid. 
M2-PK is stable in EDTA plasma for up to three days at 4C and for up to one year at -
20C. All M2-PK assays were performed by Mr Bunting. 
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Figure 58 ELISA plate after colour reaction 
 
Figure 59 ELISA plate after stopping the colour reaction prior to measurement in the plate reader 
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Figure 60 Multiskan EX Thermo Electron Corporation plate reader in action. 
CA19-9 assay 
This assay is based on a sandwich ELISA technique using the 116-NS-19-9 antibody. 
Measurement is done by the use of a chemiluminescent reaction technique and was 
performed by Derriford Combined Laboratories technicians. A calibration curve was 
used to read off the biomarker levels. 
CA72-4 assay 
The CA72-4 assay is not routinely performed in the Derriford Combined Laboratories, 
however, although it had been through a successful validation process locally and was 
available for use in this study. The sandwich ELISA technique is similar to the CA19-9 
chemiluminescent technique and utilises a biotinylated monoclonal antibody CC49 and 
the B72.3 antibody. Assays were performed by Derriford Combined Laboratories 
technicians. 
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Histopathological analysis 
Response to neoadjuvant therapy was measured as part of routine staging using the 
tumour regression grade (TRG). According to recognised methods, TRG levels 1-3 were 
classified as responders and TRG levels 4-5 were classified as non-responders. 
Data reporting and analysis 
Demographics, pre-operative data 
Patient demographics, pre-operative staging details and neoadjuvant therapy regimes 
were reported and compared in responders and non-responders to neoadjuvant 
therapy. 
Resection pathology 
Postoperative resection pathology details including T stage, N stage, lymphovascular 
invasion, presence of Barrett’s oesophagus, Lauren classification, differentiation grade 
and R0 resection status were reported and compared in responders and non-responders 
to neoadjuvant therapy. 
Analysis 
To investigate whether pre-therapy plasma biomarker levels can predict 
response/resistance to chemotherapy, biomarker levels were compared in responder 
and non-responder groups. 
The main cohort combining regional and collaborative patients was used for comparison 
of pre-therapy M2-PK levels in responders and non-responders to neoadjuvant therapy. 
It was anticipated that some patients would not have TRG data available for a number 
of reasons. A proportion of patients would exhibit progressive disease whilst undergoing 
chemotherapy and would therefore not proceed to resection where the TRG would be 
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reported. Similarly, it was anticipated that full pathological reporting including TRG 
scores may not have been available in all patients from all centres. This would lead to a 
number of patients not being included in the analysis and a reduction in the sample size. 
Although histological response (TRG) is not accurately predicted by radiological 
response, particularly in patients with radiological stable disease (RECIST criteria), those 
patients displaying progressive disease and not proceeding to resection are very unlikely 
to be scored as TRG1-3 if they had proceeded to resection and a partial response may 
be indicative of histological partial response (TRG2-3). Therefore, in order to benefit 
from the biomarker data in those patients without TRG data it was decided to perform 
a similar analysis with patients exhibiting progressive disease included in the non-
responder group and those with partial response included in the responder group. 
The regional patient cohort was used for comparison of CEA, CA19-1, CA72-4 and 
alkaline phosphatase levels in responders and non-responders since these were 
measured in serum samples that were only available in regional cohort patients. 
Likewise biomarker levels after the first cycle of chemotherapy were only available in 
patients from the regional study. 
For biomarkers expressing a difference between responder and non-responder groups, 
a sub-group analysis was used to identify differences according to chemotherapy type, 
histological type (Lauren classification) and recruiting centre 
(Regional/OCCAMS/Edinburgh).  
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Statistics 
Statistical analysis was performed by Mr Bunting using SPSS v21 under the supervision 
and with the aid of Sue Ball, Research Fellow and acting lead of the Bioinformatics and 
Statistics Department, Plymouth University. 
Continuous data, such as biomarker levels were tested for normality using the 
Kolmogorov-Smirnov test and equal variance was assessed using Levene’s test. 
For comparison of pre-operative factors in responders and non-responders, the 
unpaired student T-test was used for continuous variables. Fisher’s exact test was used 
for categorical variables when the number of subjects in any cell was ≤5. The Chi square 
test was used for categorical variable and the Chi square test for linear trend was used 
for ordinal variables. The tests above were also applied to the comparison of post-
operative factors in responders and non-responders. 
For comparison of biomarker levels in responders and non-responders, the unpaired t-
test or Mann-Whitney tests were used as appropriate.   
For any biomarkers with significantly different levels in responders compared to non-
responders, binary logistic regression analysis was performed to determine the 
performance of biomarker levels in predicting response/non-response. Fitted models 
were used to obtain predicted probabilities of non-response, across a range of 
biomarker levels. These were presented graphically, with 95% confidence intervals, as a 
predictive probabilities curve. 
Data Storage and Management 
Study data were stored and backed-up on secure, password-protected PHNT servers for 
five years using a password-protected database. Mr Bunting managed the database.  
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Case Report Forms were stored in the Postgraduate Surgical Research Office, Derriford. 
Standard Operating Procedures were maintained.  The participants were identified by a 
study specific participants’ code in the database.  The name and any other identifying 
detail were not included in any electronic file. The NHS Mail email system was used for 
communicating any patient identifiable data. 
Study Contributors 
Regional study 
The study protocol was written by the Principal Investigator, Mr Bunting and was 
reviewed by the co-investigators and the PHNT R&D department (see also Project 
Management).  Advice on the laboratory techniques and feasibility of laboratory 
analyses was taken from Dr Ruth Ayling.  Guidance on the study design was taken from 
Professor Mazurek, Justus-Liebig-University of Giessen, Germany. Mr Bunting was 
responsible for identifying eligible patients from the multidisciplinary team database. 
He was responsible for patient recruitment and taking informed consent. Mr Bunting 
personally performed venepuncture or liaised with the Phlebotomy department to co-
ordinate this. Derriford Combined Laboratory staff trained Mr Bunting in the M2-PK 
ELISA technique. 
Collaborative study 
The Collaborative study protocol was approved by Professor Rebecca Fitzgerald, Chief 
Investigator of the OCCAMS study together with OCCAMS collaborative partners, as an 
OCCAMS-linked collaborative study. Mr Rob O’Neill is the Principal Investigator and 
Collaborator in the SAHSC-linked study and approved the protocol. 
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Informed Consent 
Regional study 
Consent for the study was obtained by Mr Bunting. It was taken at either of the 
opportunities described in the subject recruitment section above. A recent diagnosis of 
oesophageal or gastric cancer can have significant psychological impact on patients.  
Investigators therefore needed to express sensitivity in all matters including 
participation in the study. The appropriateness of introduction to the study was 
considered and the timing of invitation decided accordingly. Consent was only taken 
after a full verbal explanation and written information leaflet has been given to the 
patient outlining the exact nature of the study and its implications including potential 
risks in taking part. The participants understood that they were able to withdraw from 
the study at any time with no prejudice to future care and no obligation to give an 
explanation for the withdrawal. If patients agreed to participate, written consent was 
taken by means of participant dated signature and dated signature of the investigator. 
A copy of the signed Informed Consent was given to participants.  The original was 
retained in the Research office. 
Collaborative study 
Patients had been consented under the OCCAMS and Edinburgh studies. These included 
agreements that stored blood samples may be used for future ethically approved 
research studies. Samples were anonymised and coded prior to storage. 
Discontinuation/Withdrawal of Participants from the Study 
Each participant had the right to withdraw study at any time.  In addition, the 
investigator was able to discontinue a participant from the study at any time if the 
investigator considers it necessary for any reason including: 
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 Ineligibility (either arising during the study or retrospective having been 
overlooked at screening) 
 Significant protocol deviation 
 Significant non-compliance with study requirements 
 An adverse event which resulted in inability to continue to comply with study 
procedures 
 Disease progression which resulted in an inability to continue to comply with 
study procedures 
 Consent withdrawn 
 Lost to follow up 
Source Data 
Source documents included the patients written hospital notes; the digital whiteboard 
of patient information kept on a PHNT information technology server and electronic 
records in the case of radiological scans, radiological reports and laboratory results.  
These sources were be used to create CRF entries.  The CRF was used as the source 
document for clinical information not held on the above records.  
All documents were stored safely in confidential conditions. On all study-specific 
documents other than the signed consent, the participant was referred to by the study 
participant code, not by name. 
Quality control, quality assurance procedures and study regulation 
The study was conducted in accordance with the latest approved protocol. The 
investigator ensured that it was conducted according to principles of the following: the 
Declaration of Helsinki, the International Conference on Harmonisation (ICH) guidelines 
for Good Clinical Practice (CPMP/ICH/135/95, July 1996), the Data Protection Act, the 
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NHS Research Governance Framework for Health and Social Care (2nd edition) and 
PHNT standard operating procedures. 
The study was considered low risk and as such the researchers monitored the study 
themselves. Specific reviews with input as required were performed by the Plymouth 
Hospitals NHS Trust Research Governance Manager, Chris Rollinson. 
Data were evaluated for compliance with the protocol and accuracy in relation to source 
documents by the Principal Investigator. 
Participant Confidentiality 
The trial staff ensured that participants’ anonymity was maintained. The participants 
were identified only by initials and a participant ID number on the CRF and any electronic 
database. All documents will be stored securely and only accessible by trial staff and 
authorised personnel. The study will comply with the Data Protection Act which requires 
data to be anonymised as soon as it is practical to do so. 
Project management 
Principal Investigator 
 Mr David Bunting, Speciality Registrar in General Surgery and Clinical Research 
Fellow, (PHNT) 
Supervisors/co-investigators  
 Mr Grant Sanders, Consultant Upper GI Surgeon, PHNT (MD Supervisor) 
 Dr Ruth Ayling, Consultant Clinical Chemical Pathologist, PHNT (MD Supervisor) 
 Mr Tim Wheatley, Consultant Upper GI Surgeon, PHNT (Co-investigator) 
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Director of Studies 
 Professor Janusz Jankowski, Associate Dean for Research, Plymouth University, 
Consultant Gastroenterologist, PHNT 
Peripheral site Lead Investigators 
 Dr Liz Toy (Royal Devon & Exeter NHS Foundation Trust) 
 Dr Charlotte Thomson (South Devon Healthcare NHS Foundation Trust) 
 Dr Richard Ellis (Royal Cornwall Hospitals NHS Trust) 
Statistical Advice 
 Andrew Bailey, Statistician 
 Sue Ball, Statistician 
Advisor 
 Mr Steve Hornby, Speciality Registrar 
Financing and insurance 
Funding Sources 
Research Funding of £8828.08 was awarded by Plymouth Hospitals General Charity. 
Publication policy 
Articles submitted for scientific publication will be reviewed by at least one of the study 
supervisors. All members of the study management team involved in the product of 
scientific work will appear as named authors.  Acknowledgements will be made to others 
involved in the project but not directly contributing to the articles. 
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Results 
Patients 
62 patients were recruited from the regional study and 103 patients were recruited from 
the collaborative study, see  
. This gave a total recruitment of 165 patients. 22 of these did not undergo neoadjuvant 
therapy for reasons detailed in  
 and were excluded from the study.  Of these 22 patients, 19 were from the OCCAMS 
part of the collaborative study and 3 were from the regional study. Of 143 patients 
undergoing neoadjuvant therapy, 16 did not proceed to surgical resection and were 
excluded from the study (7 regional, 9 collaborative). Of the remaining 127 patients 
undergoing resection following neoadjuvant therapy, a further 22 patients were 
excluded due to lack of sufficient resection pathology data, all from the collaborative 
study. 1 patient had no chemo-naïve blood sample and the remaining 21 did not have a 
TRG score recorded. This left 105 patients eligible for analysis. 
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Figure 61 Patient recruitment and eligibility (abbreviations: Neoad., Neoadjuvant therapy; CRT, 
chemoradiotherapy). 
Demographics and preoperative variables 
Patient demographics, pre-operative staging details and neoadjuvant therapy regimes 
in responders and non-responders are shown in Table 61. There were 27 responders and 
78 non-responders to neoadjuvant therapy. 
There were no differences in pre-therapy demographic, pathological or treatment 
factors between the two groups. 
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Pre-operative 
factors, n=105 
 Responders 
(n=27) 
Non-responders 
(n=78) 
P 
value 
test 
Age, years mean (range) 59.1 (33.2-78.0) 61.6 (34.2-79.0) 
0.37 T-test 
missing, n (%) 3 (11.1) 13 (16.5) 
Gender M:F 23:4 65:13 1.00 FE 
BMI mean (range) 26.4 (19.2-32.7) 26.5 (18.6-36.3) 0.98 T-test 
missing, n(%) 17 (63.0) 43 (55.1)   
Performance 
status 
0 22 (29.3) 53 (70.7) 
0.44 FE 
1 5 (19.2) 21 (80.8) 
not reported 0 (0.0) 4 (100.0)   
Geographical site PHT 10 (19.2) 42 (80.8) 
0.20 FE REI 3 (21.4) 11 (78.6) 
AHC 14 (35.9) 25 (64.1) 
Tumour type AC 26 (26.0) 74 (74.0) 
1.0 FE 
SCC 1 (20.0) 4 (80.0) 
Tumour Site Oesophagus 4 (15.4) 22 (84.6) 
0.26 FE Junction 19 (27.5) 50 (72.5) 
Gastric 4 (40.0) 6 (60.0) 
Pre-treatment T 
Stage, n (%) 
1 1 (100.0) 0 (0.0) 
0.51 
Chi-sq 
trend 
2 4 (36.4) 7 (63.6) 
3 17 (20.0) 67 (79.8) 
4 2 (50.0) 2 (50.0) 
not reported 3 (50.0) 3 (50.0)   
Pre-treatment N 
Stage 
0 7 (29.2) 17 (70.8) 
0.625 
Chi-sq 
trend 
1 11 (20.4) 43 (79.6) 
2 5 (27.8) 13 (72.2) 
3 0 (0.0) 2 (100.0) 
not reported 3 (42.9) 4 (57.1)   
Prognostic Stage 
Group 
1 1 (100.0) 0 (0.0) 
0.34 
Chi-sq 
trend 
2 8 (26.7) 22 (73.3) 
3 15 (21.7) 54 (78.3) 
missing 3 (60.0) 2 (40.0)   
Neoadjuvant 
regime 
Cisplatin/5FU 5 (19.2) 22 (80.8) 
0.46 FE ECX/EOX 21 (27.3) 56 (72.7) 
CROSS 1 (50.0) 1 (50.0) 
Table 61 Preoperative demographic, clinical and pathological factors in responders and non-responders. 
Percentages may not add to 100 due to rounding. (Abbreviations:  5FU, %-fluorouracil; ECX, epirubicin, cisplatin, 
capecitabine; EOX, epirubicin, oxaliplatin, capecitabine; CROSS, chemoradiotherapy as used in the CROSS trial; 
AC, adenocarcinoma; SCC, squamous cell carcinoma; FE, Fisher’s exact test; Chi-sq trend, Chi square linear-linear 
association test) 
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Postoperative resection pathology 
Postoperative resection pathology details are shown in Table 62. Pathological T stage 
and N stage were both lower in responders (P<0.001 and P=0.001 respectively). There 
was less lymphovascular invasion in responders (P=0.004) and the R0 resection rate was 
higher in responders (P=0.03). 
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Post-operative 
factors 
 Responders 
(n=27) 
Non-responders 
(n=78) 
P 
value 
test 
Pathological T 
stage 
T0 7 (100.0) 0 (0.0) 
<0.001 
Chi-sq 
trend 
T1 5 (45.5) 6 (54.5) 
T2 4 (26.7) 11 (73.3) 
T3 11 (18.3) 49 (81.7) 
T4 0 (0.0) 9 (100.0) 
Tx 0 (0.0) 3 (100.0)   
Pathological N 
stage 
N0 16 (50.0) 16 (50.0) 
0.001 
Chi-sq 
trend 
N1 7 (20.6) 27 (79.4) 
N2 3 (13.0) 20 (87.0) 
N3 1 (7.1) 13 (92.9) 
Nx 0 (0.00) 2 (100.0)   
Lymphovascular 
invasion 
Y 5 (12.2) 36 (87.8) 
0.004 FE N 19 (40.4) 28 (59.6) 
Unknown 3 (17.6) 14 (82.4) 
Barrett’s 
oesophagus 
Y 9 (21.4) 33 (78.6) 
0.49 Chi-sq 
N 14 (32.6) 29 (67.4) 
Unknown 3 (17.6) 14 (82.4)   
Signet ring cells Yes 2 (15.4) 11 (84.6) 
0.50 FE 
No 20 (29.4) 48 (70.6) 
Missing 5 (20.8) 19 (79.2)   
Differentiation 
Grade 
Well 1 (33.3) 2 (66.6)  
1.0 
Chi-sq 
trend 
Moderate 4 (17.4) 19 (82.6) 
Poor 15 (21.7) 54 (78.3) 
not reported 7 (70.0) 3 (30.0) 
R0 resection status R0 22 (32.4) 46 (67.6) 
0.03 FE 
R1 4 (12.1) 29 (87.9) 
Not reported 1 (25.0) 3 (75.0)   
Lauren 
classification 
Intestinal 
 
20 (29.4) 48 (70.6) 
0.50 FE 
Diffuse/mixed 2 (15.4%) 11 (84.6) 
Missing 5 (20.8) 19 (79.2)   
Table 62 Postoperative histopathological factors and response to neoadjuvant therapy.  
Percentages may not add to 100 due to rounding. (Abbreviations: FE, Fisher’s exact test; Chi-sq, Chi-square test; 
Chi-sq trend, Chi square linear-linear association test) 
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Biomarker results 
Pre-therapy M2-PK 
In the cohort combining regional and collaborative patients, pre-therapy M2-Pyruvate 
kinase levels were measured in 102 patients because 3 patients did not have stored 
frozen plasma available. Two of these patients were the first two patients recruited in 
the regional study and modifications of the initial laboratory processing ensured that 
future samples were saved and stored in the correct way. One further patient sample 
could not be located. Pre-therapy M2-PK levels were lower in responders compared to 
non-responders (P=0.037), see Table 63. 
Pre-therapy M2-PK in cohort including radiological response definition 
There were 13 patients without TRG data but who were shown to have radiological 
progressive disease. 3 of these patients were radiological partial responders and 10 
patients had progressive disease. Of the latter, one had radiological progressive disease 
and was resected but did not have TRG data available and the remaining 9 did not 
proceed to resection. There was a total of 118 patients available in this cohort when 
these additional 13 patients were included (see Table 64). 4 patients had missing 
biomarker data, leaving 114 patients for the analysis. M2-PK levels were higher in non-
responders compared to responders (P=0.037). 
CA19-9, CA72-4, CEA, alkaline phosphatase 
In the regional cohort alone, pre-therapy CA19-9, CA72-4, CEA and alkaline phosphatase 
levels were measured. Of 52 patients from the regional cohort, 17 were recruited 
through the screening study at a time when CEA and alkaline phosphatase were not 
being measured, therefore fewer patients had CEA/alkaline phosphatase estimation 
compared to CA19-9 and CA72-4. 1 patient had a missing CA19-9 level and 13 patients 
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had missing CA72-4 values. The CA72-4 assay was not run weekly and batches were 
processed later from frozen stored samples. A number of serum samples were not found 
in storage and others had insufficient sample volume. None of the biomarkers had 
significantly different levels in responders and non-responders, see Table 65. 
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Blood 
test 
N=105 M2-PK levels 
P-value 
(MWU) 
N valid (responders: 
non-responders) 
Missing, n(%) 
Responders Non-responders 
Mean Median Range Mean Median Range 
Test 1 
(pre-
therapy) 
102 (26:76) 3 (2.9) 27.4 27.6 8.1-50.2 36.4 33.9 12.4-111.9 0.037 
Table 63 M2-PK levels in responders and non-responders to neoadjuvant thearpy from the combined collaborative and regional cohort.  
(abbreviations: MWU, Mann-Whitney U test) 
Blood 
test 
N=118 M2-PK levels 
P-value 
(MWU) 
N valid (responders: 
non-responders) 
Missing, n(%) 
Responders Non-responders 
Mean Median Range Mean Median Range 
Test 1 
(pre-
therapy) 
114 (29:85) 4 (3.4) 29.0 29.1 8.1-60.5 37.0 34.9 12.4-111.9 0.037 
Table 64 M2-PK levels in responders and non-responders to neoadjuvant therapy from the combined collaboration and regional cohort where non-responders include radiological 
progressive disease in additional to histological non-response 
(abbreviations: MWU, Mann-Whitney U test) 
Blood 
test 
Marker 
N=52 Biomarker levels 
P-value 
(MWU) 
N valid 
(responders: non-
responders) 
Missing, n(%) 
Responders Non-responders 
Mean Median Range Mean Median Range 
Test 1 
(pre-
therapy) 
CEA 33 (7:26) 19 (36.5) 4.9 3.4 1.1-11.8 10.3 2.3 0.5-185.8 0.67 
CA19-9 51 (10:41) 1 (1.9) 23.1 20.0 2.0-69.0 37.0 14.0 1.0-428 1.0 
CA72-4 39 (8:31) 13 (25.0) 3.7 1.6 0.9-11.1 5.4 3.6 0.8-18.7 0.35 
Alk phos 30 (6:24) 22 (42.3) 70.8 62.0 48.0-123.0 78.0 80.0 20.0-130 0.35 
Test 2 
(post 1st 
cycle) 
M2-PK 20 (4:16) 32 (61.5) 17.8 17.1 11.7-25.1 24.0 20.0 6.7-68.5 0.55 
CEA 19 (3:16) 33 (63.4) 4.5 4.6 1.8-7.0 8.5 2.2 0.7-94.4 0.32 
CA19-9 18 (3:15) 34 (65.4) 36.3 34.0 14.0-61.0 29.2 16.0 1.0-100.0 0.53 
CA72-4 8 (2:6) 44 (84.6) 16.7 16.7 6.2-27.2 5.6 3.9 1.6-12.9 0.25 
Alk phos 20 (3:17) 32 (65.4) 76.7 73.0 66.0-91.0 82.9 78.0 19.0-146.0 0.70 
Table 65 Biomarker levels in responders and non-responders to to neoadjuvant thearpy from the regional cohort. 
(abbreviations: MWU, Mann-Whitney U Test; alk phos, alkaline phosphatase) 
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Sub-group analysis 
Chemotherapy type 
Levels of M2-PK differed in responders compared to non-responders in patients 
undergoing triple agent chemotherapy (ECF/ECX), P=0.028 but the difference in patients 
undergoing dual agent therapy (cisplatin/5-FU) was not significant, see Table 66. When 
radiotherapy patients were excluded, the difference was significant, P=0.03. There were 
only two patients in the chemoradiotherapy group so no statistical analysis was possible. 
Histological type (Lauren classification) 
When patients were subdivided according to histological type, M2-PK levels did not 
differ between responders and non-responders, see Table 67. 
Recruiting centre 
When patients were subdivided according to the recruiting centre, none of the sub-
groups alone had significantly different M2-PK levels in responders compared to non-
responders, Table 68. With the Edinburgh patients, M2-PK levels were remarkably 
similar in responders and non-responders. When Edinburgh patients were excluded, 
M2-PK levels were significantly lower in non-responders compared to responders 
(P=0.02). 
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Chemotherapy 
type 
N 
(Resp:nonR) 
M2-PK levels 
P-value 
(MWU) 
Responders Non-responders 
Mean Median Range Mean Median Range 
Type 1 26 (5:21) 29.6 25.3 12.6-50.2 34.9 33.3 17.1-74.3 0.61 
Type 2 74 (20:54) 26.7 27.6 8.1-37.6 37.3 35.1 12.4-111.9 0.028 
Type 3 2 (1:1) - - - - - - n/a 
Radiotherapy 
excluded (Types 
1 and 2) 
100 (25:75) 27.2 26.1 8.1-50.2 36.1 33.4 11.7-111.9 0.030 
Table 66 M2-PK levels in responders and non-responders to neoadjuvant thearpy divided according to chemotherapy type. 
Type 1 dual agent therapy (Cisplatin/5-FU), Type 2 triple agent therapy (ECF/ECX), Type 3 chemoradiothearpy. 
Histological type 
(Lauren Classification) 
 M2-PK levels  
n (Resp:nonR) 
Responders Non-responders P-value 
(MWU) Mean Median Range Mean Median Range 
Intestinal 66 (20:46) 28.2 30.1 8.1-41.8 38.0 35.7 12.4-111.9 0.09 
Diffuse/mixed 12 (1:11) - - - 32.6 32.3 17.4-54.1 n/a 
Table 67 M2-PK levels in responders and non-responders to neoadjuvant thearpy divided according to histological type. 
Recruitment centre 
 M2-PK levels  
n 
(Resp:nonR) 
Responders Non-responders P-value 
(MWU) Mean Median Range Mean Median Range 
Regional 49 (9:40) 29.9 32.2 11.1-
41.8 
39.2 36.0 12.4-
101.3 
0.23 
Collaborative- 
Edinburgh 
14 (3:11) 29.3 25.3 12.6-
50.2 
28.7 22.6 17.1-53.3 1.00 
Collaborative-OCCAMS 39 (14:25) 25.4 26.0 8.1-34.9 36.9 32.3 12.9-
111.9 
0.24 
         
Regional and OCCAMS 
(Edinburgh excluded) 
88 (23:65) 27.1 29.1 8.1-41.8 37.7 35.2 12.4-
111.9 
0.02 
Table 68 M2-PK levels in responders and non-responders to neoadjuvant thearpy divided according to Recruitment Centre.  
  
M2-PK and pre-operative, demographic, clinical or pathological factors 
In order to demonstrate that M2-PK levels are not simply a surrogate for other known 
demographic factors or tumour characteristics, the relationship between M2-PK levels 
and such factors was investigated, see Table 69 and Figure 62.  No factors were 
significantly associated with M2-PK levels with the exception of differentiation grade, 
P=0.04. Moderately differentiated tumours appeared to have higher M2-PK levels 
compared to well and poorly differentiated tumours. 
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N=102   N M2-PK median 
(range) 
Statistical Test 
 
Significance 
Age  102  
Pearson Correlation 
R=0.16 
P=0.31 
Gender Male 85 32.3 (8.1-111.9) 
M-W P=0.20 
Female 17 31.1 (16.7-50.2) 
Body mass 
index 
 
88 
 
Pearson Correlation 
R=0.06 
P=0.58 
missing 14    
Pre-treatment T 
Stage 
1 1 n/a 
K-W P=0.19 
2 10 33.9 (21.5-101.3) 
3 83 31.4 (8.1-111.9) 
4 3 25.6 (18.1-28.4) 
Not reported 5    
Pre-treatment N 
Stage 
0 22 29.9 (15.8-74.3) 
K-W P=0.46 
1 53 31.1 (8.1-101.3) 
2 18 35.4 (12.6-111.9) 
3 2 21.4 (20.9-22.0) 
Not reported 7    
Performance 
status 
0 72 28.7 (8.1-111.9) 
K-W P=0.08 
1 26 36.8 (11.1-101.3) 
Not reported 4    
Tumour Site Oesophagus 24 28.8 (11.1-101.3) 
K-W P=0.85 
Junction 68 33.2 (8.1-111.9) 
Gastric 10 29.5 (12.4-61.4) K-W  
Lymphovascular 
invasion 
Yes 40 32.3 (8.1-101.3) 
M-W P=0.95 
No 45 32.4 (12.4-111.9) 
Unknown 17    
Barrett’s 
oesophagus 
Yes 40 31.2 (11.1-101.3) 
M-W P=0.50 
No 42 32.6 (8.1-111.9) 
unknown 18    
Differentiation 
Grade 
Well 3 27.6 (23.4-38.8) 
K-W P=0.04 Moderate 23 39.2 (20.2-74.3) 
Poor 66 27.1 (8.1-111.9) 
unknown 10    
Geographical 
site 
PHT 49 34.6 (11.1-101.3) 
K-W P=0.12 REI 14 23.6 (12.6-53.3) 
AHC 39 28.3 (8.1-111.9) 
Tumour type AC 97 31.4 (8.1-111.9) 
K-W P=0.40 
SCC 5 33.3 (20.9-82.2) 
Table 69. Relationship between M2-PK levels and demographic/tumour characteristics. 
(Abbreviations: R, Pearson Correlation Coefficient; M-W, Mann Whitney test;  K-W, Kruskal-Wallis test; PHT, 
Plymouth Hospitals NHS Trust; REI, Royal Edinburgh Infirmary; AHC, Addenbrooke’s Hospital Cambridge. 
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Figure 62. Relationship between pre-therapy M2-PK levels and tumour differentiation grade. 
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Logistic regression analysis 
Binary logistic regression showed that pre-therapy M2-PK levels were able to predict 
response with each unit increase in the biomarker level being associated with a 4.1% 
(95% CI, 0.5%-7.6%) decrease in the likelihood of response (P=0.027), see Table 70. 
Binary logistic 
regression 
n Exp (B) Exp (B) CI Sig 
M2-PK 102 0.959 0.924-0.995 0.027 
Table 70 Binary logistic regression showing M2-PK level is predictive of response to neoadjuvant therapy. 
Figure 63 shows the predicted probability of not responding to neoadjuvant therapy for 
any given level of M2-PK with 95% confidence intervals. Given that currently we know 
that 26% patients will respond to neoadjuvant therapy, from this graph, it can be stated 
that to be 95% certain a patient will have a greater than 26% chance of responding to 
therapy, the M2-PK level would need to be <15 and to be 95% certain a patient will have 
a smaller than 26% chance of responding to therapy, the M2-PK level would need to be 
>65. The numbers of patients within our 105 patient cohort with such extreme values 
were 8 and 5 respectively, together representing 12.4% of the cohort.  
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Figure 63 Predicted probability of non-response based on M2-PK level. 95% Confidence interval shown by shaded 
area. 
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Discussion 
Patients 
Of the 165 patients initially recruited, only 105 were ultimately eligible for inclusion in 
the study. Of the 60 ineligible patients, the majority (50) were from the collaborative 
studies and illustrates one of the limitations of working in collaboration. Many of these 
patients were not suitable because they did not undergo neoadjuvant therapy. In many, 
neoadjuvant therapy was not indicated on the basis of staging and in fact, many had 
early tumours that were treated with endoscopic resection techniques. These samples 
were identified by the collaborative centre as potentially appropriate but it was only 
when clinical data became subsequently available that their ineligibility was identified. 
Following this realisation, the system for identification of further patient samples by the 
OCCAMS team was modified. In addition, the ‘pick list’ identified by the OCCAMS team 
was second-screened by Mr Bunting against the clinical data to check eligibility before 
transportation of samples. Since the TRG is essential to the definition of response to 
neoadjuvant therapy, the 21 patients without TRG results available were ultimately 
ineligible for analysis. The majority were from the Edinburgh cohort with the remainder 
from the OCCAMS cohort. This simply results from differences in routine pathology 
reporting between individual centres and demonstrates another limitation of 
collaborative working. One patient was excluded from analysis when it was identified 
that their blood sampling data was after the date of initiation of neoadjuvant therapy 
and therefore did not represent a chemo-naïve sample. Not being able to control the 
timing of blood tests is another limitation of collaborative working and this also 
demonstrates the importance of carefully examining data provided from external 
centres to check eligibility and compliance with the study methodology. 16 (10%) of the 
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165 patients did not undergo resection which is similar to the proportion identified in 
the historical cohort of patients undergoing neoadjuvant therapy from Chapter 3. 
Demographics and preoperative variables 
None of the demographic factors or preoperative variables was associated with 
response to neoadjuvant therapy which is in concordance with the data from the 
historical cohort presented earlier in this chapter. Patient numbers are smaller than in 
the historical study and this study was not powered to detect such differences which 
may be subject to type II error, however, from this work there is no evidence to suggest 
that any preoperative factors can be used in a model to predict response to therapy. 
Postoperative resection pathology 
Response to therapy was associated with lower postoperative lymph node stage. In 
Chapter 3, T and N down-staging was observed in histological responders therefore this 
is expected and has been reported elsewhere as discussed in Chapter 3. R0 resection 
rates were higher in responders which is also expected and indeed this is one of the 
mechanisms through which neoadjuvant therapy is thought to carry a survival 
advantage. 29.4% patients with intestinal type histology responded to therapy 
compared to 15.4% with diffuse or mixed types, however, this trend was not significant. 
This was reported as a part of the post-operative histology rather than pre-operatively 
because the classification was often not reported on the preoperative biopsies although 
since histological type is not thought to be influenced by neoadjuvant therapy affect, 
this should reflect preoperative histological type. In the historical cohort presented 
earlier in this chapter, response rates were similar in the different histological types and 
the prospective study provides no evidence to contradict this. 
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Biomarker results 
The evidence presented in Chapter 6 suggests that there may be a link between M2-PK 
activity/M2-PK levels and sensitivity to chemotherapy 260-262, 302. Specifically, a low 
enzyme activity, or high levels of the inactive dimeric form may be associated with 
resistance. This is the only study to have investigated this phenomenon in patients with 
oesophago-gastric cancer and has shown higher levels of pre-treatment dimeric M2-PK 
in non-responders to neoadjuvant therapy. 
The sub-group analyses showed significantly different M2-PK levels in responders 
compared to non-responders in patients undergoing triple agent chemotherapy (as per 
MAGIC protocol); in all patients undergoing chemotherapy (chemoradiotherapy 
excluded) and in patients recruited regionally or via the OCCAMS collaborative. In 
patients undergoing dual agent chemotherapy (without epirubicin), differences did not 
reach significance which may be due to smaller patient numbers. It is not known 
whether there is any relationship between M2-PK and sensitivity to anthracycline 
agents, however, the presence of this agent within the triple therapy regime seems to 
enhance rather than diminish the expected relationship. Patients recruited from 
Edinburgh did not show any difference in M2-PK levels between responders and non-
responders. This was a small group of patients, due in part to lack of TRG reporting, so 
significance would not likely be achievable with a similar effect size to that seen in 
patients from other recruiting centres. However, the observed M2-PK levels were very 
similar in responders and non-responders. The reasons for this lack of difference are 
unclear but may be due to very small responder numbers (3), or differences in specimen 
preparation/storage. Whilst the M2-PK levels are generally stable in plasma under 
normal laboratory processing conditions, there are many variables that can potentially 
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influence the measured M2-PK level that are difficult to control on multiple sites, 
particularly when samples have been processed prior to inclusion in this study. These 
include, time to centrifugation/separation, storage time and temperature, number and 
duration of freeze thaw cycles and sample transport conditions. 
Pre-treatment levels of markers analysed in the regional patient cohort (CEA, CA19-9, 
CA72-4 and alkaline phosphatase) did not differ between responders and non-
responders. As discussed in Chapter 5, others have suggested better responses to 
chemotherapy are found in in patients with normal baseline levels of CEA and CA19-9226; 
however, there are many differences between this study and ours. Theirs was a study in 
palliative patients, included pancreatic and biliary malignancy, response was measured 
radiologically and chemotherapy regimens included docetaxel. The present study gives 
no evidence to suggest that levels of these tumour cell antigens are associated with 
response to neoadjuvant therapy. 
Biomarker levels taken after completion of the first cycle of chemotherapy were 
available only in patients recruited in the regional study. Subject numbers were small 
for a number of reasons. It was often difficult to co-ordinate this blood test with a 
planned patient visit to hospital. This was particularly problematic at peripheral sites 
where a successful biomarker level measurement relied on a number of factors falling 
into place, which included: the patient having a hospital appointment within the right 
time frame, the patient having the correct sample form in possession, the correct blood 
tubes being collected, the specimen being transferred to the local laboratory in a timely 
manner, correct sample labelling and storage, transport of the samples to Derriford and 
correct labelling, storage and analysis at Derriford. In reality, this was very difficult to 
achieve without dedicated staff on site at peripheral centres and any further similar 
300 
 
studies would need to bear this in mind. From the small sample numbers available, there 
did not appear to be any trends worthy of further investigation. In any case, the value 
of a marker of early response to therapy at this point in time is likely to be less useful 
than a truly predictive marker measured before initiation of treatment. 
Investigating the relationship between M2-PK levels and pre-operative 
demographic/clinical variables showed that only differentiation grade was associated 
with M2-PK levels. This relationship demonstrated no clinically meaningful trend 
because compared to moderately differentiated tumours, levels in both well-
differentiated and poorly-differentiated tumours were lower. This may represent a type 
I error, whereby no true relationship exists. There is no clinical explanation for this 
statistical finding. It could be hypothesised that more aggressive, poorly differentiated 
tumour types would have higher dimeric M2-PK expression but this is certainly not 
demonstrated in the results. 
The main significant finding that M2-PK levels were higher in non-responders was 
further investigated using binary logistic regression and confirmed that levels were 
significantly associated with response. 
Predicted probabilities of non-response, obtained from the fitted logistic regression 
model give an idea of how biomarker levels could be used in a clinical environment to 
give some indication of the likelihood of responding to chemotherapy. Currently 
clinicians have no means to estimate an individual’s chance of a beneficial response and 
can only inform patients that they have a 26% chance of responding adequately. By 
knowing this baseline response rate, it was possible to identify from the graph, M2-PK 
thresholds above and below which the response rate would be different from baseline 
with a 95% certainty. The numbers of patients in these distribution tails represents those 
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in whom the M2-PK level would be clinically useful in modifying with some certainty the 
predicted response rate. These patients represent 12.4% of the cohort. Therefore 1 in 8 
patients would stand to benefit from this test. 
Limitations 
By their very nature, serum/plasma markers have obvious limitations. A single snapshot 
of the marker level is estimated in each blood sample. The marker level represents a 
surrogate marker or cellular biochemistry, however, levels may depend on a number of 
factors other than expression within the primary tumour. These include the presence of 
different cancer cell clones within the same tumour; circadian variation in tumour cell 
metabolism; rate of clearance of the marker from the bloodstream and other features 
of peripheral blood such as hyperbilirubinaemia.  
Blood sample handling introduces sources of error wherever there may be 
inconsistencies such as centrifuge time/velocity, haemolysis, storage temperature, 
storage duration and freeze-thaw cycles. 
The involvement of peripheral sites produces inconsistency in the timing of samples and 
the way specimens are processed, transported and stored. 
Working with collaborations enabled the recruitment numbers to be increased. 
However, there are clear limitations when compared to the methodology of a purpose 
designed, single-centre study. Blood specimens had been collected as part of the parent 
studies prior to the commencement of this study which means the timing of blood 
samples could not be controlled. Samples were inevitably stored for longer prior to 
analysis.  There tended to be more missing clinical and pathological data items and the 
accuracy of such data was difficult to determine. 
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Steps were made along the way to minimise the effects of the limitations above, 
however, the use of such markers in a clinical environment often involves the same 
potential inconsistencies in sample timing, collection, processing and storage. 
Therefore, a marker that is robust in spite of these limitations is more likely to succeed 
in clinical use. 
CONCLUSIONS 
In this biomarker discovery study, pre-therapy M2-PK levels can predict the likelihood 
of responding to neoadjuvant therapy in a cohort of patients with oesophago-gastric 
cancer. This test is likely to be useful for 1 in 8 patients undergoing the test. If this 
biomarker could be used in conjunction with other predictive markers as they become 
available, then a combined model could be built that may prove more clinically useful. 
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CHAPTER 8 - THESIS SUMMARY 
In Chapter 1, the overall poor prognosis in oesophago-gastric cancer was highlighted 
and whist there is some evidence that the addition of neoadjuvant therapy regimes has 
improved survival, gains are modest and limited by toxicity. Response rates to 
neoadjuvant therapy are low. There is no evidence that response rates and overall 
survival can be improved simply by adding more therapeutic agents to existing 
regimens. Authors have called for further research into predicting response to therapy 
so that such treatment is tailored to individual patients accordingly. This problem 
formed the basis of the thesis and the general idea of adopting a personalised medicine 
approach in the management of patients with oesophago-gastric cancer continued as 
an overall theme of the thesis. Chapter 1 described the numerous staging investigations 
that patients being worked up for oesophago-gastric cancer go through. These can be, 
costly, invasive and associated with a potential delay in starting curative therapies, often 
adding little to an individual’s overall management. It was decided to explore the idea 
that staging could be streamlined, offering certain investigations only to those in whom 
they were likely to change management. 
In Chapter 3, a historical cohort of patients from our unit was used to redefine response 
to neoadjuvant therapy, to assess pre-treatment clinical staging accuracy, to investigate 
neoadjuvant therapy toxicity and to explore neoadjuvant therapy efficacy. 
Response to chemotherapy according to histopathological regression was re-defined by 
undertaking a survival analysis. Staging accuracy was not sufficiently accurate for T or N 
down-staging to be included in this definition and true T/N down-staging was restricted 
to those with a histological response.  
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16.2% patients suffered severe life-threatening or fatal adverse events associated with 
neoadjuvant therapy. Overall survival was poorer in those suffering adverse events. 
Over 10% patients starting neoadjuvant therapy did not proceed to resection, and 
chances of this were greater in patients with adverse events. Even within patients 
proceeding to resection, those suffering adverse events from chemotherapy showed a 
trend towards poorer overall survival. 
Only histological responders to neoadjuvant therapy stand to gain any benefit from this 
additional treatment. Those with more advanced disease stage appear to have greater 
potential to benefit; however, these benefits may be evident at earlier stages in 
responders. Thus response to therapy may be more important than disease stage when 
considering whether the addition of neoadjuvant therapy is beneficial. Non-responders 
to therapy may even have poorer outcomes compared to patients undergoing surgery 
only. These findings, together with poor pre-treatment clinical staging accuracy suggests 
that if response to therapy can be predicted, this should be used in addition to, or 
instead of clinical staging to determine which patients should be offered neoadjuvant 
therapy. This gives further support to the need for a clinically useful means of predicting 
response to neoadjuvant therapy. 
In Chapter 4, a proposed method of streamlining staging, whereby the use of PET-CT 
and staging laparoscopy could be limited to those in whom management was most likely 
to be altered was investigated. In each case, criteria based on endoscopy and CT findings 
were able to accurately stratify patients according to whether PET-CT/laparoscopy 
would be likely to change management. 
Chapter 5 reviewed the published literature on predicting response to neoadjuvant 
therapy in patients with oesophago-gastric cancer. While there are some promising 
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molecular markers, further validation studies are needed before any marker would be 
useful in a clinical context. 
In Chapter 6, the tumour M2-PK biomarker is introduced, its role in cancer metabolism 
is explained and the rationale behind its potential as a predictive marker of response to 
neoadjuvant chemotherapy in patients with oesophago-gastric cancer is described. 
Main findings 
Chapter 7 presents the prospective, multicentre, collaborative study set up to 
investigate whether a panel of biomarkers including the novel marker M2-PK is able to 
predict response to neoadjuvant therapy in patients with oesophago-gastric cancer. Of 
all the markers investigated, only M2-PK was predictive of response and could be 
expected to modify the baseline chance of response in 1 in 8 patients. 
Study relevance and wider implications 
Non-responders may have a reduced survival compared to those undergoing surgery 
alone due to the toxicity and delay to surgery. However, a poor response to neoadjuvant 
therapy may simply reflect adverse tumour biology in patients who would have 
otherwise done poorly with surgery alone; therefore, we need to be cautious in drawing 
any conclusions when directly comparing non-responders with patients undergoing 
surgery alone. Predicted non-responders (based on an accurate prediction of response 
and a validated definition of response) would need to be randomised to surgery alone 
or neoadjuvant therapy followed by surgery in order to definitively answer the question 
of whether undertaking neoadjuvant therapy and not achieving a response is associated 
with poorer survival than undergoing surgery alone. This reiterates the importance of 
accurately re-defining and standardising response to neoadjuvant therapy and the need 
for further research into predicting the response to chemotherapy. Mr Bunting 
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continues to work with the OCCAMS collaboration on agreeing a unified definition of 
response to neoadjuvant chemotherapy and identification of predictive biomarkers. 
Diagnosis and screening 
There has already been some research aimed at investigating M2-PK as a diagnostic or 
screening biomarker.  Data in oesophago-gastric cancer are due to be published this 
year. The quantification of chemo-naïve plasma M2-PK levels in patients with 
oesophago-gastric cancer from the present study could be used to support further 
research in this area. 
Prognostic marker 
There is evidence that M2-PK may be a useful prognostic indicator in biliary tract and 
colonic cancers307, 308. This study will involve collecting data that has the potential to 
assess whether M2-PK is associated with disease progression and survival in 
oesophageal and gastric cancers. 
Other cancers 
Since many other epithelial tumours are treated with platinum, 5-fluorouracil and 
anthracycline-based chemotherapy, the results of this study may be applicable to other 
common cancers including breast, lung and colon cancer.  
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Appendix I Patient information leaflet, regional study 
Patient Information Sheet – Part 1 
Predicting the response to neoadjuvant therapy in patients with 
oesophago-gastric cancer 
Invitation 
You are being invited to take part in a research study alongside about 80 other patients 
which forms part of an educational project. Before you decide whether or not to take 
part, it is important for you to understand why the research is being done and what it 
will involve.  Please take time to read the following information carefully, and discuss it 
with others such as family, friends or your GP if you wish.  
Part 1 tells you the purpose of this study and what will happen to you if you take part. 
Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear, or if you would like more information.  Take 
time to decide whether or not you wish to take part. 
What is the purpose of the study? 
The purpose of this study is to analyse the levels of a naturally produced substances 
present in a patient’s blood.  The results will help to find out whether the substance 
levels can be used to predict how well chemotherapy will work or whether it can be used 
to monitor the effects of treatment. This information may in the future help individual 
patients and doctors to decide whether or not they should undergo pre-operative 
chemotherapy.  
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Why have I been chosen?  
You have been chosen as you have a diagnosis of cancer of the oesophagus or stomach. 
Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  If you decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form to 
confirm that you understand what is involved when taking part in this study.  If you 
decide to take part you are free to leave the study at any time and without giving a 
reason.  If you withdraw, unless you object, we will still keep records relating to the 
treatment given to you, as this is valuable to the study.  A decision to withdraw at any 
time, or a decision not to take part, will not affect the quality of care you receive. 
What will happen to me if I take part? 
You will be asked a short series of questions, for example ‘Do you smoke?’ or ‘Is there a 
history of cancer in the family?’ You will be asked to provide a sample of blood before 
any treatment is started, after the first and last cycles of chemotherapy and after 
surgery. A set of bloods is taken routinely at these times therefore another needle is 
usually not required. No extra hospital visits will be required for any part of the study. 
What are the side effects of any investigation performed as part of the study? 
Blood testing is a very safe procedure with minimal side-effects limited to local 
discomfort and occasionally minor bruising. If you do decide to take part in the study, 
you must report any problems you have to your study nurse or doctor.  There is also a 
contact number given at the end of this information sheet for you to phone if you 
become worried at any time.  In the unlikely event of an emergency occurring during the 
conduct of the study, we may contact your nominated next of kin. 
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What are other possible disadvantages and risks of taking part? 
There are no disadvantages to taking part in the study and it will not affect your 
treatment in any way.   
What are the possible benefits of taking part?  
There are no benefits to you for taking part in the study. 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your question.  If you remain unhappy and 
wish to complain formally, you can do this through the NHS Complaints Procedure.  
Details can be obtained from the hospital. 
In the event that something does go wrong and you are harmed during the research 
study there are no special compensation arrangements.  If you are harmed and this is 
due to someone’s negligence, then you may have grounds for a legal action for 
compensation but you may have to pay your legal costs.  The normal National Health 
Service complaints mechanisms will still be available to you. 
Will my taking part in this study be kept confidential? 
Yes.  All the information about your participation in this study will be kept confidential.  
The details are included in Part 2. 
Contact Details 
Chief investigator (Clinical Research Fellow): Mr David Bunting, Tel. No: 
01752431486 
Specialist Nurse:     Marlyn Bolter, Tel. No: 
01752517905 
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If the information in Part 1 has interested you and you are considering participation, 
please continue to read the additional information in Part 2 before making any decision.  
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Patient Information Sheet – Part 2 
Predicting the response to neoadjuvant therapy in patients with 
oesophago-gastric cancer 
What if new information becomes available? 
Sometimes during the course of a clinical trial, new information becomes available on 
the tests that are being studied.  If this happens, we will tell you about it and discuss 
with you whether you want to or should continue in the study.  If you decide to 
withdraw, we will make arrangements for your care to continue. If you decide to 
continue in the study you will be asked to sign an updated consent form. 
On receiving new information, we might consider it to be in your best interests to 
withdraw you from the study.  If so, we will explain the reasons and arrange for your 
care to continue. If the study is stopped for any other reason, you will be told why but 
this will have no impact on your continuing care will be arranged. 
What will happen if I don’t want to carry on with the study? 
You are welcome to withdraw your consent from the study at any stage without giving 
reason.  This will not have any impact on your on-going care. 
Will my part in this study be kept confidential? 
If you consent to take part in this study, the records obtained while you are in this study 
as well as related health records will remain strictly confidential at all times.  The 
information will be held securely on paper and electronically at your treating hospital 
under the provisions of the 1998 Data Protection Act.  Your name will not be passed to 
anyone else outside the research team or the sponsor, who is not involved in the trial.  
You will be allocated a trial number, which will be used as a code to identify you on all 
trial forms. 
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Your name will only appear on your consent form. All other records related to the 
research will have your name removed and will only feature your initials and date of 
birth.  There is the possibility that one of the documents will contain your hospital 
number, however this will not appear on the same sheet as any clinical results.  
Your records will be available to people authorised to work on the trial but may also 
need to be made available to people authorised by the Research Sponsor, which is the 
organisation responsible for ensuring that the study is carried out correctly.  A copy of 
your consent form may be sent to the Research Sponsor during the course of the study.  
By signing the consent form you agree to this access for the current study and any 
further research that may be conducted in relation to it, even if you withdraw from the 
current study.  
The information collected about you may also be shown to authorised people from the 
UK Regulatory Authorities and Independent Ethics Committee; this is to ensure that the 
study is carried out to the highest possible scientific standards.  All will have a duty of 
confidentiality to you as a research participant. 
If you withdraw consent from further study treatment, unless you object, your data and 
samples will remain on file and will be included in the final study analysis. In line with 
the Trust’s procedures, at the end of the study, your data will be securely archived for a 
minimum of 5 years.  Arrangements for confidential destruction will then be made. With 
your permission, other doctors who may be treating you will be notified that you are 
taking part in this study. 
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Informing your General Practitioner 
Your GP will not be routinely informed of your participation in the study, however if the 
need arises or you would wish it to be so then a letter along with a summary of the 
project will be sent to them. 
What are the study methods? 
78 patients will have blood samples taken before starting chemotherapy, after the first 
and last cycles of chemotherapy and after surgery. The levels of chemical markers in the 
blood will be studied in relation to the response to chemotherapy which is measured in 
a sample of the tissue removed during surgery in all patients as a routine part of the 
analysis. The ability of biomarker levels to accurately predict the response to 
chemotherapy will be investigated. This will tell us whether in the future, we may be 
able to safely withhold chemotherapy from those are not likely to benefit or perhaps 
switch to a second-line, more effective treatment earlier. 
What will happen to any samples I give? 
Samples of serum and plasma (the liquid part of blood not containing cells) will be kept 
for up to 5 years for further testing should new investigations become available. Further 
tests would only be performed for a separate study after approval by a Regional Ethics 
Committee has been granted. 
Will any Genetic testing be done? 
There is currently no plan perform genetic tests on the stored samples.  Should this occur 
then you would be contacted in writing to affirm your consent. 
What will happen to the results of this clinical trial? 
The results of the study will be published in a medical journal and presented at a 
scientific conference.  The data will be anonymous and none of the patients involved in 
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the trial will be identified in any report or publication. If you wish to be sent a copy of 
the results, please indicate this by ticking the box on the consent form. 
Will this affect my insurance policies (critical illness, mortgage protection and 
health insurance)? 
You should consider whether this will affect insurance policies and seek advice if 
necessary. 
Who is organising and funding this clinical trial? 
The study has been organised Mr David Bunting, Clinical Research Fellow. External 
funding has been secured from the Plymouth Charitable Trust Small Grants Scheme. 
Researchers are not being paid for conducting the trial. 
Who has reviewed the study? 
The study has been reviewed and is sponsored by Plymouth Hospitals NHS Trust. It has 
also been reviewed by the Plymouth University Peninsula School of Medicine and 
Dentistry.  Favourable ethical opinion for conduct in the NHS has also been granted by 
the South West Research Ethics Committee. 
Contact for further information 
You are encouraged to ask any questions you wish, before, during or after your 
treatment.  If you have any questions about the study, please speak to your study nurse 
or doctor, who will be able to provide you with up to date information about the 
procedures involved.  If you wish to read the research on which this study is based, 
please ask your study nurse or doctor. 
If you or your relatives have any concerns about any aspect of research please speak to 
the researchers using the contact details you will have been provided 
with.  Alternatively, you may wish to contact the hospital's Patient Advice and Liaison 
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Service (PALS). PALS offers support, information and assistance to patients, relatives and 
visitors and will:  
• Provide information about hospital services. 
• Offer advice on where to go to get health information. 
• Help with problems that you haven’t been able to sort out with staff on a ward or in a 
clinic. 
• If you want to make a complaint - advise you how to do so. 
• Tell you about independent organisations that can help you with a complaint. 
• Listen to your views on how we can improve our services, and pass this on to the 
appropriate people for action.  
PALS can be contacted at:  
Patient Advice & Liaison Service 
Level 7, Derriford Hospital 
Plymouth 
PL6 8DH  
Email: plh-tr.PALS@nhs.net  
If you decide you would like to take part then please read and sign and date the consent 
form.  You will be given a copy of this information sheet and the consent form to keep.  
A copy of the consent form will be filed in your patient notes, one will be filed with the 
study records and one may be sent to the Research Sponsor. 
You can have more time to think this over if you are at all unsure. 
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Thank you for taking the time to read this information sheet and to consider this study. 
Appendix II Consent form regional study 
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Appendix III Consent form OCCAMS 
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Appendix IV Consent form SAHSC 
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List of abbreviations 
AC  adenocarcinoma 
AC  adenocarcinoma 
AJCC American Joint Committee on Cancer 
ALDH-1 aldehyde dehydrogenase-1 
ALT  Alanine transaminase 
AMBP Alpha-1-Microglobulin/Bikunin Precursor. 
AUGIS Association of Upper Gastrointestinal Surgeons of Great Britain and 
Ireland 
BASO British Association of Surgical Oncology 
BSG British Society of Gastroenterology 
CEA Carcinoembryonic antigen 
Chi-sq Chi-square test 
CHK2 Checkpoint kinase 2 
CI  confidence interval 
CR  clinical response 
CRT  chemoradiotherapy 
CRT  chemoradiotherapy 
CT   computed tomography 
CT  chemotherapy 
CTCAE Common Terminology Criteria for Adverse Events 
DPD dihydropyrimidine dehydrogenase 
DPD Dihydropyrimidine dehydrogenase 
EBUS endobronchial ultrasound 
ECF  epirubicin, cisplatin & fluorouracil 
ECX  epirubicin, cisplatin & capecitabine 
EGFR epidermal growth factor receptor 
ELISA enzyme-linked immunosorbent assay 
EOX epirubicin, oxaliplatin & capecitabine 
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ER   endoscopic resection 
EUS endoscopic ultrasound 
FDG fluorodeoxyglucose 
FE   Fishers exact test 
FNA fine needle aspiration 
GC  gastric cancer 
GIST gastrointestinal stromal tumours 
GST glutathione S-transferase 
GST glutathione-S-transferase 
Hb  haemoglobin 
HER-2 human epidermal growth factor receptor 2 
IHC  immunohistochemistry 
JCC  Japanese Joint Committee  
MAGIC Medical Research Council Adjuvant Gastric Infusional Chemotherapy 
MDCT multidetector CT  
MDT multidisciplinary team 
MRC Medical Research Council 
MRI magnetic resonance imaging 
MRP1 multidrug resistance protein 1 
MST Median survival time 
MT  metallothionein 
MTHFR methylene-tetrahydrofolate reductase 
MWU Mann-Whitney U test 
NACRT neoadjuvant chemoradiotherapy 
NF-B  nuclear factor kappa-light-chain-enhancer of activated B cells 
NLR neutrophil lymphocyte ratio 
OC  oesophageal cancer 
OCCAMS Oesophageal Cancer Clinical and Molecular Stratification Study (OCCAMS) 
OS  overall survival 
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PallCT palliative chemoradiotherapy 
PCNA Proliferating cell nuclear antigen 
PCNA Proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PCR polymerase chain reaction 
PET positron emission tomography 
PFS  progression-free survival 
PHN Plymouth Hospitals NHS Trust 
PR  pathological response 
PR  pathological response 
RCHT Royal Cornwall Hospitals NHS Trust 
RDE Royal Devon and Exeter NHS Foundation Trust 
RECIST Response Evaluation Criteria in Solid Tumours 
SAHSC Scottish Academic Health Sciences Collaboration (SAHSC) BioResource. 
SC  squamous carcinoma 
SC  squamous cell carcinoma 
SIGN Scottish International Guidelines Network 
SNPs single nucleotide polymorphisms 
SUV standardized uptake value  
TMA tissue microarray 
TP  thymidine phosphorylase 
TPA tissue plasminogen activator 
TPS  tissue polypeptide-specific antigen 
TRG tumour response grade 
Trx  thioredoxin 
TS   Thymidylate synthase 
TS  Thymidylate synthetase 
UICC International Union Against Cancer 
VATS video-assisted thoracosopic surgery 
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VEGF vascular endothelial growth factor  
WHO World Health Organisation 
  
325 
 
References 
1. ONS. Cancer Incidence and Mortality in the United Kingdom, 2008-10. Office for 
National Statistics 2012. 
2. Cancer incidence for common cancers/Trends. Cancer Research UK Online 2012. 
3. ONS. Cancer Survival in England:Patients Diagnosed, 2006–2010 and Followed up to 
2011. Office for National Statistics 2012. 
4. Cancer and mortality in the United Kingdom 2005-2007. Office for National Statistics, 
Online 2012. 
5. Benesch C, Schneider C, Voelker HU, et al. The clinicopathological and prognostic 
relevance of pyruvate kinase M2 and pAkt expression in breast cancer. Anticancer Res 
2010; 30(5):1689-94. 
6. National oesophago-gastric cancer audit. The Royal College of Surgeons of England 
2010. 
7. Ferlay J SH, Bray F, Forman D, Mathers C, Parkin DM. Incidence and Mortality 
Worldwide: IARC CancerBase No.10. International Agency for Research on Cancer 
2010. 
8. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric 
junction. Br J Surg 1998; 85(11):1457-9. 
9. Edge SB BD, Compton CC et al.  AJCC Cancer Staging Manual. New York: Springer; 
2010. 
10. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: 
esophagus and esophagogastric junction. Ann Surg Oncol 2010; 17(7):1721-4. 
11. Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg 
Oncol 2010; 17(12):3077-9. 
12. Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of 
oesophageal and gastric cancer. Gut 2011; 60(11):1449-72. 
13. Allum WH, Griffin SM, Watson A, et al. Guidelines for the management of oesophageal 
and gastric cancer. Gut 2002; 50 Suppl 5:v1-23. 
14. Peters FP, Brakenhoff KP, Curvers WL, et al. Histologic evaluation of resection 
specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest 
Endosc 2008; 67(4):604-9. 
15. Thompson WM, Halvorsen RA, Jr. Staging esophageal carcinoma II: CT and MRI. Semin 
Oncol 1994; 21(4):447-52. 
16. Couper G. Staging of oesophageal and gastric cancer. In: Griffin SM RS, Shenfine J, ed. 
Oesophagogastric Surgery: Elsevier; 2014:pp. 38-61. 
17. Russell I, Edwards R, Gliddon A, et al. Cancer of Oesophagus or Gastricus - New 
Assessment of Technology of Endosonography (COGNATE): report of pragmatic 
randomised trial. Health Technol Assess 2013; 17(39):1-170. 
18. Puli SR, Reddy JB, Bechtold ML, et al. Staging accuracy of esophageal cancer by 
endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 
2008; 14(10):1479-90. 
19. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment 
of the response to induction radiochemotherapy in locally advanced oesophageal 
cancer. Ann Oncol 2002; 13(3):361-8. 
20. Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in 
esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac 
Surg 1999; 68(4):1133-6; discussion 1136-7. 
21. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging 
performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal 
cancer. J Clin Oncol 2004; 22(18):3805-12. 
22. de Graaf GW, Ayantunde AA, Parsons SL, et al. The role of staging laparoscopy in 
oesophagogastric cancers. Eur J Surg Oncol 2007; 33(8):988-92. 
326 
 
23. Crellin A. Radiotherapy and chemotherapy in treatment of oesophageal and gastric 
cancer. In: Griffin SMR, S. A., ed. Oesophago-gastric surgery: Saunders; 2009. 
24. Crosby TCA. Radiotherapy and chemotherapy in treatment of oesophageal and gastric 
cancer. In: Griffin SMR, S. A. Shenfine J, ed. Oesophageogastric Surgery: Saunders; 
2014. 
25. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus 
surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355(1):11-
20. 
26. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared 
with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339(27):1979-
84. 
27. Group MRCOCW. Surgical resection with or without preoperative chemotherapy in 
oesophageal cancer: a randomised controlled trial. Lancet 2002; 359(9319):1727-33. 
28. Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of 
surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 
2009; 27(30):5062-7. 
29. Malthaner RA, Collin S, Fenlon D. Preoperative chemotherapy for resectable thoracic 
esophageal cancer. Cochrane Database Syst Rev 2006(3):CD001556. 
30. Alderson Dea. Neoadjuvant chemotherapy for resectable oesophageal and junctional 
adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial 
(ISRCTN 01852072). J Clin Oncol 2015; 33(suppl). 
31. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and 
surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335(7):462-7. 
32. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant 
chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. 
Lancet Oncol 2007; 8(3):226-34. 
33. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant 
chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an 
updated meta-analysis. Lancet Oncol 2011; 12(7):681-92. 
34. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for 
esophageal or junctional cancer. N Engl J Med 2012; 366(22):2074-84. 
35. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative 
chemotherapy compared with chemoradiotherapy in patients with locally advanced 
adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27(6):851-6. 
36. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA 
Intergroup 113): a random assignment trial comparison of chemotherapy followed by 
surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 
25(24):3719-25. 
37. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery 
compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal 
junction. N Engl J Med 2001; 345(10):725-30. 
38. Bain GH, Petty RD. Predicting response to treatment in gastroesophageal junction 
adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist 
2010; 15(3):270-84. 
39. SIGN. Managemgent of oesophageal and gastric cancer. A national clinical guideline. 
Scottish Intercollegiate Guidelines Network (SIGN) 2006. 
40. Mirza A, Naveed A, Hayes S, et al. Assessment of Histopathological Response in Gastric 
and Gastro-Oesophageal Junction Adenocarcinoma following Neoadjuvant 
Chemotherapy: Which Scoring System to Use? ISRN Pathology 2012; 2012:1-8. 
41. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant 
chemotherapy improves significantly the long term survival of patients with resectable 
esophageal squamous cell carcinoma: final report of a randomized, controlled trial of 
preoperative chemotherapy versus surgery alone. Cancer 2001; 91(11):2165-74. 
327 
 
42. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant 
chemoradiotherapy in esophageal carcinoma is associated with significantly improved 
survival. J Clin Oncol 2005; 23(19):4330-7. 
43. Hermann RM, Horstmann O, Haller F, et al. Histomorphological tumor regression 
grading of esophageal carcinoma after neoadjuvant radiochemotherapy: which score 
to use? Dis Esophagus 2006; 19(5):329-34. 
44. Noble F, Nolan L, Bateman AC, et al. Refining pathological evaluation of neoadjuvant 
therapy for adenocarcinoma of the esophagus. World J Gastroenterol 2013; 
19(48):9282-93. 
45. Naunheim KS, Petruska PJ, Roy TS, et al. Multimodality therapy for adenocarcinoma of 
the esophagus. Ann Thorac Surg 1995; 59(5):1085-90; discussion 1090-1. 
46. Adelstein DJ, Rice TW, Becker M, et al. Use of concurrent chemotherapy, accelerated 
fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 
1997; 80(6):1011-20. 
47. Poplin E, Fleming T, Leichman L, et al. Combined therapies for squamous-cell 
carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). J Clin 
Oncol 1987; 5(4):622-8. 
48. Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete 
response after preoperative chemoradiotherapy in carcinoma of the esophagus and 
outcome after pathologic complete response. Cancer 2005; 104(11):2365-72. 
49. Ajani JA, Correa AM, Hofstetter WL, et al. Clinical parameters model for predicting 
pathologic complete response following preoperative chemoradiation in patients with 
esophageal cancer. Ann Oncol 2012; 23(10):2638-42. 
50. Brucher BL, Stein HJ, Zimmermann F, et al. Responders benefit from neoadjuvant 
radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective 
phase-II trial. Eur J Surg Oncol 2004; 30(9):963-71. 
51. Brucher BL, Swisher SG, Konigsrainer A, et al. Response to preoperative therapy in 
upper gastrointestinal cancers. Ann Surg Oncol 2009; 16(4):878-86. 
52. Ilson. Esophageal cancer chemotherapy: recent advances. my GCR online 2007. 
53. Miyazono F, Metzger R, Warnecke-Eberz U, et al. Quantitative c-erbB-2 but not c-erbB-
1 mRNA expression is a promising marker to predict minor histopathologic response to 
neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer 2004; 91(4):666-
72. 
54. Predescu D, Gheorghe M, Boeriu M, et al. Molecular factors and criteria for predicting 
the response to neoadjuvant treatment in patients with esophageal squamous cell 
carcinoma (ESCC) -- responder/non-responder. Chirurgia (Bucur) 2012; 107(5):583-90. 
55. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of 
esophageal cancer. Dis Esophagus 2006; 19(6):425-32. 
56. Zacherl J, Sendler A, Stein HJ, et al. Current status of neoadjuvant therapy for 
adenocarcinoma of the distal esophagus. World J Surg 2003; 27(9):1067-74. 
57. Fareed KR, Kaye P, Soomro IN, et al. Biomarkers of response to therapy in oesophago-
gastric cancer. Gut 2009; 58(1):127-43. 
58. Westerterp M, van Westreenen HL, Reitsma JB, et al. Esophageal cancer: CT, 
endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--
systematic review. Radiology 2005; 236(3):841-51. 
59. Smith C. Cancer profiling to identify the best therapy first time.  The Times, 2014. 
60. Forshaw MJ, Gossage JA, Chrystal K, et al. Symptomatic responses to neoadjuvant 
chemotherapy for carcinoma of the oesophagus and oesophagogastric junction: are 
they worth measuring? Clin Oncol (R Coll Radiol) 2006; 18(4):345-50. 
61. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. 
Cancer 1981; 47(1):207-14. 
62. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response 
to treatment in solid tumors. European Organization for Research and Treatment of 
328 
 
Cancer, National Cancer Institute of the United States, National Cancer Institute of 
Canada. J Natl Cancer Inst 2000; 92(3):205-16. 
63. Griffith JF, Chan AC, Chow LT, et al. Assessing chemotherapy response of squamous 
cell oesophageal carcinoma with spiral CT. Br J Radiol 1999; 72(859):678-84. 
64. Konieczny A, Meyer P, Schnider A, et al. Accuracy of multidetector-row CT for restaging 
after neoadjuvant treatment in patients with oesophageal cancer. Eur Radiol 2013; 
23(9):2492-502. 
65. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information 
from medical images using advanced feature analysis. Eur J Cancer 2012; 48(4):441-6. 
66. Kumar V, Gu Y, Basu S, et al. Radiomics: the process and the challenges. Magn Reson 
Imaging 2012; 30(9):1234-48. 
67. Hayano K, Okazumi S, Shuto K, et al. Perfusion CT can predict the response to 
chemoradiation therapy and survival in esophageal squamous cell carcinoma: initial 
clinical results. Oncol Rep 2007; 18(4):901-8. 
68. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and 
positron emission tomography in patients with metastatic gastrointestinal stromal 
tumor treated at a single institution with imatinib mesylate: proposal of new 
computed tomography response criteria. J Clin Oncol 2007; 25(13):1753-9. 
69. Stiles BM, Salzler G, Jorgensen A, et al. Complete metabolic response is not uniformly 
predictive of complete pathologic response after induction therapy for esophageal 
cancer. Ann Thorac Surg 2013; 96(5):1820-5. 
70. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2):228-47. 
71. Akita H, Doki Y, Yano M, et al. Effects of neoadjuvant chemotherapy on primary tumor 
and lymph node metastasis in esophageal squamous cell carcinoma: additive 
association with prognosis. Dis Esophagus 2009; 22(4):291-7. 
72. Verlato G, Zanoni A, Tomezzoli A, et al. Response to induction therapy in oesophageal 
and cardia carcinoma using Mandard tumour regression grade or size of residual foci. 
Br J Surg 2010; 97(5):719-25. 
73. Brucher BL, Becker K, Lordick F, et al. The clinical impact of histopathologic response 
assessment by residual tumor cell quantification in esophageal squamous cell 
carcinomas. Cancer 2006; 106(10):2119-27. 
74. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor 
regression after preoperative chemoradiotherapy of esophageal carcinoma. 
Clinicopathologic correlations. Cancer 1994; 73(11):2680-6. 
75. Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression 
after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. 
Ann Surg 2011; 253(5):934-9. 
76. Fareed KR, Ilyas M, Kaye PV, et al. Tumour regression grade (TRG) analyses in patients 
with resectable gastro-oesophageal adenocarcinomas treated with platinum-based 
neoadjuvant chemotherapy. Histopathology 2009; 55(4):399-406. 
77. Barbour AP, Jones M, Gonen M, et al. Refining esophageal cancer staging after 
neoadjuvant therapy: importance of treatment response. Ann Surg Oncol 2008; 
15(10):2894-902. 
78. Korst RJ, Kansler AL, Port JL, et al. Downstaging of T or N predicts long-term survival 
after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann 
Thorac Surg 2006; 82(2):480-4; discussion 484-5. 
79. Bollschweiler E, Holscher AH, Metzger R, et al. Prognostic significance of a new grading 
system of lymph node morphology after neoadjuvant radiochemotherapy for 
esophageal cancer. Ann Thorac Surg 2011; 92(6):2020-7. 
80. Bollschweiler E, Holscher AH, Schmidt M, et al. Neoadjuvant treatment for advanced 
esophageal cancer: response assessment before surgery and how to predict response 
to chemoradiation before starting treatment. Chin J Cancer Res 2015; 27(3):221-30. 
329 
 
81. Ninomiya Y, Yanagisawa A, Kato Y, et al. Histological indications of a favorable 
prognosis with far-advanced gastric carcinomas after preoperative chemotherapy. J 
Cancer Res Clin Oncol 1999; 125(12):699-706. 
82. JSED. Guidelines for clinical and pathologic studies on carcinoma of the esophagus, 
ninth edition: Preface, general principles, part I. Esophagus 2004(1). 
83. Mariette C, Finzi L, Fabre S, et al. Factors predictive of complete resection of operable 
esophageal cancer: a prospective study. Ann Thorac Surg 2003; 75(6):1720-6. 
84. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression 
in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 
98(7):1521-30. 
85. Davies AR, Gossage JA, Zylstra J, et al. Tumor stage after neoadjuvant chemotherapy 
determines survival after surgery for adenocarcinoma of the esophagus and 
esophagogastric junction. J Clin Oncol 2014; 32(27):2983-90. 
86. Allan BJ, Pedroso F, Gennis ER, et al. Influence of Treatment Modality in Outcomes for 
Different Stages of Resectable Esophageal Adenocarcinomas. Ann Surg Oncol 2013. 
87. Hsu PK, Chien LI, Huang CS, et al. Comparison of survival among neoadjuvant 
chemoradiation responders, non-responders and patients receiving primary resection 
for locally advanced oesophageal squamous cell carcinoma: does neoadjuvant 
chemoradiation benefit all? Interact Cardiovasc Thorac Surg 2013; 17(3):460-6. 
88. Dittrick GW, Weber JM, Shridhar R, et al. Pathologic nonresponders after neoadjuvant 
chemoradiation for esophageal cancer demonstrate no survival benefit compared with 
patients treated with primary esophagectomy. Ann Surg Oncol 2012; 19(5):1678-84. 
89. Ba-Ssalamah A, Matzek W, Baroud S, et al. Accuracy of hydro-multidetector row CT in 
the local T staging of oesophageal cancer compared to postoperative histopathological 
results. Eur Radiol 2011; 21(11):2326-35. 
90. Makino T, Fujiwara Y, Takiguchi S, et al. Preoperative T staging of gastric cancer by 
multi-detector row computed tomography. Surgery 2011; 149(5):672-9. 
91. Okines AF, Langley RE, Thompson LC, et al. Bevacizumab with peri-operative 
epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal 
adenocarcinoma: a safety report. Ann Oncol 2013; 24(3):702-9. 
92. Fareed KR, Al-Attar A, Soomro IN, et al. Tumour regression and ERCC1 nuclear protein 
expression predict clinical outcome in patients with gastro-oesophageal cancer treated 
with neoadjuvant chemotherapy. Br J Cancer 2010; 102(11):1600-7. 
93. Koh YW, Park YS, Ryu MH, et al. Postoperative nodal status and diffuse-type histology 
are independent prognostic factors in resectable advanced gastric carcinomas after 
preoperative chemotherapy. Am J Surg Pathol 2013; 37(7):1022-9. 
94. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. 
95. Dixon M, Cardoso R, Tinmouth J, et al. What studies are appropriate and necessary for 
staging gastric adenocarcinoma? Results of an international RAND/UCLA expert panel. 
Gastric Cancer 2013. 
96. Burbidge S, Mahady K, Naik K. The role of CT and staging laparoscopy in the staging of 
gastric cancer. Clin Radiol 2013; 68(3):251-5. 
97. Yamagata Y, Amikura K, Kawashima Y, et al. Staging Laparoscopy in Advanced Gastric 
Cancer: Usefulness and Issues Requiring Improvement. Hepatogastroenterology 2012; 
60(124). 
98. Richardson JR, Khan OA. In patients with radiologically-staged resectable oesophago-
gastric junctional tumours, is diagnostic laparoscopy useful as an additional staging 
procedure? Int J Surg 2012; 10(4):198-202. 
99. Nair CK, Kothari KC. Role of diagnostic laparoscopy in assessing operability in 
borderline resectable gastrointestinal cancers. J Minim Access Surg 2012; 8(2):45-9. 
100. Heath EI, Kaufman HS, Talamini MA, et al. The role of laparoscopy in preoperative 
staging of esophageal cancer. Surg Endosc 2000; 14(5):495-9. 
330 
 
101. Kim SH, Lee JM, Han JK, et al. Three-dimensional MDCT imaging and CT 
esophagography for evaluation of esophageal tumors: preliminary study. Eur Radiol 
2006; 16(11):2418-26. 
102. Panebianco V, Grazhdani H, Iafrate F, et al. 3D CT protocol in the assessment of the 
esophageal neoplastic lesions: can it improve TNM staging? Eur Radiol 2006; 
16(2):414-21. 
103. Onbas O, Eroglu A, Kantarci M, et al. Preoperative staging of esophageal carcinoma 
with multidetector CT and virtual endoscopy. Eur J Radiol 2006; 57(1):90-5. 
104. Weaver SR, Blackshaw GR, Lewis WG, et al. Comparison of special interest computed 
tomography, endosonography and histopathological stage of oesophageal cancer. Clin 
Radiol 2004; 59(6):499-504. 
105. Wu LF, Wang BZ, Feng JL, et al. Preoperative TN staging of esophageal cancer: 
comparison of miniprobe ultrasonography, spiral CT and MRI. World J Gastroenterol 
2003; 9(2):219-24. 
106. Umeoka S, Koyama T, Watanabe G, et al. Preoperative local staging of esophageal 
carcinoma using dual-phase contrast-enhanced imaging with multi-detector row 
computed tomography: value of the arterial phase images. J Comput Assist Tomogr 
2010; 34(3):406-12. 
107. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al. Staging investigations for 
oesophageal cancer: a meta-analysis. Br J Cancer 2008; 98(3):547-57. 
108. Pfau PR, Perlman SB, Stanko P, et al. The role and clinical value of EUS in a 
multimodality esophageal carcinoma staging program with CT and positron emission 
tomography. Gastrointest Endosc 2007; 65(3):377-84. 
109. Kim HJ, Kim AY, Oh ST, et al. Gastric cancer staging at multi-detector row CT 
gastrography: comparison of transverse and volumetric CT scanning. Radiology 2005; 
236(3):879-85. 
110. Kim AY, Kim HJ, Ha HK. Gastric cancer by multidetector row CT: preoperative staging. 
Abdom Imaging 2005; 30(4):465-72. 
111. Hwang SW, Lee DH, Lee SH, et al. Preoperative staging of gastric cancer by endoscopic 
ultrasonography and multidetector-row computed tomography. J Gastroenterol 
Hepatol 2010; 25(3):512-8. 
112. Park HS, Lee JM, Kim SH, et al. Three-dimensional MDCT for preoperative local staging 
of gastric cancer using gas and water distention methods: a retrospective cohort study. 
AJR Am J Roentgenol 2010; 195(6):1316-23. 
113. Yang DM, Kim HC, Jin W, et al. 64 multidetector-row computed tomography for 
preoperative evaluation of gastric cancer: histological correlation. J Comput Assist 
Tomogr 2007; 31(1):98-103. 
114. Chen CY, Hsu JS, Wu DC, et al. Gastric cancer: preoperative local staging with 3D multi-
detector row CT--correlation with surgical and histopathologic results. Radiology 2007; 
242(2):472-82. 
115. Gaur P, Sepesi B, Hofstetter WL, et al. Endoscopic esophageal tumor length: a 
prognostic factor for patients with esophageal cancer. Cancer 2011; 117(1):63-9. 
116. Bonavina L, Incarbone R, Lattuada E, et al. Preoperative laparoscopy in management of 
patients with carcinoma of the esophagus and of the esophagogastric junction. J Surg 
Oncol 1997; 65(3):171-4. 
117. Romijn MG, van Overhagen H, Spillenaar Bilgen EJ, et al. Laparoscopy and laparoscopic 
ultrasonography in staging of oesophageal and cardial carcinoma. Br J Surg 1998; 
85(7):1010-2. 
118. Krasna MJ, Jiao X, Sonett JR, et al. Thoracoscopic and laparoscopic lymph node staging 
in esophageal cancer: do clinicopathological factors affect the outcome? Ann Thorac 
Surg 2002; 73(6):1710-3. 
119. Barrington S, Scarsbrook A. Evidence-based indications for the use of PET-CT in the 
United Kingdom. The Royal College of Physicians and The Royal College of Radiologists 
2012. 
331 
 
120. Yuan S, Yu Y, Chao KS, et al. Additional value of PET/CT over PET in assessment of 
locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 
2006; 47(8):1255-9. 
121. Wong WL, Chambers RJ. Role of PET/PET CT in the staging and restaging of thoracic 
oesophageal cancer and gastro-oesophageal cancer: a literature review. Abdom 
Imaging 2008; 33(2):183-90. 
122. Choi J, Kim SG, Kim JS, et al. Comparison of endoscopic ultrasonography (EUS), 
positron emission tomography (PET), and computed tomography (CT) in the 
preoperative locoregional staging of resectable esophageal cancer. Surg Endosc 2010; 
24(6):1380-6. 
123. Salahudeen HM, Balan A, Naik K, et al. Impact of the introduction of integrated PET-CT 
into the preoperative staging pathway of patients with potentially operable 
oesophageal carcinoma. Clin Radiol 2008; 63(7):765-73. 
124. Facey K, Bradbury I, Laking G, et al. Overview of the clinical effectiveness of positron 
emission tomography imaging in selected cancers. Health Technol Assess 2007; 
11(44):iii-iv, xi-267. 
125. Williams RN, Ubhi SS, Sutton CD, et al. The early use of PET-CT alters the management 
of patients with esophageal cancer. J Gastrointest Surg 2009; 13(5):868-73. 
126. Noble F, Bailey D, Tung K, et al. Impact of integrated PET/CT in the staging of 
oesophageal cancer: a UK population-based cohort study. Clin Radiol 2009; 64(7):699-
705. 
127. Berrisford RG, Wong WL, Day D, et al. The decision to operate: role of integrated 
computed tomography positron emission tomography in staging oesophageal and 
oesophagogastric junction cancer by the multidisciplinary team. Eur J Cardiothorac 
Surg 2008; 33(6):1112-6. 
128. Blencowe NS, Whistance RN, Strong S, et al. Evaluating the role of fluorodeoxyglucose 
positron emission tomography-computed tomography in multi-disciplinary team 
recommendations for oesophago-gastric cancer. Br J Cancer 2013; 109(6):1445-50. 
129. van Westreenen HL, Westerterp M, Sloof GW, et al. Limited additional value of 
positron emission tomography in staging oesophageal cancer. Br J Surg 2007; 
94(12):1515-20. 
130. Torrance AD, Almond LM, Fry J, et al. Has integrated 18F FDG PET/CT improved 
staging, reduced early recurrence or increased survival in oesophageal cancer? 
Surgeon 2013. 
131. Han D, Yu J, Zhong X, et al. Comparison of the diagnostic value of 3-deoxy-3-18F-
fluorothymidine and 18F-fluorodeoxyglucose positron emission 
tomography/computed tomography in the assessment of regional lymph node in 
thoracic esophageal squamous cell carcinoma: a pilot study. Dis Esophagus 2012; 
25(5):416-26. 
132. Bingham BA, Hatef DA, Chevez-Barrios P, et al. Increased FDG activity in a 
dermatofibroma in esophageal cancer patient. Clin Nucl Med 2013; 38(3):e140-2. 
133. Robb WB, Mariette C. Predicting the response to chemotherapy in gastric 
adenocarcinoma: who benefits from neoadjuvant chemotherapy? Recent Results 
Cancer Res 2012; 196:241-68. 
134. Uemura N, Kondo T. Current status of predictive biomarkers for neoadjuvant therapy 
in esophageal cancer. World J Gastrointest Pathophysiol 2014; 5(3):322-34. 
135. Ott K, Herrmann K, Krause BJ, et al. The Value of PET Imaging in Patients with Localized 
Gastroesophageal Cancer. Gastrointest Cancer Res 2008; 2(6):287-94. 
136. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred 
definitions and conceptual framework. Clin Pharmacol Ther 2001; 69(3):89-95. 
137. Matuszcak C, Haier J, Hummel R, et al. MicroRNAs: Promising chemoresistance 
biomarkers in gastric cancer with diagnostic and therapeutic potential. World Journal 
of Gastroenterology 2014; 20(38):13658-13666. 
332 
 
138. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection 
of cancer. J Natl Cancer Inst 2001; 93(14):1054-61. 
139. Benowitz S. Biomarker bloom slowed by validation concerns. Journal of the national 
cancer institute 2004; 96(18):1356-7. 
140. Andre F, McShane LM, Michiels S, et al. Biomarker studies: a call for a comprehensive 
biomarker study registry. Nat Rev Clin Oncol 2011; 8(3):171-6. 
141. Hayashida Y, Honda K, Osaka Y, et al. Possible prediction of chemoradiosensitivity of 
esophageal cancer by serum protein profiling. Clin Cancer Res 2005; 11(22):8042-7. 
142. Maher SG, Gillham CM, Duggan SP, et al. Gene expression analysis of diagnostic 
biopsies predicts pathological response to neoadjuvant chemoradiotherapy of 
esophageal cancer. Ann Surg 2009; 250(5):729-37. 
143. Maher SG, McDowell DT, Collins BC, et al. Serum proteomic profiling reveals that 
pretreatment complement protein levels are predictive of esophageal cancer patient 
response to neoadjuvant chemoradiation. Ann Surg 2011; 254(5):809-16; discussion 
816-7. 
144. Ko MA, Zehong G, Virtanen C, et al. MicroRNA expression profiling of esophageal 
cancer before and after induction chemoradiotherapy. Annals of Thoracic Surgery 
2012; 94(4):1094-1103. 
145. Chen PC, Chen YC, Lai LC, et al. Use of germline polymorphisms in predicting 
concurrent chemoradiotherapy response in esophageal cancer. Int J Radiat Oncol Biol 
Phys 2012; 82(5):1996-2003. 
146. Kogo M, Suzuki A, Kaneko K, et al. Scoring system for predicting response to 
chemoradiotherapy, including 5-Fluorouracil and platinum, for patients with 
esophageal cancer. Dig Dis Sci 2008; 53(9):2415-21. 
147. MacGuill M, Mulligan E, Ravi N, et al. Clinicopathologic factors predicting complete 
pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. Dis 
Esophagus 2006; 19(4):273-6. 
148. Ribi K, Koeberle D, Schuller JC, et al. Is a change in patient-reported dysphagia after 
induction chemotherapy in locally advanced esophageal cancer a predictive factor for 
pathological response to neoadjuvant chemoradiation? Support Care Cancer 2009; 
17(8):1109-16. 
149. Lorenzen S, Blank S, Lordick F, et al. Prediction of response and prognosis by a score 
including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer 
patients. Ann Surg Oncol 2012; 19(7):2119-27. 
150. Chau I, Norman AR, Cunningham D, et al. The impact of primary tumour origins in 
patients with advanced oesophageal, oesophago-gastric junction and gastric 
adenocarcinoma--individual patient data from 1775 patients in four randomised 
controlled trials. Ann Oncol 2009; 20(5):885-91. 
151. Brown WA, Thomas J, Gotley D, et al. Use of oesophagogastroscopy to assess the 
response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg 2004; 91(2):199-
204. 
152. Motoori M, Yano M, Yasuda T, et al. Early response to neoadjuvant chemotherapy in 
advanced esophageal cancer evaluated by computed tomography predicts the utility 
of a second cycle of chemotherapy. Mol Clin Oncol 2013; 1(3):521-526. 
153. Jayachandran P, Pai RK, Quon A, et al. Postchemoradiotherapy positron emission 
tomography predicts pathologic response and survival in patients with esophageal 
cancer. Int J Radiat Oncol Biol Phys 2012; 84(2):471-7. 
154. van Westreenen HL, Plukker JT, Cobben DC, et al. Prognostic value of the standardized 
uptake value in esophageal cancer. AJR Am J Roentgenol 2005; 185(2):436-40. 
155. Wieder HA, Ott K, Lordick F, et al. Prediction of tumor response by FDG-PET: 
comparison of the accuracy of single and sequential studies in patients with 
adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 2007; 
34(12):1925-32. 
333 
 
156. Hong D, Lunagomez S, Kim EE, et al. Value of baseline positron emission tomography 
for predicting overall survival in patient with nonmetastatic esophageal or 
gastroesophageal junction carcinoma. Cancer 2005; 104(8):1620-6. 
157. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and 
recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 
24(29):4692-8. 
158. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative 
chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic 
imaging. J Clin Oncol 2001; 19(12):3058-65. 
159. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide 
treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase 
II trial. Lancet Oncol 2007; 8(9):797-805. 
160. Gillham CM, Lucey JA, Keogan M, et al. (18)FDG uptake during induction 
chemoradiation for oesophageal cancer fails to predict histomorphological tumour 
response. Br J Cancer 2006; 95(9):1174-9. 
161. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity 
during chemoradiotherapy of esophageal squamous cell carcinoma and response to 
treatment. J Clin Oncol 2004; 22(5):900-8. 
162. van Heijl M, Omloo JM, van Berge Henegouwen MI, et al. Fluorodeoxyglucose positron 
emission tomography for evaluating early response during neoadjuvant 
chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg 
2011; 253(1):56-63. 
163. Malik V, Lucey JA, Duffy GJ, et al. Early repeated 18F-FDG PET scans during 
neoadjuvant chemoradiation fail to predict histopathologic response or survival 
benefit in adenocarcinoma of the esophagus. J Nucl Med 2010; 51(12):1863-9. 
164. Vallbohmer D, Holscher AH, Dietlein M, et al. [18F]-Fluorodeoxyglucose-positron 
emission tomography for the assessment of histopathologic response and prognosis 
after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009; 
250(6):888-94. 
165. Cuenca X, Hennequin C, Hindie E, et al. Evaluation of early response to concomitant 
chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally 
advanced oesophageal carcinomas. Eur J Nucl Med Mol Imaging 2013; 40(4):477-85. 
166. Kwee RM. Prediction of tumor response to neoadjuvant therapy in patients with 
esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 2010; 
254(3):707-17. 
167. Klayton T, Li T, Yu JQ, et al. The role of qualitative and quantitative analysis of F18-FDG 
positron emission tomography in predicting pathologic response following 
chemoradiotherapy in patients with esophageal carcinoma. J Gastrointest Cancer 
2012; 43(4):612-8. 
168. Kwee RM, Vliegen RF. Predicting tumour response to chemoradiotherapy in 
oesophageal cancer by early interim 18F-FDG PET: where do we stand and where 
should we go? Eur J Nucl Med Mol Imaging 2013; 40(4):475-6. 
169. Akamatsu M, Matsumoto T, Oka K, et al. c-erbB-2 oncoprotein expression related to 
chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol 
Phys 2003; 57(5):1323-7. 
170. Duhaylongsod FG, Gottfried MR, Iglehart JD, et al. The significance of c-erb B-2 and 
p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 
1995; 221(6):677-83; discussion 683-4. 
171. Zhang SS, Huang QY, Yang H, et al. Correlation of p53 status with the response to 
chemotherapy-based treatment in esophageal cancer: a meta-analysis. Ann Surg Oncol 
2013; 20(7):2419-27. 
172. Ishida M, Morita M, Saeki H, et al. Expression of p53 and p21 and the clinical response 
for hyperthermochemoradiotherapy in patients with squamous cell carcinoma of the 
esophagus. Anticancer Research 2007; 27(5 B):3501-3506. 
334 
 
173. Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action 
pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 
24(23):3789-98. 
174. Okumura H, Natsugoe S, Matsumoto M, et al. The predictive value of p53, p53R2, and 
p21 for the effect of chemoradiation therapy on oesophageal squamous cell 
carcinoma. Br J Cancer 2005; 92(2):284-9. 
175. Alexander BM, Wang XZ, Niemierko A, et al. DNA repair biomarkers predict response 
to neoadjuvant chemoradiotherapy in esophageal cancer. International Journal of 
Radiation Oncology Biology Physics 2012; 83(1):164-171. 
176. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: 
correlation with the prognosis and response to chemotherapy. Int J Cancer 2001; 
95(2):92-5. 
177. Okumura H, Uchikado Y, Setoyama T, et al. Biomarkers for predicting the response of 
esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy. Surg 
Today 2014; 44(3):421-8. 
178. Kulke MH, Odze RD, Mueller JD, et al. Prognostic significance of vascular endothelial 
growth factor and cyclooxygenase 2 expression in patients receiving preoperative 
chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg 2004; 127(6):1579-86. 
179. Takatori H, Natsugoe S, Okumura H, et al. Predictive value of COX-2 for the effect of 
chemoradiotherapy on esophageal squamous cell carcinoma. Oncol Rep 2005; 
13(4):697-701. 
180. Samejima R, Kitajima Y, Yunotani S, et al. Cyclin D1 is a possible predictor of sensitivity 
to chemoradiotherapy for esophageal squamous cell carcinoma. Anticancer Res 1999; 
19(6C):5515-21. 
181. Brucher BL, Keller G, Werner M, et al. Using Q-RT-PCR to measure cyclin D1, TS, TP, 
DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients 
with esophageal squamous cell carcinoma following radiochemotherapy. Int J 
Colorectal Dis 2009; 24(1):69-77. 
182. Miyata H, Doki Y, Shiozaki H, et al. CDC25B and p53 are independently implicated in 
radiation sensitivity for human esophageal cancers. Clin Cancer Res 2000; 6(12):4859-
65. 
183. Kishi K, Doki Y, Miyata H, et al. Prediction of the response to chemoradiation and 
prognosis in oesophageal squamous cancer. Br J Surg 2002; 89(5):597-603. 
184. Okumura H, Natsugoe S, Matsumoto M, et al. Predictive value of p53 and 14-3-3sigma 
for the effect of chemoradiation therapy on esophageal squamous cell carcinoma. J 
Surg Oncol 2005; 91(1):84-9. 
185. Fukuda H, Takiguchi N, Koda K, et al. Thymidylate synthase and dihydropyrimidine 
dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin 
neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest 2006; 
24(3):235-41. 
186. Langer R, Specht K, Becker K, et al. Comparison of pretherapeutic and posttherapeutic 
expression levels of chemotherapy-associated genes in adenocarcinomas of the 
esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy. 
Am J Clin Pathol 2007; 128(2):191-7. 
187. Napieralski R, Ott K, Kremer M, et al. Combined GADD45A and thymidine 
phosphorylase expression levels predict response and survival of neoadjuvant-treated 
gastric cancer patients. Clin Cancer Res 2005; 11(8):3025-31. 
188. Imdahl A, Jenkner J, Ihling C, et al. Is MIB-1 proliferation index a predictor for response 
to neoadjuvant therapy in patients with esophageal cancer? Am J Surg 2000; 
179(6):514-20. 
189. Kitamura K, Saeki H, Kawaguchi H, et al. Immunohistochemical status of the p53 
protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to 
neoadjuvant therapy in patients with esophageal cancer. Hepatogastroenterology 
2000; 47(32):419-23. 
335 
 
190. Takeuchi H, Ozawa S, Ando N, et al. Cell-cycle regulators and the Ki-67 labeling index 
can predict the response to chemoradiotherapy and the survival of patients with 
locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol 2003; 
10(7):792-800. 
191. Hickey K, Grehan D, Reid IM, et al. Expression of epidermal growth factor receptor and 
proliferating cell nuclear antigen predicts response of esophageal squamous cell 
carcinoma to chemoradiotherapy. Cancer 1994; 74(6):1693-8. 
192. Imdahl A, Bognar G, Schulte-Monting J, et al. Predictive factors for response to 
neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 
2002; 21(4):657-63. 
193. Shimada Y, Watanabe G, Yamasaki S, et al. Histological response of cisplatin predicts 
patients' survival in oesophageal cancer and p53 protein accumulation in pretreatment 
biopsy is associated with cisplatin sensitivity. Eur J Cancer 2000; 36(8):987-93. 
194. Beardsmore DM, Verbeke CS, Davies CL, et al. Apoptotic and proliferative indexes in 
esophageal cancer: predictors of response to neoadjuvant therapy [corrected]. J 
Gastrointest Surg 2003; 7(1):77-86; discussion 86-7. 
195. Sobajima J, Kumamoto K, Haga N, et al. Early evaluation of the apoptotic index ratio is 
useful in predicting the efficacy of chemoradiotherapy in esophageal squamous cell 
carcinoma. Oncol Lett 2012; 3(2):287-292. 
196. Makino T, Yamasaki M, Miyata H, et al. p53 Mutation status predicts pathological 
response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg 
Oncol 2010; 17(3):804-11. 
197. Nakashima S, Natsugoe S, Matsumoto M, et al. Expression of p53 and p21 is useful for 
the prediction of preoperative chemotherapeutic effects in esophageal carcinoma. 
Anticancer Res 2000; 20(3B):1933-7. 
198. Kim MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor 
outcome in oesophageal cancer. Eur J Cancer 2008; 44(1):54-60. 
199. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement 
thymidylate synthase mRNA levels in predicting response and survival for gastric 
cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin 
Oncol 1998; 16(1):309-16. 
200. Warnecke-Eberz U, Metzger R, Miyazono F, et al. High specificity of quantitative 
excision repair cross-complementing 1 messenger RNA expression for prediction of 
minor histopathological response to neoadjuvant radiochemotherapy in esophageal 
cancer. Clin Cancer Res 2004; 10(11):3794-9. 
201. Metzger R, Warnecke-Eberz U, Alakus H, et al. Neoadjuvant radiochemotherapy in 
adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of 
response and prognosis. J Gastrointest Surg 2012; 16(1):26-34; discussion 34. 
202. Warnecke-Eberz U, Vallbohmer D, Alakus H, et al. ERCC1 and XRCC1 gene 
polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal 
cancer. J Gastrointest Surg 2009; 13(8):1411-21. 
203. Noguchi T, Shibata T, Fumoto S, et al. DNA-PKcs expression in esophageal cancer as a 
predictor for chemoradiation therapeutic sensitivity. Ann Surg Oncol 2002; 9(10):1017-
22. 
204. Alexander HR, Grem JL, Hamilton JM, et al. Thymidylate synthase protein expression: 
Association with response to neoadjuvant chemotherapy and resection for locally 
advanced gastric and gastroesophageal adenocarcinoma. Cancer J Sci Am 1995; 
1(1):49-54. 
205. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and 
ERCC1 are risk factors for survival in patients treated with trimodality therapy for 
esophageal cancer. Clin Cancer Res 2005; 11(6):2215-21. 
206. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in 
adenocarcinoma of the stomach: a predictor for primary tumor response and overall 
survival. J Clin Oncol 1996; 14(1):176-82. 
336 
 
207. Abdel-Latif MM, O'Riordan J, Windle HJ, et al. NF-kappaB activation in esophageal 
adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to 
neoadjuvant chemoradiotherapy. Ann Surg 2004; 239(4):491-500. 
208. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear 
factor kappab with chemoradiation resistance and poor outcome in esophageal 
carcinoma. J Clin Oncol 2006; 24(5):748-54. 
209. Izzo JG, Correa AM, Wu TT, et al. Pretherapy nuclear factor-kappaB status, 
chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol 
Cancer Ther 2006; 5(11):2844-50. 
210. Sarbia M, Stahl M, Fink U, et al. Prognostic significance of cyclin D1 in esophageal 
squamous cell carcinoma patients treated with surgery alone or combined therapy 
modalities. Int J Cancer 1999; 84(1):86-91. 
211. Narumiya K, Metzger R, Bollschweiler E, et al. Impact of ABCB1 C3435T polymorphism 
on lymph node regression in multimodality treatment of locally advanced esophageal 
cancer. Pharmacogenomics 2011; 12(2):205-14. 
212. Sarbia M, Ott N, Puhringer-Oppermann F, et al. The predictive value of molecular 
markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of 
the oesophagus. Br J Cancer 2007; 97(10):1404-8. 
213. Langer R, Specht K, Becker K, et al. Association of pretherapeutic expression of 
chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett 
carcinoma. Clin Cancer Res 2005; 11(20):7462-9. 
214. Yamamoto M, Tsujinaka T, Shiozaki H, et al. Metallothionein expression correlates with 
the pathological response of patients with esophageal cancer undergoing preoperative 
chemoradiation therapy. Oncology 1999; 56(4):332-7. 
215. Ajani JA, Wang X, Song S, et al. ALDH-1 expression levels predict response or resistance 
to preoperative chemoradiation in resectable esophageal cancer patients. Molecular 
Oncology 2014; 8(1):142-149. 
216. Sugimura K, Miyata H, Tanaka K, et al. Let-7 expression is a significant determinant of 
response to chemotherapy through the regulation of IL-6/STAT3 pathway in 
esophageal squamous cell carcinoma. Clinical Cancer Research 2012; 18(18):5144-
5153. 
217. Teng RY, Zhou JC, Jiang ZN, et al. The relationship between Lin28 and the 
chemotherapy response of gastric cancer. OncoTargets and Therapy 2013; 6:1341-
1345. 
218. Munzig A, Bauer L, Slotta-Huspenina J, et al. Predictive value of Notch associated genes 
for response and survival in neoadjuvant treated gastric cancer. European Journal of 
Cancer 2014; 50. 
219. Di Fiore F, Lecleire S, Pop D, et al. Baseline nutritional status is predictive of response 
to treatment and survival in patients treated by definitive chemoradiotherapy for a 
locally advanced esophageal cancer. Am J Gastroenterol 2007; 102(11):2557-63. 
220. Noble F, Hopkins J, Curtis N, et al. The role of systemic inflammatory and nutritional 
blood-borne markers in predicting response to neoadjuvant chemotherapy and 
survival in oesophagogastric cancer. Med Oncol 2013; 30(3):596. 
221. Liu Y, Chen J, Shao N, et al. Clinical value of hematologic test in predicting tumor 
response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma. 
World J Surg Oncol 2014; 12(1):43. 
222. Hamai Y, Hihara J, Taomoto J, et al. Hemoglobin Level Influences Tumor Response and 
Survival After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell 
Carcinoma. World J Surg 2014. 
223. Yi Y, Li B, Sun H, et al. Predictors of sensitivity to chemoradiotherapy of esophageal 
squamous cell carcinoma. Tumour Biol 2010; 31(4):333-40. 
224. Cho IR, Park JC, Yoon JY, et al. Pre-treatment neutrophil to lymphocyte ratio as a 
marker for predicting chemotherapeutic response and prognosis for metastatic 
advanced gastric cancer. Gastroenterology 2012; 142(5 SUPPL. 1). 
337 
 
225. Tomimaru Y, Yano M, Takachi K, et al. Correlation between pretherapeutic d-dimer 
levels and response to neoadjuvant chemotherapy in patients with advanced 
esophageal cancer. Dis Esophagus 2008; 21(4):281-7. 
226. Bystrom P, Berglund A, Nygren P, et al. An explorative study on the clinical utility of 
baseline and serial serum tumour marker measurements in advanced upper 
gastrointestinal cancer. Oncol Rep 2010; 24(6):1645-52. 
227. Yi Y, Li B, Wang Z, et al. CYFRA21-1 and CEA are useful markers for predicting the 
sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers 
2009; 14(7):480-5. 
228. Quillien V, Raoul JL, Laurent JF, et al. Comparison of Cyfra 21-1, TPA and SCC tumor 
markers in esophageal squamous cell carcinoma. Oncol Rep 1998; 5(6):1561-5. 
229. Ott K, Rachakonda PS, Panzram B, et al. DNA repair gene and MTHFR gene 
polymorphisms as prognostic markers in locally advanced adenocarcinoma of the 
esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant 
chemotherapy. Ann Surg Oncol 2011; 18(9):2688-98. 
230. Gusella M, De G, Bertolaso L, et al. Detoxification and dna repair gene polymorphisms: 
Association with pathological response and survival in locally advanced esophageal 
cancer (LAEC) patients receiving neoadjuvant chemoradiotherapy with cisplatin, 
docetaxel and 5-fluorouracil. Long term results. Diseases of the Esophagus 2012; 25. 
231. Lu ZM, Luo TH, Nie MM, et al. Influence of ERCC1 and ERCC4 polymorphisms on 
response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. 
Tumour Biol 2014; 35(4):2941-8. 
232. Brabender J, Vallbohmer D, Grimminger P, et al. ERCC1 RNA expression in peripheral 
blood predicts minor histopathological response to neoadjuvant radio-chemotherapy 
in patients with locally advanced cancer of the esophagus. J Gastrointest Surg 2008; 
12(11):1815-21. 
233. Li QF, Yao RY, Liu KW, et al. Genetic polymorphism of GSTP1: prediction of clinical 
outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean 
Med Sci 2010; 25(6):846-52. 
234. Keam B, Im SA, Han SW, et al. Modified FOLFOX-6 chemotherapy in advanced gastric 
cancer: Results of phase II study and comprehensive analysis of polymorphisms as a 
predictive and prognostic marker. BMC Cancer 2008; 8:148. 
235. Grimminger P, Vallbohmer D, Schneider PM, et al. Dihydropyrimidine dehydrogenase 
and thymidylate synthase gene expressions in blood as predictive parameters for the 
response to neoadjuvant radiochemotherapy in esophageal cancer. Gastroenterology 
2009; 136(5 SUPPL. 1). 
236. Zhang XP, Bai ZB, Chen BA, et al. Polymorphisms of dihydropyrimidine dehydrogenase 
gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based 
adjuvant chemotherapy in Chinese population. Chin Med J (Engl) 2012; 125(5):741-6. 
237. Oh SY, Kwon HC, Kim SH, et al. The relationship of vascular endothelial growth factor 
gene polymorphisms and clinical outcome in advanced gastric cancer patients treated 
with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer 2013; 13:43. 
238. Chiang Y, Cheng J, Graber M, et al. Serum vascular endothelial growth factor-a and 
transforming growth factor-beta1 can predict pathological response and disease-free 
survival of esophageal cancer patients treated with neoadjuvant chemoradiation 
therapy followed by esophagectomy. International Journal of Radiation Oncology 
Biology Physics 2014; 90(1 SUPPL. 1):S9-S10. 
239. Tanaka K, Miyata H, Yamasaki M, et al. Circulating miR-200c levels significantly predict 
response to chemotherapy and prognosis of patients undergoing neoadjuvant 
chemotherapy for esophageal cancer. Ann Surg Oncol 2013; 20 Suppl 3:S607-15. 
240. Liu X, Huang MZ, Chen ZY, et al. LRP5 polymorphism-A potential predictor of the 
clinical outcome in advanced gastric cancer patients treated with EOF regimen. Chin J 
Cancer Res 2014; 26(4):478-85. 
338 
 
241. Pan JY, Ajani JA, Gu J, et al. Association of Aurora-A (STK15) kinase polymorphisms with 
clinical outcome of esophageal cancer treated with preoperative chemoradiation. 
Cancer 2012; 118(17):4346-53. 
242. Huang H, Han Y, Gao J, et al. High level of serum AMBP is associated with poor 
response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients. 
Medical Oncology 2013; 30(4). 
243. Shimoda T. [Japanese classification of esophageal cancer, the 10th edition--
Pathological part]. Nihon Rinsho 2011; 69 Suppl 6:109-20. 
244. Shimada H, Hoshino T, Okazumi S, et al. Expression of angiogenic factors predicts 
response to chemoradiotherapy and prognosis of oesophageal squamous cell 
carcinoma. Br J Cancer 2002; 86(4):552-7. 
245. Ott K, Vogelsang H, Mueller J, et al. Chromosomal instability rather than p53 mutation 
is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric 
carcinoma. Clin Cancer Res 2003; 9(6):2307-15. 
246. Sohda M, Ishikawa H, Masuda N, et al. Pretreatment evaluation of combined HIF-
1alpha, p53 and p21 expression is a useful and sensitive indicator of response to 
radiation and chemotherapy in esophageal cancer. Int J Cancer 2004; 110(6):838-44. 
247. Hu HB, Kuang L, Zeng XM, et al. Predictive value of thymidylate synthase expression in 
gastric cancer: a systematic review with meta-analysis. Asian Pac J Cancer Prev 2012; 
13(1):261-7. 
248. Wang Z, Chen JQ, Liu JL, et al. Polymorphisms in ERCC1, GSTs, TS and MTHFR predict 
clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based 
chemotherapy: a systematic review. BMC Gastroenterol 2012; 12:137. 
249. Goekkurt E, Hoehn S, Wolschke C, et al. Polymorphisms of glutathione S-transferases 
(GST) and thymidylate synthase (TS)--novel predictors for response and survival in 
gastric cancer patients. Br J Cancer 2006; 94(2):281-6. 
250. Warnecke-Eberz U, Hokita S, Xi H, et al. Overexpression of survivin mRNA is associated 
with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal 
cancer. Oncol Rep 2005; 13(6):1241-6. 
251. Xi H, Baldus SE, Warnecke-Eberz U, et al. High cyclooxygenase-2 expression following 
neoadjuvant radiochemotherapy is associated with minor histopathologic response 
and poor prognosis in esophageal cancer. Clin Cancer Res 2005; 11(23):8341-7. 
252. Sunada F, Itabashi M, Ohkura H, et al. p53 negativity, CDC25B positivity, and 
metallothionein negativity are predictors of a response of esophageal squamous cell 
carcinoma to chemoradiotherapy. World J Gastroenterol 2005; 11(36):5696-700. 
253. Kim CH, Kim HK, Rettig RL, et al. miRNA signature associated with outcome of gastric 
cancer patients following chemotherapy. BMC Med Genomics 2011; 4:79. 
254. Pectasides D, Mylonakis A, Kostopoulou M, et al. CEA, CA 19-9, and CA-50 in 
monitoring gastric carcinoma. Am J Clin Oncol 1997; 20(4):348-53. 
255. Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for 
gastric cancer: a systematic review of literature by the Task Force of the Japanese 
Gastric Cancer Association. Gastric Cancer 2013. 
256. Font A, Salazar R, Maurel J, et al. Cisplatin plus weekly CPT-11/docetaxel in advanced 
esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, 
XRCC3 and UGT1A1 polymorphisms. Cancer Chemother Pharmacol 2008; 62(6):1075-
83. 
257. Marin JJ, Briz O, Monte MJ, et al. Genetic variants in genes involved in mechanisms of 
chemoresistance to anticancer drugs. Curr Cancer Drug Targets 2012; 12(4):402-38. 
258. Warburg O PK, Negelein E. Uber den Stoffwechsel der Tumoren. Biochem 1924; 
152:319-44. 
259. Bayley JP, Devilee P. The Warburg effect in 2012. Curr Opin Oncol 2012; 24(1):62-7. 
260. Shin YK, Yoo BC, Hong YS, et al. Upregulation of glycolytic enzymes in proteins secreted 
from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 2009; 
30(12):2182-92. 
339 
 
261. Martinez-Balibrea E, Plasencia C, Gines A, et al. A proteomic approach links decreased 
pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal 
cancer and in human cell lines. Mol Cancer Ther 2009; 8(4):771-8. 
262. Yoo BC, Ku JL, Hong SH, et al. Decreased pyruvate kinase M2 activity linked to cisplatin 
resistance in human gastric carcinoma cell lines. Int J Cancer 2004; 108(4):532-9. 
263. Chaneton B, Gottlieb E. Rocking cell metabolism: revised functions of the key glycolytic 
regulator PKM2 in cancer. Trends Biochem Sci 2012; 37(8):309-16. 
264. Porporato PE, Dhup S, Dadhich RK, et al. Anticancer targets in the glycolytic 
metabolism of tumors: a comprehensive review. Front Pharmacol 2011; 2:49. 
265. Auld D, Shen M, Skoumbourdis AP, et al. Identification of activators for the M2 isoform 
of human pyruvate kinase.  Probe Reports from the NIH Molecular Libraries Program. 
Bethesda MD; 2010. 
266. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system 
in tumor cells. Int J Biochem Cell Biol 2011; 43(7):969-80. 
267. Imamura K, Tanaka T. Multimolecular forms of pyruvate kinase from rat and other 
mammalian tissues. I. Electrophoretic studies. J Biochem 1972; 71(6):1043-51. 
268. DeSouza LV, Krakovska O, Darfler MM, et al. mTRAQ-based quantification of potential 
endometrial carcinoma biomarkers from archived formalin-fixed paraffin-embedded 
tissues. Proteomics 2010; 10(17):3108-16. 
269. Du XL, Hu H, Lin DC, et al. Proteomic profiling of proteins dysregulted in Chinese 
esophageal squamous cell carcinoma. J Mol Med (Berl) 2007; 85(8):863-75. 
270. Eigenbrodt E, Basenau D, Holthusen S, et al. Quantification of tumor type M2 pyruvate 
kinase (Tu M2-PK) in human carcinomas. Anticancer Res 1997; 17(4B):3153-6. 
271. Koss K, Harrison RF, Gregory J, et al. The metabolic marker tumour pyruvate kinase 
type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-
adenocarcinoma sequence in Barrett's oesophagus. J Clin Pathol 2004; 57(11):1156-9. 
272. Kumar Y, Mazurek S, Yang S, et al. In vivo factors influencing tumour M2-pyruvate 
kinase level in human pancreatic cancer cell lines. Tumour Biol 2010; 31(2):69-77. 
273. Eigenbrodt E, Reinacher M, Scheefers-Borchel U, et al. Double role for pyruvate kinase 
type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit Rev 
Oncog 1992; 3(1-2):91-115. 
274. Eigenbrodt E GH. Glycolysis-one of the keys to cancer? Trends Pharmacol Sci 1980; 
1:240-5. 
275. Zwerschke W, Mazurek S, Massimi P, et al. Modulation of type M2 pyruvate kinase 
activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci U S A 
1999; 96(4):1291-6. 
276. Shimada N, Shinagawa T, Ishii S. Modulation of M2-type pyruvate kinase activity by the 
cytoplasmic PML tumor suppressor protein. Genes Cells 2008; 13(3):245-54. 
277. Spoden GA, Morandell D, Ehehalt D, et al. The SUMO-E3 ligase PIAS3 targets pyruvate 
kinase M2. J Cell Biochem 2009; 107(2):293-302. 
278. Schneider J, Neu K, Grimm H, et al. Tumor M2-pyruvate kinase in lung cancer patients: 
immunohistochemical detection and disease monitoring. Anticancer Res 2002; 
22(1A):311-8. 
279. Oremek GM, Teigelkamp S, Kramer W, et al. The pyruvate kinase isoenzyme tumor M2 
(Tu M2-PK) as a tumor marker for renal carcinoma. Anticancer Res 1999; 19(4A):2599-
601. 
280. Mellati AA, Yucel M, Altinors N, et al. Regulation of M2-type pyruvate kinase from 
human meningioma by allosteric effectors fructose 1,6 diphosphate and L-alanine. 
Cancer Biochem Biophys 1992; 13(1):33-41. 
281. Mazurek S, Boschek CB, Hugo F, et al. Pyruvate kinase type M2 and its role in tumor 
growth and spreading. Semin Cancer Biol 2005; 15(4):300-8. 
282. Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome 
and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc 
2007(4):99-124. 
340 
 
283. Reinacher M, Eigenbrodt E. Immunohistological demonstration of the same type of 
pyruvate kinase isoenzyme (M2-Pk) in tumors of chicken and rat. Virchows Arch B Cell 
Pathol Incl Mol Pathol 1981; 37(1):79-88. 
284. Steinberg P, Klingelhoffer A, Schafer A, et al. Expression of pyruvate kinase M2 in 
preneoplastic hepatic foci of N-nitrosomorpholine-treated rats. Virchows Arch 1999; 
434(3):213-20. 
285. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate 
kinase is important for cancer metabolism and tumour growth. Nature 2008; 
452(7184):230-3. 
286. Anastasiou D, Poulogiannis G, Asara JM, et al. Inhibition of pyruvate kinase M2 by 
reactive oxygen species contributes to cellular antioxidant responses. Science 2011; 
334(6060):1278-83. 
287. Gao X, Wang H, Yang JJ, et al. Pyruvate kinase M2 regulates gene transcription by 
acting as a protein kinase. Mol Cell 2012; 45(5):598-609. 
288. Kwon OH, Kang TW, Kim JH, et al. Pyruvate kinase M2 promotes the growth of gastric 
cancer cells via regulation of Bcl-xL expression at transcriptional level. Biochem Biophys 
Res Commun 2012; 423(1):38-44. 
289. Lu Z. Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle 
progression and tumorigenesis. Chin J Cancer 2012; 31(1):5-7. 
290. Luo W, Semenza GL. Pyruvate kinase M2 regulates glucose metabolism by functioning 
as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget 2011; 
2(7):551-6. 
291. Stetak A, Veress R, Ovadi J, et al. Nuclear translocation of the tumor marker pyruvate 
kinase M2 induces programmed cell death. Cancer Res 2007; 67(4):1602-8. 
292. Aloysius MM, Zaitoun AM, Bates TE, et al. Complete absence of M2-pyruvate kinase 
expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal 
neoplasia. BMC Cancer 2009; 9:327. 
293. Schneider J, Morr H, Velcovsky HG, et al. Quantitative detection of tumor M2-pyruvate 
kinase in plasma of patients with lung cancer in comparison to other lung diseases. 
Cancer Detect Prev 2000; 24(6):531-5. 
294. Acebo P, Giner D, Calvo P, et al. Cancer abolishes the tissue type-specific differences in 
the phenotype of energetic metabolism. Transl Oncol 2009; 2(3):138-45. 
295. Hathurusinghe HR, Goonetilleke KS, Siriwardena AK. Current status of tumor M2 
pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy. Ann 
Surg Oncol 2007; 14(10):2714-20. 
296. Hardt PD, Ngoumou BK, Rupp J, et al. Tumor M2-pyruvate kinase: a promising tumor 
marker in the diagnosis of gastro-intestinal cancer. Anticancer Res 2000; 20(6D):4965-
8. 
297. Schneider J, Bitterlich N, Schulze G. Improved sensitivity in the diagnosis of gastro-
intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-
PK. Anticancer Res 2005; 25(3A):1507-15. 
298. Lim JY, Yoon SO, Seol SY, et al. Overexpression of the M2 isoform of pyruvate kinase is 
an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol 
2012; 18(30):4037-43. 
299. Anastasiou D, Yu Y, Israelsen WJ, et al. Pyruvate kinase M2 activators promote 
tetramer formation and suppress tumorigenesis. Nat Chem Biol 2012; 8(10):839-47. 
300. Chen J, Xie J, Jiang Z, et al. Shikonin and its analogs inhibit cancer cell glycolysis by 
targeting tumor pyruvate kinase-M2. Oncogene 2011; 30(42):4297-306. 
301. Guo XP, Zhang XY, Zhang SD. [Clinical trial on the effects of shikonin mixture on later 
stage lung cancer]. Zhong Xi Yi Jie He Za Zhi 1991; 11(10):598-9, 580. 
302. Li SL, Ye F, Cai WJ, et al. Quantitative proteome analysis of multidrug resistance in 
human ovarian cancer cell line. J Cell Biochem 2010; 109(4):625-33. 
303. Arner ES, Nakamura H, Sasada T, et al. Analysis of the inhibition of mammalian 
thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum 
341 
 
(II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med 
2001; 31(10):1170-8. 
304. Sasada T, Iwata S, Sato N, et al. Redox control of resistance to cis-
diamminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against 
CDDP-induced cytotoxicity. J Clin Invest 1996; 97(10):2268-76. 
305. Sasada T, Nakamura H, Ueda S, et al. Possible involvement of thioredoxin reductase as 
well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free 
Radic Biol Med 1999; 27(5-6):504-14. 
306. Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy 
to overcome drug resistance associated with mitochondrial respiratory defect and 
hypoxia. Cancer Res 2005; 65(2):613-21. 
307. Dhar DK, Olde Damink SW, Brindley JH, et al. Pyruvate kinase M2 is a novel diagnostic 
marker and predicts tumor progression in human biliary tract cancer. Cancer 2013; 
119(3):575-85. 
308. Fatela-Cantillo D, Fernandez-Suarez A, Moreno MA, et al. Prognostic value of plasmatic 
tumor M2 pyruvate kinase and carcinoembryonic antigen in the survival of colorectal 
cancer patients. Tumour Biol 2012; 33(3):825-32. 
 
 
